Sotsiaalministeerium · 25. juuli 2019
Sisu (failidest)
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Director
GRANT AGREEMENT
NUMBER — 848096 — SHARP JA
This ‘Agreement’(‘the Agreement’) is between the following parties:
on the one part,
the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under
the powers delegated by the European Commission ('the Commission'), represented for the purposes
of signature of this Agreement by Véronique WASBAUER, Director, or his/her duly authorised
representative,
and
on the other part,
1. ‘the coordinator’:
TERVEYDEN JA HYVINVOINNIN LAITOS (THL), established in MANNERHEIMINTIE 166,
HELSINKI 00271, Finland, VAT number: FI22295006, represented for the purposes of signing the
Agreement by Markku Tervahauta
and the following other beneficiaries if they have signed their ‘Accession Form’ (see Annex 3 and
Article 40):
2. ROBERT KOCH-INSTITUT (RKI), established in Nordufer 20, Berlin 13353, Germany, VAT
number: DE165893430,
3. ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-
ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO (INMI), established in
Via Portuense, 292, ROMA 00149, Italy, VAT number: IT05080991002,
4. BUNDESMINISTERIUM FUER ARBEIT, SOZIALES, GESUNDHEIT UND
KONSUMENTENSCHUTZ (BMASGK), established in Radetzkystrasse 2, WIEN 1030, Austria,
5. MINISTRY OF CIVIL AFFAIRS (MCA), established in Trg Bosne i Hercegovine 1,
SARAJEVO 71000, Bosnia and Herzegovina,
6. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), established in ROCKEFELLEROVA
7, ZAGREB 10000, Croatia, VAT number: HR75297532041,
7. STATNI USTAV JADERNE, CHEMICKE A BIOLOGICKE OCHRANY VVI (SUJCHBO),
established in KAMENNA 71, MILIN 26231, Czech Republic, VAT number: CZ70565813,
1
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
8. STATENS SERUM INSTITUT (SSI), established in ARTILLERIVEJ 5, KOBENHAVN S 2300,
Denmark, VAT number: DK46837428,
9. SOTSIAALMINISTEERIUM (MSAE), established in Suur-Ameerika 1, TALLINN 10122,
Estonia,
10. MINISTERE DES AFFAIRES SOCIALES ET DE LA SANTE (MOH-FR), established in
AVENUE DUQUESNE 14, PARIS CEDEX 75350, France, VAT number: N/A,
11. KENTRO ELENCHOU & PROLIPSIS NOSIMATON (HCDCP(KEELPNO)), established
in AGRAFON STREET 3-5, MAROUSI 15123, Greece, VAT number: EL090193594,
12. NEMZETI NEPEGESZSEGUGYI KOZPONT (NNK), established in ALBERT FLORIAN
UT 2-6, BUDAPEST 1097, Hungary, VAT number: HU15598787,
13. NEATLIEKAMAS MEDICINISKAS PALIDZIBA (SEMS), established in LAKTAS IELA 8,
RIGA 1013, Latvia, VAT number: LV90009029104,
14. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (MOHLT),
established in VILNIAUS G 33, VILNIUS LT 01506, Lithuania,
15. Ministry for Health - Government of Malta (MFH), established in Palazzo Castellania,
Merchants Street 15, Valletta VLT 200, Malta, VAT number: MT12979127,
16. RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), established
in Antonie Van Leeuwenhoeklaan 9, BILTHOVEN 3721 MA, Netherlands, VAT number:
NL821772302B01,
17. HELSEDIREKTORATET (HD), established in VITAMINVEIEN 4, OSLO 0213, Norway, VAT
number: NO983544622,
18. NARODOWY INSTYTUT ZDROWIA PUBLICZNEGO-PANSTWOWY ZAKLAD
HIGIENY (NIZP-PZH), established in CHOCIMSKA 24, WARSZAWA 00791, Poland, VAT
number: PL5250008732,
19. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (MS), established in Av. João
Crisóstomo, 9, LISBOA 1049-062, Portugal,
20. INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS),
established in DR SUBOTICA STREET 5, BEOGRAD 11000, Serbia, VAT number: RS102000930,
21. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ), established in TRUBARJEVA
CESTA 2, LJUBLJANA 1000, Slovenia, VAT number: SI44724535,
22. INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5,
MADRID 28029, Spain, VAT number: ESQ2827015E,
23. FOLKHALSOMYNDIGHETEN (FOHM), established in NOBELS VAG 18, SOLNA 171 82,
Sweden, VAT number: SE202100654501,
24. Department of Health (DH), established in Quarry House, Quarry Hill, Leeds LS2 7UE, United
Kingdom, VAT number: 888815064,
2
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
25. HEALTH SERVICE EXECUTIVE HSE (HSE), established in LIMETREE AVENUE 2ND
FLO OAK HOUSE, NAAS, Ireland, VAT number: IE66093541,
26. AGENTIA NATIONALA PENTRU SANATATE PUBLICA (NAPH), established in 67A
GHEORGHE ASACHI ST, CHISINAU 2028, Moldova (Republic of),
Unless otherwise specified, references to ‘beneficiary’ or ‘beneficiaries’ include the coordinator.
The parties referred to above have agreed to enter into the Agreement under the terms and conditions
below.
By signing the Agreement or the Accession Form, the beneficiaries accept the grant and agree to
implement the action under their own responsibility and in accordance with the Agreement, with all
the obligations and conditions it sets out.
The Grant Agreement is composed of:
Terms and Conditions
Annex 1 Description of the action
Annex 2 Estimated budget for the action
Annex 2a Not applicable
Annex 3 Accession Forms
Annex 4 Model for the financial statements
Annex 5 Model for the certificate on the financial statements
3
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
TERMS AND CONDITIONS
TABLE OF CONTENTS
CHAPTER 1 GENERAL ............................................................................................................................................... 9
ARTICLE 1 — SUBJECT OF THE AGREEMENT.........................................................................................9
CHAPTER 2 ACTION ...................................................................................................................................................9
ARTICLE 2 — ACTION TO BE IMPLEMENTED.........................................................................................9
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION......................................................9
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS........................................................ 9
4.1 Estimated budget.................................................................................................................................. 9
4.2 Budget transfers....................................................................................................................................9
CHAPTER 3 GRANT .................................................................................................................................................... 9
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATE AND FORMS OF
COSTS..............................................................................................................................................9
5.1 Maximum grant amount....................................................................................................................... 9
5.2 Form of grant, reimbursement rate and forms of costs....................................................................... 9
5.3 Final grant amount — Calculation.....................................................................................................10
5.4 Revised final grant amount — Calculation....................................................................................... 11
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS................................................................................12
6.1 General conditions for costs to be eligible........................................................................................ 12
6.2 Specific conditions for costs to be eligible........................................................................................12
6.3 Conditions for costs of affiliated entities to be eligible.....................................................................15
6.4 Ineligible costs....................................................................................................................................15
6.5 Consequences of declaration of ineligible costs................................................................................ 16
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES ........................................................................ 16
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE ACTION ................ 16
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION.........................16
7.1 General obligation to properly implement the action........................................................................ 16
7.2 Consequences of non-compliance...................................................................................................... 16
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES INVOLVED IN THE
ACTION.........................................................................................................................................17
ARTICLE 8a — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT RECEIVING EU
FUNDING...................................................................................................................................... 17
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES............................................................17
9.1 Rules for purchasing goods, works or services................................................................................. 17
4
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
9.2 Consequences of non-compliance...................................................................................................... 17
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS............................18
10.1 Rules for subcontracting action tasks.............................................................................................. 18
10.2 Consequences of non-compliance.................................................................................................... 18
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES........................18
11.1 Rules for calling upon affiliated entities to implement part of the action........................................19
11.2 Consequences of non-compliance.................................................................................................... 21
ARTICLE 11a — FINANCIAL SUPPORT TO THIRD PARTIES.................................................................21
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT ADMINISTRATION .............. 21
ARTICLE 12 — GENERAL OBLIGATION TO INFORM............................................................................21
12.1 General obligation to provide information upon request.................................................................21
12.2 Obligation to keep information up to date and to inform about events and circumstances likely to
affect the Agreement........................................................................................................................... 21
12.3 Consequences of non-compliance.................................................................................................... 22
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION.........................................22
13.1 Obligation to keep records and other supporting documentation.................................................... 22
13.2 Consequences of non-compliance.................................................................................................... 23
ARTICLE 14 — SUBMISSION OF DELIVERABLES................................................................................. 23
14.1 Obligation to submit deliverables.................................................................................................... 23
14.2 Consequences of non-compliance.................................................................................................... 23
ARTICLE 15 — REPORTING — PAYMENT REQUESTS.......................................................................... 23
15.1 Obligation to submit reports............................................................................................................ 23
15.2 Reporting periods............................................................................................................................. 23
15.2a Request(s) for further pre-financing payment(s)............................................................................23
15.3 Periodic reports — Requests for interim payments......................................................................... 24
15.4 Final report — Request for payment of the balance....................................................................... 25
15.5 Information on cumulative expenditure incurred.............................................................................25
15.6 Currency for financial statements and conversion into euro........................................................... 25
15.7 Language of reports..........................................................................................................................26
15.8 Consequences of non-compliance.................................................................................................... 26
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS...........................................................26
16.1 Payments to be made....................................................................................................................... 26
16.2 Pre-financing payment — Amount .................................................................................................26
16.3 Interim payments — Amount — Calculation..................................................................................27
16.4 Payment of the balance — Amount — Calculation........................................................................ 27
5
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
16.5 Notification of amounts due.............................................................................................................28
16.6 Currency for payments..................................................................................................................... 28
16.7 Payments to the coordinator — Distribution to the beneficiaries....................................................28
16.8 Bank account for payments..............................................................................................................28
16.9 Costs of payment transfers...............................................................................................................28
16.10 Date of payment............................................................................................................................. 29
16.11 Consequences of non-compliance.................................................................................................. 29
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF
FINDINGS..................................................................................................................................... 29
17.1 Checks, reviews and audits by the Agency and the Commission....................................................29
17.2 Investigations by the European Anti-Fraud Office (OLAF)............................................................ 31
17.3 Checks and audits by the European Court of Auditors (ECA)........................................................32
17.4 Checks, reviews, audits and investigations for international organisations..................................... 32
17.5 Consequences of findings in checks, reviews, audits and investigations — Extension of
findings.................................................................................................................................................32
17.6 Consequences of non-compliance.................................................................................................... 33
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION....................................................... 33
18.1 Right to evaluate the impact of the action.......................................................................................34
18.2 Consequences of non-compliance.................................................................................................... 34
SECTION 3 OTHER RIGHTS AND OBLIGATIONS .......................................................................................34
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS (INCLUDING
INTELLECTUAL AND INDUSTRIAL PROPERTY RIGHTS)................................................. 34
19.1 Pre-existing rights and access rights to pre-existing rights..............................................................34
19.2 Ownership of results and rights of use............................................................................................ 34
19.3 Consequences of non-compliance.................................................................................................... 34
ARTICLE 20 — CONFLICT OF INTERESTS.............................................................................................. 35
20.1 Obligation to avoid a conflict of interests....................................................................................... 35
20.2 Consequences of non-compliance.................................................................................................... 35
ARTICLE 21 — CONFIDENTIALITY...........................................................................................................35
21.1 General obligation to maintain confidentiality................................................................................ 35
21.2 Consequences of non-compliance.................................................................................................... 35
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING....................................35
22.1 Communication activities by the beneficiaries................................................................................ 36
22.2 Communication activities by the Agency and the Commission...................................................... 36
22.3 Consequences of non-compliance.................................................................................................... 37
ARTICLE 23 — PROCESSING OF PERSONAL DATA...............................................................................37
6
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
23.1 Processing of personal data by the Agency and the Commission................................................... 37
23.2 Processing of personal data by the beneficiaries............................................................................. 38
23.3 Consequences of non-compliance.................................................................................................... 38
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY....................38
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES ....................................... 38
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES............................39
25.1 Roles and responsibilities towards the Agency............................................................................... 39
25.2 Internal division of roles and responsibilities.................................................................................. 39
25.3 Internal arrangements between beneficiaries — Consortium agreement.........................................40
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — SANCTIONS
— DAMAGES — SUSPENSION — TERMINATION — FORCE MAJEURE ............................... 40
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY —
SANCTIONS .............................................................................................................................................40
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS.............................................................................. 40
26.1 Conditions......................................................................................................................................... 40
26.2 Ineligible costs to be rejected — Calculation — Procedure............................................................40
26.3 Effects............................................................................................................................................... 41
ARTICLE 27 — REDUCTION OF THE GRANT......................................................................................... 41
27.1 Conditions......................................................................................................................................... 41
27.2 Amount to be reduced — Calculation — Procedure.......................................................................41
27.3 Effects............................................................................................................................................... 42
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS............................................................................... 42
28.1 Amount to be recovered — Calculation — Procedure....................................................................42
ARTICLE 29 — ADMINISTRATIVE SANCTIONS..................................................................................... 44
SECTION 2 LIABILITY FOR DAMAGES ........................................................................................................ 44
ARTICLE 30 — LIABILITY FOR DAMAGES.............................................................................................44
30.1 Liability of the Agency.................................................................................................................... 44
30.2 Liability of the beneficiaries............................................................................................................ 45
SECTION 3 SUSPENSION AND TERMINATION ............................................................................................45
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE....................................................................... 45
31.1 Conditions......................................................................................................................................... 45
31.2 Procedure.......................................................................................................................................... 45
ARTICLE 32 — SUSPENSION OF PAYMENTS.......................................................................................... 45
32.1 Conditions......................................................................................................................................... 45
32.2 Procedure.......................................................................................................................................... 46
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION................................................... 46
7
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
33.1 Suspension of the action implementation, by the beneficiaries....................................................... 46
33.2 Suspension of the action implementation, by the Agency...............................................................47
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION OF ONE OR
MORE BENEFICIARIES..............................................................................................................48
34.1 Termination of the Agreement, by the beneficiaries........................................................................48
34.2 Termination of the participation of one or more beneficiaries, by the beneficiaries........................49
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by the
Agency................................................................................................................................................. 50
SECTION 4 FORCE MAJEURE ..........................................................................................................................52
ARTICLE 35 — FORCE MAJEURE.............................................................................................................. 52
CHAPTER 7 FINAL PROVISIONS .......................................................................................................................... 53
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES...............................................................53
36.1 Form and means of communication.................................................................................................53
36.2 Date of communication.................................................................................................................... 54
36.3 Addresses for communication.......................................................................................................... 54
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT.....................................................................54
37.1 Precedence of the Terms and Conditions over the Annexes............................................................54
37.2 Privileges and immunities................................................................................................................ 55
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES........................................... 55
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT......................................................................... 55
39.1 Conditions......................................................................................................................................... 55
39.2 Procedure.......................................................................................................................................... 55
ARTICLE 40 — ACCESSION TO THE AGREEMENT............................................................................... 56
40.1 Accession of the beneficiaries mentioned in the preamble..............................................................56
40.2 Addition of new beneficiaries.......................................................................................................... 56
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES.............................................. 56
41.1 Applicable law..................................................................................................................................56
41.2 Dispute settlement............................................................................................................................ 56
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT................................................................ 57
8
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
CHAPTER 1 GENERAL
ARTICLE 1 — SUBJECT OF THE AGREEMENT
This Agreement sets out the rights and obligations and the terms and conditions applicable to the grant
awarded to the beneficiaries for implementing the action set out in Chapter 2.
CHAPTER 2 ACTION
ARTICLE 2 — ACTION TO BE IMPLEMENTED
The grant is awarded for the action entitled ‘Strengthened International HeAlth Regulations and
Preparedness in the EU - Joint Action — SHARP JA’ (‘action’), as described in Annex 1.
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION
The duration of the action will be 36 months as of 01/04/2019 (‘starting date of the action’).
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS
4.1 Estimated budget
The ‘estimated budget’ for the action is set out in Annex 2.
It contains the estimated eligible costs and the forms of costs, broken down by beneficiary (and
affiliated entity) and budget category (see Articles 5, 6 and 11).
4.2 Budget transfers
The estimated budget breakdown indicated in Annex 2 may be adjusted — without an amendment
(see Article 39) — by transfers of amounts between beneficiaries, budget categories and/or forms of
costs set out in Annex 2, if the action is implemented as described in Annex 1.
However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1,
unless such additional subcontracts are approved by an amendment or in accordance with Article 10.
CHAPTER 3 GRANT
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATE AND
FORMS OF COSTS
5.1 Maximum grant amount
The ‘maximum grant amount’ is EUR 7,900,000.00 (seven million nine hundred thousand EURO).
5.2 Form of grant, reimbursement rate and forms of costs
9
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
The grant reimburses 80% of the action's eligible costs (see Article 6) (‘reimbursement of eligible
costs grant’) (see Annex 2).
The estimated eligible costs of the action are EUR 9,875,000.00 (nine million eight hundred and
seventy five thousand EURO).
Eligible costs (see Article 6) must be declared under the following forms ('forms of costs' or 'costs
forms'):
(a) for direct personnel costs: as actually incurred costs (actual costs);
(b) for direct costs of subcontracting: as actually incurred costs (actual costs);
(c) for other direct costs: as actually incurred costs (actual costs);
(d) for indirect costs: on the basis of a flat-rate applied as set out in Article 6.2.D (‘flat-rate costs’);
5.3 Final grant amount — Calculation
The ‘final grant amount’ depends on the actual extent to which the action is implemented in
accordance with the Agreement’s terms and conditions.
This amount is calculated by the Agency — when the payment of the balance is made — in the
following steps:
Step 1 – Application of the reimbursement rate to the eligible costs
Step 2 – Limit to the maximum grant amount
Step 3 – Reduction due to the no-profit rule
Step 4 – Reduction due to substantial errors, irregularities or fraud or serious breach of obligations
5.3.1 Step 1 — Application of the reimbursement rate to the eligible costs
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate costs;
see Article 6) declared by the beneficiaries and affiliated entities (see Article 15) and approved by
the Agency (see Article 16).
5.3.2 Step 2 — Limit to the maximum grant amount
If the amount obtained following Step 1 is higher than the maximum grant amount set out in
Article 5.1, it will be limited to the latter.
5.3.3 Step 3 — Reduction due to the no-profit rule
The grant must not produce a profit.
‘Profit’ means the surplus of the amount obtained following Steps 1 and 2 plus the action’s total
receipts, over the action’s total eligible costs.
The ‘action’s total eligible costs’ are the consolidated total eligible costs approved by the Agency.
10
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
The ‘action’s total receipts’ are the consolidated total receipts generated during its duration (see
Article 3).
The following are considered receipts:
(a) income generated by the action;
(b) financial contributions given by third parties to the beneficiary or to an affiliated entity
specifically to be used for costs that are eligible under the action.
The following are however not considered receipts:
(a) financial contributions by third parties, if they may be used to cover costs other than the eligible
costs (see Article 6);
(b) financial contributions by third parties with no obligation to repay any amount unused at the
end of the period set out in Article 3.
If there is a profit, it will be deducted in proportion to the final rate of reimbursement of the eligible
actual costs approved by the Agency (as compared to the amount calculated following Steps 1 and 2).
5.3.4 Step 4 — Reduction due to substantial errors, irregularities or fraud or serious breach
of obligations
If the grant is reduced (see Article 27), the Agency will calculate the reduced grant amount by
deducting the amount of the reduction (calculated in proportion to the seriousness of the errors,
irregularities or fraud or breach of obligations, in accordance with Article 27.2) from the maximum
grant amount set out in Article 5.1.
The final grant amount will be the lower of the following two:
- the amount obtained following Steps 1 to 3 or
- the reduced grant amount following Step 4.
5.4 Revised final grant amount — Calculation
If — after the payment of the balance (in particular, after checks, reviews, audits or investigations;
see Article 17) — the Agency rejects costs (see Article 26) or reduces the grant (see Article 27), it
will calculate the ‘revised final grant amount’ for the action or for the beneficiary concerned.
This amount is calculated by the Agency on the basis of the findings, as follows:
- in case of rejection of costs: by applying the reimbursement rate to the revised eligible costs
approved by the Agency for the beneficiary concerned;
- in case of reduction of the grant: by deducting the amount of the reduction (calculated in
proportion to the seriousness of the errors, irregularities or fraud or breach of obligations, in
accordance with Article 27.2) from the maximum grant amount set out in Article 5.1 or from the
maximum EU contribution indicated for the beneficiary in the estimated budget (see Annex 2).
In case of rejection of costs and reduction of the grant, the revised final grant amount will be the
lower of the two amounts above.
11
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS
6.1 General conditions for costs to be eligible
‘Eligible costs’ are costs that meet the following criteria:
(a) for actual costs:
(i) they must be actually incurred by the beneficiary;
(ii) they must be incurred in the period set out in Article 3, with the exception of costs relating
to the submission of the periodic report for the last reporting period and the final report
(see Article 15);
(iii) they must be indicated in the estimated budget set out in Annex 2;
(iv) they must be incurred in connection with the action as described in Annex 1 and necessary
for its implementation;
(v) they must be identifiable and verifiable, in particular recorded in the beneficiary’s accounts
in accordance with the accounting standards applicable in the country where the beneficiary
is established and with the beneficiary’s usual cost accounting practices;
(vi) they must comply with the applicable national law on taxes, labour and social security, and
(vii) they must be reasonable, justified and must comply with the principle of sound financial
management, in particular regarding economy and efficiency;
(b) for unit costs: not applicable;
(c) for flat-rate costs:
(i) they must be calculated by applying the flat-rate set out in Annex 2, and
(ii) the costs (actual costs) to which the flat-rate is applied must comply with the conditions for
eligibility set out in this Article.
(d) for lump sum costs: not applicable;
6.2 Specific conditions for costs to be eligible
Costs are eligible if they comply with the general conditions (see above) and the specific conditions
set out below, for each of the following budget categories:
A. direct personnel costs;
B. direct costs of subcontracting;
C. other direct costs;
D. indirect costs;
‘Direct costs’ are costs that are directly linked to the action implementation and can therefore be
attributed to it directly. They must not include any indirect costs (see Point D below).
12
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
‘Indirect costs’ are costs that are not directly linked to the action implementation and therefore cannot
be attributed directly to it.
A. Direct personnel costs
Types of eligible personnel costs
A.1 Personnel costs are eligible if they are related to personnel working for the beneficiary under an
employment contract (or equivalent appointing act) and assigned to the action (‘costs for employees
(or equivalent)’). They must be limited to salaries, social security contributions, taxes and other
costs included in the remuneration, if they arise from national law or the employment contract (or
equivalent appointing act).
They may also include additional remuneration for personnel assigned to the action (including
payments on the basis of supplementary contracts regardless of their nature), if:
(a) it is part of the beneficiary’s usual remuneration practices and is paid in a consistent manner
whenever the same kind of work or expertise is required;
(b) the criteria used to calculate the supplementary payments are objective and generally applied
by the beneficiary, regardless of the source of funding used.
A.2 The costs for natural persons working under a direct contract with the beneficiary other than
an employment contract or seconded by a third party against payment are eligible personnel costs,
if:
(a) the person works under the beneficiary’s instructions and, unless otherwise agreed with the
beneficiary, on the beneficiary’s premises;
(b) the result of the work carried out belongs to the beneficiary, and
(c) the costs are not significantly different from those for personnel performing similar tasks under
an employment contract with the beneficiary.
Calculation
Personnel costs must be calculated by the beneficiaries as follows:
- for persons working exclusively on the action:
{monthly rate for the person
multiplied by
number of actual months worked on the action}.
The months declared for these persons may not be declared for any other EU or Euratom grant.
The ‘monthly rate’ is calculated as follows:
{annual personnel costs for the person
divided by
12}
13
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
using the personnel costs for each full financial year covered by the reporting period concerned.
If a financial year is not closed at the end of the reporting period, the beneficiaries must use the
monthly rate of the last closed financial year available.
- for all other persons:
{daily rate for the person
multiplied by
number of actual days worked on the action (rounded up or down to the nearest half-day)}.
The number of actual days declared for a person must be identifiable and verifiable (see
Article 13).
The total number of days declared in EU or Euratom grants, for a person for a year, cannot be
higher than the annual productive days used for the calculations of the daily rate. Therefore,
the maximum number of days that can be declared for the grant are:
{number of annual productive days for the year (see below)
minus
total number of days declared by the beneficiary, for that person for that year, for other EU or Euratom
grants}.
The ‘daily rate’ is calculated as follows:
{annual personnel costs for the person
divided by
number of individual annual productive days}
using the personnel costs and the number of annual productive days for each full financial
year covered by the reporting period concerned. If a financial year is not closed at the end of
the reporting period, the beneficiaries must use the daily rate of the last closed financial year
available.
The ‘number of individual annual productive days’ is the total actual days worked by the person
in the year. It may not include holidays and other absences (such as sick leave, maternity leave,
special leave, etc). However, it may include overtime and time spent in meetings, trainings and
other similar activities.
B. Direct costs of subcontracting (including related duties, taxes and charges, such as non-
deductible value added tax (VAT) paid by beneficiaries that are not public bodies acting as public
authority) are eligible if the conditions in Article 10.1.1 are met.
C. Other direct costs
C.1 Travel costs and related subsistence allowances (including related duties, taxes and charges,
such as non-deductible value added tax (VAT) paid by beneficiaries that are not public bodies acting
as public authority) are eligible if they are in line with the beneficiary’s usual practices on travel.
C.2 The depreciation costs of equipment, infrastructure or other assets (new or second-hand)
as recorded in the beneficiary’s accounts are eligible, if they were purchased in accordance
14
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
with Article 9.1.1 and written off in accordance with international accounting standards and the
beneficiary’s usual accounting practices.
The costs of renting or leasing equipment, infrastructure or other assets (including related duties,
taxes and charges, such as non-deductible value added tax (VAT) paid by beneficiaries that are not
public bodies acting as public authority) are also eligible, if they do not exceed the depreciation costs
of similar equipment, infrastructure or assets and do not include any financing fees.
The only portion of the costs that will be taken into account is that which corresponds to the duration
of the action and rate of actual use for the purposes of the action.
C.3 Costs of other goods and services (including related duties, taxes and charges, such as non-
deductible value added tax (VAT) paid by beneficiaries that are not public bodies acting as public
authority) are eligible, if they are purchased specifically for the action and in accordance with
Article 9.1.1.
Such goods and services include, for instance, consumables and supplies, dissemination, protection
of results, certificates on the financial statements (if they are required by the Agreement), translations
and publications.
D. Indirect costs
Indirect costs are eligible if they are declared on the basis of the flat-rate of 7% of the eligible direct
costs (see Article 5.2 and Points A to C above).
Beneficiaries receiving an operating grant1 financed by the EU or Euratom budget cannot declare
indirect costs for the period covered by the operating grant.
6.3 Conditions for costs of affiliated entities to be eligible
Costs incurred by affiliated entities are eligible if they fulfil — mutatis mutandis — the general and
specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 11.1.1.
6.4 Ineligible costs
‘Ineligible costs’ are:
(a) costs that do not comply with the conditions set out above (Article 6.1 to 6.3), in particular:
(i) costs related to return on capital;
(ii) debt and debt service charges;
(iii) provisions for future losses or debts;
(iv) interest owed;
1 For the definition, see Article 121(1)(b) of Regulation (EU, Euratom) No 966/2012 of the European Parliament and
of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing
Council Regulation (EC, Euratom) No 1605/2002 (OJ L 218, 26.10.2012, p.1) (‘Financial Regulation No 966/2012’):
‘operating grant’ means direct financial contribution, by way of donation, from the budget in order to finance the
functioning of a body which pursues an aim of general EU interest or has an objective forming part of and supporting
an EU policy.
15
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(v) doubtful debts;
(vi) currency exchange losses;
(vii) bank costs charged by the beneficiary’s bank for transfers from the Agency;
(viii) excessive or reckless expenditure;
(ix) deductible VAT;
(x) costs incurred during suspension of the implementation of the action (see Article 33);
(xi) in-kind contributions provided by third parties;
(b) costs declared under another EU or Euratom grant (including grants awarded by a Member
State and financed by the EU or Euratom budget and grants awarded by bodies other than the
Agency for the purpose of implementing the EU or Euratom budget); in particular, indirect
costs if the beneficiary is already receiving an operating grant financed by the EU or Euratom
budget in the same period;
(c) costs for staff of a national (or local) administration, for activities that are part of the
administration’s normal activities (i.e. not undertaken only because of the grant);
(d) costs (especially travel and subsistence costs) for staff or representatives of EU institutions,
bodies or agencies.
6.5 Consequences of declaration of ineligible costs
Declared costs that are ineligible will be rejected (see Article 26).
This may also lead to any of the other measures described in Chapter 6.
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE
ACTION
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION
7.1 General obligation to properly implement the action
The beneficiaries must implement the action as described in Annex 1 and in compliance with the
provisions of the Agreement and all legal obligations under applicable EU, international and national
law.
7.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
16
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES
INVOLVED IN THE ACTION
The beneficiaries must have the appropriate resources to implement the action.
If it is necessary to implement the action, the beneficiaries may:
- purchase goods, works and services (see Article 9);
- call upon subcontractors to implement action tasks described in Annex 1 (see Article 10);
- call upon affiliated entities to implement action tasks described in Annex 1 (see Article 11).
In these cases, the beneficiaries retain sole responsibility towards the Agency and the other
beneficiaries for implementing the action.
ARTICLE 8a — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT
RECEIVING EU FUNDING
Not applicable
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES
9.1 Rules for purchasing goods, works or services
9.1.1 If necessary to implement the action, the beneficiaries may purchase goods, works or services.
The beneficiaries must make such purchases ensuring the best value for money or, if appropriate, the
lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their contractors.
9.1.2 Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC2 (or
2014/24/EU3) or ‘contracting entities’ within the meaning of Directive 2004/17/EC4 (or 2014/25/EU5)
must comply with the applicable national law on public procurement.
9.2 Consequences of non-compliance
2 Directive 2004/18/EC of the European Parliament and of the Council of 31 March 2004 on the coordination of
procedures for the award of public work contracts, public supply contracts and public service contracts (OJ L 134,
30.04.2004, p. 114).
3 Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and
repealing Directive 2004/18/EC (OJ L 94, 28.3.2014, p. 65).
4 Directive 2004/17/EC of the European Parliament and of the Council of 31 March 2004 coordinating the procurement
procedures of entities operating in the water, energy, transport and postal services sectors (OJ L 134, 30.04.2004, p. 1).
5 Directive 2014/25/EU of the European Parliament and of the Council of 26 February 2014 on procurement by entities
operating in the water, energy, transport and postal services sectors and repealing Directive 2004/17/EC (OJ L 94,
28.3.2014, p. 243).
17
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
If a beneficiary breaches any of its obligations under Article 9.1.1, the costs related to the contract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
If a beneficiary breaches any of its obligations under Article 9.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS
10.1 Rules for subcontracting action tasks
10.1.1 If necessary to implement the action, the beneficiaries may award subcontracts covering the
implementation of certain action tasks described in Annex 1.
Subcontracting may cover only a limited part of the action.
The beneficiaries must award the subcontracts ensuring the best value for money or, if appropriate,
the lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The tasks to be implemented and the estimated cost for each subcontract must be set out in Annex
1 and the total estimated costs of subcontracting per beneficiary must be set out in Annex 2. The
Agency may however approve subcontracts not set out in Annex 1 and 2 without amendment (see
Article 39), if:
- they are specifically justified in the periodic technical report and
- they do not entail changes to the Agreement which would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants.
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their subcontractors.
10.1.2 The beneficiaries must ensure that their obligations under Articles 20, 21, 22 and 30 also apply
to the subcontractors.
Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC (or
2014/24/EU) or ‘contracting entities’ within the meaning of Directive 2004/17/EC (or 2014/25/EU)
must comply with the applicable national law on public procurement.
10.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 10.1.1, the costs related to the subcontract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
If a beneficiary breaches any of its obligations under Article 10.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES
18
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
11.1 Rules for calling upon affiliated entities to implement part of the action
11.1.1 The following 'affiliated entities'6 may implement the action tasks attributed to them in
Annex 1:
- RUOKAVIRASTO (FFA), affiliated or linked to THL
- KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET (UKF), affiliated
or linked to RKI
- FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER
TIERGESUNDHEIT (FLI), affiliated or linked to RKI
- BUNDESMINISTERIUM DER VERTEIDIGUNG (BwIM), affiliated or linked to RKI
- PHILIPPS UNIVERSITAET MARBURG (UMR), affiliated or linked to RKI
- BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNITM), affiliated or linked to
RKI
- Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata (IZSPB), affiliated or linked
to INMI
- ISTITUTO SUPERIORE DI SANITA (ISS), affiliated or linked to INMI
- MINISTERO DELLA SALUTE (MoH), affiliated or linked to INMI
- ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL'EMILIA
ROMAGNA BRUNO UBERTINI (IZLER), affiliated or linked to INMI
- Vienna Hospital Association /Kaiser Franz Josef Hospital / Department of Medicine IV/ Vienna
(VHA), affiliated or linked to BMASGK
- OSTERREICHISCHE AGENTUR FUR GESUNDHEIT UND ERNAHRUNGSSICHERHEIT
GMBH (AGES), affiliated or linked to BMASGK
- MINISTARSTVO ZDRAVSTVA REPUBLIKE HRVATSKE (MH-BSI), affiliated or linked to
CIPH
- KLINIKA ZA INFEKTIVNE BOLESTI DR. FRAN MIHALJEVIC (UHID), affiliated or linked
to CIPH
- TERVISEAMET (HB), affiliated or linked to MSAE
- AGENCE NATIONALE DE SANTE PUBLIQUE (SPF), affiliated or linked to MOH-FR
6 For the definition, see Article 122 of the Financial Regulation (EU, Euratom) No 966/2012: entities affiliated to the
beneficiary are:
(a) entities that form a ‘sole beneficiary’ (i.e. where an entity is formed of several entities that satisfy the criteria for
being awarded a grant, including where the entity is specifically established for the purpose of implementing
an action to be financed by a grant);
(b) entities that satisfy the eligibility criteria and that do not fall within one of the situations referred to in Article
131(4) and that have a link with the beneficiary, in particular a legal or capital link, which is neither limited to
the action nor established for the sole purpose of its implementation.
19
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
- Fondation de Coopération Scientifique Méditerranée Infection (IHUMI), affiliated or linked to
MOH-FR
- MINISTERE DE LA DEFENSE (MOD-FR), affiliated or linked to MOH-FR
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),
affiliated or linked to MOH-FR
- PANEPISTIMIO THESSALIAS (UoTHESSALY), affiliated or linked to HCDCP(KEELPNO)
- MINISTRY OF HEALTH (EKEPY/NHOC), affiliated or linked to HCDCP(KEELPNO)
- ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON (NKUA), affiliated or linked
to HCDCP(KEELPNO)
- ARISTOTELIO PANEPISTIMIO THESSALONIKIS (AUTH), affiliated or linked to
HCDCP(KEELPNO)
- NACIONALINE VISUOMENES SVEIKATOS PRIEZIUROS LABORATORIJA (NVSPL),
affiliated or linked to MOHLT
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (Erasmus MC), affiliated
or linked to RIVM
- FOLKEHELSEINSTITUTTET (FHI), affiliated or linked to HD
- PANSTWOWY INSTYTUT WETERYNARYJNY - PANSTWOWY INSTYTUT
BADAWCZY (NVRI), affiliated or linked to NIZP-PZH
- INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE (INSA), affiliated or linked to
MS
- UNIVERZA V LJUBLJANI (UL-MF), affiliated or linked to NIJZ
- SERVICIO MADRILENO DE SALUD (SERMAS), affiliated or linked to ISCIII
- FUNDACION VASCA DE INNOVACION E INVESTIGACION SANITARIAS (BC),
affiliated or linked to ISCIII
- FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL
UNIVERSIATRIO LA PAZ (FIBHULP), affiliated or linked to ISCIII
- Servicio Vasco de Salud Osakidetza (OSAKIDETZA), affiliated or linked to ISCIII
- PUBLIC HEALTH WALES NATIONAL HEALTH SERVICE TRUST (PHW), affiliated or
linked to DH
- ROYAL FREE LONDON NHS FOUNDATION TRUST (RFL), affiliated or linked to DH
The affiliated entities may declare as eligible the costs they incur for implementing the action tasks
in accordance with Article 6.3.
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
20
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their affiliated entities.
11.1.2 The beneficiaries must ensure that their obligations under Articles 13, 15, 20, 21 and 22 also
apply to their affiliated entities.
11.2 Consequences of non-compliance
If any obligation under Article 11.1.1 is breached, the costs of the affiliated entity will be ineligible
(see Article 6) and will be rejected (see Article 26).
If any obligation under Article 11.1.2 is breached, the grant may be reduced (see Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 11a — FINANCIAL SUPPORT TO THIRD PARTIES
Not applicable
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT
ADMINISTRATION
ARTICLE 12 — GENERAL OBLIGATION TO INFORM
12.1 General obligation to provide information upon request
The beneficiaries must provide — during implementation of the action or afterwards and in accordance
with Article 25.2 — any information requested in order to verify eligibility of the costs, proper
implementation of the action and compliance with any other obligation under the Agreement.
12.2 Obligation to keep information up to date and to inform about events and
circumstances likely to affect the Agreement
Each beneficiary must keep information stored in the Participant Portal Beneficiary Register (via
the electronic exchange system; see Article 36) up to date, in particular, its name, address, legal
representatives, legal form and organisation type.
Each beneficiary must immediately inform the coordinator — which must immediately inform the
Agency and the other beneficiaries — of any of the following:
(a) events which are likely to affect significantly or delay the implementation of the action or the
EU’s financial interests, in particular:
(i) changes in its legal, financial, technical, organisational or ownership situation or those
of its affiliated entities and
(ii) changes in the name, address, legal form, organisation type of its affiliated entities;
(b) circumstances affecting:
(i) the decision to award the grant or
21
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(ii) compliance with requirements under the Agreement.
12.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION
13.1 Obligation to keep records and other supporting documentation
The beneficiaries must — for a period of five years after the payment of the balance — keep records
and other supporting documentation, in order to prove the proper implementation of the action and
the costs they declare as eligible.
They must make them available upon request (see Article 12) or in the context of checks, reviews,
audits or investigations (see Article 17).
If there are on-going checks, reviews, audits, investigations, litigation or other pursuits of claims under
the Agreement (including the extension of findings; see Article 17), the beneficiaries must keep the
records and other supporting documentation until the end of these procedures.
The beneficiaries must keep the original documents. Digital and digitalised documents are considered
originals if they are authorised by the applicable national law. The Agency may accept non-original
documents if it considers that they offer a comparable level of assurance.
13.1.1 Records and other supporting documentation on the technical implementation
The beneficiaries must keep records and other supporting documentation on the technical
implementation of the action, in line with the accepted standards in the respective field.
13.1.2 Records and other documentation to support the costs declared
The beneficiaries must keep the records and documentation supporting the costs declared, in particular
the following:
(a) for actual costs: adequate records and other supporting documentation to prove the costs
declared, such as contracts, subcontracts, invoices and accounting records. In addition, the
beneficiaries’ usual cost accounting practices and internal control procedures must enable direct
reconciliation between the amounts declared, the amounts recorded in their accounts and the
amounts stated in the supporting documentation;
(b) for unit costs: not applicable;
(c) for flat-rate costs: adequate records and other supporting documentation to prove the eligibility
of the costs to which the flat-rate is applied. The beneficiaries do not need to identify the costs
covered or provide supporting documentation (such as accounting statements) to prove the
amount declared at a flat-rate;
22
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(d) for lump sum costs: not applicable;
In addition, for personnel costs (declared as actual costs), the beneficiaries must keep time records
for the number of days declared. The time records must be in writing and approved by the persons
working on the action and their supervisors, at least monthly. In the absence of reliable time records
of the days worked on the action, the Agency may accept alternative evidence supporting the number
of days declared, if it considers that it offers an adequate level of assurance.
As an exception, for persons working exclusively on the action, there is no need to keep time records,
if the beneficiary signs a declaration confirming that the persons concerned have worked exclusively
on the action.
For costs declared by affiliated entities (see Article 11), it is the beneficiary that must keep the originals
of the financial statements and the certificates on the financial statements of its affiliated entities.
13.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, costs insufficiently substantiated
will be ineligible (see Article 6) and will be rejected (see Article 26), and the grant may be reduced
(see Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 14 — SUBMISSION OF DELIVERABLES
14.1 Obligation to submit deliverables
The coordinator must submit the ‘deliverables’ identified in Annex 1, in accordance with the timing
and conditions set out in it.
14.2 Consequences of non-compliance
If the coordinator breaches any of its obligations under this Article, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 15 — REPORTING — PAYMENT REQUESTS
15.1 Obligation to submit reports
The coordinator must submit to the Agency (see Article 36) the technical and financial report(s) set
out in this Article. These reports include request(s) for payment and must be drawn up using the forms
and templates provided in the electronic exchange system (see Article 36).
15.2 Reporting periods
The action is divided into the following ‘reporting periods’:
- RP1: from month 1 to month 18
- RP2: from month 19 to month 36
15.2a Request(s) for further pre-financing payment(s)
23
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Not applicable
15.3 Periodic reports — Requests for interim payments
The coordinator must submit a periodic report within 60 days following the end of each reporting
period.
The periodic report must include the following:
(a) a ‘periodic technical report’ containing:
(i) an explanation of the work carried out by the beneficiaries;
(ii) an overview of the progress towards the objectives of the action, including milestones
and deliverables identified in Annex 1.
This report must include explanations justifying the differences between work expected
to be carried out in accordance with Annex 1 and that actually carried out;
(iii) a summary for publication by the Agency;
(iv) the answers to the ‘questionnaire’: covering issues related to the action implementation
and its impact;
(b) a ‘periodic financial report’ containing:
(i) an ‘individual financial statement’ (see Annex 4) from each beneficiary and from each
affiliated entity, for the reporting period concerned.
The individual financial statement must detail the eligible costs (actual costs and flat-rate
costs; see Article 6) for each budget category (see Annex 2).
The beneficiaries and affiliated entities must declare all eligible costs, even if — for
actual costs and flat-rate costs — they exceed the amounts indicated in the estimated
budget (see Annex 2). Amounts which are not declared in the individual financial
statement will not be taken into account by the Agency.
If an individual financial statement is not submitted for a reporting period, it may be
included in the periodic financial report for the next reporting period.
The individual financial statements of the last reporting period must also detail the
receipts of the action (see Article 5.3.3).
Each beneficiary and each affiliated entity must certify that:
- the information provided is full, reliable and true;
- the costs declared are eligible (see Article 6);
- the costs can be substantiated by adequate records and supporting documentation
(see Article 13) that will be produced upon request (see Article 12) or in the context
of checks, reviews, audits and investigations (see Article 17), and
24
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
- for the last reporting period: that all the receipts have been declared (see
Article 5.3.3);
(ii) an explanation of the use of resources and the information on subcontracting (see
Article 10) from each beneficiary and from each affiliated entity, for the reporting period
concerned;
(iii) not applicable;
(iv) a ‘periodic summary financial statement’, created automatically by the electronic
exchange system, consolidating the individual financial statements for the reporting
period concerned and including — except for the last reporting period — the request
for interim payment;
(v) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for
each beneficiary and for each affiliated entity, if:
- the (cumulative) amount of EU contribution it requests as reimbursement of actual
costs (and for which no certificate has yet been submitted) is EUR 325 000 or
more and
- the maximum EU contribution indicated, for that beneficiary or affiliated entity,
in the estimated budget (see Annex 2) as reimbursement of actual costs is
EUR 750 000 or more.
15.4 Final report — Request for payment of the balance
In addition to the periodic report for the last reporting period, the coordinator must submit the final
report within 60 days following the end of the last reporting period.
The final report must include the following:
(a) a ‘final technical report’ with a summary for publication containing:
(i) an overview of the results and their dissemination;
(ii) the conclusions on the action and
(iii) the impact of the action;
(b) a ‘final financial report’ containing a ‘final summary financial statement’, created
automatically by the electronic exchange system, consolidating the individual financial
statements for all reporting periods and including the request for payment of the balance.
15.5 Information on cumulative expenditure incurred
Not applicable
15.6 Currency for financial statements and conversion into euro
Financial statements must be drafted in euro.
25
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Beneficiaries and affiliated entities with accounting established in a currency other than the euro
must convert the costs recorded in their accounts into euro at the average of the daily exchange
rates published in the C series of the Official Journal of the European Union, calculated over the
corresponding reporting period.
If no daily euro exchange rate is published in the Official Journal of the European Union for the
currency in question, they must be converted at the average of the monthly accounting rates published
on the Commission’s website, calculated over the corresponding reporting period.
Beneficiaries and affiliated entities with accounting established in euro must convert costs incurred
in another currency into euro according to their usual accounting practices.
15.7 Language of reports
All report(s) (including financial statements) must be submitted in the language of the Agreement.
15.8 Consequences of non-compliance
If the report(s) submitted do not comply with this Article, the Agency may suspend the payment
deadline (see Article 31) and apply any of the other measures described in Chapter 6.
If the coordinator breaches its obligation to submit the report(s) and if it fails to comply with this
obligation within 30 days following a written reminder, the Agency may terminate the Agreement
(see Article 34) or apply any of the other measures described in Chapter 6.
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS
16.1 Payments to be made
The following payments will be made to the coordinator:
- a pre-financing payment;
- one or more interim payments, on the basis of the request(s) for interim payment (see
Article 15), and
- one payment of the balance, on the basis of the request for payment of the balance (see
Article 15).
16.2 Pre-financing payment — Amount
The aim of the pre-financing is to provide the beneficiaries with a float.
It remains the property of the EU until the payment of the balance.
The amount of the pre-financing payment will be EUR 3,950,000.00 (three million nine hundred and
fifty thousand EURO).
The Agency will — except if Article 32 applies — make the pre-financing payment to the coordinator
within 30 days, either from the entry into force of the Agreement (see Article 42) or from 10 days
before the starting date of the action (see Article 3) , whichever is the latest.
26
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
16.3 Interim payments — Amount — Calculation
Interim payments reimburse the eligible costs incurred for the implementation of the action during
the corresponding reporting periods.
The Agency will pay to the coordinator the amount due as interim payment within 60 days from
receiving the periodic report (see Article 15.3), except if Articles 31 or 32 apply.
Payment is subject to the approval of the periodic report. Its approval does not imply recognition of
compliance, authenticity, completeness or correctness of its content.
The amount due as interim payment is calculated by the Agency in the following steps:
Step 1 – Application of the reimbursement rate
Step 2 – Limit to 90% of the maximum grant amount
16.3.1 Step 1 — Application of the reimbursement rate
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate costs;
see Article 6) declared by the beneficiaries and the affiliated entities (see Article 15) and approved by
the Agency (see above) for the concerned reporting period.
16.3.2 Step 2 — Limit to 90% of the maximum grant amount
The total amount of pre-financing and interim payments must not exceed 90% of the maximum grant
amount set out in Article 5.1. The maximum amount for the interim payment will be calculated as
follows:
{90% of the maximum grant amount (see Article 5.1)
minus
{pre-financing and previous interim payments}}.
16.4 Payment of the balance — Amount — Calculation
The payment of the balance reimburses the remaining part of the eligible costs incurred by the
beneficiaries for the implementation of the action.
If the total amount of earlier payments is greater than the final grant amount (see Article 5.3), the
payment of the balance takes the form of a recovery (see Article 28).
If the total amount of earlier payments is lower than the final grant amount, the Agency will pay the
balance within 60 days from receiving the final report (see Article 15.4), except if Articles 31 or 32
apply.
Payment is subject to the approval of the final report. Its approval does not imply recognition of
compliance, authenticity, completeness or correctness of its content.
The amount due as the balance is calculated by the Agency by deducting the total amount of pre-
financing and interim payments (if any) already made, from the final grant amount determined in
accordance with Article 5.3:
{final grant amount (see Article 5.3)
27
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
minus
{pre-financing and interim payments (if any) made}}.
If the balance is positive, it will be paid to the coordinator.
The amount to be paid may however be offset — without the beneficiaries’ consent — against any
other amount owed by a beneficiary to the Agency, the Commission or another executive agency
(under the EU or Euratom budget), up to the maximum EU contribution indicated, for that beneficiary,
in the estimated budget (see Annex 2).
If the balance is negative, it will be recovered from the coordinator (see Article 28).
16.5 Notification of amounts due
When making payments, the Agency will formally notify to the coordinator the amount due,
specifying that it concerns an interim payment or the payment of the balance.
For the payment of the balance, the notification will also specify the final grant amount.
In the case of reduction of the grant or recovery of undue amounts, the notification will be preceded
by the contradictory procedure set out in Articles 27 and 28.
16.6 Currency for payments
The Agency will make all payments in euro.
16.7 Payments to the coordinator — Distribution to the beneficiaries
Payments will be made to the coordinator.
Payments to the coordinator will discharge the Agency from its payment obligation.
The coordinator must distribute the payments between the beneficiaries without unjustified delay.
Pre-financing may however be distributed only:
(a) if 90% of the beneficiaries have acceded to the Agreement (see Article 40) and
(b) to beneficiaries that have acceded to the Agreement (see Article 40).
16.8 Bank account for payments
All payments will be made to the following bank account:
Name of bank: POHJOLA PANKKI OYJ (POHJOLA BANK PLC)
Full name of the account holder: TERVEYDEN JA HYVINVOINNIN LAITOS THL
NATIONAL INSTITUTE HEALTH WELFARE
Full account number (including bank codes):
IBAN code: FI8450000120250682
16.9 Costs of payment transfers
28
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
The cost of the payment transfers is borne as follows:
- the Agency bears the cost of transfers charged by its bank;
- the beneficiary bears the cost of transfers charged by its bank;
- the party causing a repetition of a transfer bears all costs of the repeated transfer.
16.10 Date of payment
Payments by the Agency are considered to have been carried out on the date when they are debited
to its account.
16.11 Consequences of non-compliance
16.11.1 If the Agency does not pay within the payment deadlines (see above), the beneficiaries are
entitled to late-payment interest at the rate applied by the European Central Bank (ECB) for its main
refinancing operations in euros (‘reference rate’), plus three and a half points. The reference rate is
the rate in force on the first day of the month in which the payment deadline expires, as published in
the C series of the Official Journal of the European Union.
If the late-payment interest is lower than or equal to EUR 200, it will be paid to the coordinator only
upon request submitted within two months of receiving the late payment.
Late-payment interest is not due if all beneficiaries are EU Member States (including regional and
local government authorities or other public bodies acting on behalf of a Member State for the purpose
of this Agreement).
Suspension of the payment deadline or payments (see Articles 31 and 32) will not be considered as
late payment.
Late-payment interest covers the period running from the day following the due date for payment (see
above), up to and including the date of payment.
Late-payment interest is not considered for the purposes of calculating the final grant amount.
16.11.2 If the coordinator breaches any of its obligations under this Article, the grant may be reduced
(see Article 27) and the Agreement or the participation of the coordinator may be terminated (see
Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION
OF FINDINGS
17.1 Checks, reviews and audits by the Agency and the Commission
17.1.1 Right to carry out checks
The Agency or the Commission will — during the implementation of the action or afterwards — check
the proper implementation of the action and compliance with the obligations under the Agreement,
including assessing deliverables and reports.
29
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
For this purpose, the Agency or the Commission may be assisted by external persons or bodies.
The Agency or the Commission may also request additional information in accordance with Article 12.
The Agency or the Commission may request beneficiaries to provide such information to it directly.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
17.1.2 Right to carry out reviews
The Agency or the Commission may — during the implementation of the action or afterwards —
carry out reviews on the proper implementation of the action (including assessment of deliverables
and reports) and compliance with the obligations under the Agreement.
Reviews may be started up to five years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the review is carried out on a third party (see Articles 9 to 11a), the beneficiary concerned must
inform the third party.
The Agency or the Commission may carry out reviews directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information and data in addition to deliverables and reports already submitted (including information
on the use of resources). The Agency or the Commission may request beneficiaries to provide such
information to it directly.
The coordinator or beneficiary concerned may be requested to participate in meetings, including with
external experts.
For on-the-spot reviews, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the review findings, a ‘review report’ will be drawn up.
The Agency or the Commission will formally notify the review report to the coordinator or beneficiary
concerned, which has 30 days to formally notify observations (‘contradictory review procedure’).
Reviews (including review reports) are in the language of the Agreement.
17.1.3 Right to carry out audits
The Agency or the Commission may — during the implementation of the action or afterwards —
carry out audits on the proper implementation of the action and compliance with the obligations under
the Agreement.
30
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Audits may be started up to five years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the audit is carried out on a third party (see Articles 9 to 11a), the beneficiary concerned must inform
the third party.
The Agency or the Commission may carry out audits directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information (including complete accounts, individual salary statements or other personal data) to
verify compliance with the Agreement. The Agency or the Commission may request beneficiaries to
provide such information to it directly.
For on-the-spot audits, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the audit findings, a ‘draft audit report’ will be drawn up.
The Agency or the Commission will formally notify the draft audit report to the coordinator or
beneficiary concerned, which has 30 days to formally notify observations (‘contradictory audit
procedure’). This period may be extended by the Agency or the Commission in justified cases.
The ‘final audit report’ will take into account observations by the coordinator or beneficiary
concerned. The report will be formally notified to it.
Audits (including audit reports) are in the language of the Agreement.
The Agency or the Commission may also access the beneficiaries’ statutory records for the periodical
assessment of flat-rate amounts.
17.2 Investigations by the European Anti-Fraud Office (OLAF)
Under Regulations No 883/20137 and No 2185/968 (and in accordance with their provisions and
procedures), the European Anti-Fraud Office (OLAF) may — at any moment during implementation
of the action or afterwards — carry out investigations, including on-the-spot checks and inspections,
to establish whether there has been fraud, corruption or any other illegal activity affecting the financial
interests of the EU.
7 Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013
concerning investigations conducted by the European Anti-Fraud Office (OLAF) and repealing Regulation (EC)
No 1073/1999 of the European Parliament and of the Council and Council Regulation (Euratom) No 1074/1999 (OJ
L 232, 18.09.2013, p. 1).
8 Council Regulation (Euratom, EC) No 2185/1996 of 11 November 1996 concerning on-the-spot checks and inspections
carried out by the Commission in order to protect the European Communities' financial interests against fraud and other
irregularities (OJ L 292, 15.11.1996, p. 2).
31
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
17.3 Checks and audits by the European Court of Auditors (ECA)
Under Article 287 of the Treaty on the Functioning of the European Union (TFEU) and Article 161 of
the Financial Regulation No 966/20129, the European Court of Auditors (ECA) may — at any moment
during implementation of the action or afterwards — carry out audits.
The ECA has the right of access for the purpose of checks and audits.
17.4 Checks, reviews, audits and investigations for international organisations
Not applicable
17.5 Consequences of findings in checks, reviews, audits and investigations — Extension of
findings
17.5.1 Findings in this grant
Findings in checks, reviews, audits or investigations carried out in the context of this grant may lead
to the rejection of ineligible costs (see Article 26), reduction of the grant (see Article 27), recovery of
undue amounts (see Article 28) or to any of the other measures described in Chapter 6.
Rejection of costs or reduction of the grant after the payment of the balance will lead to a revised final
grant amount (see Article 5.4).
Findings in checks, reviews, audits or investigations may lead to a request for amendment for the
modification of Annex 1 (see Article 39).
Checks, reviews, audits or investigations that find systemic or recurrent errors, irregularities, fraud or
breach of obligations may also lead to consequences in other EU or Euratom grants awarded under
similar conditions (‘extension of findings from this grant to other grants’).
Moreover, findings arising from an OLAF investigation may lead to criminal prosecution under
national law.
17.5.2 Findings in other grants
The Agency or the Commission may extend findings from other grants to this grant (‘extension of
findings from other grants to this grant’), if:
(a) the beneficiary concerned is found, in other EU or Euratom grants awarded under similar
conditions, to have committed systemic or recurrent errors, irregularities, fraud or breach of
obligations that have a material impact on this grant and
(b) those findings are formally notified to the beneficiary concerned — together with the list of
grants affected by the findings — no later than five years after the payment of the balance
of this grant.
The extension of findings may lead to the rejection of costs (see Article 26), reduction of the grant
9 Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the
financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No
1605/2002 (OJ L 298, 26.10.2012, p. 1).
32
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(see Article 27), recovery of undue amounts (see Article 28), suspension of payments (see Article 32),
suspension of the action implementation (see Article 33) or termination (see Article 34).
17.5.3 Procedure
The Agency or the Commission will formally notify the beneficiary concerned the systemic or
recurrent errors and its intention to extend these audit findings, together with the list of grants affected.
17.5.3.1 If the findings concern eligibility of costs: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings;
(b) the request to submit revised financial statements for all grants affected;
(c) the correction rate for extrapolation established by the Agency or the Commission on
the basis of the systemic or recurrent errors, to calculate the amounts to be rejected, if the
beneficiary concerned:
(i) considers that the submission of revised financial statements is not possible or practicable
or
(ii) does not submit revised financial statements.
The beneficiary concerned has 90 days from receiving notification to submit observations, revised
financial statements or to propose a duly substantiated alternative correction method. This period
may be extended by the Agency or the Commission in justified cases.
The Agency or the Commission may then start a rejection procedure in accordance with Article 26,
either on the basis of the revised financial statements, the alternative method or the correction rate
announced.
17.5.3.2 If the findings concern substantial errors, irregularities or fraud or serious breach of
obligations: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings and
(b) the flat-rate the Agency or the Commission intends to apply according to the principle of
proportionality.
The beneficiary concerned has 90 days from receiving notification to submit observations or to
propose a duly substantiated alternative flat-rate.
The Agency or the Commission may then start a reduction procedure in accordance with Article 27,
either on the basis of the alternative flat-rate or the flat-rate announced.
17.6 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, any insufficiently substantiated costs
will be ineligible (see Article 6) and will be rejected (see Article 26).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION
33
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
18.1 Right to evaluate the impact of the action
The Agency or the Commission may carry out interim and final evaluations of the impact of the action
measured against the objective of the EU programme.
Evaluations may be started during implementation of the action and up to five years after the
payment of the balance. The evaluation is considered to start on the date of the formal notification
to the coordinator or beneficiaries.
The Agency or the Commission may make these evaluations directly (using its own staff) or indirectly
(using external bodies or persons it has authorised to do so).
The coordinator or beneficiaries must provide any information relevant to evaluate the impact of the
action, including information in electronic format.
18.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the Agency may apply the measures
described in Chapter 6.
SECTION 3 OTHER RIGHTS AND OBLIGATIONS
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS
(INCLUDING INTELLECTUAL AND INDUSTRIAL PROPERTY
RIGHTS)
19.1 Pre-existing rights and access rights to pre-existing rights
Where industrial and intellectual property rights (including rights of third parties) exist prior to the
Agreement, the beneficiaries must establish a list of these pre-existing industrial and intellectual
property rights, specifying the owner and any persons that have a right of use.
The coordinator must — before starting the action — submit this list to the Agency.
Each beneficiary must give the other beneficiaries and their affiliated entities access to any pre-existing
industrial and intellectual property rights needed for the implementation of the action and compliance
with the obligations under the Agreement.
19.2 Ownership of results and rights of use
The results of the action (including the reports and other documents relating to it) are owned by the
beneficiaries.
The beneficiaries must give the Agency and the Commission the right to use the results for their
communication activities under Article 22.
19.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
34
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 20 — CONFLICT OF INTERESTS
20.1 Obligation to avoid a conflict of interests
The beneficiaries must take all measures to prevent any situation where the impartial and objective
implementation of the action is compromised for reasons involving economic interest, political or
national affinity, family or emotional ties or any other shared interest (‘conflict of interests’).
They must formally notify to the Agency without delay any situation constituting or likely to lead to
a conflict of interests and immediately take all the necessary steps to rectify this situation.
The Agency may verify that the measures taken are appropriate and may require additional measures
to be taken by a specified deadline.
20.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27) and the Agreement or participation of the beneficiary may be terminated (see Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 21 — CONFIDENTIALITY
21.1 General obligation to maintain confidentiality
During implementation of the action and for five years after the payment of the balance, the parties
must keep confidential any data, documents or other material (in any form) that is identified as
confidential at the time it is disclosed (‘confidential information’).
They may use confidential information to implement the Agreement.
The confidentiality obligations no longer apply if:
(a) the disclosing party agrees to release the other party;
(b) the information becomes generally and publicly available, without breaching any
confidentiality obligation;
(c) the disclosure of the confidential information is required by EU or national law.
21.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING
35
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
22.1 Communication activities by the beneficiaries
22.1.1 General obligation to promote the action and its results
The beneficiaries must promote the action and its results.
22.1.2 Information on EU funding — Obligation and right to use the EU emblem
Unless the Agency requests or agrees otherwise, any communication activity related to the action
(including at conferences, seminars, in information material, such as brochures, leaflets, posters,
presentations, etc., in electronic form, via social media, etc.) and any infrastructure, equipment or
major results funded by the grant must:
- display the EU emblem and
- include the following text:
“This [insert appropriate description, e.g. report, publication, conference, infrastructure, equipment, insert
type of result, etc.] was funded by the European Union’s Health Programme (2014-2020).”
When displayed in association with another logo, the EU emblem must have appropriate prominence.
For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem
without first obtaining approval from the Agency.
This does not, however, give them the right to exclusive use.
Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by
registration or by any other means.
22.1.3 Disclaimer excluding Agency and Commission responsibility
Any communication activity related to the action must indicate the following disclaimer:
"The content of this [insert appropriate description, e.g. report, publication, conference, etc.] represents
the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views
of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) or any other body of the European Union. The European Commission and the Agency do not
accept any responsibility for use that may be made of the information it contains.”
22.2 Communication activities by the Agency and the Commission
22.2.1 Right to use the beneficiaries’ materials, documents or information
The Agency and the Commission may use information relating to the action, documents notably
summaries for publication and public deliverables as well as any other material, such as pictures or
audio-visual material received from any beneficiary (including in electronic form).
This does not change the confidentiality obligations in Article 21, which still apply.
The right to use the beneficiary’s materials, documents and information includes:
(a) use for its own purposes (in particular, making them available to persons working for the
Agency, the Commission or any other EU institution, body, office or agency or body or
36
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
institutions in EU Member States; and copying or reproducing them in whole or in part, in
unlimited numbers);
(b) distribution to the public (in particular, publication as hard copies and in electronic or digital
format, publication on the internet, as a downloadable or non-downloadable file, broadcasting
by any channel, public display or presentation, communicating through press information
services, or inclusion in widely accessible databases or indexes);
(c) editing or redrafting for communication and publicising activities (including shortening,
summarising, inserting other elements (such as meta-data, legends, other graphic, visual, audio
or text elements), extracting parts (e.g. audio or video files), dividing into parts, use in a
compilation);
(d) translation;
(e) giving access in response to individual requests under Regulation No 1049/200110, without
the right to reproduce or exploit;
(f) storage in paper, electronic or other form;
(g) archiving, in line with applicable document-management rules, and
(h) the right to authorise third parties to act on its behalf or sub-license the modes of use set out
in Points (b), (c), (d) and (f) to third parties if needed for the communication and publicising
activities of the Agency or the Commission.
If the right of use is subject to rights of a third party (including personnel of the beneficiary), the
beneficiary must ensure that it complies with its obligations under this Agreement (in particular, by
obtaining the necessary approval from the third parties concerned).
Where applicable (and if provided by the beneficiaries), the Agency or the Commission will insert
the following information:
“© – [year] – [name of the copyright owner]. All rights reserved. Licensed to the Consumers, Health,
Agriculture and Food Executive Agency (CHAFEA) and the European Union (EU) under conditions.”
22.3 Consequences of non-compliance
If the beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 23 — PROCESSING OF PERSONAL DATA
23.1 Processing of personal data by the Agency and the Commission
Any personal data under the Agreement will be processed by the Agency or the Commission under
10 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access
to European Parliament, Council and Commission documents, OJ L 145, 31.5.2001, p. 43.
37
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Regulation No 23/200111 and according to the ‘notifications of the processing operations’ to the Data
Protection Officer (DPO) of the Agency or the Commission (publicly accessible in the DPO register).
Such data will be processed by the ‘data controller’ of the Agency or the Commission, for the
purposes of implementing, managing and monitoring the Agreement or protecting the financial
interests of the EU or Euratom (including checks, reviews, audits and investigations; see Article 17).
The persons whose personal data are processed have the right to access and correct their own personal
data. For this purpose, they must send any queries about the processing of their personal data to the data
controller, via the contact point indicated in the privacy statement(s) on the Agency and Commission
websites.
They also have the right to have recourse at any time to the European Data Protection Supervisor
(EDPS).
23.2 Processing of personal data by the beneficiaries
The beneficiaries must process personal data under the Agreement in compliance with applicable EU
and national law on data protection (including authorisations or notification requirements).
The beneficiaries may grant their personnel access only to data that is strictly necessary for
implementing, managing and monitoring the Agreement.
The beneficiaries must inform the personnel whose personal data are collected and processed by the
Agency or the Commission. For this purpose, they must provide them with the privacy statement(s)
(see above), before transmitting their data to the Agency or the Commission.
23.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 23.2, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY
The beneficiaries may not assign any of their claims for payment against the Agency to any third
party, except if approved by the Agency on the basis of a reasoned, written request by the coordinator
(on behalf of the beneficiary concerned).
If the Agency has not accepted the assignment or the terms of it are not observed, the assignment
will have no effect on it.
In no circumstances will an assignment release the beneficiaries from their obligations towards the
Agency.
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
11 Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection
of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free
movement of such data (OJ L 8, 12.01.2001, p. 1).
38
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
25.1 Roles and responsibilities towards the Agency
The beneficiaries have full responsibility for implementing the action and complying with the
Agreement.
The beneficiaries are jointly and severally liable for the technical implementation of the action as
described in Annex 1. If a beneficiary fails to implement its part of the action, the other beneficiaries
become responsible for implementing this part (without being entitled to any additional EU funding
for doing so), unless the Agency expressly relieves them of this obligation.
The financial responsibility of each beneficiary is governed by Articles 28, 29 and 30.
25.2 Internal division of roles and responsibilities
The internal roles and responsibilities of the beneficiaries are divided as follows:
(a) Each beneficiary must:
(i) keep information stored in the Participant Portal Beneficiary Register (via the electronic
exchange system) up to date (see Article 12);
(ii) inform the coordinator immediately of any events or circumstances likely to affect
significantly or delay the implementation of the action (see Article 12);
(iii) submit to the coordinator in good time:
- individual financial statements for itself and its affiliated entities and, if required,
certificates on the financial statements (see Article 15);
- the data needed to draw up the technical reports (see Article 15);
- any other documents or information required by the Agency or the Commission
under the Agreement, unless the Agreement requires the beneficiary to submit this
information directly.
(b) The coordinator must:
(i) monitor that the action is implemented properly (see Article 7);
(ii) act as the intermediary for all communications between the beneficiaries and the Agency
(in particular, providing the Agency with the information described in Article 12), unless
the Agreement specifies otherwise;
(iii) provide a pre-financing guarantee if requested by the Agency (see Article 16.2);
(iv) request and review any documents or information required by the Agency and verify
their completeness and correctness before passing them on to the Agency;
(v) submit the deliverables and reports to the Agency (see Articles 14 and 15);
39
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(vi) ensure that all payments are made to the other beneficiaries without unjustified delay
(see Article 16).
The coordinator may not subcontract the above-mentioned tasks.
25.3 Internal arrangements between beneficiaries — Consortium agreement
The beneficiaries must have internal arrangements regarding their operation and co-ordination to
ensure that the action is implemented properly. These internal arrangements must be set out in a written
‘consortium agreement’ between the beneficiaries, which may cover:
- internal organisation of the consortium;
- management of access to the electronic exchange system;
- distribution of EU funding;
- additional rules on rights and obligations related to pre-existing rights and results (see
Article 19);
- settlement of internal disputes;
- liability, indemnification and confidentiality arrangements between the beneficiaries.
The consortium agreement must not contain any provision contrary to the Agreement.
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— SANCTIONS — DAMAGES — SUSPENSION — TERMINATION —
FORCE MAJEURE
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— SANCTIONS
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS
26.1 Conditions
The Agency will — at the time of an interim payment, at the payment of the balance or afterwards
— reject any costs which are ineligible (see Article 6), in particular following checks, reviews, audits
or investigations (see Article 17).
The rejection may also be based on the extension of findings from other grants to this grant (see
Article 17.5.2).
26.2 Ineligible costs to be rejected — Calculation — Procedure
Ineligible costs will be rejected in full.
If the rejection of costs does not lead to a recovery (see Article 28), the Agency will formally notify
40
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
the coordinator or beneficiary concerned of the rejection of costs, the amounts and the reasons why
(if applicable, together with the notification of amounts due; see Article 16.5). The coordinator or
beneficiary concerned may — within 30 days of receiving notification — formally notify the Agency
of its disagreement and the reasons why.
If the rejection of costs leads to a recovery, the Agency will follow the contradictory procedure with
pre-information letter set out in Article 28.
26.3 Effects
If the Agency rejects costs at the time of an interim payment or the payment of the balance, it will
deduct them from the total eligible costs declared, for the action, in the periodic or final summary
financial statement (see Article 15.3 and 15.4). It will then calculate the interim payment or payment
of the balance as set out in Article 16.3 or 16.4.
If the Agency — after an interim payment but before the payment of the balance — rejects costs
declared in a periodic summary financial statement, it will deduct them from the costs declared in the
next periodic summary financial statement or final summary financial statement. It will then calculate
the interim payment or payment of the balance as set out in Article 16.3 or 16.4.
If the Agency rejects costs after the payment of the balance, it will deduct the amount rejected from
the total eligible costs declared, by the beneficiary, in the final summary financial statement. It will
then calculate the revised final grant amount as set out in Article 5.4. If the revised final grant amount
is lower than the final grant amount, the Agency will recover the difference (see Article 28).
ARTICLE 27 — REDUCTION OF THE GRANT
27.1 Conditions
The Agency may — at the payment of the balance or afterwards — reduce the grant, if:
(a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2).
27.2 Amount to be reduced — Calculation — Procedure
The amount of the reduction will be proportionate to the seriousness of the errors, irregularities or
fraud or breach of obligations.
41
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Before reduction of the grant, the Agency will formally notify a ‘pre-information letter’ to the
coordinator or beneficiary concerned:
- informing it of its intention to reduce the grant, the amount it intends to reduce and the reasons
why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive any observations or decides to pursue reduction despite the observations
it has received, it will formally notify confirmation of the reduction (if applicable, together with the
notification of amounts due; see Article 16).
27.3 Effects
If the Agency reduces the grant at the time of the payment of the balance, it will calculate the
reduced grant amount for the action and then determine the amount due as payment of the balance
(see Article 5.3.4 and 16.4).
If the Agency reduces the grant after the payment of the balance, it will calculate the revised final
grant amount for the action or for the beneficiary concerned (see Article 5.4). If the revised final grant
amount is lower than the final grant amount, the Agency will recover the difference (see Article 28).
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS
28.1 Amount to be recovered — Calculation — Procedure
The Agency will — at the payment of the balance or afterwards — claim back any amount that
was paid but is not due under the Agreement.
The coordinator is fully liable for repaying debts of the consortium (under the Agreement) even if it
has not been the final recipient of those amounts.
In addition, the beneficiaries (including the coordinator) are jointly and severally liable for repaying
any unpaid debts under the Agreement (due by the consortium or any beneficiary, including late-
payment interest) — up to the maximum EU contribution indicated, for each beneficiary, in the
estimated budget (as last amended; see Annex 2).
Undue amounts paid by the Agency for costs declared by an affiliated entity will be considered as
amounts unduly paid to the beneficiary.
28.1.1 Recovery at payment of the balance
If the payment of the balance takes the form of a recovery (see Article 16.4), the Agency will formally
notify a ‘pre-information letter’ to the coordinator:
- informing it of its intention to recover, the amount due as the balance and the reasons why and
- inviting the coordinator to submit observations within 30 days of receiving notification.
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator a
42
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
debit note with the terms and the date for payment (together with the notification of amounts due;
see Article 16.5).
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s consent — against any amounts owed to the
coordinator by the Agency, Commission or another executive agency (from the EU or Euratom
budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) not applicable;
(c) by holding the other beneficiaries jointly and severally liable — up to the maximum EU
contribution indicated, for each beneficiary, in the estimated budget (as last amended; see
Annex 2)
(d) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
28.1.2 Recovery of amounts after payment of the balance
If — after the payment of the balance — the Agency revised the final grant amount for the action or
for the beneficiary concerned (see Article 5.4), due to a rejection of costs or reduction of the grant, and
the revised final grant amount is lower than the final grant amount (see Article 5.3), the Agency will:
- if the rejection or reduction does not concern a specific beneficiary or its affiliated entities:
claim back the difference from the coordinator (even if it has not been the final recipient of
the amount in question)
or
- otherwise: claim back the difference from the beneficiary concerned.
The Agency will formally notify a pre-information letter to the coordinator or beneficiary concerned:
- informing it of its intention to recover, the amount to be repaid and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
43
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator or
beneficiary concerned a debit note. This note will also specify the terms and the date for payment.
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s or beneficiary’s consent — against any amounts
owed to the coordinator or beneficiary by the Agency, Commission or another executive agency
(from the EU or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) by holding the other beneficiaries jointly and severally liable, up to the maximum EU
contribution indicated, for each beneficiary, in the estimated budget (as last amended; see
Annex 2)
(c) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the date
for payment in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
ARTICLE 29 — ADMINISTRATIVE SANCTIONS
In addition to contractual measures, the Agency or the Commission may also adopt administrative
sanctions under Articles 106 and 131(4) of the Financial Regulation No 966/2012 (i.e. exclusion from
future procurement contracts, grants and expert contracts and/or financial penalties).
SECTION 2 LIABILITY FOR DAMAGES
ARTICLE 30 — LIABILITY FOR DAMAGES
30.1 Liability of the Agency
The Agency cannot be held liable for any damage caused to the beneficiaries or to third parties as a
consequence of implementing the Agreement, including for gross negligence.
The Agency cannot be held liable for any damage caused by any of the beneficiaries or third parties
involved in the action, as a consequence of implementing the Agreement.
44
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
30.2 Liability of the beneficiaries
Except in case of force majeure (see Article 35), the beneficiaries must compensate the Agency for
any damage it sustains as a result of the implementation of the action or because the action was not
implemented in full compliance with the Agreement.
SECTION 3 SUSPENSION AND TERMINATION
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE
31.1 Conditions
The Agency may — at any moment — suspend the payment deadline (see Article 16.2 to 16.4) if a
request for payment (see Article 15) cannot be approved because:
(a) it does not comply with the provisions of the Agreement (see Article 15);
(b) the technical or financial report(s) have not been submitted or are not complete or additional
information is needed, or
(c) there is doubt about the eligibility of the costs declared in the financial statements and additional
checks, reviews, audits or investigations are necessary.
31.2 Procedure
The Agency will formally notify the coordinator of the suspension and the reasons why.
The suspension will take effect the day notification is sent by the Agency (see Article 36).
If the conditions for suspending the payment deadline are no longer met, the suspension will be lifted
— and the remaining period will resume.
If the suspension exceeds two months, the coordinator may request the Agency if the suspension will
continue.
If the payment deadline has been suspended due to the non-compliance of the technical or financial
report(s) (see Article 15) and the revised report or statement is not submitted or was submitted but
is also rejected, the Agency may also terminate the Agreement or the participation of the beneficiary
(see Article 34.3.1(i)).
ARTICLE 32 — SUSPENSION OF PAYMENTS
32.1 Conditions
The Agency may — at any moment — suspend payments, in whole or in part for one or more
beneficiaries, if:
(a) a beneficiary (or a natural person who has the power to represent or take decision on its behalf)
has committed or is suspected of having committed:
(i) substantial errors, irregularities or fraud or
45
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(ii) serious breach of obligations under this Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decision on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2).
If payments are suspended for one or more beneficiaries, the Agency will make partial payment(s)
for the part(s) not suspended. If suspension concerns the payment of the balance, the payment (or
recovery) of the amount(s) concerned after suspension is lifted will be considered to be the payment
that closes the action.
32.2 Procedure
Before suspending payments, the Agency will formally notify the coordinator or beneficiary
concerned:
- informing it of its intention to suspend payments and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the suspension procedure is not continued.
The suspension will take effect the day the confirmation notification is sent by the Agency.
If the conditions for resuming payments are met, the suspension will be lifted. The Agency will
formally notify the coordinator or beneficiary concerned.
During the suspension, the periodic report(s) for all reporting periods except the last one (see
Article 15.3) must not contain any individual financial statement(s) from the beneficiary concerned
and its affiliated entities. The coordinator must include them in the next periodic report after the
suspension is lifted or — if suspension is not lifted before the end of the action — in the last periodic
report.
The beneficiaries may suspend implementation of the action (see Article 33.1) or terminate the
Agreement or the participation of the beneficiary concerned (see Article 34.1 and 34.2).
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION
33.1 Suspension of the action implementation, by the beneficiaries
33.1.1 Conditions
The beneficiaries may suspend implementation of the action or any part of it, if exceptional
circumstances — in particular force majeure (see Article 35) — make implementation impossible or
excessively difficult.
46
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
33.1.2 Procedure
The coordinator must immediately formally notify to the Agency the suspension (see Article 36),
stating:
- the reasons why and
- the expected date of resumption.
The suspension will take effect the day this notification is received by the Agency.
Once circumstances allow for implementation to resume, the coordinator must immediately formally
notify the Agency and request an amendment of the Agreement, to set the date on which the action
will be resumed, extend the duration of the action and make other changes necessary to adapt the action
to the new situation (see Article 39) — unless the Agreement or the participation of a beneficiary has
been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This
date may be before the date on which the amendment enters into force.
Costs incurred during suspension of the action implementation are not eligible (see Article 6).
33.2 Suspension of the action implementation, by the Agency
33.2.1 Conditions
The Agency may suspend implementation of the action or any part of it, if:
(a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed or is suspected of having committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under this Agreement or during the award procedure
(including improper implementation of the action, submission of false declaration, failure
to provide required information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2).
33.2.2 Procedure
Before suspending implementation of the action, the Agency will formally notify the coordinator or
beneficiary concerned:
- informing it of its intention to suspend the implementation and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
47
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the procedure is not continued.
The suspension will take effect five days after confirmation notification is received (or on a later date
specified in the notification).
It will be lifted if the conditions for resuming implementation of the action are met.
The coordinator or beneficiary concerned will be formally notified of the lifting and the Agreement
will be amended, to set the date on which the action will be resumed, extend the duration of the action
and make other changes necessary to adapt the action to the new situation (see Article 39) — unless
the Agreement has already been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This date
may be before the date on which the amendment enters into force.
Costs incurred during suspension are not eligible (see Article 6).
The beneficiaries may not claim damages due to suspension by the Agency (see Article 30).
Suspension of the action implementation does not affect the Agency’s right to terminate the Agreement
or participation of a beneficiary (see Article 34), reduce the grant or recover amounts unduly paid
(see Articles 27 and 28).
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION
OF ONE OR MORE BENEFICIARIES
34.1 Termination of the Agreement, by the beneficiaries
34.1.1 Conditions and procedure
The beneficiaries may terminate the Agreement.
The coordinator must formally notify termination to the Agency (see Article 36), stating:
- the reasons why and
- the date the termination will take effect. This date must be after the notification.
If no reasons are given or if the Agency considers the reasons do not justify termination, the Agreement
will be considered to have been ‘terminated improperly’.
The termination will take effect on the day specified in the notification.
34.1.2 Effects
The coordinator must — within 60 days from when termination takes effect — submit a periodic report
(for the open reporting period until termination; see Article 15.3) and the final report (see Article 15.4).
If the Agency does not receive the report(s) within the deadline (see above), only costs which are
included in an approved periodic report will be taken into account.
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see Article 16.4)
48
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
on the basis of the report(s) submitted. Only costs incurred until termination are eligible (see Article 6).
Costs relating to contracts due for execution only after termination are not eligible.
Improper termination may lead to a reduction of the grant (see Article 27).
After termination, the beneficiaries’ obligations (in particular, Articles 15, 17, 18, 19, 20, 21, 22, 24,
26, 27 and 28) continue to apply.
34.2 Termination of the participation of one or more beneficiaries, by the beneficiaries
34.2.1 Conditions and procedure
The participation of one or more beneficiaries may be terminated by the coordinator, on request of
the beneficiary concerned or on behalf of the other beneficiaries.
The coordinator must formally notify termination to the Agency (see Article 36) and inform the
beneficiary concerned.
If the coordinator’s participation is terminated without its agreement, the formal notification must be
done by another beneficiary (acting on behalf of the other beneficiaries).
The notification must include:
- the reasons why;
- the opinion of the beneficiary concerned (or proof that this opinion has been requested in
writing);
- the date the termination takes effect. This date must be after the notification, and
- a request for amendment (see Article 39), with a proposal for reallocation of the tasks and the
estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the
addition of one or more new beneficiaries (see Article 40). If termination takes effect after the
period set out in Article 3, no request for amendment must be included, unless the beneficiary
concerned is the coordinator. In this case, the request for amendment must propose a new
coordinator.
If this information is not given or if the Agency considers that the reasons do not justify termination,
the participation will be considered to have been terminated improperly.
The termination will take effect on the day specified in the notification.
34.2.2 Effects
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
(ii) a financial statement covering the period from the end of the last reporting period to the date
when termination takes effect.
This information must be included by the coordinator in the periodic report for the next reporting
period (see Article 15.3).
49
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
If the request for amendment is rejected by the Agency (because it calls into question the decision
awarding the grant or breaches the principle of equal treatment of applicants), the Agreement may be
terminated according to Article 34.3.1(c).
If the request for amendment is accepted by the Agency, the Agreement is amended to introduce the
necessary changes (see Article 39).
Improper termination may lead to a reduction of the grant (see Article 27) or termination of the
Agreement (see Article 34).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18, 19, 21,
22, 24, 26, 27 and 28) continue to apply.
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by
the Agency
34.3.1 Conditions
The Agency may terminate the Agreement or the participation of one or more beneficiaries, if:
(a) one or more beneficiaries do not accede to the Agreement (see Article 40);
(b) a change to their legal, financial, technical, organisational or ownership situation (or those of
its affiliated entities) is likely to substantially affect or delay the implementation of the action
or calls into question the decision to award the grant;
(c) following termination of participation for one or more beneficiaries (see above), the necessary
changes to the Agreement would call into question the decision awarding the grant or breach
the principle of equal treatment of applicants (see Article 39);
(d) implementation of the action is prevented by force majeure (see Article 35) or suspended by
the coordinator (see Article 33.1) and either:
(i) resumption is impossible, or
(ii) the necessary changes to the Agreement would call into question the decision awarding
the grant or breach the principle of equal treatment of applicants;
(e) a beneficiary is declared bankrupt, being wound up, having its affairs administered by the
courts, has entered into an arrangement with creditors, has suspended business activities, or
is subject to any other similar proceedings or procedures under national law;
(f) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has been found guilty of professional misconduct, proven by any means;
(g) a beneficiary does not comply with the applicable national law on taxes and social security;
(h) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed fraud, corruption, or is involved in a criminal organisation, money
laundering or any other illegal activity;
(i) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed:
50
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles);
(j) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions
— systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have
a material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2);
(k) despite a specific request by the Agency, a beneficiary does not request — through the
coordinator — an amendment to the Agreement to end the participation of one of its affiliated
entities that is in one of the situations under points (e), (f), (g), (h), (i) or (j) and to reallocate
its tasks
34.3.2 Procedure
Before terminating the Agreement or participation of one or more beneficiaries, the Agency will
formally notify the coordinator or beneficiary concerned:
- informing it of its intention to terminate and the reasons why and
- inviting it, within 30 days of receiving notification, to submit observations and — in case of
Point (i.ii) above — to inform the Agency of the measures to ensure compliance with the
obligations under the Agreement.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify to the coordinator or beneficiary concerned confirmation of
the termination and the date it will take effect. Otherwise, it will formally notify that the procedure
is not continued.
The termination will take effect:
- for terminations under Points (b), (c), (e), (g), (i.ii) and (k) above: on the day specified in the
notification of the confirmation (see above);
- for terminations under Points (a), (d), (f), (h), (i.i) and (j) above: on the day after the notification
of the confirmation is received.
34.3.3 Effects
(a) for termination of the Agreement:
The coordinator must — within 60 days from when termination takes effect — submit a periodic
report (for the last open reporting period until termination; see Article 15.3) and a final report
(see Article 15.4).
If the Agreement is terminated for breach of the obligation to submit reports (see Articles 15.8
and 34.3.1(i)), the coordinator may not submit any reports after termination.
51
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
If the Agency does not receive the report(s) within the deadline (see above), only costs which
are included in an approved periodic report will be taken into account.
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see
Article 16.4) on the basis of the report(s) submitted. Only costs incurred until termination
takes effect are eligible (see Article 6). Costs relating to contracts due for execution only after
termination are not eligible.
This does not affect the Agency’s right to reduce the grant (see Article 27) or to impose
administrative sanctions (Article 29).
The beneficiaries may not claim damages due to termination by the Agency (see Article 30).
After termination, the beneficiaries’ obligations (in particular Articles 15, 17, 18, 19, 21, 22,
24, 26, 27 and 28) continue to apply.
(b) for termination of the participation of one or more beneficiaries:
The coordinator must — within 60 days from when termination takes effect — submit a request
for amendment (see Article 39), with a proposal for reallocation of the tasks and estimated
budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the addition of
one or more new beneficiaries (see Article 40). If termination is notified after the period set out
in Article 3, no request for amendment must be submitted unless the beneficiary concerned is
the coordinator. In this case the request for amendment must propose a new coordinator.
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
(ii) a financial statement covering the period from the end of the last reporting period to the
date when termination takes effect.
This information must be included by the coordinator in periodic report for the next reporting
period (see Article 15.3).
If the request for amendment is rejected by the Agency (because it calls into question the
decision awarding the grant or breaches the principle of equal treatment of applicants), the
Agreement may be terminated according to Article 34.3.1(c).
If the request for amendment is accepted by the Agency, the Agreement is amended to
introduce the necessary changes (see Article 39).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18, 19,
20, 21, 22, 24, 26, 27 and 28) continue to apply.
SECTION 4 FORCE MAJEURE
ARTICLE 35 — FORCE MAJEURE
‘Force majeure’ means any situation or event that:
52
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
- prevents either party from fulfilling their obligations under the Agreement,
- was unforeseeable, exceptional situation and beyond the parties’ control,
- was not due to error or negligence on their part (or on the part of third parties involved in the
action), and
- proves to be inevitable in spite of exercising all due diligence.
The following cannot be invoked as force majeure:
- any default of a service, defect in equipment or material or delays in making them available,
unless they stem directly from a relevant case of force majeure,
- labour disputes or strikes, or
- financial difficulties.
Any situation constituting force majeure must be formally notified to the other party without delay,
stating the nature, likely duration and foreseeable effects.
The parties must immediately take all the necessary steps to limit any damage due to force majeure
and do their best to resume implementation of the action as soon as possible.
The party prevented by force majeure from fulfilling its obligations under the Agreement cannot be
considered in breach of them.
CHAPTER 7 FINAL PROVISIONS
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES
36.1 Form and means of communication
Communication under the Agreement (information, requests, submissions, 'formal notifications', etc.)
must:
- be made in writing and
- bear the number of the Agreement.
Until the payment of the balance: all communication must be made through the electronic exchange
system and using the forms and templates provided there.
After the payment of the balance: formal notifications must be made by registered post with proof
of delivery (‘formal notification on paper’).
Communications in the electronic exchange system must be made by persons authorised according to
the Participant Portal Terms & Conditions. For naming the authorised persons, each beneficiary must
have designated — before the signature of this Agreement — a ‘legal entity appointed representative
(LEAR)’. The role and tasks of the LEAR are stipulated in his/her appointment letter (see Participant
Portal Terms & Conditions).
53
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
If the electronic exchange system is temporarily unavailable, instructions will be given on the Agency
and Commission websites.
36.2 Date of communication
Communications are considered to have been made when they are sent by the sending party (i.e. on
the date and time they are sent through the electronic exchange system).
Formal notifications through the electronic exchange system are considered to have been made when
they are received by the receiving party (i.e. on the date and time of acceptance by the receiving party,
as indicated by the time stamp). A formal notification that has not been accepted within 10 days after
sending is considered to have been accepted.
Formal notifications on paper sent by registered post with proof of delivery (only after the payment
of the balance) are considered to have been made on either:
- the delivery date registered by the postal service or
- the deadline for collection at the post office.
If the electronic exchange system is temporarily unavailable, the sending party cannot be considered
in breach of its obligation to send a communication within a specified deadline.
36.3 Addresses for communication
The electronic exchange system must be accessed via the following URL:
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/myarea/projects
The Agency will formally notify the coordinator and beneficiaries in advance any changes to this URL.
Formal notifications on paper (only after the payment of the balance) addressed to the Agency must
be sent to the following address:
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA)
Health and Food Safety Unit Health and Food Safety Unit
Drosbach Building
L-2920 Luxembourg
Formal notifications on paper (only after the payment of the balance) addressed to the beneficiaries
must be sent to their legal address as specified in the Participant Portal Beneficiary Register.
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT
37.1 Precedence of the Terms and Conditions over the Annexes
The provisions in the Terms and Conditions of the Agreement take precedence over its Annexes.
Annex 2 takes precedence over Annex 1.
54
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
37.2 Privileges and immunities
Not applicable
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES
In accordance with Regulation No 1182/7112, periods expressed in days, months or years are calculated
from the moment the triggering event occurs.
The day during which that event occurs is not considered as falling within the period.
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT
39.1 Conditions
The Agreement may be amended, unless the amendment entails changes to the Agreement which
would call into question the decision awarding the grant or breach the principle of equal treatment
of applicants.
Amendments may be requested by any of the parties.
39.2 Procedure
The party requesting an amendment must submit a request for amendment signed in the electronic
exchange system (see Article 36).
The coordinator submits and receives requests for amendment on behalf of the beneficiaries (see
Annex 3).
If a change of coordinator is requested without its agreement, the submission must be done by another
beneficiary (acting on behalf of the other beneficiaries).
The request for amendment must include:
- the reasons why;
- the appropriate supporting documents, and
- for a change of coordinator without its agreement: the opinion of the coordinator (or proof that
this opinion has been requested in writing).
The Agency may request additional information.
If the party receiving the request agrees, it must sign the amendment in the electronic exchange system
within 45 days of receiving notification (or any additional information the Agency has requested). If
it does not agree, it must formally notify its disagreement within the same deadline. The deadline may
be extended, if necessary for the assessment of the request. If no notification is received within the
deadline, the request is considered to have been rejected.
12 Regulation (EEC, Euratom) No 1182/71 of the Council of 3 June 1971 determining the rules applicable to periods, dates
and time-limits (OJ L 124, 8/6/1971, p. 1).
55
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
An amendment enters into force on the day of the signature of the receiving party.
An amendment takes effect on the date agreed by the parties or, in the absence of such an agreement,
on the date on which the amendment enters into force.
ARTICLE 40 — ACCESSION TO THE AGREEMENT
40.1 Accession of the beneficiaries mentioned in the preamble
The other beneficiaries must accede to the Agreement by signing the Accession Form (see Annex 3) in
the electronic exchange system (see Article 36) within 30 days after its entry into force (see Article 42).
They will assume the rights and obligations under the Agreement with effect from the date of its entry
into force (see Article 42).
If a beneficiary does not accede to the Agreement within the above deadline, the coordinator must
— within 30 days — request an amendment to make any changes necessary to ensure proper
implementation of the action. This does not affect the Agency's right to terminate the Agreement (see
Article 34).
40.2 Addition of new beneficiaries
In justified cases, the beneficiaries may request the addition of a new beneficiary.
For this purpose, the coordinator must submit a request for amendment in accordance with Article 39.
It must include an Accession Form (see Annex 3) signed by the new beneficiary in the electronic
exchange system (see Article 36).
New beneficiaries must assume the rights and obligations under the Agreement with effect from the
date of their accession specified in the Accession Form (see Annex 3).
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES
41.1 Applicable law
The Agreement is governed by the applicable EU law, supplemented if necessary by the law of
Belgium.
41.2 Dispute settlement
If a dispute concerning the interpretation, application or validity of the Agreement cannot be settled
amicably, the General Court — or, on appeal, the Court of Justice of the European Union — has sole
jurisdiction. Such actions must be brought under Article 272 of the Treaty on the Functioning of the
EU (TFEU).
As an exception, if such a dispute is between the Agency and ‘MINISTRY OF CIVIL
AFFAIRS’, ‘HELSEDIREKTORATET’, ‘INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR
MILAN JOVANOVIC BATUT’, ‘AGENTIA NATIONALA PENTRU SANATATE PUBLICA’, the
competent Belgian courts have sole jurisdiction.
If a dispute concerns administrative sanctions, offsetting or an enforceable decision under
56
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2019)4052454 26/06/2019
Article 79(2) of the Financial Regulation No 966/2012 and Article 299 TFEU (see Articles 28, 29 and
30), the beneficiaries must bring action before the General Court — or, on appeal, the Court of Justice
of the European Union — under Article 263 TFEU. Actions against enforceable decisions must be
brought against the Commission (not against the Agency).
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT
The Agreement will enter into force on the day of signature by the Agency or the coordinator,
depending on which is later.
SIGNATURES
For the coordinator For the Agency
[--TGSMark#signature-996697893_75_210--] [--TGSMark#signature-service_75_210--]
57
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Health and Food Safety Unit
ANNEX 1 (part A)
Project
NUMBER — 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Table of Contents
1.1. The project summary................................................................................................................................. 3
1.2. The list of beneficiaries..............................................................................................................................4
1.3. Workplan Tables - Detailed implementation..............................................................................................6
1.3.1. WT1 List of work packages........................................................................................................... 6
1.3.2. WT2 List of deliverables................................................................................................................ 7
1.3.3. WT3 Work package descriptions................................................................................................... 9
Work package 1........................................................................................................................... 9
Work package 2......................................................................................................................... 14
Work package 3......................................................................................................................... 17
Work package 4......................................................................................................................... 22
Work package 5......................................................................................................................... 25
Work package 6......................................................................................................................... 30
Work package 7......................................................................................................................... 36
Work package 8......................................................................................................................... 41
Work package 9......................................................................................................................... 46
Work package 10....................................................................................................................... 49
1.3.4. WT4 List of milestones................................................................................................................ 52
1.3.5. WT5 Critical Implementation risks and mitigation actions........................................................... 55
1.3.6 WT6 Summary of project effort in person-months........................................................................57
1.3.7. WT7 Tentative schedule of project reviews.................................................................................60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.1. The project summary
Project Number 1 848096 Project Acronym 2 SHARP JA
One form per project
General information
Strengthened International HeAlth Regulations and Preparedness in the EU - Joint
Project title 3
Action
Starting date 4 01/04/2019
Duration in months 5 36
Call (part) identifier 6 HP-JA-2018
JA-01-2018
Joint Action to strengthen preparedness including laboratories in the EU against serious
Topic
cross-border threats to health and support the implementation of International Health
Regulations (IHR)
Fixed EC Keywords
Free keywords IHR, preparedness, response, health security, core capacity, public health
Abstract 7
The SHARP Joint Action will strengthen implementation of Decision 1082/2013/EU, supporting the EU level
preparedness and responses to health threats and the implementation of the International Health Regulations (2005).
The Joint Action implements actions mentioned in Annex 1 of the Annual Work plan 2018 of the EU Health
Programme 2014-2020.
Through the Joint Action, the member and partner states and the Unions common ability to prevent, detect and
respond to biological outbreaks, chemical contamination and environmental and unknown threats to human health will
be strengthened. Special efforts will be employed to fill gaps that have been or will be identified in priority countries
(countries that have biggest gaps in the capacity required for full IHR capability). The Joint action consists of 10
Work Packages, covering core public health capacities according to the IHR (2005). In addition to a coordination
function, these will cover areas such as Communication, Evaluation, Sustainability, IHR core capacity, Preparedness,
Laboratories, Training and exercises, Chemical threats and Clinical management.
SHARP will also collaborate with several other Joint Actions, specifically the “Healthy Gateways” that addresses
Points of Entry, the Joint Action on Vaccination (EU-JAV) and the Joint Action on Antimicrobial Resistance (EU-
JAMRAI).
The partnership of the joint action consists of 26 Associated Partners and 33 Affiliated Entities, which all will receive
Commission co-funding. In addition there are 9 Collaborating Partners that will self-fund all activities that they
participate in. Totally 30 countries (24 EU members, 3 EEA/EFTA members and 3 European neighborhood countries)
participate in the Joint Action. The SHARP JA will liaise with and collaborate with the ECDC, the WHO EURO
regional office and the WHO Health Emergency and IHR unit in Lyon, and IANPHI in relevant activities. Special
emphasis will be made to avoid duplication of work for the member states.
Page 3 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.2. List of Beneficiaries
Project Number 1 848096 Project Acronym 2 SHARP JA
List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
TERVEYDEN JA HYVINVOINNIN
1 THL Finland 1 36
LAITOS
2 ROBERT KOCH-INSTITUT RKI Germany 1 36
ISTITUTO NAZIONALE PER LE
MALATTIE INFETTIVE LAZZARO
3 INMI Italy 1 36
SPALLANZANI-ISTITUTO DI RICOVERO
E CURA A CARATTERE SCIENTIFICO
BUNDESMINISTERIUM FUER ARBEIT,
4 SOZIALES, GESUNDHEIT UND BMASGK Austria 1 36
KONSUMENTENSCHUTZ
Bosnia and
5 MINISTRY OF CIVIL AFFAIRS MCA 1 36
Herzegovina
HRVATSKI ZAVOD ZA JAVNO
6 CIPH Croatia 1 36
ZDRAVSTVO
STATNI USTAV JADERNE, CHEMICKE A
7 SUJCHBO Czech Republic 1 36
BIOLOGICKE OCHRANY VVI
8 STATENS SERUM INSTITUT SSI Denmark 1 36
9 SOTSIAALMINISTEERIUM MSAE Estonia 1 36
MINISTERE DES AFFAIRES SOCIALES
10 MOH-FR France 1 36
ET DE LA SANTE
KENTRO ELENCHOU & PROLIPSIS
11 HCDCP(KEELPNO) Greece 1 36
NOSIMATON
NEMZETI NEPEGESZSEGUGYI
12 NNK Hungary 1 36
KOZPONT
NEATLIEKAMAS MEDICINISKAS
13 SEMS Latvia 1 36
PALIDZIBA
LIETUVOS RESPUBLIKOS SVEIKATOS
14 MOHLT Lithuania 1 36
APSAUGOS MINISTERIJA
15 Ministry for Health - Government of Malta MFH Malta 1 36
RIJKSINSTITUUT VOOR
16 RIVM Netherlands 1 36
VOLKSGEZONDHEID EN MILIEU
17 HELSEDIREKTORATET HD Norway 1 36
NARODOWY INSTYTUT ZDROWIA
18 PUBLICZNEGO-PANSTWOWY ZAKLAD NIZP-PZH Poland 1 36
HIGIENY
MINISTERIO DA SAUDE - REPUBLICA
19 MS Portugal 1 36
PORTUGUESA
INSTITUT ZA ZASTITU ZDRAVLJA
20 IPHS Serbia 1 36
SRBIJEDR MILAN JOVANOVIC BATUT
Page 4 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.2. List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
NACIONALNI INSTITUT ZA JAVNO
21 NIJZ Slovenia 1 36
ZDRAVJE
22 INSTITUTO DE SALUD CARLOS III ISCIII Spain 1 36
23 FOLKHALSOMYNDIGHETEN FOHM Sweden 1 36
24 Department of Health DH United Kingdom 1 36
25 HEALTH SERVICE EXECUTIVE HSE HSE Ireland 1 36
AGENTIA NATIONALA PENTRU Moldova
26 NAPH 1 36
SANATATE PUBLICA (Republic of)
Page 5 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.3. Workplan Tables - Detailed implementation
1.3.1. WT1 List of work packages
WP Person- Start End
WP Title Lead beneficiary10
Number9 months11 month12 month13
WP1 Coordination 1 - THL 126.91 1 36
WP2 Communication and dissemination 24 - DH 40.30 1 36
WP3 Evaluation of the action 11 - HCDCP(KEELPNO) 68.10 1 36
Integration in National Policies and
WP4 10 - MOH-FR 51.40 1 36
Sustainability
IHR core capacity strengthening and
WP5 23 - FOHM 201.45 1 36
assessment
WP6 Preparedness and Response planning 16 - RIVM 191.12 1 36
Laboratory preparedness and
WP7 2 - RKI 301.54 1 36
responsiveness
Training and local exercises,
WP8 20 - IPHS 223.26 1 36
exchange of working practices
WP9 Chemical safety and chemical threats 24 - DH 107.70 1 36
Case management and infection
WP10 3 - INMI 79.40 1 36
prevention and control preparedness
Total 1,391.18
Page 6 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.3.2. WT2 list of deliverables
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type 15 Date (in
Number14 number9 level16
months)17
D1.1 Interim report WP1 1 - THL Report Public 18
D1.2 Final report WP1 1 - THL Report Public 36
D2.1 Leaflet WP2 24 - DH Report Public 3
Websites,
D2.2 Website WP2 24 - DH patents Public 4
filling, etc.
D2.3 Layman report WP2 24 - DH Report Public 36
A blueprint of
D2.4 WP2 24 - DH Report Public 36
dissemination
Communication and
D2.5 WP2 24 - DH Report Public 36
dissemination report
11 -
D3.1 Evaluation plan WP3 Report Public 3
HCDCP(KEELPNO)
Midterm internal 11 -
D3.2 WP3 Report Public 24
evaluation reports HCDCP(KEELPNO)
Final internal 11 -
D3.3 WP3 Report Public 36
evaluation report HCDCP(KEELPNO)
Midterm external 11 -
D3.4 WP3 Report Public 24
evaluation report HCDCP(KEELPNO)
Final external 11 -
D3.5 WP3 Report Public 36
evaluation report HCDCP(KEELPNO)
Guidance on
D4.1 WP4 10 - MOH-FR Report Public 7
sustainability
D4.2 Sustainability Report WP4 10 - MOH-FR Report Public 24
D5.1 WP5 Work plan WP5 23 - FOHM Report Public 5
Reports on improving
D5.2 WP5 23 - FOHM Report Public 36
IHR implementation
Confidential,
only for members
Report on international
of the consortium
D5.3 collaboration between WP5 17 - HD Report 34
(including the
authorities during crises
Commission
Services)
Report on the use
D5.4 WP5 23 - FOHM Report Public 36
exercises and AAR
Review of planning and
D6.1 WP6 16 - RIVM Report Public 18
evaluation tools
Confidential,
Report on Disease X only for members
D6.2 WP6 16 - RIVM Report 33
scenario of the consortium
(including the
Page 7 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Commission
Services)
Confidential,
only for members
Report on assurance
of the consortium
D7.1 of high quality of WP7 2 - RKI Report 36
(including the
diagnostic
Commission
Services)
Confidential,
only for members
Report on modern
of the consortium
D7.2 molecular diagnostic WP7 3 - INMI Report 36
(including the
methods
Commission
Services)
Confidential,
only for members
Recommendations for of the consortium
D7.3 WP7 23 - FOHM Report 34
risk management (including the
Commission
Services)
Report on training
D8.1 WP8 20 - IPHS Report Public 15
needs
D8.2 Final training report WP8 20 - IPHS Report Public 36
Basic and advanced
D8.3 WP8 20 - IPHS Report Public 21
training curricula
D9.1 Fact-finding report WP9 24 - DH Report Public 12
Chemical laboratory
D9.2 response network – WP9 17 - HD Report Public 24
scoping report
D9.3 WP9 Final report WP9 24 - DH Report Public 36
Report on SOPs
D9.4 WP9 24 - DH Report Public 36
developed
Report on existing
D10.1 WP10 22 - ISCIII Report Public 33
facilities
D10.2 Feasibility study report WP10 17 - HD Report Public 18
Report on syndrome-
D10.3 WP10 3 - INMI Report Public 32
based approach
Page 8 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.3.3. WT3 Work package descriptions
Work package number 9 WP1 Lead beneficiary 10 1 - THL
Work package title Coordination
Start month 1 End month 36
Objectives
To coordinate the Joint Action through well-functioning management which includes timely reporting, budget control
and support for successful implementation.
Description of work and role of partners
WP1 - Coordination [Months: 1-36]
THL, RKI, INMI, BMASGK, MCA, CIPH, SUJCHBO, SSI, MSAE, MOH-FR, HCDCP(KEELPNO), NNK, SEMS,
MOHLT, MFH, RIVM, HD, NIZP-PZH, MS , IPHS, NIJZ, ISCIII, FOHM, DH, HSE, NAPH
Coordinator: THL
Co-Coordinators: INMI, RKI
Participating partners: all JA partners and affiliated entities
The JA includes 10 work packages:
- Horizontal: WP1 Coordination, WP2 Dissemination, WP3 Evaluation,
WP4 Sustainability and policy development, WP8 Training and local exercises, exchange of working practices;
- Core work packages: WP5 IHR core capacity strengthening and assessment, WP6 Preparedness and response planning;
WP7 Laboratory preparedness, WP9 Chemical safety and chemical threats and WP10 Case management and Infection
Prevention and Control Preparedness.
The Coordinator ensures that the project work packages work together in order to gain the objectives of the Joint
Action. The coordinator leads the project with the support of the steering committee, oversees the execution of the Work
Packages and may take part in their execution, as appropriate. The coordinator will facilitate the building of country
ownership together with the Work Package leaders.
Tasks of the Coordinator according to the Guide for applicants:
• Monitor that the action is implemented properly;
• Act as the intermediary for all communications between the beneficiaries and the Agency, unless the MGA specifies
otherwise;
• Request and review any documents or information required by the Agency and verify their completeness and
correctness before passing them on to the Agency;
• Submit the deliverables and reports to the Agency;
• Ensure that all payments are made to the other beneficiaries without unjustified delay;
• Inform the Agency of the amounts paid to each beneficiary, when required in the MGA or requested by the Agency,
or in the context of ex post Audits.
The management structure of the JA consists of THL Coordination Team, Steering Committee and Advisory Board. In
addition, each WP has its own leadership and internal meetings/teleconferences.
The Co-coordinators are responsible for supporting in quality assurance of deliverables and representing the joint action
in international meetings and conferences when Coordinator is unable to do it. More detailed ToR will be agreed with
the Coordinator.
Steering Committee (SC) is chaired by THL. Each WP has one vote in the SC, but both WP lead and co-lead can
participate. Observers are invited from Chafea, DG SANTE, ECDC and from other organisations as needed. The tasks
of the SC include support to the Coordinator in (i) supervising the overall project management and internal project
communication, (ii) monitoring the use of budget and agreeing on possible changes in the allocations, (iii) monitoring
the progress of the JA against the activities and timetable planned and agreeing on possible changes, (iv) reporting to
EC through THL.
The SC will meet at least 7 times during the implementation of the JA. The meetings will be organized in connection
of Kick-off meeting, Partnership Forums and other major meetings.
Page 9 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
In addition to meeting face-to-face, the SC will discuss current issues via phone/skype meetings at least every second
month.
In case of European cross-border outbreak, the SC can provide technical advice, if asked.
Advisory Board (AB) will be set up by the SC, and members will be invited from EC (Chafea, DG SANTE, DG ECHO),
the ECDC, WHO Europe, and other actors like e.g., IANPHI – the International Association of National Public Health
Institutes, Public Health Agency, Canada, SCHEER Rapid Risk Assessment Working Group for Chemical Threats and
JA Healthy Gateways, as well as other experts to be identified in the beginning of the action. The Steering Committee
of SHARP will decide whom to invite into the AB at its first meeting. The Board will choose a chairperson; and it will
advise the JA Steering Committee in substantial issues concerning the core work packages. The Advisory Board will
be invited to have their meeting in connection with Kick-off meeting and Partnership Forums, and the members will be
invited to the Closing conference. The Board is planned to have four meetings. The Steering Committee members will
participate at the AB meetings, and THL will act as a secretary.
Partnership Forum (PF) will consist of a representative of each competent authority and shall meet four times during
the project period (during Kick-off, 2 Partnership Forums and Closing conference). The Partnership Forum will be
consulted for major decisions of SC either at PF meetings or by silent procedure. Collaborating stakeholders will be
invited to participate at PF meetings on their own cost. They will have speaking, but no voting rights.
Collaboration with IHR NFPs and ECDC preparedness and response NFPs will be consolidated e.g. by inviting them
to the Thematic meeting on preparedness and IHR strengthening during Finnish presidency of EU.
A plan for conflict resolution will be developed having its basis in the Consortium agreement between partners.
Monitoring of the progress of the action is the responsibility of the coordinator, WP3 evaluation leadership and the
Steering Committee together.
The coordinator will work in tight collaboration with WP4 and other WP leaders in order to ensure sustainability of
the results of the action.
Activities:
1. Kick-off meeting (M2)
2. Two Partnership Forums (M12, M24)
3. Seven Steering Committee meetings (M2, M7, M12, M18, M24, M30, M36)
4. Four Advisory Board meetings (M2, M12, M24, M36)
5. Interim report (M18)
6. Thematic meeting on preparedness and IHR strengthening during Finnish EU Presidency (autumn 2019); to be
organized together with WP2 (M7)
7. Closing conference (M36)
8. Final report (M36).
Subcontracting:
1 – THL will use subcontracting to hire an expert to support EU presidency meeting planning and execution.
Participation per Partner
Partner number and short name WP1 effort
1 - THL 95.40
FFA 0.50
2 - RKI 4.00
UKF 0.20
BwIM 0.30
UMR 0.10
BNITM 0.20
3 - INMI 2.00
Page 10 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Partner number and short name WP1 effort
IZSPB 0.10
ISS 0.20
MoH 0.50
IZLER 0.40
4 - BMASGK 0.50
AGES 0.10
5 - MCA 0.50
6 - CIPH 0.20
7 - SUJCHBO 0.50
8 - SSI 0.50
9 - MSAE 0.30
HB 0.20
10 - MOH-FR 1.00
IHUMI 0.50
MOD-FR 0.10
INSERM 0.20
11 - HCDCP(KEELPNO) 1.50
NKUA 0.10
AUTH 0.50
12 - NNK 0.50
13 - SEMS 0.50
14 - MOHLT 0.50
NVSPL 0.50
15 - MFH 0.50
16 - RIVM 1.00
Erasmus MC 0.20
17 - HD 1.00
FHI 0.50
18 - NIZP-PZH 0.50
NVRI 0.50
19 - MS 1.00
INSA 1.00
20 - IPHS 1.75
21 - NIJZ 0.50
UL-MF 0.50
22 - ISCIII 0.50
Page 11 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Partner number and short name WP1 effort
SERMAS 0.10
BC 0.10
OSAKIDETZA 0.40
23 - FOHM 1.00
24 - DH 1.00
PHW 0.66
RFL 0.10
25 - HSE 1.00
26 - NAPH 0.50
Total 126.91
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
D1.1 Interim report 1 - THL Report Public 18
D1.2 Final report 1 - THL Report Public 36
Description of deliverables
D1.1 : Interim report [18]
Progress report for the first 18 months of the JA
D1.2 : Final report [36]
Final report of the action
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Kick-off meeting of the Joint
MS1 Kick-off meeting 1 - THL 2
action for all partners
Establishment of Steering The Steering Committee
MS2 Committee and Advisory 1 - THL 2 and Advisory Board will be
Board officially established.
Consortium agreement
MS3 Consortium agreement 1 - THL 4 between all partners of the
Joint action
Two Partnership forums will
MS4 Partnership Forums 1 - THL 24 be organised: 1st in M12 and
2nd in M24
Page 12 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Closing conference of the
MS5 Closing conference 1 - THL 36
Joint action
Page 13 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP2 Lead beneficiary 10 24 - DH
Work package title Communication and dissemination
Start month 1 End month 36
Objectives
To achieve efficient and effective visibility, awareness and acceptance of the project to internal and external stakeholders.
The stakeholders will cover the target groups defined at the proposal chapter 3, as well as other actors which will be
identified during stakeholder analysis (Task 2. 2)
Description of work and role of partners
WP2 - Communication and dissemination [Months: 1-36]
DH, THL, RKI, MCA, SUJCHBO, MOH-FR, HCDCP(KEELPNO), MFH, RIVM, HD, MS , IPHS, NIJZ, ISCIII
Lead: Public Health Wales – affiliated to DH/PHE
Co-lead: THL
A specific and appropriate communications and dissemination strategy ensuring visibility for, and awareness of, the
project will be developed, implemented and evaluated. The outcome of this will mean greater awareness of the Joint
Action and its benefits to the European population.
The communications WP aims to generate long term, sustainable benefits by increasing communications and
dissemination capability and capacity across the work packages.
The intention is to leave a blueprint for effective programme communications for future Joint Actions in collaboration
with WP4.
The Work package will address:
1. Dissemination about the project, its events, reports and results
2. Communication of key messages to relevant audiences, about the substance of the JA, including recommendations
This WP will comprise six phases of work described below:
Task 2.1: Set Communications Objectives (M1-3)
• Understand the business and public health objectives of the programme
• Set out specific communications objectives arising from these, including both internal programme communications,
and external communications
• Agree dissemination plan with the Joint Action Steering committee
• Develop and agree sign-off process for latter stages of communications strategy development
• Hold Communications Planning session with Programme Coordination Team to work through objectives and key
elements below to ensure these reflect and respond to the objectives set out by the other Work Packages.
Task 2.2: Audience Needs (M4-6)
• Identify and segment internal and external audiences for the programme
• Conduct stakeholder analysis, segmenting audience into levels of interest and influence in readiness for development
of channel strategy and key messages
• Hold communications workshops with Work package communications leads to understand their specific needs and
challenges (e.g. system maturity, technology);
• Identify language needs – including which countries have statutory duties to communicate in particular languages;
• Consider any specific cultural issues that will help or hinder effective communications, including language, access
to resources and channels in communications. The main communication language of the JA will be English, limited
amount of translations can be offered.
Task 2.3: Key Messages (M7-10)
• Produce and agree a set of key messages for each stage of the programme which reflect the work of the Work Packages.
• Tailor messages where appropriate
• Translate messages where appropriate
• Adapt messages to suitable channels
Task 2.4: Channels (M7-10)
Page 14 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
• Identify a channel mix, giving consideration to language requirements or whether a single overarching multilingual
channel is more appropriate
• Develop a channel strategy which will include actions on visibility and awareness, including use of social media.
Consider using conferences, journals, press releases alongside existing local communications networks specific to IHR
where these exist.
• Commission a bespoke website for the programme
• Set up social media channels like e.g. Twitter, LinkedIn, Facebook etc.
• Identify long-term, sustainable ownership for channels
• Commission programme branding to run through all channels and other project documentation
Task 2.5: Communications planning (M9-12) and implementation (M11- 35)
• Develop a communications plan incorporating the above elements, including tailored communications toolkits for use
by Work package leads
• Work with WP1 to disseminate project aims, progress and results, especially in connection with the Kick-off meeting,
two Partnership Forums, the thematic meeting during Finnish EU presidency in autumn 2019 and Final meeting of
SHARP.
• Work with WP8 to ensure coordinated dissemination of toolkits above alongside exchange of working practices.
• Implement communications plan
Task 2.6: Measurement and evaluation of communications activity (M1-2, 12, 24, 34-36)
• Work in collaboration with WP3 to set and agree communications evaluation indicators from the beginning
• Support the development of communications evaluation report after 12 and 24 months, amending communications
plan if appropriate
• Work alongside WP3 to support and participate in full dissemination evaluation in months 34-36
• Handover plan for decommissioning/ closure. This should include plans for sustainable way forward following the
end point of the Joint Action. This will require linking in with a range of existing dissemination structures from within
the members states, and will be done in collaboration with WP4.
Participation per Partner
Partner number and short name WP2 effort
1 - THL 6.00
2 - RKI 0.10
5 - MCA 0.50
7 - SUJCHBO 0.90
10 - MOH-FR 0.50
IHUMI 0.50
MOD-FR 0.10
11 - HCDCP(KEELPNO) 1.50
15 - MFH 0.25
16 - RIVM 0.65
17 - HD 0.00
FHI 0.20
19 - MS 1.00
20 - IPHS 2.83
21 - NIJZ 1.00
22 - ISCIII 0.50
24 - DH 1.20
Page 15 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Partner number and short name WP2 effort
PHW 22.57
Total 40.30
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
D2.1 Leaflet 24 - DH Report Public 3
Websites,
D2.2 Website 24 - DH patents Public 4
filling, etc.
D2.3 Layman report 24 - DH Report Public 36
A blueprint of
D2.4 24 - DH Report Public 36
dissemination
Communication and
D2.5 24 - DH Report Public 36
dissemination report
Description of deliverables
D2.1 : Leaflet [3]
Leaflet to promote the action
D2.2 : Website [4]
A website to inform about and promote the Joint action
D2.3 : Layman report [36]
Layman report of the final report
D2.4 : A blueprint of dissemination [36]
A blueprint of dissemination for future Joint Actions
D2.5 : Communication and dissemination report [36]
Final report of the Communication and dissemination work package
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Stakeholder analysis for
MS6 Stakeholder analysis 24 - DH 4 targeting the dissemination
activities
Communications plan
MS7 Communications plan 24 - DH 9
including key messages
Communication channel Channel strategy prepared,
MS8 24 - DH 9
strategy including social media
Page 16 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP3 Lead beneficiary 10 11 - HCDCP(KEELPNO)
Work package title Evaluation of the action
Start month 1 End month 36
Objectives
To perform a systematic and objective assessment of the relevance, efficiency, effectiveness, impact, economic and
financial viability, as well as sustainability of the project in the context of its objectives.
Description of work and role of partners
WP3 - Evaluation of the action [Months: 1-36]
HCDCP(KEELPNO), THL, RKI, INMI, MCA, SUJCHBO, MOH-FR, NNK, MFH, RIVM, HD, MS , IPHS, NIJZ,
ISCIII, FOHM, DH
The expected results of this Work Package are:
• An evaluation plan/strategy and interface developed to be used by all project partners
• Methods and tools for internal project progress monitoring, quality assurance indexing and internal evaluation
procedures developed
• The project’s progress and timekeeping monitored
• Intermediate and final project results and outcomes evaluated
• Possible deficiencies in work packages’ tasks identified, as well as mitigation strategies proposed, so that deliverables
meet set quality standards.
The evaluation will draw on routine reports produced by the partners during implementation and will include additional
investigations by external experts.
The WP tasks are broken down as follows:
Task 3.1 Evaluation plan development
The evaluation plan will examine the process, outputs and outcome(s) (internal, external) of the WPs of the project
through systematic review in terms of results (if objectives were met) as well as in terms of quality standards met.
The common evaluation plan will be designed based on the information regarding the finalized tasks of each WP and
planned milestones, available at M1 from each WP leader.
Furthermore, the evaluation plan will present the methodology which will be used for the internal and external evaluation
of the Project. It will specify the evaluation strategy and objectives, indicators (based on Specific objective tables in
chapter 2.2.), as well as the expected outcomes, deliverables and milestones. It will also define:
• the standards that will be used,
• the internal monitoring system
• the timetable for the key stakeholders involved.
Finally, it will present the external evaluation procedures including evaluation criteria, questions, indicators (2.2) and
data collection and analysis methods.
Task 3.2 On-going internal evaluation
Internal evaluation procedures will be applied throughout the duration of the project and will emphasize on the efficacy
of WP tasks, focusing on:
• Measuring to what extent the project’s general and specific objectives have been achieved.
• Assessing the processes related to the project, to ensure that the project activities are implemented as expected.
• Measuring to what extent the project has reached / achieved its main outputs (deliverables, milestones, main results).
• Measuring to what extent the outcomes of the project, meet the needs of the project’s target groups identified by WP
leads
• Measuring to what extent the project has engaged other sectors on national level (e.g. food safety, environmental
health, civil protection)
At mid stage of the project cycle, a process evaluation (formative) will take place, focusing on the planning and
organization of the project activities. In particular, on whether
- activities were implemented according to the initial plan,
- obstacles and difficulties were swiftly detected and mitigated
Page 17 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Standard evaluation tools (i.e. surveys and interviews) will be used to extract preliminary results, regarding the
timeliness and implementation quality of WP tasks. The role of the mid-stage evaluation is to provide feedback as far as
potential changes required in order to improve processes and activities of the project, increasing their potential impact
on its set target groups.
The evaluation tools (a log-frame matrix for each WP, a master scoring model, a set of summative and formative tools
both quantitative and qualitative as Dartboard, structured and/or semi-structured interviews, focus groups etc.) used for
evaluating the JA deliverables will be based on a set of indicators on the implementation of planned activities. Outcome/
output measurements will serve as a continuous assessment tool for each WP. All deliverables and information from
meetings and training events and workshops (agenda, participants’ lists and minutes) will be collected and analyzed for
evaluation purposes. Organizers and participants of all events and meetings will be called to participate in a combination
of formative and summative evaluation surveys.
The final internal evaluation report will include a tool that can be used to evaluate the project impact beyond its duration.
A sustainability plan for the evaluation tool will be incorporated in the framework of task 4.3 of WP4“Development of
the SHARP sustainability plan” with the cooperation of the WP3 and WP4 leaders. This simple evaluation tool will assist
policy makers and users of SHARP-related actions to effectively assess impact beyond the project's implementation
period and provide valuable information on what worked and what not and effectively help planning for future projects
and Joint Actions. It will be drafted at the last month of the project (M36).
The co-coordinators (RKI and INMI) are tasked with performing quality control and assessment of the Joint Action
deliverables (see WP1). This constitutes an integral part of the internal evaluation process and WP3 will coordinate its
activities closely with these partners.
Task 3.3 External Evaluation of the effect and impact of the JA
The external evaluation will ensure the objectiveness in the evaluation process. Independent evaluator will concentrate
on the impact of the JA and will determine the relevance, effectiveness, outcome and impact of the JA activities in the
light of its objectives. It will focus on whether the stated objectives and related indicators (2.2) have been achieved,
measuring at the same time the level of the target group’s satisfaction through quantitative and qualitative methods. It
will be performed by independent external evaluators procured by the WP leader. The Terms of Reference for external
evaluation will be agreed with the Steering Committee of the JA and the external evaluators will be selected after
tendering in collaboration with the SC. The external evaluators will participate in selected project meetings.
External evaluation will not be ongoing. Instead, we will task the external evaluation team for two work cycles. The
first Cycle A between M18 and M24, and the second Cycle B between M31 and M36. The activities of the external
evaluation are summarized as follows:
Phase 0: Preparatory phase
• The WP leader will set up the reference group, write the terms of reference and will recruit the external evaluation team
according to the foreseen procurement procedures. The external evaluator will be mobilized by M18. The preceding
period of 6 months will be dedicated to the procurement of the external evaluation, i.e. preparation of terms of reference
and their publication, award of external evaluator and contracting.
Phase 1: Desk Phases: Cycle A (M18-24), Cycle B (M31-36)
• The appointed external evaluation team will analyze the logic of the project. A set of key performance indicators will be
proposed and validated by the external evaluation team in cooperation with the Steering Committee taking into account
the process, output and outcome indicators defined in the specific objective tables of the work packages. A meeting
of the Steering Committee, the WP leader and the external evaluator team will take place on M18; A methodological
approach for the external evaluation will be mutually agreed between the evaluator and the SC prioritizing the evaluation
of the JA’s results and outcomes on a predefined assembly of target group representatives.
• The objectives achieved in the revised period of the JA will be examined, vis-a-vis the original planning and project’s
award criteria. The information will be mapped against the areas of evaluation questions which focus primarily on issues
related to
- Relevance
- Efficacy
- Impact (only limited evaluation possible in this phase, real impact can be seen only one or more years after closing
of the Project)
- Sustainability
• The team will specify the indicators and will provide answers to the questions on the basis of existing information.
Page 18 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
• It identifies the assumptions remaining to be tested in the field and develops its work plan for data collection and
analysis.
During the Cycle A and B the external evaluator will review respectively a number of documents produced at the given
point of the project implementation.
The action of external evaluators will include target groups (internal and external) to be agreed from the beginning and
the orientation of the evaluation will be based on the impact of the actions of the program on these target groups
Phase 2: Field phase
• The evaluation team will implement its work plan for data collection. It will apply preferred techniques (surveys,
interviews, case studies etc.) and will test the assumptions. This will allow the assessment of the degree of the project’s
impact on the target groups that will be explicitly described at the Desk Phase in collaboration with the SC (Policy
makers, national focal points, relevant authorities, health providers and EU citizens where applicable).
Phase 3: Synthesis phase
• The evaluation team will draw up its reports (with deadlines for the midterm on M24 and for the final on M36),
which will include the findings and conclusions as a response to the questions asked, as well as an overall assessment
of the projects impact. The first report will include recommendations for improvement in some aspects of the JA when
needed. . The reports will first be sent as a draft to the Steering Committee of the JA, four weeks before the finalized
report. The comments will be included where applicable, after which the report will be finalized and communicated.
• The final report will be subject to a quality assessment.
The final external evaluation report will comprise of the findings of the evaluation as well as recommendations for
future projects and lessons learned. It will assess the measured impact of the JA to the specified target groups to the
extent it will be possible at this phase and as it was expected by the applicants of the JA SHARP. In specific, they will
assess the extent of support to the implementation of Decision 1082/2013/EU on serious cross-border threats to health
and to which degree the target groups have consistently strengthened their core capacities improving EU’s preparedness
against health threats. In effect, the evaluator will assess the outcome referring to developed/sustained capacities and
added value, the impact on society and expected sustainability.
Phase 4: Dissemination and follow up phase
After informing the partnership, the evaluation (report, executive summary, article and/or presentation) will be
disseminated to the relevant project stakeholders.
Evaluation tools to be utilised:
- Evaluation surveys (to random sample and/or preselected target group representatives)
- Participation in selected project meetings
- In-depth interview with all WP leaders.
- Development of a tool to monitor results and outcomes during the project but also for evaluating impact and
sustainability
The lead partner of this WP is KEELPNO (GR). However, all partners will be mobilized during its activities, especially
the leaders of all WPs. WP4, sustainability and policy development will be particularly involved, as one key desired
outcome of the project would be the establishment of sustained IHR core capacity in all partner countries.
Subcontracting
11 – HCDCP will subcontract experts for external evaluation as described above.
Participation per Partner
Partner number and short name WP3 effort
1 - THL 1.00
2 - RKI 0.10
3 - INMI 0.50
5 - MCA 0.50
7 - SUJCHBO 0.90
Page 19 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Partner number and short name WP3 effort
10 - MOH-FR 0.75
IHUMI 1.00
MOD-FR 0.10
11 - HCDCP(KEELPNO) 53.00
12 - NNK 1.00
15 - MFH 0.25
16 - RIVM 1.10
Erasmus MC 0.30
17 - HD 0.00
FHI 0.20
19 - MS 1.50
20 - IPHS 2.00
21 - NIJZ 1.00
22 - ISCIII 0.50
23 - FOHM 1.00
24 - DH 1.40
Total 68.10
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
D3.1 Evaluation plan 11 - HCDCP(KEELPNO) Report Public 3
Midterm internal
D3.2 11 - HCDCP(KEELPNO) Report Public 24
evaluation reports
Final internal evaluation
D3.3 11 - HCDCP(KEELPNO) Report Public 36
report
Midterm external
D3.4 11 - HCDCP(KEELPNO) Report Public 24
evaluation report
Final external evaluation
D3.5 11 - HCDCP(KEELPNO) Report Public 36
report
Description of deliverables
D3.1 : Evaluation plan [3]
A developed and approved evaluation plan including objectives, methodology, indicators and time plan. The
evaluation plan will be based on a baseline assessment.
D3.2 : Midterm internal evaluation reports [24]
The interim report will serve to fine tune and adjust activities and priorities in the second half of the JA. It will be
a formative review of the progress, achieved up to that point, in relation to budget criteria, quality criteria, time
Page 20 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
and effectiveness criteria. The report will also provide recommendation for improvements in the second half of the
project, where applicable. It will be drafted on the end of each year (M12, M24).
D3.3 : Final internal evaluation report [36]
Final evaluation report will include the comprehensive assessment to what extent the aims and objectives are met. It
will be a summative review of all activities conducted. The report will examine the project’s achievements, vis#a#vis
the original planning. The final report will include a tool that can be used to evaluate the project impact beyond its
duration (see the WP description).
D3.4 : Midterm external evaluation report [24]
The external evaluators will draft in the middle of the project duration a report stating the progress so far (M24).
D3.5 : Final external evaluation report [36]
The final findings of the impact assessment will be reported. It will depict the assessment of the project achievements
in relation to the results planned, identify strengths and weaknesses as well as factors that have impeded the
achievement of the planned objectives.
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Meeting with all WP leads to
Planning meeting with WP
MS9 11 - HCDCP(KEELPNO) 2 plan evaluation (in connection
leads
with the kick off meeting)
Evaluation plan ready and
MS10 Evaluation plan 11 - HCDCP(KEELPNO) 3
evaluation tool available
External evaluation procured
MS11 External evaluation mobilised 11 - HCDCP(KEELPNO) 18 and the external evaluation
team is mobilized
Presentation of the internal
Presentation of the internal
MS12 11 - HCDCP(KEELPNO) 24 evaluation results at the
evaluation results
meetings in M12 and M24
Page 21 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP4 Lead beneficiary 10 10 - MOH-FR
Work package title Integration in National Policies and Sustainability
Start month 1 End month 36
Objectives
The specific objective of this WP is to integrate best practices on IHR and preparedness in national policies and improve
cooperation mechanisms between EU Member states.
Description of work and role of partners
WP4 - Integration in National Policies and Sustainability [Months: 1-36]
MOH-FR, THL, RKI, MCA, SUJCHBO, MSAE, MFH, RIVM, IPHS, NIJZ, FOHM, DH
Key activities carried out by the different WPs of this Joint Action are expected to improve preparedness and response
planning, and the purpose of this WP is to build a sustainability plan, to ensure uptake and sustainability of the
Joint Action outcomes from WP5 to WP10 at EU, national and/or regional level, and enabling to comply with the
implementation of the IHR (2005) and relating Decision 1082/2013/EU.
Task 4.1. Guidance tool (M7-13)
Task leader: MOH-FR
Participants: THL (FI), PHW (UK), HCDCP (GR), RIVM (NL), FOHM (SE), HD (NO), ISCIII (ES), RKI (DE), INMI
(IT), IPHS (RS), PHE/DH (UK), NIJZ (SI)
The purpose of task 4.1 is to develop a guidance tool aiming at ensuring that all core WPs take into account the
sustainability of their outcomes within their work and reports. WP4 task leaders will closely follow-up and contribute
to the work done by other WPs through participation at meetings, iterative process of deliverables, observation and
guidance on other WP’s outputs. A workshop will be organized with the Steering Committee members to draft the
guidance frame.
Task 4.2. Selection of best practices (M12-18)
Task leader: RIVM-NL
Participants: THL (FI), PHW (UK), HCDCP (GR), RIVM (NL), FOHM (SE), HD (NO), ISCIII (ES), RKI (DE), INMI
(IT), IPHS (RS), PHE/DH (UK), NIJZ (SI), SUJCHBO (CZ).
The purpose of task 4.2 is to select best practices for integration into sustainability plan. Pilot actions supporting a
sustainable integration of best practices will be developed based on the interim internal evaluation report (M12) in
collaboration with WP3, and based on the review of the existing IHR and laboratory preparedness and response tools
and mechanisms done by WP6. Identified actions will be included into the sustainability plan. This selection will be
developed in close collaboration with the Health Security Committee, during its bi-annual meeting. A workshop 2 (M18)
will be organized with the Steering Committee, the Advisory Board and the Health Security Committee to review those
selected outcomes and confer about the next steps, to be included in the sustainability plan and national policies. The
integration of some selected best practices into national policies will be piloted throughout the project in collaboration
with other WPs.
Task 4.3. Development of the SHARP sustainability plan (M19-24)
Task leader: MOH-FR
Participants: THL (FI), PHW (UK), HCDCP (GR), RIVM (NL), FOHM (SE), HD (NO), ISCIII (ES), RKI (DE), INMI
(IT), IPHS (RS), PHE/DH (UK), NIJZ (SI), MCA(B/H), MFH (Malta).
The purpose of this task is to develop a generic sustainability plan to foster long term integration of selected WP
outcomes into EU/ national / regional policies and mechanisms and to define the conditions for operationalization.
It will include a selection of priorities and best practices, the identification of required resources (budget, training,
HR) and partners to be involved, an advocacy strategy on identified priorities in coordination with WP2 and WP3,
and a sustainable communication and coordination between Member States. This sustainability plan will be developed
in close collaboration with WP1 and WP5 and the Health Security Committee members, to ensure optimal uptake.
It is expected to contribute to the objectives and indicators related to national legislations, policy and financing, as
outlined in particular in WHO Joint External Evaluation tool. A workshop 3 involving SHARP Steering Committee
and Advisory Board as well as the EC Health Security Committee members will be organized to present a final draft
of the sustainability report at M24.
Page 22 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Participation per Partner
Partner number and short name WP4 effort
1 - THL 2.00
2 - RKI 0.10
5 - MCA 0.50
7 - SUJCHBO 4.00
9 - MSAE 0.20
10 - MOH-FR 32.00
15 - MFH 0.50
16 - RIVM 3.60
Erasmus MC 0.60
20 - IPHS 2.40
21 - NIJZ 3.00
23 - FOHM 2.00
24 - DH 0.50
Total 51.40
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Guidance on
D4.1 10 - MOH-FR Report Public 7
sustainability
D4.2 Sustainability Report 10 - MOH-FR Report Public 24
Description of deliverables
D4.1 : Guidance on sustainability [7]
Guidance tool to ensure that sustainability is taken into consideration by all WPs throughout the Joint action
D4.2 : Sustainability Report [24]
Sustainability Report on SHARP sustainability strategy, that will include for each topic (i.e. each WP) priorities and
concrete examples of integration into national plans and for regional organizations, including required training and
communication strategies
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
A workshop will be organized
with the Steering Committee
MS13 Workshop on guidance tool 10 - MOH-FR 7
members to draft the guidance
on sustainability.
Page 23 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
A workshop with the Steering
Committee, the Advisory
MS14 Workshop on best practices 10 - MOH-FR 18 Board and the Health Security
Committee to review selected
best practices
Presentation of sustainability
report at workshop 3 and
Approval of sustainability
MS15 10 - MOH-FR 24 final approval of the SHARP
plan
sustainability plan by the
stakeholders
Page 24 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP5 Lead beneficiary 10 23 - FOHM
Work package title IHR core capacity strengthening and assessment
Start month 1 End month 36
Objectives
Specific objective of the work package is to improve core capacity in EU Member States as required by IHR and
Decision 1082/2013/ EU.
Description of work and role of partners
WP5 - IHR core capacity strengthening and assessment [Months: 1-36]
FOHM, THL, RKI, INMI, MCA, CIPH, MOH-FR, HCDCP(KEELPNO), SEMS, MOHLT, MFH, RIVM, HD,
NIZP-PZH, MS , IPHS, NIJZ, ISCIII, DH, NAPH
Expected results
1. Participating lower GNI countries who have not conducted a Joint External Evaluation (JEE) supported to get prepared
for an external assessment of their IHR Core Capacity, i.e. JEE or other agreed standardised external evaluation process;
countries helped in the assessment of capacity for future development and sustainability of necessary core capacity as
required by IHR and Decision 1082/2013/EU;
2. Participating lower GNI that have conducted a JEE; assisted by addressing problem areas identified in the post JEE
country reports.
3. Challenges in national and international collaboration between governments and national authorities identified, and
measures elaborated for the operationalization of obligations related to response from health systems, cross-sectoral
efforts and effective assistance between Member States when needed
4. The usefulness of using information from national and international exercises and after action reviews in assessing
the state of public health preparedness in the EU evaluated
Within the work package, up to twelve selected lower GNI countries will be funded for participation in the planned
workshops and teleconferences/webinars and for preparatory work in between. The activities will be divided into four
main parts; the first part focusing on increasing knowledge about the evaluation process and best practice in preparation
it, the second part focusing on post-evaluation follow up of joint identified weaknesses in core capacities, the third
part focusing on cross country collaboration in emergencies, the fourth part on assessing the usefulness of including
exercises and after action reviews in evaluations of preparedness.
Task 5.1 – Improving IHR implementation
Lead: SE (FoHM); Co-lead: SI (NIJZ), LT(SEMS), PL (NIZP-PZH)
Participants: GR (HCDCP), ES (ISCIII), HR (CIPH), LT (MOHLT), MT (MFH), RS (IPHS), BA (MCA), MD (NAPH),
FI (THL), IT (MOH), FR (MOH), UK (DH/PHE), NL (RIVM), NO(FHI)
Workshops and teleconferences/webinars - Workshops under subtasks 5.1.1 and 5.1.2 will be hosted together to further
enable exchange of knowledge between countries. Workshops 1 and 2 will be joint and hosted by SEMS (SI), workshops
3 and 4 will be joint and hosted by NIJZ (LV) and workshops 5 and 6 will be joint and hosted by NIZP-PZH (PL).
Partners from low GNI-countries included in this WP will participate in all workshops. Partners from participating high
GNI countries (NL, IT, UK, FI, DE, except SE and NO that leads WP) will participate to share knowledge and best
practice (when applicable).
Subtask 5.1.1 – Increasing knowledge about the practicalities and added value of external evaluation processes Activities
supporting expected result 1
Workshops 1, 3 and 6
Participation
IHR national focal points and/or participants from national public health agencies (or analogous as applicable)
responsible for IHR implementation from lower GNI countries as well as representatives from WHO and ECDC and
other partner countries who have already performed a JEE and can contribute with knowledge of the process, benefits
and challenges with it.
Outcome
Selected low GNI countries will have been assisted in preparing for a JEE by information and best practice sharing from
other participating countries thereby gaining better knowledge about the JEE process and how to prepare for one should
they decide to do one. This process by itself will increase the participating countries knowledge on IHR preparedness
and thereby their general preparedness. The knowledge gained will be tested by pre- and post- work out questionnaires.
Page 25 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Subtask 5.1.2 Facilitating strengthening of selected core capacities. Workshops 2,4 and 6
For selected countries that who have already performed a JEE
Three common areas in need of further development as identified by evaluation of the JEE country reports and the
post JEE country action plans (if existing) will be addressed in yearly workshops and yearly follow up teleconferences/
webinars. For each area representatives of countries and experts with expertise in specific areas will be invited to share
their knowledge and best practice.
Participation
IHR national focal points and/or participants from national health agencies responsible for IHR implementation from
low GNI countries who have performed a JEE as well as representatives from WHO and ECDC and invited experts from
countries who have expertise in the problem areas chosen. Needs in relation to training or specific technical competence
for example chemicals, will be addressed in collaboration with the appropriate work package.
Objectives
Selected low GNI countries who have conducted an external evaluation will be assisted in how to solve and proceed
to increase their preparedness by addressing selected common core capacity challenges identified in their JEE country
reports.
Outcome
Participating countries will through workshops and practical sharing of best practices have a better understanding on
how proceed to increase preparedness in identified areas in need of strengthening.
Task 5.2 International collaboration between authorities during crisis (Task Lead: HD) Two workshops will be arranged:
5.2.1 Workshop on international collaboration between authorities during crisis (M34) (Host: MS and INSA Portugal)
To find out if there is a need for an agreement of intention between neighboring countries to assist each other in the
event of large scale emergencies; and to define what are the main obstacles against receiving help or assisting. A major
conclusion from the Ebola outbreak is that there is a need for improving the implementation of state obligations (Decision
1082/2013/EU and IHR 2005 annex 1) to establish core capacities related to public health response which will require
national and international coordination. Prerequisites for the participating member states: The sending and receiving of
patients, personnel and capacities is a multi-sectoral effort; competent authorities participating in this workshop should
identify key challenges for them in the event of a large-scale public health emergency where cross-border assistance
is needed before participating in the WS.
A table-top exercise will be organized as part of the workshop on the following topics:
• Possible scenarios for a prepared discussion related to health system response and civil preparedness response could
be: Certification/authorization of health care personnel and national legal obstacles
• Legal issues related to personnel operating in another country o Donor country or recipient country
o Employer responsibility
o Responsibility for insurance – personal safety, malpractice
• Pull-out clause
• Financial – who pays, how to create predictability
• Medical issues related to AMR, as AMR situation is important for the choice of treatment protocol locally. In some
countries (e.g. Norway) health care workers who test positive to MRSA are not allowed to have patient contact. Patients
would also be isolated until tested negative. This problem is likely to increase in the future and should be addressed.
• Medical practices – i.e. which protocols to follow, who leads the medical team, etc.
• Practical, i.e. responsibility and minimum requirements for transport, logistics, security, housing
Participation
Competent authorities from health and civil protection (one from each) in line with the workshop objectives. Objectives
To identify key challenges in national and international collaboration between governments and national authorities,
and to elaborate on measures for the operationalization of obligations related to response from health systems, cross-
sectoral efforts and effective assistance between member states when needed.
Outcome
The WS will support relevant government authorities in preparedness planning and health emergencies response.
5.2.2 Workshop on cooperation between public health and civil protection and on clinical consultation
The objective of the workshop is to identify key challenges in national and international collaboration between
governments and national authorities, and to elaborate on measures for the operationalization of obligations related
to response from health systems, cross-sectoral efforts and effective assistance between member states when needed.
Norwegian experience during the 2014 Ebola crisis was that many cross border legal issues had to be solved to enable
operation abroad. Legal issues are thus highlighted in the workshop.
The workshop will have two main topics:
Page 26 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1. Cooperation between public health and civilc protection: Both the public health perspective and the civilc protection
mechanism build capacities to be able to send human and other resources across borders (Lead: HD). Thus ResEU build
rapid response capacities including medical units (EMTs) to be deployed when national capacities are insufficient or
overwhelmed. It is necessary to discuss which legal issues need to be solved in order to send and receive help in a
timely manner. There is a need to harmonize these responses and increase cooperation between national sectors and the
European Commission (DG SANTE, DG ECHO) and WHO respectively in order to avoid duplication. The following
topics have been raised for discussion:
• What would be the respective role of the different actors (MS, DG SANTE, DG ECHO and WHO), how do they
complement each other
• What would be the trigger for involving the civil protection, in what type of scenarios
• How to ensure that communication flows between the different actors, both on national level and on international level
• Where would be the added value of the civil protection mechanism compared to the pure health responders
2. Clinical consultation: in collaboration with WP10
Task 10.3 in WP10 aims to discuss the feasibility of an expert clinical consultation and support service. In this task
of WP5, the need for a legal framework for patient referral, for trans-country medical consultation, and for clinical
information exchange is raised as challenges to be addressed, A legal framework for trans country medical consultation
should be in place to fulfill the obligation according to IHR (2005) chap 13 annex 1 (g) to: " establish, operate and
maintain a national public health emergency response plan, including the creation of multidisciplinary/multi sectoral
teams to respond to events that may constitute a public health emergency of international concern; (h) to provide the
foregoing on a 24-hour basis."
Lead: INMI, co-lead: MOH-FR Participation
Competent authorities from health and civil protection including legal competence in line with the workshop objectives
from 3 high GNI countries (NO; FR; IT and 3 low GNI countries PO; LT:RO - all to be confirmed) and representatives
from DG SANTE, DG ECHO, ECDC and WHO.
Outcome
The WS will support relevant government authorities need for preparedness planning and health emergencies response.
To be presented and discussed in Workshop 5.2.1
Task 5.3. Feasibility of using information from national and international exercises and after action reviews in assessing
state of public health preparedness in the EU – Expected result 4
Task Lead: NO (NIPH)
Support efforts and initiatives from ECDC, WHO and their collaborating centre RIVM, and building on exercises and
after action reviews conducted as part of the JA (especially linked to WP8)
Participation
In coordination with ECDC and WHO EURO, all participating countries will be including, with focus on low GNI
countries
Objectives
To support ongoing processes lead by ECDC and WHO to compile and use the results of preparedness exercises and after
action reviews systematically to inform the monitoring and evaluation of IHR (2005) core capacities and implementation
of Decision 1082/2013/EU at the European level.
Outcome
Improved use of results from exercises and AAR as part of a comprehensive monitoring and evaluation strategy for
IHR (2005) core capacities and implementation of Decision 1082/2013/EU at the European level.
Participation per Partner
Partner number and short name WP5 effort
1 - THL 2.00
2 - RKI 0.10
3 - INMI 0.00
MoH 0.75
5 - MCA 8.00
6 - CIPH 7.65
Page 27 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Partner number and short name WP5 effort
MH-BSI 4.50
10 - MOH-FR 4.50
SPF 0.70
11 - HCDCP(KEELPNO) 10.00
13 - SEMS 38.00
14 - MOHLT 3.00
15 - MFH 2.00
16 - RIVM 1.00
17 - HD 19.50
FHI 8.00
18 - NIZP-PZH 20.00
19 - MS 5.50
20 - IPHS 16.45
21 - NIJZ 17.00
22 - ISCIII 4.00
23 - FOHM 23.25
24 - DH 2.05
26 - NAPH 3.50
Total 201.45
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
D5.1 WP5 Work plan 23 - FOHM Report Public 5
Reports on improving
D5.2 23 - FOHM Report Public 36
IHR implementation
Confidential, only
Report on international for members of the
D5.3 collaboration between 17 - HD Report consortium (including 34
authorities during crises the Commission
Services)
Report on the use
D5.4 23 - FOHM Report Public 36
exercises and AAR
Description of deliverables
D5.1 : WP5 Work plan [5]
Work plan with selected challenges/gaps
D5.2 : Reports on improving IHR implementation [36]
Page 28 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Reports on knowledge and practices and added value of external evaluation processes and facilitating strengthening
of selected core capacities in the EU and neighboring countries (M12, 24 ,36)
D5.3 : Report on international collaboration between authorities during crises [34]
Report on international collaboration between authorities during crises based on implementation of Task 5.2.
D5.4 : Report on the use exercises and AAR [36]
Report on the use of exercises and AAR as part of monitoring for IHR (2005) core capacities and implementation of
Decision 1082/2013/EU at the European level.
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
WP5 workshops 1 and 2
MS16 WP5 Workshop 1 and 2 23 - FOHM 10
organised
MS17 Table-top exercise 17 - HD 34 Table-top exercise organised
WP5 workshops 3 and 4
MS18 WP5 Workshop 3 and 4 23 - FOHM 22
organised
WP5 workshops 5 and 6
MS19 WP5 Workshop 5 and 6 23 - FOHM 34
organised
Page 29 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP6 Lead beneficiary 10 16 - RIVM
Work package title Preparedness and Response planning
Start month 1 End month 36
Objectives
The specific objective of WP6 is to support EU MS and JA partner countries in developing operational inter-sectoral
preparedness and response plans for serious cross-border health threats with an integrated all hazards approach
Description of work and role of partners
WP6 - Preparedness and Response planning [Months: 1-36]
RIVM, THL, RKI, INMI, BMASGK, MCA, CIPH, SUJCHBO, MOH-FR, NNK, SEMS, MOHLT, MFH, NIZP-
PZH, MS , IPHS, NIJZ, ISCIII, DH
Lead: RIVM (NL)/EMC (NL); Co-lead: ISCIII (ES)
Expected Results:
1. Development of an integrated multisectoral preparedness and response plan
2. Scenario for “Disease X” developed, simulated and evaluated
3. All hazard e-learnings and tabletop exercise protocols, using different methods for multisectoral collaboration
developed, tested and evaluated
4. Best practices guidelines, both general and tailor-made standards for all hazard integrated preparedness and response
planning are provided to all participating countries. These are based on analysis of performances from “Disease X”
scenario simulation and all hazards e-learnings and tabletop exercises, performed in WP6.
The specific objective of the WP6 will be achieved through the following tasks:
Task 6.1: Identifying core elements of an integrated multi-sectoral preparedness and response plan
Lead: RIVM; Participants: FI (THL and FFA), DE (RKI), IT (INMI and MoH), AU (AGES), UK (DH/PHE), ES (ISCIII)
BA (MCA), HR (CIPH and UHID), CZ (SUJCHBO), HU (NNK), LV (SEMS), LT (MOHLT), MT (MFH), PL (NIZP-
PZH and NVRI), PT (MS), RS ( IPHS), SI (NIJZ).
Identification of core elements in the available IHR assessment tools in the Member States and JA partner countries for
the different sectors (e.g. public health, clinical, biological and chemical). The specific needs and minimum requirements
for the sectors involved in the IHR Preparedness and Response cycle (as defined in the ECDC Health Emergency
Preparedness Self-Assessment (HEPSA) Tool) will be identified.
6.1.1: Review of international and/or national tools and planning instruments for preparedness and response focused on
multisectoral integration for the public health laboratory services, clinical and chemical sectors
Lead: RIVM/EMC; input from WP5, WP7, WP9, WP10
6.1.1.2 Literature review
This integrative review of literature, websites, search for grey literature and collection of not-published tools used in
practice by the participating countries will enlighten how different sectors and countries define “core elements”. This
will be carried out to reach common understanding of terms, to find out which core elements are available and/or applied
in preparedness and response planning for different sectors (i.e. public health, clinical, chemical, and others) and to
identify gaps and overlaps. The outcome of the literature review will serve as basis for the subsequent workshop 6.1.1.3.
6.1.1.3 Workshop
Lead: MS, Portugal
Multisectoral collaboration: A workshop will be organized with the aim to collect relevant tools, instruments or core
elements that were not identified in the literature review, or have different meaning or weight for different sectors or
countries. The starting point for this workshop will be the outcome of the Literature review 6.1.1.2 as well as identified
existing documents, such as ECDC Health Emergency Preparedness Self-Assessment (HEPSA) Tool, the Joint External
Evaluation (JEE) reports, the, EU Laboratory Capability Monitoring System (EULabCap, 2016), WHO Laboratory
assessment tool (2012), and the WHO Strategic framework for emergency preparedness (2017) (https://ecdc.europa.eu/
sites/portal/files/documents/2016_EULabCap_EUreport_web_300418_final.pdf;
https://www.who.int/ihr/publications/laboratory_tool/en/; https://www.who.int/ihr/publications/9789241511827/en/)
and other documents as suggested by the experts from WP7, WP9 and WP10, and documents to be identified.
Page 30 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Outcome should be mutual understanding and agreement of terms, tools, instruments and core elements in the integrated
multi-sectoral preparedness and response plans. Including other relevant sectors, for example the veterinary sector more
tightly into the multi-sectoral plan will be discussed.
6.1.2: Achieving consensus among countries on the core elements of a multisectoral preparedness and response plan
Lead: RIVM/EMC, input from WP4 – W10
A checklist of preparedness and response aspects will be developed for sectors integrated in the Preparedness and
Response cycle, including highly specialized laboratories.
6.1.2.1 Expert meeting
Lead: MFM/DEH, Malta
Consensus meeting on core elements of integrated multisectoral preparedness and response plans, most relevant to the
“Disease X” scenario and the critical process steps for further development of the scenario.
Following the outcome of Workshop 6.1.1.3, consensus of the core elements within the integrated multisectoral
preparedness and response plan will be reached. These core elements are translated into practical tools and instruments
for simulation “Disease X” scenario with emphasis on applicability in different countries, including low GNI countries.
6.1.2.2 Expert online consultation and agreement
This (online) consultation will address the agreed core elements from the expert meeting, their applicability in low GNI
countries, inventory of expertise available, and minimum required and needs for adaptation to optimize the pay-off
from the simulation in all participating countries. The result is a consensus list or core elements for a multi-sectoral
preparedness plan, applicable in low GNI countries.
Task 6.2: Supporting partners and Member States in development of a draft for an integrated multisectoral Preparedness
and Response plan
Lead: RIVM; Participants: FI (THL and FFA), DE (RKI), IT (INMI and MoH), AU (AGES), UK (DH/PHE), ES (ISCIII)
BA (MCA), HR (CIPH and UHID), CZ (SUJCHBO), HU (NNK), LV (SEMS), LT (MOHLT), MT (MFH), PL (NIZP-
PZH and NVRI), PT (MS), RS ( IPHS), SI (NIJZ)
Based on the selected core elements, a draft for multisectoral plan will be developed. The backbone of the plan will be
the IHR preparedness and response cycle. The WP6 leaders will support the participants in development of the country
specific multisectoral Preparedness and Response plans.
6.2.1 Workshop on identification of the specific needs
Lead: NIJZ, Slovenia
Based on inventories of minimum level of expertise necessary, the agreed set of core capacities and the agreed process
steps from Task 6.1, a workshop will be organized to further clarify gaps, feasibility and barriers for participating
countries to develop a multisectoral Preparedness and Response plan with particular focus on low GNI countries.
The outcome of the workshops will thus be the identification of country and/or sector specific needs, which will serve
as framework for development of flexible and tailor-made protocol(s) for “Disease X” scenario simulation.
The core principle of the scenario is testing capacities and capabilities of and communication between the different
networks in a situation of an (emerging) unknown medical high-risk threat.
Task 6.3 Testing the multisectoral Preparedness and Response plan in “Disease X” scenario
Lead: RIVM/EMC; Participants: FI (THL and FFA), DE (RKI), IT(INMI and MoH), AU (AGES), UK (DH/PHE), ES
(ISCIII) B&H (MCA), HR (CIPH) CZ (SUJCHBO), HU (NNK), LV (SEMS), LT (MOHLT), MT (MFH), PL
“Disease X” scenario, i.e. a scenario for a novel disease that is unknown and requires multisectoral collaboration, will
be developed with the ingredients from tasks 6.1 and 6.2 and will be simulated to test the country specific multisectoral
IHR preparedness and response plans. Through consultations, the “Disease X” scenario will be adapted into several
subversions so that it applies to all included sectors.
6.3.1. Development of the scenario
“Disease X“ scenario will be developed in consultation with Member States, JA partner countries and in particular
low GNI countries. The scenario should include at least a high-consequence infectious disease (HCID) requiring
multisectoral collaboration. Based on the outcomes of tasks 6.1 and 6.2, the protocol(s) for “Disease X” scenario and
the accompanying checklist are developed.
6.3.1.1 Consultation on protocol development
An online consultation allows for engagement of all partners in the protocol development, national internal consultation
on needs, feasibilities and barriers, flexible drafting, revision and mutual agreement upon a final version of the protocol.
Page 31 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
The protocol will also include a checklist and it will be adapted/ adaptable to all included sectors and for all participating
countries, including low GNI countries.
6.3.1.2 Checklist for the “Disease X” scenario simulation
Part of the protocol development of “Disease X” scenario is development of a complete checklist to be used in the
optimal preparation of the simulation, as aid in the performance of the simulation and helping tool in evaluation. This
checklist should be detailed for all sectors involved and focuses on the particular characteristics of “Disease X” scenario,
i.e. a high-threat event. This means for example that with regard to national laboratory preparedness the participants
should check availability of specific requirements for highly specialized laboratories (e.g. compliance with dual use
regulation, restricted shipping conditions etc.) or networks to use or consult (input from WP7, WP9 and WP10).
6.3.2 Applying the ”Disease X” scenario for country specific simulation exercises
Lead: MFM/DEH, Malta
To test country specific multisectoral preparedness and response plans, “Disease X” simulation scenarios will be rolled
out in the participating countries. Country specific preparedness and response plans are tested in “Disease X” simulation
exercises and evaluated according to the agreed protocol selected by and tailor-made for the participating partner
countries.
6.3.3 Survey among lower GNI countries after the “Disease X” scenario simulation exercise to improve the multisectoral
Preparedness and Response plans
A survey among lower GNI countries will be carried out three months after the “Disease X” scenario simulation.
This will be carried out to inventory outcomes and country specific recommendations from the simulation for further
implementation of the country specific multisectoral preparedness and response plans, or to improve the plans. This
will support to translate the national plans tested in a high-risk event into an all hazard multisectoral preparedness and
response plan.
6.3.3.1 Online consultation
Online survey to inventory outcomes and recommendations from exercise “Disease X” simulation. Attention will be
paid to country specific identified success and fails factors, gaps and needs, which are relevant for implementation of
the integrated multisectoral preparedness and response plan. Preparatory to expert meeting 6.3.7.
6.3.3.2 Expert meeting
Lead: ISCII, Spain
The expert meeting will evaluate lessons learned from the simulations, and the outcomes and recommendations from
the survey and online consultation. Also the critical steps needed to translate the plans into all hazard multisectoral
preparedness and response plans will be evaluated, with particular emphasis on applicability in low GNI countries. The
outcome of this meeting will also serve as framework for protocol development of e-learnings and tabletop exercises
(Task 6.4) and best practices catalogues and guidelines (Task 6.5).
Task 6.4: Learning from “Disease X” scenario: testing the multisectoral preparedness and response plan in e-learnings
and tabletop exercises
Lead: EMC/ RIVM; Participants: FI (THL and FFA), DE (RKI), IT (INMI and MoH), AU (AGES), UK (DH/PHE),
ES (ISCIII) BA (MCA), HR (CIPH and UHID), CZ (SUJCHBO), HU (NNK), LV (SEMS), LT (MOHLT), MT (MFH),
PL (NIZP-PZH and NVRI), PT (MS), RS ( IPHS), SI (NIJZ)
The simulation of “Disease X” scenario provides the most robust assessment of the strengths and weaknesses of the
multisectoral collaboration within a country in relation to the Preparedness and Response cycle. These strengths and
limitations will be addressed in flexible e-learnings and tabletop exercises.
6.4.1. Inventory of best practices
Lead: ISCIII (ES). Participants: FI (THL and FFA), DE (RKI), IT (INMI and MoH), AU (AGES), UK (DH/ PHE), ES
(ISCIII) BA (MCA), HR (CIPH and UHID), CZ (SUJCHBO), HU (NNK), LV (SEMS), LT (MOHLT), MT (MFH), PL
(NIZP-PZH and NVRI), PT (MS), RS ( IPHS), SI (NIJZ)
Inventory of best practices by using a selected amount of recent threats, to serve as input into the all-hazards -e-learning
and tabletop protocols – in collaboration with WP4and WP5.
6.4.1.1 Literature review
In preparation of all hazard e-learnings and tabletop exercises a literature review will be carried out. This review will
include a selected amount of recent threats, with emphasis on preparedness and response methods used, and success
and fail factors.
Task 6.5. Supporting partners and Member States in development of an integrated all hazards multisectoral Preparedness
and Response plan
Page 32 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Based on the selected core elements in Workshop / Expert meeting 6.1.1.3, the integrated multisectoral plan(s) will be
adapted for all hazards application. Again the backbone of the plan will be the IHR preparedness and response cycle.
The WP6 leaders will support the participants in development of the country specific multisectoral Preparedness and
Response plans.
6.5.1 Workshop on lessons learned
Lead: NIZP-PZH, Poland
Lessons learned from the high-risk preparedness and response plans tested will form the base for this workshop. The
workshop will focus on the translation of these plans into all hazards applicability. Gaps, feasibility and barriers for
participating countries need to be identified in order to achieve successful development of such all hazard multisectoral
preparedness and response plan for all participating countries, with particular focus on low GNI countries. The outcome
of this workshop will serve as the framework for protocols for accessible e-learnings and tabletop exercises for different
sectors (e.g. public health, clinical, chemical, zoonotic, and others) accounting for minimum level of expertise necessary,
and an agreed set of core capacities.
6.5.2 Development of integrated all hazards e-learning and tabletop exercise protocols and testing for operability
E-learnings and tabletop exercises are accessible simulations to test different all hazard threats for different sectors
at any frequency and/or depth needed. The simulations will test the day-to day preparedness and response capacities
and capabilities of all parties involved in the national plan. An important role of these simulations is testing the
communications, and knowledge of each party’s role in the simulated event. The tested scenarios may include any health
event, including infectious diseases requiring multisectoral collaboration. .
6.5.2.1 Consultation on protocol development
An online consultation allows for engagement of all possible partners in the protocol development, national internal
consultation on needs, feasibilities and barriers and flexible drafting, revision and mutual agreement upon a final version
of the protocol and checklist and to assure that it adapted/ adaptable to all included sectors and for all participating
countries (including low GNI countries).
6.5.2.2 Checklist to support e-learning and tabletop exercise protocols
A checklist will be created to facilitate all hazard e-learning or tabletop exercise implementation and optimization, as
part of protocol development for e-learning and tabletop exercises. The checklist will be used for preparation of the
simulations, as aid in the performance of the simulations, and as helping tool in evaluation.
This checklists will be detailed for all sectors involved and focus on the particular characteristics of the different e-
learning and table top scenarios ( e.g. foodborne infections, powder letters, airborne health threats (e.g. legionella,
chemical), and veterinary /zoonotic threats (e.g. Q-fever).
6.5.2.3 E-learnings and tabletop exercises
SHARP partners will test their country specific integrated all hazards multisectoral preparedness and response plans
with at least one agreed, selected protocol, tailor-made for these participating countries.
6.5.5 Survey among low GNI countries to inventory outcomes and country specific recommendations from the e-
leanings and tabletop exercises.
Lead: ISCIII, Spain
This survey is part of the evaluation of e-learnings and tabletop exercises with focus on lower GNI countries. This
subtask is important to translate the national plans tested in all hazard event in order to optimize their all hazard
multisectoral preparedness and response plans.
6.5.5.1 Online consultation
Three months after e-learnings or tabletop exercises online surveys are conducted to evaluate the simulations, identify
success and fail factors, gaps and lessons learned. An inventory of critical elements for improving implementation of
the integrated all hazards multisectoral preparedness and response plans in participating countries will be carried out.
Task 6.6 Translation into best practices and sustainability (with WP4 and WP5).
Lead: ISCIII (ES). Participants: FI (THL and FFA), DE (RKI), IT (INMI and MoH), AU (AGES), UK (DH/ PHE), ES
(ISCIII) BA (MCA), HR (CIPH and UHID), CZ (SUJCHBO), HU (NNK), LV (SEMS), LT (MOHLT), MT (MFH), PL
(NIZP-PZH and NVRI), PT (MS), RS ( IPHS), SI (NIJZ), NL (RIVM)
In order to achieve sustainable, integrated Preparedness and Response plans in the Member States and JA participating
countries and to facilitate further improvements, the lessons learned from the activities within this WP are documented
in best practices catalogues and guidelines. The framework for this will be discussed in the final workshop.
6.6.1 Workshop on multisectoral collaboration
Lead: SEMS, Latvia
Page 33 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
The aim of this workshop is to collect relevant best practices, fail and success factors that were not identified in the
simulations, workshops and reviews, or factors that have different meaning or weight for different sectors or countries.
Outcome should be mutual understanding and agreement of best practices to be translated into best practices catalogues
and guidelines applicable to all MS and JA participating countries and relevant for the different sectors.
Participation per Partner
Partner number and short name WP6 effort
1 - THL 2.00
FFA 1.00
2 - RKI 0.10
3 - INMI 1.00
MoH 0.75
4 - BMASGK 0.00
AGES 0.50
5 - MCA 3.80
6 - CIPH 1.60
UHID 3.50
7 - SUJCHBO 5.50
10 - MOH-FR 4.75
12 - NNK 0.80
13 - SEMS 6.00
14 - MOHLT 3.00
15 - MFH 1.50
16 - RIVM 58.00
Erasmus MC 13.77
18 - NIZP-PZH 18.00
NVRI 4.00
19 - MS 7.00
20 - IPHS 12.10
21 - NIJZ 19.00
22 - ISCIII 22.25
24 - DH 1.20
Total 191.12
Page 34 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Review of planning and
D6.1 16 - RIVM Report Public 18
evaluation tools
Confidential, only
for members of the
Report on Disease X
D6.2 16 - RIVM Report consortium (including 33
scenario
the Commission
Services)
Description of deliverables
D6.1 : Review of planning and evaluation tools [18]
Review of integrated evidence-based planning and evaluation tools and for Preparedness and Response cycle
D6.2 : Report on Disease X scenario [33]
Report on “Disease X” scenario, including inventory progress and barriers for implementation in low GNI countries
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Disease X scenario,
with integrated IHR-
“Disease X” scenario laboratory preparedness and
MS20 16 - RIVM 24
simulated response, developed by and
implemented as exercise in
low GNI countries
All hazards scenario based
All hazards e-learning tool e-learning tool developed,
MS21 16 - RIVM 33
launched tested and implemented, with
focus on low GNI countries
Four workshops conducted:
1. to collect tools; 2. to
clarify gaps and feasibility
to develop a multisectoral
MS22 WP6 workshops conducted 16 - RIVM 27 preparedness and response
plan for participating
countries; 3. to translate plans
into all-hazards approach; and
4. to collect best practices.
Country-specific all hazards
MS23 Table-top exercises conducted 16 - RIVM 33 multisectoral preparedness
and response plans tested.
Page 35 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP7 Lead beneficiary 10 2 - RKI
Work package title Laboratory preparedness and responsiveness
Start month 1 End month 36
Objectives
Strengthened laboratory preparedness and responsiveness to detect highly pathogenic infectious agents of Risk Group
3 (RG3) bacteria / Risk Group 4 (RG4) viruses with quality assured methods in laboratories of MS and SHARP JA
partner countries, and evaluating new diagnostic approaches and improving biosafety procedures.
Specific objectives
1. To ensure the application of best practices and quality assured methods in detection and analyses of highly pathogenic
infectious agents in laboratories of SHARP JA partner countries.
2. To improve and consolidate the biorisk management in laboratories of SHARP JA partner countries dedicated to the
diagnostics of highly pathogenic infectious agents.
Description of work and role of partners
WP7 - Laboratory preparedness and responsiveness [Months: 1-36]
RKI, THL, INMI, BMASGK, MCA, CIPH, SUJCHBO, SSI, MSAE, MOH-FR, HCDCP(KEELPNO), NNK,
MOHLT, MFH, RIVM, HD, NIZP-PZH, MS , IPHS, NIJZ, ISCIII, FOHM, DH, NAPH
The work package will be structured in specific tasks with task leaders, task co-leaders, and working groups for specific
sub-tasks. Special funding will be given to task leaders and co-leaders as well as designated working group leaders
to carry out specific activities together with other partners, while basic funding will be given to all partners to cover
essential activities like participation in meetings, shipment of samples for EQAE and the repository.
Special attention will be given for partners from low GNI MS for their implementation in the various tasks of the WP.
Task 7.1 External Quality Assurance Exercise (EQAE) Lead: RKI/ZBS2, DE; Co-lead: UMR, DE (affiliated entity)
- RKI/ZBS2 and UMR will prepare, organize, and provide annual EQAEs on relevant bacteria (according to
accreditation DIN EN ISO 17043) (topic 1.1) and viruses (topic 1.2) considering the actual risk assessment for highly
infectious agents.
- Scenarios could include natural, accidental, or intentional outbreaks of infectious diseases. The EQAE will be
embedded in interoperability exercises including PH/IHR whenever possible. Only for BSL4 laboratories, neutralization
tests, using human or animal sera (according to availability), will be performed.
- Nominated partners and affiliated entities (laboratories) will participate in the EQAEs. For practical reasons, the
number of participants in each EQAE will be limited to a maximum per JA partner country to be negotiated.
- The participants will be asked in advance for their capabilities to detect and characterize bacteria, viruses, and to
conduct antibody detection as well as antimicrobial susceptibility testing for bacteria. Accordingly, they will receive
adequately composed sample sets.
- In the framework of WP7, a proposal will be developed to stabilize the function of EQAE organization for diagnostics
of highly pathogenic agents in Europe as well as to ensure the long-term maintenance of the centralized bacterial
repository.
Two topics:
1.1 EQAE on RG3 bacteria
1.2 EQAE on RG4 viruses
Common EQAE and simulation exercise will be planned. Ad-hoc EQAEs directed to specific pathogens and methods
will be conducted in outbreak situations.
Task 7.2 Diagnostic approaches
Lead: INMI, IT; Co-lead: BwIM, DE (affiliated entity)
Laboratories represent one of the core capacities that must be consolidated and further developed for the implementation
of IHR and strengthening core laboratory capacities is the main aim of this task. The task will consider the following
aspects:
- Identification of relevant target pathogens including relevant RG2/3 agents for differential diagnoses; linkage with
WP6.
Page 36 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
- The evaluation of best diagnostic approaches and methods, including in-house and commercial diagnostic assays, will
be done to define laboratory recommendations, including biosafety and shipment aspects, and evaluation/update of lab
capabilities in the EU.
- For highly pathogenic infectious agents, very often in-house assays are used, but for some of these pathogens also
commercial assays are available. In this case, the access to these assays especially might be easier than to develop own
in-house tests, especially for lower GNI countries, and can provide better standardization of diagnostic procedures. On
the other hand, the quality of evaluation of commercial assays is often not well demonstrated and this gap could be
filled by activities in the network. Thus, we would like to consider both in-house and commercial assays for evaluation
of their applicability in diagnostic laboratories. The results obtained during the previous JA EMERGE are used as a
basis for the evaluation.
- Focusing on highly pathogenic infectious agents, this evaluation will generate networking added value to the existing
EULabCap data base which is currently lacking this information. A mutual usage and exchange of these data bases
is envisaged. The new Regulation (EU) 2017/746 on In vitro Diagnostic Medical Devices (IVDMD) will as well be
considered.
- Contribute to the definition of strategies to support outbreak response within and outside the EU, including mobile
laboratory or laboratory support in epidemic/endemic countries; linkage with WP6.
- Establishment and maintenance of cooperation between SHARP JA partner countries with and without BSL3 and
4 laboratories, including procedures for sample sharing. Mapping of existing cooperation and facilitating new inter-
laboratory agreements.
- Work on pathogen inactivation in the context of diagnostics and emergency response.
- Participate in transversal activities, like training and dissemination, as well as for external assessment of countries’
laboratory capabilities in the framework of IHR implementation; linkage with WP4, 5, 6 and 8.
- Coordination and support of sample sharing in case of outbreaks or for preparedness to laboratory detection of
pathogens considered prone to cause outbreaks, in analogy of what has been done in the previous JA EMERGE and
is ongoing in GHSAG for GHSI countries.
- Networking in collaboration with other Tasks and WP; with research laboratory projects and EU projects seeking
to support outbreak response in endemic countries; with veterinary laboratories already included in this Joint Action
serving as multiplicators at national levels, and with international organizations in order to develop synergies and reduce
overlapping.
Working Group 7.2.1 “NGS approaches for detection, tracking and tracing of highly pathogenic infectious
agents” (Lead: EMC, NL; Co-lead PHE, UK)
The working group will concentrate on metagenomics approach for known and unknown agent detection, both for
bacteria and viruses. Based on state-of-the-art techniques of deep sequencing used among partners and the results of
metagenomics EQAE from the JA EMERGE, work to improve the expertise among the European partners is essential.
Working Group 7.2.2 “Basic diagnostics” (Lead: INMI, IT; Co-lead: BwIM, DE)
The implementation of basic diagnostics of highly pathogenic agents will be improved in designated partner country
laboratories, especially in those with lower resources. The identification of cost-effective diagnostic methods under low
financial and infrastructural resources including mobile laboratories, the availability of high-containment laboratory
facilities, and diagnostics in high-containment clinical facilities (Point of Care Diagnostics, POCD) will be carried out.
Relevant methodological approaches will be identified and assessed by the working group. Recommendations of best
practice will be developed. There is a strong link with Task 1 wherefrom partially the reference material for EQAE can
be used for the evaluation of the identified methods.
Working Group 7.2.3 “Antimicrobial susceptibility testing (AST)” (Lead: BwIM, DE)
The goal of the working group is to implement and further optimize previously developed fast and reliable methods
for detection of antimicrobial resistances in wild type strains of RG3 bacteria and to set breakpoints for all substances
used for therapy of these agents.
Partners will further improve and standardize the methods for phenotypic antimicrobial susceptibility testing (AST) of
highly pathogenic bacteria. The techniques will be transferred to all nominated partners by SOPs and a reading guide
for testing and validation, respectively. The developed methods and the transfer of expertise will be used to detect
antimicrobial resistances of highly pathogenic bacteria in the participating countries and during cross-border outbreaks
and to enable the detection of intentionally released multi-resistant RG3 bacteria. Furthermore, the working group will
cooperate with WP6 (Preparedness and response planning) and WP10 (Case management, infection prevention and
control preparedness) to develop guidelines for therapy of patients suffering from infections caused by highly pathogenic
bacteria using first-line drugs and in case of antimicrobial resistances. To discuss the data, an additional AST meeting
will be offered and representatives of EUCAST should be invited for the meeting.
Task 7.3 Laboratory biorisk management (Lead: FoHM, SE; Co-lead PHE, UK)
Page 37 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Two subtasks:
7.3.1 Biorisk management in BSL3/4 laboratories
7.3.2 Inactivation procedures for reducing the biorisk in diagnostics of highly pathogenic agents.
Common documents on self-evaluation will be planned and in outbreak situations, appropriate recommendations will
be developed and applied.
7.3.1 The overarching goal of this task is to provide assistance to SHARP JA partner countries for self-evaluation of
their capacity in biorisk management as well as to provide assistance for the initiation of capacity building efforts to
address identified gaps. Within the task, a multidimensional guidance tool to the existing self-evaluation tools will be
developed as a deliverable. Moreover, based on existing knowledge and experience, recommendations for biosafety and
biosecurity under “field” conditions, for mobile labs and labs under rural conditions will be developed as a deliverable.
7.3.2 Inactivation and disinfection of bacteria and viruses is a critical step in the biosafety of the laboratory as well
as upon transfer of diagnostic or research material between laboratories. The focus will be on accumulating data on
evidence-based methods for inactivation in relevant clinical samples or under laboratory conditions, using, where
possible, a standardised format of testing so that the results can be validated at any institute. The analysis of data will
include finding potential gaps and recent advances within the field. The results will include dissemination on feasible
alternative methods to all laboratories within the consortium.
Subcontracting
02 – RKI will use subcontracting to hire a company to support for at least 6 EQAE, development of data entry masks,
data collection, statistical analysis of EQAE results, templates for reporting, special IT hardware and software will be
applied, this activity cannot be carried out by particpants, outsourcing is in complience with EQAE#schemes.
RKI will hire a senior scientist consultant for WP7 after retirement of Dr. Grunow.
05 – MCA will subcontract two experts from high-level laboratories – one from Sarajevo and one from Mostar – in
order to participate in EQAE.
Participation per Partner
Partner number and short name WP7 effort
1 - THL 2.00
2 - RKI 43.24
FLI 1.29
BwIM 17.00
UMR 0.90
BNITM 16.40
3 - INMI 31.40
IZSPB 0.90
ISS 2.40
IZLER 1.00
4 - BMASGK 0.00
AGES 1.34
5 - MCA 1.70
6 - CIPH 0.25
UHID 0.30
7 - SUJCHBO 3.00
8 - SSI 1.00
9 - MSAE 0.00
Page 38 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Partner number and short name WP7 effort
HB 13.00
10 - MOH-FR 0.00
MOD-FR 1.30
INSERM 1.00
11 - HCDCP(KEELPNO) 0.00
NKUA 20.52
AUTH 6.54
12 - NNK 22.40
14 - MOHLT 0.00
NVSPL 4.30
15 - MFH 0.50
16 - RIVM 0.10
Erasmus MC 16.01
17 - HD 2.00
FHI 2.00
18 - NIZP-PZH 9.00
NVRI 5.50
19 - MS 0.00
INSA 8.00
20 - IPHS 3.00
21 - NIJZ 0.00
UL-MF 3.00
22 - ISCIII 26.00
BC 0.15
OSAKIDETZA 0.60
23 - FOHM 17.00
24 - DH 9.50
26 - NAPH 6.00
Total 301.54
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Confidential, only
Report on assurance of
D7.1 2 - RKI Report for members of the 36
high quality of diagnostic
consortium (including
Page 39 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
the Commission
Services)
Confidential, only
Report on modern for members of the
D7.2 molecular diagnostic 3 - INMI Report consortium (including 36
methods the Commission
Services)
Confidential, only
for members of the
Recommendations for
D7.3 23 - FOHM Report consortium (including 34
risk management
the Commission
Services)
Description of deliverables
D7.1 : Report on assurance of high quality of diagnostic [36]
Report on assurance of high quality of diagnostics for highly infectious pathogens applied in microbiological
laboratories of participating SHARP JA countries by conducting annual EQAEs.
D7.2 : Report on modern molecular diagnostic methods [36]
Report on assessment of and recommendations for application of modern molecular diagnostic methods, including
AST
D7.3 : Recommendations for risk management [34]
Recommendations for risk management and risk reduction in diagnostics of highly pathogenic agents.
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
First EQAE (M12), last
MS24 Implementation of EQAEs 2 - RKI 30
EQAE (M30)
Implementation of specific
MS25 Specific diagnostic tasks 3 - INMI 30 diagnostic tasks (M12),
completion (M30)
Development of a programme
for supported self-evaluation
Programme for self-
of laboratory biosafety
MS26 evaluation of laboratory 23 - FOHM 32
and biosecurity (M15),
biosecurity
recommendations and on-site
evaluation (M32)
Page 40 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP8 Lead beneficiary 10 20 - IPHS
Work package title Training and local exercises, exchange of working practices
Start month 1 End month 36
Objectives
The specific objective of the WP8 is strengthening IHR implementation for serious cross-border health threats in the
JA partner countries through cross-sectoral basic and advanced trainings.
Description of work and role of partners
WP8 - Training and local exercises, exchange of working practices [Months: 1-36]
IPHS, THL, RKI, INMI, BMASGK, MCA, CIPH, SUJCHBO, SSI, MSAE, MOH-FR, HCDCP(KEELPNO), NNK,
SEMS, MOHLT, MFH, RIVM, HD, NIZP-PZH, MS , NIJZ, ISCIII, FOHM, DH, NAPH
Expected results:
- The level of IHR capacities to prevent, prepare, detect and respond to cross-border threats to health improved
- Practices related to IHR capacity building exchanged with the special emphasis to strengthening the capacities of
countries with GNI less than 90% of EU average ;
Cross-sectoral capacities for detection, preparedness and response to emerging public health threats scaled up.
This work package (WP8) will ensure synergies with other EU and global level activities related to strengthening the IHR
implementation involved in training and exchange of work practices, for example HSC Action plan on preparedness and
IHR implementation, WHO Action Plan to Improve Public Health Preparedness and Response in the WHO European
Region, Health Programme actions and activities, such as the ongoing Healthy Gateways, JAV, JA AMR Commission
frameworks; and on a global level with WHO and global health security frameworks and initiatives.
In general, WP8 will focus on applied activities rather than basic scientific research. A kick-off meeting between all
countries involved in WP will initiate the activities of the project (3rd month). Another meeting will be held after
finalisation of cross-sectoral training needs assessment (month 18th) to agree on the agenda and methodology of the
advanced trainings.
All countries with GNI less than 90% of EU average are expected to participate at training activities.
Task 8.1. Assessment of the cross-sectoral training needs in JA partner countries related to preparedness and IHR
implementation
Lead: IPHS, co-lead: ISCIII. Participation: DH (PHE), all institutions involved in the WP8
Subtask 8.1.1 An assessment of the cross-sectoral training needs of countries will be conducted (months 13th to 15th),
building on the previously conducted ECDC and WHO training needs assessments, followed by analysis of results.
No extra survey of training needs might be necessary. The analysis of reports from WHO Joint External Evaluations,
Progress report on preparedness and response planning under decision 1082/2013/EU (art. 4) and EC/ECDC technical
assessments will indicate areas where training may be required. Assessment results should be discussed with countries
for their feedback and a report on assessment of the cross-sectoral training needs across countries (including region-
specific needs). Lead: IPHS. Participation: PHE, FHI, NIZ-PZH, all institutions involved in the WP8.
Subtask 8.1.2 An inventory of existing IHR-related training activities and materials available (including main topics,
available languages and whether the material is available for use by others) will be compiled. A survey amongst
partners of possible training offers might be helpful for further definition of training activities. Lead: ISCIII co-lead:
SSI, Participation: BMASGK, HCDCP/ KEELPNO, FHI, MS, NIZ-PZH.
Task 8.2. Development of curricula for basic and advanced face-to-face and on-line training
Lead: IPHS, co-lead: RKI, Participants: PHE, MoH-FR, NIJZS, RIVM, ISCIII, HCDCP/ KEELPNO,FHI, NIZ-PZH,
MS
The aim of the training will be to strengthen the IHR (2005) core capacities according to country needs.
WP8 will develop a training curriculum and generic module-based basic IHR-training package which can be adapted
for different priority regions based on country needs with special emphasis to capacity building of low GNI countries.
The training will utilize and build-on existing material from WHO, ECDC and WP8 countries training experience. It
will base on the outcomes of subtask 1.2. Training will comprise of both face-to-face trainings and on-line problem-
based learning delivered on a learning platform with field exercises and simulations. The sharing of best practices and
Page 41 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
challenges between countries will be encouraged during trainings. Guidelines for face-to-face and on-line exercises will
be developed.
Specific advanced learning modules will depend on the results of the training needs assessment and inventory (see Task
1) and could include: identification and reporting of public health emergencies, joint emergency preparedness, early
detection (epidemic intelligence, surveillance, monitoring and evaluation, laboratory preparedness and surveillance),
risk assessment, risk management, risk communication, inter-sectoral collaboration and communication, chemical
hazards, Simulation Exercises (SimEx), After Action Reviews (event assessment) and cross-border surveillance and
response. All partners from countries with GNI less than 90% of EU average will be invited to participate at both basic
and advanced training modules.
To ensure ownership and applicability to countries, a participatory approach will be used in the development of the
training curricula and modules. There will also be an opportunity for feedback on the training package before it is
finalised.
Task 8.3. Training implementation
Lead: IPHS, co-lead: RKI, NIZ-PZH, HCDCP/ KEELPNO, OKI. Participants, MoH-FR, NIJZS, DH (PHE), SSI, FHI,
RIVM, ISCIII, MS, All WP8 participants
Within this task, workshops, trainings, exercises (national and international), laboratory trainings and trainings for
chemical hazards will be implemented according to findings of training needs assessment.
Task 8.3.1. Implementation of basic and advanced trainings
Leading by IPHS, co-leading RKI, DH (PHE), HCDCP/ KEELPNO. Participants, NNK, MoH-FR, NIJZS, SSI, NIPH,
RIVM, All WP8 participants
It is planned to perform:
• 2 basic IHR-workshops. (year 1)
• 4 advanced (years 2 and 3) three-day workshops (including international field exercises with multi-sectoral
involvement, lab and chemical trainings). Each of these four thematic workshops will be provided at two different
locations in order to enable all interested parties the opportunity to participate.
Contents of advanced trainings, laboratory trainings for participants involved in WP 7 (lead by NPHC/NNK (Hungary)
and FoHM (Sweden), and trainings for chemical hazards (Lead by DH/PHE) will be performed according to the results
of the training needs assessment (Task 1).
The basic and advanced trainings will be organized in Serbia, Spain, Bosnia and Herzegovina, Latvia, Malta, Croatia,
lab trainings in Hungary and Portugal, and international exercises in Greece and Slovenia.
Task 8.3.2 Secondments, study tours or internships to supranational organizations or other countries
Participating countries might allocate training budget distributed to their country under WP8 for secondment of staff to
WHO, ECDC or high GNI-partner countries. ECDC and WHO have been asked to host such individuals.
Task 8.3.3 National exercises implementation
In all low GNI countries will be organized multi-sectorial exercises with participation of all institutions responsible for
IHR implementation.
The process for implementation of each specific training:
• Develop training concept note
• Develop, print and distribute training flyer
• Develop and finalize training agenda & invite presenters/facilitators
• Adjust and finalize training materials based on country/region needs
• Complete training package incl. facilitators guides
• Hold training workshop
• Evaluate training
• Write training report
Inter-active teaching methods, including scenario-based table-top exercises, will be primarily used to allow for exchange
of experiences and knowledge between participants.
All trainings will be evaluated by participants using an evaluation questionnaire.
Task 8.4. WP8 activities coordination and implementation
WP leader and co-leader will coordinate, organize and monitor the activities that are included in this WP. It will be
done by:
tele/skype conferences with WP8 participants
Page 42 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
face-to-face meetings – 2 meetings in M3 (Serbia), M15 (Portugal)
Participation per Partner
Partner number and short name WP8 effort
1 - THL 2.00
2 - RKI 24.10
FLI 0.15
BwIM 0.10
UMR 0.08
BNITM 0.05
3 - INMI 0.00
IZSPB 1.00
ISS 0.20
IZLER 0.50
4 - BMASGK 2.48
AGES 0.10
5 - MCA 5.60
6 - CIPH 1.70
UHID 1.20
7 - SUJCHBO 7.50
8 - SSI 4.75
9 - MSAE 0.20
HB 12.30
10 - MOH-FR 4.00
MOD-FR 2.70
11 - HCDCP(KEELPNO) 10.00
UoTHESSALY 4.00
EKEPY/NHOC 4.00
NKUA 1.00
AUTH 4.00
12 - NNK 4.00
13 - SEMS 5.00
14 - MOHLT 2.00
NVSPL 0.50
15 - MFH 1.00
16 - RIVM 7.50
Erasmus MC 2.00
Page 43 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Partner number and short name WP8 effort
17 - HD 0.00
FHI 5.00
18 - NIZP-PZH 10.00
NVRI 4.00
19 - MS 4.00
INSA 3.25
20 - IPHS 54.00
21 - NIJZ 8.00
UL-MF 0.50
22 - ISCIII 5.50
FIBHULP 2.00
23 - FOHM 1.00
24 - DH 6.30
PHW 1.00
26 - NAPH 3.00
Total 223.26
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
D8.1 Report on training needs 20 - IPHS Report Public 15
D8.2 Final training report 20 - IPHS Report Public 36
Basic and advanced
D8.3 20 - IPHS Report Public 21
training curricula
Description of deliverables
D8.1 : Report on training needs [15]
Report on assessment of the cross-sectoral training needs across countries
D8.2 : Final training report [36]
Final report on all training provided in WP8, including the training packages and on-line platform
D8.3 : Basic and advanced training curricula [21]
Report on curricula developed for basic and advanced face-to-face and on-line training
Page 44 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Two basic (M12) and four
Basic and advanced trainings
MS27 20 - IPHS 35 advanced workshops (M35)
conducted
organized
On-line platform for capacity
MS28 Online platform for training 20 - IPHS 24 building and advanced
training developed
Two WP8 meetings organised
MS29 WP8 meetings 20 - IPHS 15
(M3, M15)
Page 45 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP9 Lead beneficiary 10 24 - DH
Work package title Chemical safety and chemical threats
Start month 1 End month 36
Objectives
The specific objective of WP9 is to improve implementation of IHR chemical core capacities, strengthening
preparedness and response to cross-border chemical health threats within MSs and across the EU
Description of work and role of partners
WP9 - Chemical safety and chemical threats [Months: 1-36]
DH, THL, MOH-FR, NNK, MFH, RIVM, HD, NIJZ, NAPH
Task 9.1 Gap analysis
Lead: DH/PHE; Co-Lead: FoHM; Participants: NIJZ, HD, MFH (NAPH, Moldova)
In collaboration with WP5, a fact-finding/gap analysis will be conducted to determine which areas require further action,
with a view to strengthen chemical core capacity implementation under IHR.
Task 9.2 Strengthening existing mechanisms
Lead: DH/PHE; Co-Leads: RIVM, NIJZ Participants: MoH-FR, HD
In collaboration with WP4 and WP5, existing mechanisms for chemical incident preparedness, risk communication and
operational response will be identified and where necessary strengthened, to promote their uptake by all EU countries.
Task 9.3 Surveillance of chemical incidents
Lead: DH/PHE; Co-Leads: RIVM, HD; Participants: NIJZ, MFH (Malta), NAPH (Moldova)
Under IHR, tested surveillance systems are required for the detection, verification and risk assessment of chemical
events of (potential) international health concern as part of a multi-hazard surveillance strategy. As a first step, the
benefits of chemical event surveillance, in relation to public health preparedness will be reviewed, and used this as a
baseline to inform subsequent activities.
Task 9.4 Training program and materials
Lead: DH/PHE; Co-Leads: IPHS, RKI; Participants: NIJZ, RIVM
In association with other WPs as required, materials will be devised and developed to identify and assess best practices,
gaps, bottlenecks and lessons learned from previous events. These will include workshop material and chemical incident
exercise scenarios, to be held on areas such as:
- Preparedness of EU MSs to cross-border chemical health threats (according to IHR and Dec 1082/2013) including
e.g. continuity planning, intersectoral collaboration
- Surveillance, alerting and notifying of cross-border chemical health threats
- The rapid risk assessment of chemical health threats
- Public health response and safety when dealing with/responding to potential chemical health threats
- Improving access to information on roles and responsibilities of the Commission and other EU organisations
Material will be prepared for two workshops, to be integrated with existing WP5 and WP8 activities. The developed
materials may also be used in other workshops/training activities in the Joint Action to cover chemical threats.
Task 9.5 Exercises
Lead: DH/PHE; Co-leads: IPHS, RKI; Participants: NIJZ, RIVM
In collaboration with WP5 and WP8, WP9 will contribute exercise material to existing WP activities. This will enable
WP9 to test current preparedness and response arrangements to a serious cross border threat to health involving chemical
and environmental hazards within the scope of IHR and EU Decision 1082/2013/EU.
Task 9.6 Standard Operating Procedures (SOPs)
Lead: DH/PHE; Co-leads: NIJZ, RIVM; Participants: MFH (Malta), NAPH (Moldova)
To ensure a baseline competency among EU MSs on their approach to cross-border chemical health threats and promote
sustainability of the outputs of this Joint Action, SOPs will be produced, based on findings from the workshops and the
best practices, gaps and bottlenecks identified previously.
Subcontracting
24 - DH will subcontract experts on poison and toxicology for the surveillance and medical management activities.
Page 46 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Participation per Partner
Partner number and short name WP9 effort
1 - THL 2.85
FFA 2.00
10 - MOH-FR 0.00
MOD-FR 0.20
12 - NNK 1.00
15 - MFH 0.25
16 - RIVM 5.70
17 - HD 0.00
FHI 4.75
21 - NIJZ 57.70
24 - DH 30.25
26 - NAPH 3.00
Total 107.70
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
D9.1 Fact-finding report 24 - DH Report Public 12
Chemical laboratory
D9.2 response network – 17 - HD Report Public 24
scoping report
D9.3 WP9 Final report 24 - DH Report Public 36
Report on SOPs
D9.4 24 - DH Report Public 36
developed
Description of deliverables
D9.1 : Fact-finding report [12]
A report detailing the current state of play with regard to cross-border chemical health threat preparedness at the EU
and MS level.
D9.2 : Chemical laboratory response network – scoping report [24]
A report outlining the desirability and the feasibility to set-up a European chemical laboratory network to respond to
serious chemical health threats.
D9.3 : WP9 Final report [36]
A report detailing of SOPs; summaries of reports (e.g. on surveillance and training materials); as well as approaches
to ensure sustainability.
D9.4 : Report on SOPs developed [36]
Report on SOPs developed for participating countries
Page 47 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
WP9 Joint meeting with Joint meeting with all partners
MS30 24 - DH 2
partners and other WPs and other relevant WPs
Stakeholder consultation and
MS31 Stakeholder consultation 24 - DH 9
gap analysis
WP9 Training and exercise Production of training and
MS32 24 - DH 18
materials exercise materials
MS33 Surveillance strategy report 24 - DH 24 Surveillance strategy report
Two workshops conducted
MS34 WP9 workshops 24 - DH 30
(M18 and M30)
Consolidate, refine and
Mechanisms for cross-
promote existing mechanisms
MS35 border chemical health threat 24 - DH 36
for cross-border chemical
preparedness
health threat preparedness
Training & exercises
MS36 Training and exercises report 24 - DH 36
outcomes report
Page 48 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work package number 9 WP10 Lead beneficiary 10 3 - INMI
Work package title Case management and infection prevention and control preparedness
Start month 1 End month 36
Objectives
The specific objective of this WP is to improve clinical and biorisk management, hospital preparedness and response
to high-consequence infectious diseases (HCID).
This WP aims to strengthen IHR, through the enhancement of preparedness and response within Europe to possible
cross-border health threats due to the HCID, and to assure co-operation, communication, and exchange of information
among clinicians and public health officers.
Description of work and role of partners
WP10 - Case management and infection prevention and control preparedness [Months: 1-36]
INMI, THL, RKI, BMASGK, CIPH, SSI, MOH-FR, MFH, HD, ISCIII, FOHM, DH
WP10 activities will strengthen case management and Infection Prevention and Control (IPC) Preparedness in
participating countries. The WP contributes to the overall and comprehensive strengthening of the IHR though several
activities coordinated and integrated with other WPs:
- Mapping and assessing the existing facilities and country clinical preparedness. The map will inform WP5 and WP6
regarding the clinical capacities and development of preparedness and response tools and indicators.
- The feasibility study for an expert clinical support service will be part of the workshop with WP5 – (WP5 Task 5.2:
International collaboration between authorities during crises)
- The Workshops planned in Task 10.4 will be coordinated together with WP8. The workshop on the syndromic approach
will fall in the training activities (WP8) for early recognition of potential case with high-consequence infectious diseases
(HCID).
- WP10: Clinical capacity assessment - Linked to WP6 assessment on preparedness, WP10 will benefit of the Disease
X scenario (WP6) and will contribute to the clinical and biorisk management of the scenario development
- Interaction with WP7 and laboratory networks, joint participation to workshops and through the collaboration with
other WPs in the development of assessment tools.
The following tasks will ensure achievement of the WP objectives:
Task 10.1 Mapping of existing facilities (Lead: SERVAS; Co-Lead: RFL)
Existing Infection Prevention and Control (IPC) facilities will be mapped. Interactive maps will link the geography of
communities with availability and accessibility of health services, or disease prevention and control services. The map
will provide a comprehensive picture of the expertise for management of HCID.
Task 10.2 Assessment of country hospital preparedness and capacity for HCID, including high isolation clinical centers
(Lead: UKF; Co-Lead: INMI; participants: IHUMI)
Based on the Map (Mapping of existing facilities, Task 1), an electronic follow-up by self-assessment questionnaire
will be developed and filled by each MS and JA partners.
- Under Task 10.2, two workshops will be organized:
- Workshop 10.2.1 – To define recommendation for assessment (WS arranged by UKF in Germany).
- Workshop 10.2.2 – To discuss recommendation for improvement of the assessed facilities (WS arranged by INMI
in Italy)
Task 10.3 Feasibility study for an expert clinical support service for HCID (Lead: HD; Co-Lead: FoHM) This task aims
to define the characteristics of an expert clinical consultation and support service. This will result in a set of technical
recommendations which would be part of the evaluation in WP5 where identification of key challenges in national and
international collaboration between governments and national authorities will be conducted in a dedicated workshop/
exercise.
Task 10.4 Application of a “syndrome based” approach for prompt and early clinical management of HCID (Lead:
INMI; Co-Lead: SSI; Participants: VHA, IHUMI, THL)
The implementation of this task will be carried out through different phases for identification and management of the
HCID.
Page 49 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Under Task 10.4, two workshops will be organized:
- Workshop 10.4.1 – This workshop will involve all SHARP partners and will be focused on the identification of the list
of HCID, case definition of each HCID; systematic identification of major disease drivers and threats, and; evaluation
of validated severity scores. (WS arranged by INMI in Italy).
- Workshop 10.4.2 – This workshop will involve the dissemination and discussion of the obtained results. (WS arranged
by SSI in Denmark)
Subcontracting:
1 – THL will use subcontracting to hire clinical experts from a Finnish infectious diseases hospital for the activities
of WP10.
Participation per Partner
Partner number and short name WP10 effort
1 - THL 2.00
2 - RKI 0.10
UKF 8.80
3 - INMI 32.70
4 - BMASGK 0.00
VHA 5.00
6 - CIPH 0.25
UHID 1.60
8 - SSI 3.00
10 - MOH-FR 0.00
IHUMI 11.00
MOD-FR 0.20
15 - MFH 0.25
17 - HD 4.00
22 - ISCIII 0.00
SERMAS 6.00
23 - FOHM 1.50
24 - DH 0.00
RFL 3.00
Total 79.40
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Report on existing
D10.1 22 - ISCIII Report Public 33
facilities
D10.2 Feasibility study report 17 - HD Report Public 18
Page 50 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Report on syndrome-
D10.3 3 - INMI Report Public 32
based approach
Description of deliverables
D10.1 : Report on existing facilities [33]
Report on the assessment of existing facilities, including mapping
D10.2 : Feasibility study report [18]
Report on feasibility study for an expert clinical support service for high-consequence infectious diseases
D10.3 : Report on syndrome-based approach [32]
Report on the implementation of a syndrome based clinical protocol
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Development of the protocol
Protocol for assessment of
MS37 22 - ISCIII 12 for the assessment of
facilities
capacities and facilities
Collection of data on
hospital preparedness and
Data collection on hospital capacity in dealing with
MS38 2 - RKI 24
preparedness high-consequence infectious
diseases in JA participating
countries.
Protocol for feasibility study
Protocol for WP10 feasibility
MS39 17 - HD 12 for an expert clinical support
study
service for HCID
Protocols for syndrome-based Development of syndrome
MS40 3 - INMI 18
approach based protocols
Page 51 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.3.4. WT4 List of milestones
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
Kick-off meeting of the Joint
MS1 Kick-off meeting WP1 1 - THL 2
action for all partners
Establishment of The Steering Committee
MS2 Steering Committee WP1 1 - THL 2 and Advisory Board will be
and Advisory Board officially established.
Consortium agreement
MS3 Consortium agreement WP1 1 - THL 4 between all partners of the
Joint action
Two Partnership forums will
MS4 Partnership Forums WP1 1 - THL 24 be organised: 1st in M12 and
2nd in M24
Closing conference of the
MS5 Closing conference WP1 1 - THL 36
Joint action
Stakeholder analysis for
MS6 Stakeholder analysis WP2 24 - DH 4 targeting the dissemination
activities
Communications plan
MS7 Communications plan WP2 24 - DH 9
including key messages
Communication Channel strategy prepared,
MS8 WP2 24 - DH 9
channel strategy including social media
Meeting with all WP leads to
Planning meeting with
MS9 WP3 11 - HCDCP(KEELPNO) 2 plan evaluation (in connection
WP leads
with the kick off meeting)
Evaluation plan ready and
MS10 Evaluation plan WP3 11 - HCDCP(KEELPNO) 3
evaluation tool available
External evaluation procured
External evaluation
MS11 WP3 11 - HCDCP(KEELPNO) 18 and the external evaluation
mobilised
team is mobilized
Presentation of the Presentation of the internal
MS12 internal evaluation WP3 11 - HCDCP(KEELPNO) 24 evaluation results at the
results meetings in M12 and M24
A workshop will be organized
Workshop on guidance with the Steering Committee
MS13 WP4 10 - MOH-FR 7
tool members to draft the guidance
on sustainability.
A workshop with the Steering
Committee, the Advisory
Workshop on best
MS14 WP4 10 - MOH-FR 18 Board and the Health Security
practices
Committee to review selected
best practices
Presentation of sustainability
Approval of
MS15 WP4 10 - MOH-FR 24 report at workshop 3 and
sustainability plan
final approval of the SHARP
Page 52 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
sustainability plan by the
stakeholders
WP5 workshops 1 and 2
MS16 WP5 Workshop 1 and 2 WP5 23 - FOHM 10
organised
MS17 Table-top exercise WP5 17 - HD 34 Table-top exercise organised
WP5 workshops 3 and 4
MS18 WP5 Workshop 3 and 4 WP5 23 - FOHM 22
organised
WP5 workshops 5 and 6
MS19 WP5 Workshop 5 and 6 WP5 23 - FOHM 34
organised
Disease X scenario,
with integrated IHR-
“Disease X” scenario laboratory preparedness and
MS20 WP6 16 - RIVM 24
simulated response, developed by and
implemented as exercise in
low GNI countries
All hazards scenario based
All hazards e-learning e-learning tool developed,
MS21 WP6 16 - RIVM 33
tool launched tested and implemented, with
focus on low GNI countries
Four workshops conducted:
1. to collect tools; 2. to
clarify gaps and feasibility
to develop a multisectoral
WP6 workshops
MS22 WP6 16 - RIVM 27 preparedness and response
conducted
plan for participating
countries; 3. to translate plans
into all-hazards approach; and
4. to collect best practices.
Country-specific all hazards
Table-top exercises
MS23 WP6 16 - RIVM 33 multisectoral preparedness
conducted
and response plans tested.
Implementation of First EQAE (M12), last
MS24 WP7 2 - RKI 30
EQAEs EQAE (M30)
Implementation of specific
Specific diagnostic
MS25 WP7 3 - INMI 30 diagnostic tasks (M12),
tasks
completion (M30)
Development of a programme
for supported self-evaluation
Programme for self-
of laboratory biosafety
MS26 evaluation of laboratory WP7 23 - FOHM 32
and biosecurity (M15),
biosecurity
recommendations and on-site
evaluation (M32)
Two basic (M12) and four
Basic and advanced
MS27 WP8 20 - IPHS 35 advanced workshops (M35)
trainings conducted
organized
Page 53 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
On-line platform for capacity
Online platform for
MS28 WP8 20 - IPHS 24 building and advanced
training
training developed
Two WP8 meetings organised
MS29 WP8 meetings WP8 20 - IPHS 15
(M3, M15)
WP9 Joint meeting
Joint meeting with all partners
MS30 with partners and other WP9 24 - DH 2
and other relevant WPs
WPs
Stakeholder Stakeholder consultation and
MS31 WP9 24 - DH 9
consultation gap analysis
WP9 Training and Production of training and
MS32 WP9 24 - DH 18
exercise materials exercise materials
Surveillance strategy
MS33 WP9 24 - DH 24 Surveillance strategy report
report
Two workshops conducted
MS34 WP9 workshops WP9 24 - DH 30
(M18 and M30)
Consolidate, refine and
Mechanisms for cross-
promote existing mechanisms
MS35 border chemical health WP9 24 - DH 36
for cross-border chemical
threat preparedness
health threat preparedness
Training and exercises Training & exercises
MS36 WP9 24 - DH 36
report outcomes report
Development of the protocol
Protocol for assessment
MS37 WP10 22 - ISCIII 12 for the assessment of
of facilities
capacities and facilities
Collection of data on
hospital preparedness and
Data collection on capacity in dealing with
MS38 WP10 2 - RKI 24
hospital preparedness high-consequence infectious
diseases in JA participating
countries.
Protocol for feasibility study
Protocol for WP10
MS39 WP10 17 - HD 12 for an expert clinical support
feasibility study
service for HCID
Protocols for
Development of syndrome
MS40 syndrome-based WP10 3 - INMI 18
based protocols
approach
Page 54 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.3.5. WT5 Critical Implementation risks and mitigation actions
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
Biased partner composition.
IHR core capacity requires
engagement of multiple
sectors and a wide area
Engaging more partners from other sectors, e.g.
of different public health
including food safety, zoonotic veterinary public
expertise. The partnership
health, environmental health and civil protection
is heavily dominated by WP1, WP10, WP2,
in the course of time in this JA. This will be
1 laboratory networks and WP3, WP4, WP5, WP6,
monitored by the WP1 (Coordination) and WP3
from many countries no WP7, WP8, WP9
(Evaluation). This action has been added to WP3
public health agency with
description, and multi-sectoral aspect is one task
prevention and control
in WP8.
mandates are involved.
Very few partners from
non-human health sectors
involved.
Insufficient information,
interest, and participation
from the Member States; WP1, WP10, WP2, Continuous discussions with policy-makers,
2 Policy-makers do not support WP3, WP4, WP5, WP6, ministries, other stakeholders on objectives of the
JA activities on national WP7, WP8, WP9 JA.
level; Other stakeholders not
engaged.
Insufficient human resources
for implementation and WP1, WP10, WP2,
Continuous follow-up by the responsible WPs and
3 coordination of the JA, due WP3, WP4, WP5, WP6,
a leaders and Coordinator (WP1).
to large number of partners WP7, WP8, WP9
and affiliated entities.
WP1, WP10, WP2,
Withdrawal or default of a Division of remaining tasks among other
4 WP3, WP4, WP5, WP6,
central partner. consortium members.
WP7, WP8, WP9
Inadequate activities All WPs, especially WP5 and WP8. Clear
on mapping of the gaps WP1, WP10, WP2, communication in between the core WPs
5 and mapping of the IHR WP3, WP4, WP5, WP6, responsible for mapping. Mapping is carried out
capacities for the effective WP7, WP8, WP9 under WP5 and WP8 and described in detail in
implementation of the JA. WP descriptions.
Inadequate response rate
from stakeholders during WP1, WP10, WP2,
Involvement of all partners, policy-makers,
6 the mapping of the gaps WP3, WP4, WP5, WP6,
stakeholders.
and mapping of the IHR WP7, WP8, WP9
capacities.
WP1, WP10, WP2, All WPs, especially WP1 (Coordination).
Low quality of written
7 WP3, WP4, WP5, WP6, Continuous follow-up and feed-back by the
deliverables.
WP7, WP8, WP9 responsible WP leaders.
Delays in submitting parts of WP1, WP10, WP2,
Continuous follow-up by WP leaders and
8 the written reports, resulting WP3, WP4, WP5, WP6,
Coordinator on the progress of WPs.
in delays in dissemination. WP7, WP8, WP9
Increased prices of the WP1, WP10, WP2,
Re-allocation of the planned activities and
9 laboratory equipment, WP3, WP4, WP5, WP6,
purchases.
consumables, other services. WP7, WP8, WP9
Page 55 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
Lack of data from the Early engagement and discussion with partners,
WP1, WP10, WP2,
partners or poor engagement discussion with DG Sante National Focal Points
10 WP3, WP4, WP5, WP6,
of the ECDC, WHO or other at ministry level, Discussion with Brussels EU
WP7, WP8, WP9
key external partners. attaches.
Continuous follow-up by WP leaders and
Coordinator on the progress of WPs, feed-back
Low quality of the WP1, WP10, WP2,
through questionnaires, reallocation of tasks. In
11 workshops, trainings and WP3, WP4, WP5, WP6,
several WP descriptions (e.g. WP5 and WP6)
seminars. WP7, WP8, WP9
workshops and actions have been divided in
preparatory (analysis) and operational phases.
Conflicts between the WP1, WP10, WP2,
Open communication, clarifying the tasks and
12 partners and affiliated WP3, WP4, WP5, WP6,
objectives of the WPs, mediation by Coordinator.
entities. WP7, WP8, WP9
WP9: 1) Work with the coordinator and EU
Commission to explore methods of engaging
with the JA. 2) Transfer WP9 activities to co-lead
Slovenia and secure support from other partners,
e.g. with another country with sufficient expertise
Brexit: UK is leader in two in the public health approach to chemical health
work packages, in WP2 and threats such as RIVM in the Netherlands or FOI
WP9. If UK is unable to in Sweden. 3) Remove WP9 and include activities
WP1, WP10, WP2,
participate in the SHARP in existing work packages, for example WP 5,6
13 WP3, WP4, WP5, WP6,
JA due to the Brexit (as and 8. However, this option is least preferred
WP7, WP8, WP9
planned beyond March 2019) as it increases the risk of chemical work being
the following mitigation lost or de-prioritised in relation to existing WP
measures are suggested: activities. WP2: 1) Work with the coordinator
and EU Commission to explore methods of
engaging with the JA. 2) Transfer WP2 activities
to the coordinator (THL), which is already co-
lead of WP2. THL will recruit more staff for
communication and dissemination for WP2.
Page 56 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.3.6. WT6 Summary of project effort in person-months
Total Person/Months
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10
per Participant
1 - THL 95.40 6 1 2 2 2 2 2 2.85 2 117.25
· FFA 0.50 0 0 0 0 1 0 0 2 0 3.50
2 - RKI 4 0.10 0.10 0.10 0.10 0.10 43.24 24.10 0 0.10 71.94
· UKF 0.20 0 0 0 0 0 0 0 0 8.80 9
· FLI 0 0 0 0 0 0 1.29 0.15 0 0 1.44
· BwIM 0.30 0 0 0 0 0 17 0.10 0 0 17.40
· UMR 0.10 0 0 0 0 0 0.90 0.08 0 0 1.08
· BNITM 0.20 0 0 0 0 0 16.40 0.05 0 0 16.65
3 - INMI 2 0 0.50 0 0 1 31.40 0 0 32.70 67.60
· IZSPB 0.10 0 0 0 0 0 0.90 1 0 0 2
· ISS 0.20 0 0 0 0 0 2.40 0.20 0 0 2.80
· MoH 0.50 0 0 0 0.75 0.75 0 0 0 0 2
· IZLER 0.40 0 0 0 0 0 1 0.50 0 0 1.90
4 - BMASGK 0.50 0 0 0 0 0 0 2.48 0 0 2.98
· VHA 0 0 0 0 0 0 0 0 0 5 5
· AGES 0.10 0 0 0 0 0.50 1.34 0.10 0 0 2.04
5 - MCA 0.50 0.50 0.50 0.50 8 3.80 1.70 5.60 0 0 21.10
6 - CIPH 0.20 0 0 0 7.65 1.60 0.25 1.70 0 0.25 11.65
· MH-BSI 0 0 0 0 4.50 0 0 0 0 0 4.50
· UHID 0 0 0 0 0 3.50 0.30 1.20 0 1.60 6.60
7 - SUJCHBO 0.50 0.90 0.90 4 0 5.50 3 7.50 0 0 22.30
8 - SSI 0.50 0 0 0 0 0 1 4.75 0 3 9.25
9 - MSAE 0.30 0 0 0.20 0 0 0 0.20 0 0 0.70
Page 57 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Total Person/Months
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10
per Participant
· HB 0.20 0 0 0 0 0 13 12.30 0 0 25.50
10 - MOH-FR 1 0.50 0.75 32 4.50 4.75 0 4 0 0 47.50
· SPF 0 0 0 0 0.70 0 0 0 0 0 0.70
· IHUMI 0.50 0.50 1 0 0 0 0 0 0 11 13
· MOD-FR 0.10 0.10 0.10 0 0 0 1.30 2.70 0.20 0.20 4.70
· INSERM 0.20 0 0 0 0 0 1 0 0 0 1.20
11 - HCDCP(KEELPNO) 1.50 1.50 53 0 10 0 0 10 0 0 76
· UoTHESSALY 0 0 0 0 0 0 0 4 0 0 4
· EKEPY/NHOC 0 0 0 0 0 0 0 4 0 0 4
· NKUA 0.10 0 0 0 0 0 20.52 1 0 0 21.62
· AUTH 0.50 0 0 0 0 0 6.54 4 0 0 11.04
12 - NNK 0.50 0 1 0 0 0.80 22.40 4 1 0 29.70
13 - SEMS 0.50 0 0 0 38 6 0 5 0 0 49.50
14 - MOHLT 0.50 0 0 0 3 3 0 2 0 0 8.50
· NVSPL 0.50 0 0 0 0 0 4.30 0.50 0 0 5.30
15 - MFH 0.50 0.25 0.25 0.50 2 1.50 0.50 1 0.25 0.25 7
16 - RIVM 1 0.65 1.10 3.60 1 58 0.10 7.50 5.70 0 78.65
· Erasmus MC 0.20 0 0.30 0.60 0 13.77 16.01 2 0 0 32.88
17 - HD 1 0 0 0 19.50 0 2 0 0 4 26.50
· FHI 0.50 0.20 0.20 0 8 0 2 5 4.75 0 20.65
18 - NIZP-PZH 0.50 0 0 0 20 18 9 10 0 0 57.50
· NVRI 0.50 0 0 0 0 4 5.50 4 0 0 14
19 - MS 1 1 1.50 0 5.50 7 0 4 0 0 20
· INSA 1 0 0 0 0 0 8 3.25 0 0 12.25
20 - IPHS 1.75 2.83 2 2.40 16.45 12.10 3 54 0 0 94.53
21 - NIJZ 0.50 1 1 3 17 19 0 8 57.70 0 107.20
Page 58 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Total Person/Months
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10
per Participant
· UL-MF 0.50 0 0 0 0 0 3 0.50 0 0 4
22 - ISCIII 0.50 0.50 0.50 0 4 22.25 26 5.50 0 0 59.25
· SERMAS 0.10 0 0 0 0 0 0 0 0 6 6.10
· BC 0.10 0 0 0 0 0 0.15 0 0 0 0.25
· FIBHULP 0 0 0 0 0 0 0 2 0 0 2
· OSAKIDETZA 0.40 0 0 0 0 0 0.60 0 0 0 1
23 - FOHM 1 0 1 2 23.25 0 17 1 0 1.50 46.75
24 - DH 1 1.20 1.40 0.50 2.05 1.20 9.50 6.30 30.25 0 53.40
· PHW 0.66 22.57 0 0 0 0 0 1 0 0 24.23
· RFL 0.10 0 0 0 0 0 0 0 0 3 3.10
25 - HSE 1 0 0 0 0 0 0 0 0 0 1
26 - NAPH 0.50 0 0 0 3.50 0 6 3 3 0 16
Total Person/Months 126.91 40.30 68.10 51.40 201.45 191.12 301.54 223.26 107.70 79.40 1391.18
Page 59 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.3.7. WT7 Tentative schedule of project reviews
Review Tentative Planned venue
Comments, if any
number 19 timing of review
RV1 18 Teleconference
RV2 36 Teleconference
Page 60 of 60
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1. Project number
The project number has been assigned by the Commission as the unique identifier for your project. It cannot be
changed. The project number should appear on each page of the grant agreement preparation documents (part A
and part B) to prevent errors during its handling.
2. Project acronym
Use the project acronym as given in the submitted proposal. It can generally not be changed. The same acronym should
appear on each page of the grant agreement preparation documents (part A and part B) to prevent errors during its
handling.
3. Project title
Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are
possible if agreed during the preparation of the grant agreement.
4. Starting date
Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement,
the project will start on the first day of the month following the entry into force of the Grant Agreement (NB : entry into
force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a
written justification.
5. Duration
Insert the duration of the project in full months.
6. Call (part) identifier
The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated
in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the
Commission in the letter inviting to prepare the grant agreement.
7. Abstract
8. Project Entry Month
The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start
dates being relative to this start date.
9. Work Package number
Work package number: WP1, WP2, WP3, ..., WPn
10. Lead beneficiary
This must be one of the beneficiaries in the grant (not a third party) - Number of the beneficiary leading the work in this
work package
11. Person-months per work package
The total number of person-months allocated to each work package.
12. Start month
Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other
start dates being relative to this start date.
13. End month
Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date.
14. Deliverable number
Deliverable numbers: D1 - Dn
15. Type
Please indicate the type of the deliverable using one of the following codes:
R Document, report
DEM Demonstrator, pilot, prototype
DEC Websites, patent fillings, videos, etc.
OTHER
ETHICS Ethics requirement
ORDP Open Research Data Pilot
DATA data sets, microdata, etc.
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
16. Dissemination level
Please indicate the dissemination level using one of the following codes:
PU Public
CO Confidential, only for members of the consortium (including the Commission Services)
EU-RES Classified Information: RESTREINT UE (Commission Decision 2005/444/EC)
EU-CON Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC)
EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC)
17. Delivery date for Deliverable
Month in which the deliverables will be available, month 1 marking the start date of the project, and all delivery dates
being relative to this start date.
18. Milestone number
Milestone number:MS1, MS2, ..., MSn
19. Review number
Review number: RV1, RV2, ..., RVn
20. Installation Number
Number progressively the installations of a same infrastructure. An installation is a part of an infrastructure that could be
used independently from the rest.
21. Installation country
Code of the country where the installation is located or IO if the access provider (the beneficiary or linked third party) is
an international organization, an ERIC or a similar legal entity.
22. Type of access
VA if virtual access,
TA-uc if trans-national access with access costs declared on the basis of unit cost,
TA-ac if trans-national access with access costs declared as actual costs, and
TA-cb if trans-national access with access costs declared as a combination of actual costs and costs on the basis of
unit cost.
23. Access costs
Cost of the access provided under the project. For virtual access fill only the second column. For trans-national access
fill one of the two columns or both according to the way access costs are declared. Trans-national access costs on the
basis of unit cost will result from the unit cost by the quantity of access to be provided.
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Annex 1 to the Grant Agreement
SHARP JA - Strengthened International HeAlth Regulations and
Preparedness in the EU - Joint Action to strengthen preparedness in the
EU against serious cross-border threats to health and support the
implementation of the International Health Regulations
Chafea – 3rd Health Programme
Multi-beneficiary Project Grant (HP-PJ, HP-JA)
Call: HP-JA-2018, Topic: JA-01-2018, N:o 848096
June 24, 2019
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
TABLE OF CONTENTS
2. PART B .......................................................................................................................................................................... 19
2.1. Problem analysis including evidence base ............................................................................................................. 39
2.2. Aims and objectives of the project ........................................................................................................................ 56
2.2.1. General objective of the project............................................................................................................................. 56
2.2.2. Specific objectives of the project........................................................................................................................... 57
2.3. Target groups ......................................................................................................................................................... 66
2.4. Political Relevance ................................................................................................................................................ 66
2.4.1. Contribution to meeting the objectives and priorities defined in the annual work programme ............................. 66
2.4.2. Added value at EU level in the field of public health ............................................................................................ 67
2.4.3. Pertinence of geographical coverage ..................................................................................................................... 68
2.4.4. Consideration of the social, cultural and political context ..................................................................................... 68
2.5. Methods and means ............................................................................................................................................... 70
2.6. Expected outcomes ................................................................................................................................................ 86
2.7. Timetable / Gantt Chart ......................................................................................................................................... 90
2.8. Project management structure................................................................................................................................ 95
2.8.1. Quality of the partnership ...................................................................................................................................... 95
2.8.2. Capacity of the staff............................................................................................................................................... 96
2.8.3 Financial management .......................................................................................................................................... 131
2.9. Budget ................................................................................................................................................................. 131
2.9.1. Content description and justification ................................................................................................................... 131
2.9.2 Detailed budget ..................................................................................................................................................... 132
2.10. Collaborating stakeholders .................................................................................................................................. 174
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
1 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2. PART B
HISTORY OF CHANGES
Outline of the Changes (20 June 2019)
Comments from Chafea/DG SANTE: Response (THL)
848096: HP-JA 2018 – SHARP - Comments on 3rd June 20, 2019
submission version dated 24 April 2019
Part A
Subcontracting costs should be explained in the WP Text concerning subcontracting costs has been
descriptions. added into the end of the following WP
descriptions: WP1, WP3, WP7, WP9 and WP10.
Part B
Exceptional utility approved for SHARP (financing 80 % The budgets have been modified accordingly.
by the EC and 20% own contribution)
11-HCDCP – we were informed that KEELPNO has The new organisation NPHO is not yet ready to
been restructured and became the National Public be attached into the proposal. The proposal is
Health Organization (NPHO) is a legal entity of Public submitted with KEELPNO, and there will be an
Law supervised by the Ministry of Health. It is amendment later to change the partner to
established under the Law 4600/9.3.2019 and it is the NPHO.
universal successor of the pre-existing Centre for
Diseases Control and Prevention (KEELPNO), which The cost for the subcontractor is for the
was abolished by the same law; from the website: external evaluation. There is a justification in
https://eody.gov.gr/en/npho/: can you please check the detailed budget form: “The external
when you should use the new entity PIC and evaluation will be subcontracted to an
denomination? independent entity with relevant experience in
- Staff vs. Subcontracting vs. Other costs: There have the field of health security and specifically in
been proposed costs for 2 internal Evaluation Officers evaluation of health programmes. The external
as staff members of around 62.000 EUR at the same evaluation team will be comprised of the
time an external Evaluation as subcontracting of evaluation team leader and evaluation
74.000 EUR and still costs for Audit Certificate. Could researchers who will perform the impact
you please explain and justify? assessment of the JA. Apart from the external
evaluation services the cost will include the
travel and subsistence cost for the external
evaluation team for participating in
selected project meetings.” The external
evaluation will be implemented in two phases:
in the middle and the end of the project.
The cost for the internal evaluation (1 Senior +
1 officer) is justified in the detailed budget
form as well. The internal evaluation of SHARP
will continue throughout the project, and due
to a big amount of work packages and
partners, as well as the big size of the project,
two evaluation experts are needed.
Audit costs are at a separate budget line, as
this task is for different kind of experts than the
external evaluation.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
2 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
17-HD-FHI. Audit costs: There have been budgeted The EU contribution for HD-FHI is 183,025.09
Audit costs for a EU contribution of EUR 137.368,82, EUR after approval of the exceptional utility.
whereas the audit of the project is obligatory for The audit cost for HD-FHI has been removed
reimbursement of costs amounting to 200.000,00 EUR keeping the overall budget the same.
and the cumulative payment of 150.000,00 EUR. Could
you please explain and justify and correct the budget
accordingly?
22-ISCIII-FIBHULP and OSAKIDETZA – no budget Budgets for FIBHULP and OSAKIDETZA have
planned – is that correct? Affiliated entities included in been added.
the Grant Agreement should have some budget even
if they are not going to receive any EU contribution.
24-DH-PHW. Audit costs: There have been budgeted DH-PHW EU contribution is 184,146.93 after
Audit costs for a EU contribution of EUR 138.110,20, approval of the exceptional utility.
whereas the audit of the project is obligatory for The audit cost has been removed keeping the
reimbursement of costs amounting to 200.000,00 EUR overall budget the same.
and the cumulative payment of 150.000,00 EUR. Could
you please explain and justify and correct the budget
accordingly?
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
3 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Outline of the Changes (April 10, 2019)
Comments from Chafea/DG SANTE: Response (THL)
848096: HP-JA 2018 – SHARP - Comments on 3rd April 10, 2019
submission version 15/03/2019
In line with the ERS criterion 2 Technical quality
comments:
WP6: Following on feedback, text and
S2: The WP descriptions, especially 4, 5, 6 and 8 are outcomes of WP6 have been extensively
long and rich in jargon. Use previous reports, surveys revised, with focus on intersectoral
and projects (incl. Art. 4 Monitoring) to go directly to interoperability and active participation of low
the main questions: GNI countries. Texts have been simplified and
What are the gaps in Decision 1082/2013/EU outcomes made more concrete in form of
and IHR implementation? protocols, best practices catalogues and
What do you plan to do to fill those gaps? guidelines.
What is the evidence that your activities will
WP4 was revised already in the previous
fill the gaps?
submission, now only small changes done
What are the expected and ambitious
according to the later comment.
outcomes and deliverables?
Focus on concrete outcomes, like SOPs, business WP5 and WP8 have been revised according to
continuity planning, interoperability, intersectoral the detailed comments.
collaboration, protocols, and best practices –
capacities that will be available in a crisis – not only
meetings, workshops and exercises.
Our main comments are oriented towards WP 5 and WP6:
WP 6, here in more details: The new WP6 revision clarifies that WP6
For WP 6, there continues to be too strong actions are about intersectoral operability, i.e.
focus on labs at the near complete expense of between public health, clinical, laboratory,
generic preparedness and response planning. chemical and other (e.g. veterinary) sectors.
Our main comments are oriented towards WP 5 and WP5:
WP 6, here in more details: Task 10.3 in WP10 aims to discuss the
For WP 5, the inclusion of “a need for legal feasibility of an expert clinical consultation and
framework for patient referral…trans country support service. In this task of WP5, the need
medical consultation…clinical information for a legal framework for patient referral, for
exchange” is more cross border healthcare trans-country medical consultation, and for
and not in the remit of “IHR core capacity clinical information exchange is raised as
challenges to be addressed.
strengthening and assessment”.
A legal framework for trans-country medical
consultation should be in place to fulfill the
obligation according to IHR (2005) chap 13
annex 1 (g) to: "establish, operate and maintain
a national public health emergency response
plan, including the creation of
multidisciplinary/multi sectoral teams to
respond to events that may constitute a public
health emergency of international concern; (h)
to provide the foregoing on a 24-hour basis."
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
4 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1. Annex 1 (Part B)
i. General
There are also quite significant editing issues in the THL:
latest submission which requires review (For example, Part B has been checked and re-edited by the
p. 71: WP 10 has the summary of chemical’s expected Coordinator. Writing and typing errors and
outcome). general mistakes have been corrected.
There are general mistakes, missing parts and some
elements copy-pasted.
ii. Detailed comments THL:
- 2.1 We consider that the 2 paragraphs are
- 2.1 Introduction and state of play : first two
important for the context
paragraphs kept as same despite comments
- p.4 Updated text. Point 7 terror is
- P. 24 – see no link to point 7 on terror or 4 on
dependent on civil capacity in terms of
EWRS or 8 on crisis communication
case management
- P. 25 – still a large focus on WHO/global
- P.25 We do not consider the discussion to
- P. 26 – reference for the comment on economic
be focused on WHO. The EU actions are
impacts costing in the billions
certainly intertwined with and even
- P. 28 & 29 – the figure numbers are off and do not
dependent on the global framework.
match with the text
- P. 26. Reference 17. addresses this
- P. 28 : “close collaboration with the “points of
question
entry” “healthy gateways” JA is planned,
- P. 28 & 29. Figure numbers have been
“collaboration between HG and SHARP WP
corrected
5,6,9,10 is envisioned: not reflected in the
- P. 28. The exact way for cooperation will be
description
elaborated during the project
- P. 31 – first paragraph of challenges and gaps: - P. 31. First paragraph sets the stage of the
purpose of this description not clear and mentions problem. We have added two sentences to
deliberate events when this JA does not address clarify why deliberate events are
deliberate mentioned, even though
- P. 31 – no mention of the additional ECDC reports - P. 31. The ECDC has indeed produced a
as per previous comments large body of different preparedness
related reports and tools, but none of
these contains comprehensive and
comparable data on member state
preparedness. They are either specific for a
certain scenario (Ebola, influenza, MERS) or
are restricted to just a few countries. The
LabCap report is the only one which is
comprehensive and can thus be used for a
general priority ranking. During the project,
the information in the different specialized
reports will certainly be utilized.
- P. 32 – the ranking: is this acceptable to MS? - P. 32. the priority ranking method was
Whilst this ranking is present here, can a clear link accepted by all the WP leads and co-leads
to be noted about when it will be used in the JA? in the planning meeting in February in
For example, WPs mention low GNI but is that just Helsinki. None of the partners have
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
5 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
low GNI country or the low GNI countries of this objected or criticized the use of it despite
table? having all seen it. It is not intended to be
publicly presented but to be used as an
internal project tool. It is used mainly in the
planning phase when WP leads are
discussing activities with the partners, to
give priority for participation to those
partners that have the lowest combination
scores.
- P. 33 – the gaps 1,2 and 3 have not been - P.33. These gaps have now been
developed as per previous comment addressed in the different WPs, as
appropriate. As for Gap 3, it can
only be partially covered through
this Joint Action. The links to
other sectors are nevertheless
planned to be covered in the work
done in WP6 especially, partially
within WP5.
- P. 34 – comments from before not addressed: - P. 34.
o Direct support for dedicated national WP5 text has been corrected to:
coordination workforce – where is this in
the WPs? 1. Supporting the countries in initiation of the
o Direct consultation – where is this in the evaluation process with regards to IHR
WPs? implementation and thereby aiding in
evaluation of capacities and needs for capacity
o Country visits to exchange best practice –
building.
where is this in the WPs?
2. For low GNI countries that have already
- Gaps in capacity – what is the deliverable? performed a JEE, participating countries will
Feasibility study report? through peer to peer exchange of knowledge
and best practice, develop national plans to
address the common identified gaps
3. Improving capacity… (as before)
- 4. Gaps in capacity – this relates
to the deliverable D5.4 Report on
the use of exercises and AAR.
- P. 34 – WP 6 – preparedness planning and WP6 has been substantially re-written and the
intersectoral collaboration should be focus – planned actions modified to reflect feedback.
this is still not apparent and now there is a Text on p. 34 is replaced by: “The focus of the
sentence highlighting that the special focus of WP is to improve the integration of multiple
this WP is the integration of labs sectors (among others specialized laboratory
- P.34 – WP6, first point: mapping: “all threats services, clinical sector) in the overall IHR
integration on laboratory WP7, chemical WP9 response to public health threats and incidents
and clinical WP10: missing clinical in the actual in the medical, biological and chemical sector”
WP description
- P.35 – “It is likely that the perception…than in P. 35. the sentence has been changed as
most other parts of the world” – to reword follows: “It is possible that the perception of
more diplomatically what constitutes sufficient human resources is
highly dependent on the expectations and
perceived ambition level, and shows variation
across the globe.”
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
6 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
- P. 35 – question on what resources in WP9 has WP9:
not been addressed P.35 – ‘Resources’ refers to outputs from
- P. 36 – question on whether chemical previous projects on public health
surveillance is the only IHR element for management of chemical incidents. Example
compliance has not been addressed resources to include (but are not limited to)
response documents for a chemical incident
and use of RASCHEM.
Text modified: “existing mechanisms, tools and
resources produced in previous EU-funded
projects (e.g. RASCHEM tool, CERM sheets,
Rapid Risk Assessment etc.) between and
within EU Member States (MSs) and
participating SHARP JA countries.”
P.36 – We have changed the wording to mirror
the IHR JEE and WHO chemical event guidance,
which uses terminology such as the prevention,
detection, risk assessment and response to
chemical events. We hope this emphasizes that
we will not solely focus on surveillance as an
IHR element for compliance.
- P. 40 – target for the outcome indicator: Target changed to:
specific how many national policies and Minimum 2 best practices and
mechanisms it aims to have integrated recommendations are integrated into national
policies and 1 best practice is integrated into
mechanisms.
- P. 41 – targets: need more specification – 1 Targets of specific objective no 2 (WP5) have
what? Study? Workshop? Countries and if yes been specified to be clearer.
which ones (e.g. low GNI?)?
- P. 42
o consensus meetings and online The whole Specific objective table of WP6 has
consultations not mentioned before been revised.
o “To engage partners in defining best
practices” – of what?
o Community engagement mentioned
nowhere else
o Barrier inventory for participation
mentioned nowhere else
o 4 e-learning tools?
o Simulation and e-learning tool
communicated – to whom?
o Checklists on local inventory – what
does local mean? – does this imply
one for each country?
o Catalogue and guidelines for
community engagement – again,
mentioned nowhere else
o “aware of availability of integrated
preparedness and response cycle…” –
has not addressed earlier comment –
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
7 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
aren’t JA partners already aware of
this?
o “aware” not a quantifiable indicator?
- P. 43 – how is a report a target for the WP7 (Specific Objective 4.1) – Indicators and
outcome indicators? targets have been specified and modified
accordingly:
- P. 43 “quality assurance of diagnostic methods Indicator: Quality assurance of diagnostic
has been improved” -> could be explained? methods has been improved by refinement of
single steps in the diagnostic approaches, by
improving validation procedures of previously
adopted methods, introduction of new
methods or consolidation of existing high
quality standards.
Target: 1 report indicating that at least 5
laboratories have improved diagnostic
methods and the other participants have
maintained and consolidated their high
diagnostic quality, Mo 35.
- P. 44 – how is a report a target for the WP7 (Specific Objective 4.2)
outcome indicators? Indicator: Number of laboratories which have
applied the revised and newly developed
- P. 44 “number of laboratories which have biorisk management recommendations
applied the newly developed biorisk
Target: At least 5 reports by partners on
management procedures” and then target “5
implementation of the biorisk management
reports” -> what is the actual target
recommendations, Mo 30
- P. 44 same as page 43: clarify the WP7 (Specific Objective 4.2)
measurement of improvement Indicator: The biorisk management of RG3 and
RG4 agents has been improved by an extended
risk assessment and introduction of
new/additional biosafety/biosecurity measures
Target: 1 report indicating that at least 5
laboratories have introduced new measures for
biorisk management and others have
maintained/consolidated the high standard of
biorisk management , Mo 35
- P. 45 – “training materials developed” – Changed to:
please clarify. For all WPs? Certain training Training materials for WP8 developed.
materials?
- P. 46 – target for improved implementation of WP9 outcome indicator target changed to:
IHR chemical core capacities – does this mean At least 70% of the MSs to have utilized the
100% implementation in the MSs who advice documents provided by WP9 in their
identified need? If yes, is this an achievable planning, preparedness, risk assessment and
target? response to chemical events.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
8 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
- P. 47
o Targets to be more precise (e.g. “each Specific objective table of WP10 has been
country” of the JA? Or EU? - revised.
Implemented in at least one clinic in
Process indicator targets corrected:
three countries – specific by when this
4 workshops (minimum one
will happen and which countries? JA? participant for each country of the
EU?) JA) by month 30
o Output indicators – shouldn’t this also Implemented in at least one clinic in
include reports? Protocols? 3 countries of the JA by M32
Two output indicators added:
Feasibility study for an expert clinical
support service for high-consequence
infectious diseases – target: 1 report by
M18
Protocol for syndrome-based
approach for prompt and early
clinical management of high-
consequence infectious diseases –
o Impact indicator – nothing for biorisk? target: 1 protocol for each of the
three involved pilot countries by M18
Impact indicator added:
Participating hospitals have utilized the JA
guidance on biorisk management
- P. 48 – WHO is still not included as a target. P. 48
First responders and local and regional - WHO has been included as target group, in
outbreak investigation teams – are these addition, ECDC, IANPHI, and FAO has been
include anywhere in WPs? If they are not added. First responders have been removed
included, how can they be mentioned as a from the list.
target?
- P.49: It is correct that the project
- P. 49
directly addresses mainly
o Paragraph on EU policy frameworks – frameworks 1) and 2) but we
agreed for 1) and 2) – but see no link certainly consider that there are
or work with any of the other at least indirect links to all the
frameworks. other listed frameworks. Some
o “evacuation capacity” – have not seen are stronger than the others, but
this addressed in any WPs for example within the
- Horizon2020 programme and its
predecessors there have been
multiple projects addressing
issues relevant for the SHARP JA
- P.49: both WP5 and WP10
address the evacuation context;
legal issues of sending and
receiving personnel and actual
practical questions of where to
evacuate and how. This is to be
addressed in good practices too.
- P. 52 – mentions WP 4 as a core WP here WP4 is horizontal WP instead of a core WP. The
whilst elsewhere it is not described as care but sentence has been corrected.
as horizontal (annex 1 part A, p.9)
o Is all the below descriptions of WPs Means and methods sections have been
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
9 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
supposed to be a continuation of revised.
means and methods? If yes, they do
not solely focus on this in their
descriptions – to be revised to be
more precise as they are mostly copy
paste from annex 1 part A
- P. 53 - WP 2 – this is not a methods and WP2 text has been revised.
means description
- P. 56
o “support WHO” – to be reworded? The sentence has been rephrased:
“Contribute to the ongoing processes of WHO
and ECDC…”
- WP 6 WP6
o Is this a means and methods description?
o “model for access through bilateral and/or o Text has been extensively revised with
multilateral agreements in emergency simplified, more unambiguous
situations” – this is mentioned nowhere wording.
else o Emphasis on low GNI countries has
been clarified through the methods
o “Engaging multiple sectors” – where is this
and means section, and the supportive
explained or discussed elsewhere in WP
role of WP6 leads has been explained.
6? Which sectors are being engaged o WP6 figure has been removed and
exactly? replaced by the HEPSA figure.
o “with a specific focus on low GNI
countries” – where is this explained or
discussed elsewhere?
o SoPs, best practices etc. for intersectoral
collaboration – this is mentioned nowhere
else?
o The figure is unclear
- - P.58 - “long-term goal will be to support the plan WP7: Sentence has been modified:
of setting up a reference laboratory network for “One long-term goal will be to further develop
highly pathogenic infectious agents at European recommendations and a plan for setting up a
level” – up for discussion with EC and ECDC on sustainable cross-sectoral reference laboratory
how to do it, but still is considered a goal of the network for highly pathogenic infectious
WP . the goal is the support to the set up? Or the agents at European level, which will be
reference lab network itself? proposed to the European Commission and
European Agencies like ECDC for further
discussion and implementation.”
- P. 59 : “various partners have experiences in POCD WP7: Paragraph has been modified:
and HHTK” – who? How will it be shared? “Various partners have experiences in POCD
and HHTK, also applied in international
outbreak response (WHO-GOARN) and in
endemic countries. This knowledge will be
shared between partners at WP7 meetings and
practical applications will be exercised and/or
trained in framework of EQAE or training
courses (WP8).”
- P. 60 - first mention of CBRN – nowhere else – so WP7: We agree and the sentence was
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
10 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
is this really achievable/a target? modified:
“In case of unknown or all hazards CBRN
threats, the laboratory network on highly
pathogenic infectious agents will be part of the
public health response as long as biological
threats are not excluded and will participate to
the close interaction between relevant
agencies, organizations, and networks will be
established. Further, the network can provide
support in regard of biological threats to EU MS
without adequate CBRN diagnostic
capabilities.”
- P. 61: “ensure that nationally relevant laboratory WP7: The comment is not clear. IHR-NFP is
institutions have access to communication mentioned here. Some phrase was added
channels to interact with the IHR national focal which should clarify the sentence.
point NFP” – throughout the WP : collaboration “Ensure that nationally relevant laboratory
with partners of JA etc, but no mention of IHR institutions have access to communication
NFPs. channels to interact with the IHR national focal
point (IHR-NFP); this will be exercised by
linkage with WP4, 5, 6.”
- P.61: 7.2.2. is missing: Basic diagnostics WP7: editing error during the last submission,
paragraph was lost. Description of Working
Group 7.2.2. has been added:
Working Group 7.2.2 “Basic diagnostics”
“In addition to technically high advanced
approaches targeted by Working Group 7.2.1,
the implementation of basic diagnostics of
highly pathogenic infectious agents would be a
minimal requirement in designated partner
country laboratories, especially in those with
lower resources.
The identification of cost-effective diagnostic
methods under low financial and
infrastructural resources including mobile
laboratories, the availability of high-
containment laboratory facilities, and
diagnostics in high-containment clinical
facilities (Point of Care Diagnostics, POCD) will
be carried out. Access of partners from lower
GNI countries to high-containment facilities by
cooperative agreements will be further
fostered. Relevant methodological approaches
will be identified and assessed by the working
group. Recommendations of best practice will
be developed. There is a strong link with Task
7.1 wherefrom partially the reference material
for EQAE can be used for the evaluation of the
identified methods.”
- P. 68 Mitigation is possible, even if we can’t prevent
o “…posed by any cross border health all health threats.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
11 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
threat” – is this really achievable? “Electronical clinical consultation”: sentence
o “electronic clinical consultation” – removed from the section 2.6 Expected
where is this mentioned elsewhere? outcomes. Refers to the first WP10 draft
version.
Rephrased: “to enhance collaboration to share
o “develop agreements to share specialized services”. This is related to WP5
specialized services” – where is this workshop on international collaboration
mentioned elsewhere? between authorities during crisis.
- P. 69 – WP6
- Community engagement – again, described WP6: “community engagement” is removed
nowhere else – please clarify from the text.
- P. 71 – WP 10 THL (and WP10)
o The expected outcomes is a copy and This was an editing error at the last submission
paste from the chemical WP – to be phase. WP10 expected outcomes have been
changed corrected.
2. Annex 1 (Part A)
1.1.3 General
- WP6 remains problematic as it continues to be WP6 text has been extensively changed to
highly oriented towards labs. Previous BCPs, clarify that the aim of WP6 is to develop and
community engagement are removed and it is strengthen intersectoral collaboration between
now noted: “A special focus of the WP is to public health, clinical, biological and chemical
improve the integration of specialized laboratory and other sectors, such as
laboratory services to the overall response”. veterinary. Laboratory input will come from
WP7 and WP9.
- WP 5 has included a workshop in 5.2.2 on “a The reason of including the workshop in WP5 is
need for a legal framework for patient that this is planned as collaboration between
referral; a legal framework for trans-country WP10 Task 10.3 and WP5. WP10 includes
medical consultation; a legal framework for feasibility study of an expert clinical support
clinical information exchange” – is this IHR or service for epidemic-prone diseases :
is this cross border healthcare? “A protocol for the utilization of the service will
be also developed and an inventory of existing
electronic platforms for teleconsultation will be
explored. This will result in a set of technical
recommendations which would be part of the
evaluation in WP5 where identification of key
challenges in national and international
collaboration between governments and
national authorities will be conducted in a
dedicated workshop. During this Workshop,
legal framework for patient referral; legal
framework for trans-country medical
consultation; legal framework for clinical
information exchange will be explored”.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
12 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1.1.4 Detailed Comments
- Project summary (p. 3): “ priority countries The sentence has been corrected: “priority
(countries that have not yet reached the countries (countries that have biggest gaps in
capacity required for full IHR capability)” the capacity required for full IHR capability)”.
Are there any countries in the EU that Naturally this includes a condition that those
have met full IHR capability? countries are interested to develop their IHR
capacity.
- For all work package descriptions – in the
sections “list of deliverables”, there is Repetition of deliverables has been removed.
repetition of deliverables
- Dissemination levels – except for WP7 - all Dissemination levels have been checked, and
dissemination levels are public – can this be two more deliverables have been classified as
reviewed to ensure correctness? confidential:
For example, the report in WP5 on WP5 – D5.3 Report on international
“international collaboration between collaboration between authorities during crisis
authorities during crises” for public has been changed to be confidential.
dissemination?
WP6 – D6.1 Report on Disease X simulation has
been changed to be confidential.
- WP 3 – “tool that can be used to evaluate the The following is added to the WP3 description:
project impact beyond its duration” A sustainability plan for the evaluation tool will
What is the sustainability of such a tool? be incorporated in the framework of task 4.3 of
Clarify if there is work expected to be WP4 “Development of the SHARP sustainability
done to create a mechanism for how this plan” with the cooperation of the WP3 and
tool will be used and by whom after the JA WP4 leaders. This simple evaluation tool will
assist policy makers and users of SHARP-
is finished in order to use it?
related actions to effectively assess impact
beyond the project's implementation period
and provide valuable information on what
worked and what not and effectively help
planning for future projects and Joint Actions.
- WP 4 – “The feasibility to include some WP4
selected best practices into national policies Changed to: “The integration of some selected
will be piloted throughout the project and in best practices into national policies will be
collaboration with other WPs” piloted throughout the project in collaboration
Please clarify – how can feasibility be with other WPs.”
piloted?
- WP 5 The following addition has been done to the
o “medical issues related to AMR” WP5 description:
How is AMR related to the topic here? “AMR situation is important for the choice of
treatment protocol locally. In some countries
(e.g. Norway) health care workers who test
positive to MRSA are not allowed to have
patient contact. Patients would also be isolated
until tested negative. This problem is likely to
increase in the future and should be
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
13 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
addressed.”
Corrected to “civil protection”.
o Civil protection, rather than “civic The chapter has been revised:
protection”
“Thus ResEU build rapid response capacities
including medical units (EMTs) to be
o “There is a need to harmonize these deployed when national capacities are
and increase cooperation between insufficient or overwhelmed. It is necessary
national sectors and the EC….legal to discuss which legal issues need to be
issues to be solved to send help in a solved in order to send and receive help in a
timely manner as well as the following timely manner. There is a need to harmonize
topics” these responses and increase cooperation
The scope here needs to be more clarified between national sectors and the European
as meaning is unclear Commission (DG SANTE, DG ECHO) and WHO
respectively in order to avoid duplication.”
Clinical consultation: WP5 plans to collaborate
o Clinical consultation – is there a with WP10 on the legal issues. The workshop
reason why this is included in WP5 5.2.2 completes the Task 10.3. of WP10.
rather than in WP 10? If yes, please A legal framework for trans country medical
highlight why consultation should be in place to fulfil the
More broadly, on this clinical consolation obligation of IHR (2005) to: " establish, operate
and legal aspect – is “a legal framework and maintain a national public health
for trans-country medical consultation” an emergency response plan, including the
IHR core capacity? creation of multidisciplinary/multi sectoral
teams to respond to events that may constitute
a public health emergency of international
concern; (h) to provide the foregoing on a 24-
hour basis." See also the response at previous
page.
However Norway’s experience from setting up
a clinic in Sierra Leone in 2014 suggests this is
necessary to resolve before deploying health
care workers cross borders as expected in IHR
(2005) art 13 annex 1 (g and h).
- WP6 WP6 text has been extensively changed to
clarify that the aim of WP6 is to develop and
Overall, this continues to be highly focused on strengthen intersectoral collaboration between
labs. Whilst they are important, there is only one different sectors. Laboratory input will come
element of a preparedness and response plan. The from WP7 and WP9.
added value of the review of planning and
evaluation tools remains unclear and now also Overall the tasks of WP6 are rewritten to more
seems to be orienting towards laboratories as concretely describe the planned actions within
well. This very much focused on labs and when the WP, i.e.
not mentioning labs, it appears to be quite 1. Identifying core elements of an integrated
abstract. multisectoral preparedness and response
plan
2. Supporting partners and MS in
development of an integrated multisectoral
Preparedness and Response plan
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
14 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
3. Testing the multisectoral preparedness and
response plan, “Disease X” scenario
4. Learning from “Disease X”: testing the
multisectoral preparedness and response
plan in e-learnings and tabletop exercises
5. Translation into best practices and
sustainability (with WP4 and WP5)
- WP6 WP6:
o “Review of and preparation of an Task 6.1.1. This task has been changed to
integrated preparedness and response “Review of international and/or national tools
plan protocol” and planning instruments for preparedness and
Can this be clarified – does this mean response focused on multi sector integration
there will be a review of all preparedness for the following sectors: public health
and response plans of MS or does this laboratory services, clinical and chemical
mean that the review of tools will be sectors”.
undertaken?
o Task 6.1 – the previous comment was This is further clarified in 6.1.1.3. Workshop
please clarify added value of and its objectives and outcomes, i.e. mutual
reviewing evaluation and planning agreement on the core elements for integrated
instruments multisectoral preparedness and response
Please clarify as per previous comments planning, and mutual understanding of terms
and languages between sectors.
Please also clarify on why laboratory WP6 text and actions has been extensively
specific tools leads to an all hazards changed to clarify that the aim of the WP is to
approach – all hazards approach would develop and strengthen multisectoral
imply PoEs, Zoonotic events, food safety, collaboration between public health, clinical,
chemical events and radiation biological and chemical laboratory and other
emergencies. sectors. In all tasks, the multisectoral aspect of
this WP is emphasized and included.
Seems like they only mentioned lab and
chemical but not the other ones
o Task 6.1.2 “based on the accepted set Task 6.1.2 has been revised and is now
of…for further applicability in a high described in task 6.2 “Supporting partners and
threat “disease x” scenario through member states in development of an integrated
international consultation” multisectoral Preparedness and Response plan”
please clarify scope of an international and is clarified in the text as follows: “Based on
consultation the selected core elements, a draft
Please clarify further applicability – what multisectoral plan will be developed. The
does this mean? A further analysis of backbone of the plan will be the preparedness
whether what exists is sufficient to and response cycle. The WP6 leaders will
identify disease x? support the participants in development of the
country specific multisectoral Preparedness
and Response plans.”
o Task 6.1.2 “to identify the minimum This text is removed and it is replaced by the
level of competent human subtask 6.1.2.1 Expert meeting. It is not about
resources…of high containment laboratory preparedness but intersectoral
laboratories” preparedness.
So that labs would be ready in the case of
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
15 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
a disease x? please clarify further
o - Task 6.3 : all hazard approach Task 6.3 : all hazard approach – in the revised
- As mentioned above: implies PoE, Zoonotic WP6 description this is Task 6.5.:
events, food safety, chemical events and Also see response above. WP6 text is
radiation emergencies, this is also were you extensively changed to clarify that the aim of
would assume Healthy Gateways would take the WP is to develop and strengthen
part? For PoE? multisectoral collaboration between public
health, clinical, biological and chemical
-
laboratory and other sectors. In all tasks, the
multisectoral aspect of this WP is emphasized
and included.
All hazards approach in Task 6.5. will include
all kinds of events, except radiation
emergencies as this is not covered in a
technical work package. Collaboration and
integration with Healthy Gateways will be
provided for Points of Entry. RIVM is WP
leader also in Healthy Gateways. This role in
both Joints Actions will support the alignment.
- WP7 WP7: The paragraph was modified:
- Not many changes in the WP - The evaluation of best diagnostic approaches
o Task 7.2 : and methods, including in-house and
- Including “in-house and commercial diagnostic commercial diagnostic assays, will be done to
test kits” : are these referring to 7.2.2. HHTK? define laboratory recommendations, including
biosafety and shipment aspects, and
evaluation/update of lab capabilities in the EU.
For highly pathogenic infectious agents, very
often in-house assays are used, but for some of
these pathogens also commercial assays are
available. In this case, the access to these
assays might be easier than to develop own in-
house tests, especially for lower GNI countries
and can provide a better standardization of
diagnostic procedures. On the other hand, the
quality of evaluation of commercial assays is
often not well demonstrated and this gap could
be filled by activities in the network. Thus, we
would like to consider both in-house and
commercial assays for evaluation of their
applicability in diagnostic laboratories. The
results obtained during the previous JA
EMERGE are used as a basis for the evaluation.
- WP7 WP7: Sentence was modified:
o Task 7.2 : - Networking in collaboration with other Tasks
- “networking in collaboration with other and WP, with research laboratory projects and
tasks… veterinary laboratories” – to clarify EU projects seeking to support outbreak
how vet-lab will be included response in endemic countries, and with
- Only one mention of better support to low veterinary laboratories already included in this
GNI countries “lower resources”. They Joint Action. Serving as multiplicators at
explained that lower GNI are participating in national levels, and with international
this WP, is this enough or should it be more organizations in order to develop synergies and
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
16 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
included in the process? reduce overlapping.
- WP7: See included sentence in the overall
description of the WP above. At this point,
basic diagnostics are meant as minimal
diagnostic requirements considering low
resources:
Special attention will be given for partners
from low GNI MS for their implementation in
the various tasks of the WP.
- WP8 WP8: reference added:
o Task 8.1 – there is still no reference to “No extra survey of training needs might be
the 2018 report on preparedness and necessary. The analysis of reports from WHO
response planning as per last Joint External Evaluations, Progress report on
comments preparedness and response planning under
o Deliverables sections decision 1082/2013/EU (art. 4) and EC/ECDC
Training report (S) – would be technical assessments will indicate areas where
plural and thus, also need due training may be required.”
date for the different reports WP8: List of deliverables, D8.2 specified:
or will they all be due in
D8.2 : Final training report [36]. Description:
month 36?
Final report on all training provided in WP8,
including the training packages and on-line
platform.
- WP9 WP9
o Deliverables section – different format Deliverables section: The surplus text has been
than all the rest. In addition, it is removed; the deliverables are now succinct
copy/paste from the description of and in-line with the format of other WPs.
work and are not always deliverables
(e.g. Task 9.2 – what is the actual
deliverable?)
- WP10 WP10
o Clarify WP 10 Task 10.4 “workshops - Task 10.4 workshop description has
coordinated together with WP8” been specified and clarified in the text
o Milestones - Minor changes in section “Description
WP10 data collection – just of work and role of partners”
data collection? - Milestones: MS40 “WP10 data
collection” corrected to: “Data
collection on hospital preparedness”
with explanation: “Collection of data
on hospital preparedness and capacity
in dealing with high-consequence
infectious diseases in JA participating
countries.”
In addition, the following changes have been included into the proposal:
Part B:
2.7. Timetable/Gantt chart has been revised according to the changes in WPs.
2.9.2 Detailed budgets – changes in the budgets of: THL, AGES, MCA, NNK, RIVM, EMC. In addition EVIRA has
been changed to FFA and BIOEF has been changed to BC.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
17 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.10. Collaborating stakeholders:
Two organisations from Bosnia and Herzegovina (University Clinical Center Sarajevo and
University Clinical Hospital Mostar) have been removed, as they wish to participate in
tender for subcontracting by MCA.
Ministry of Health, Spain, has been added into the list.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
18 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2. PART B
HISTORY OF CHANGES
Part A: List of beneficiaries
The following partners had been nominated to the joint action (JA), but resigned during the application process due to lack of human resources:
- Federal Public Service Health, Food Chain Safety and Environment, Belgium
- Department of Medical and Public Health Services of the Ministry of Health Cyprus
- Directorate of Health, Iceland
- National Institute of Public Health, Romania
Organisations from Belgium and Iceland stayed as collaborating partners of the JA.
WP1 Description
Thematic meeting on preparedness and IHR during Finnish Presidency of Nordic Council of Ministers in 2021 has been removed in order to be able to transfer money for low GNI
countries.
Comments from Chafea/DG SANTE to the Proposal_SHARP_HP-JA-01-2018_PARTB_v2 Response (THL)
(1 March 2019)
Chafea: The technical annex is conceived using the logic framework model, thus, the The structure of the whole Proposal has been changed, according
introduction/background presents the "problem"/challenges on preparedness and to Chafea and DG SANTE recommendations.
response in the EU and neighbor countries. Then, you are expected to explain how you
will address the problems, presenting the evidence of the proposed interventions, with
the aim to improve preparedness and response capacities.
Next you should present the aims, general and specific objectives (SMART), indicators
(SMART) (process, outputs and outcomes) and expected outcomes (what the effect
/impact is envisaged by the joint implementation of the different workpackages
actions).
For each specific objective (WP) you should define the methods on the specific section Work Package descriptions have been modified according to
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
19 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
(5. Methods and means). Here you have the opportunity to integrate activities, such as Chafea and DG SANTE recommendations.
data collection, trainings, meetings, which will be performed by different WPs and
Parts of background text in WP descriptions have been transferred
explain how the specific activities under one WP will lead /contribute to the other WP
to section Means and methods.
activities (sequential).
Under the WP description, you should define how the activities will contribute to the
specific objective, WP tasks description and planning, including milestones and
deliverables, partners involved (working groups).
Please check the actual text, which clear shows that there is no one "coordinated
action", there is a need of editing, the conclusion of this draft proposal is that there are
several independent actions/groups, with parallel WP.
There is a need to revise the table 2.2 specific objectives of the project and indicators, All specific objective tables have been revised.
the targets should be SMART, the current targets are presenting a month or an output.
For specific objective, the WP leaders should define the indicators and its targets by
answering the questions: what will be done, by when, how many will benefit (trained,
participants)?
The target is considered as the minimum which is expected to be delivered.
Please check consistence between the different sections of the technical annex, the Consistency in between different parts of the Proposal has been
defined process indicators and the milestones should be linked, the output indicators improved. Objectives of the Proposal, output indicators,
and the deliverables and the outcome indicators with the expected outcomes. The WP deliverables, outcome indicators and expected outcomes have
3 description makes reference to the definition of indicators for monitoring and the been revised.
external evaluation, in reality you should use those already defined in the technical
annex 2.2 Objectives and indicators and 6. Expected outcomes.
Chafea /DG SANTE comments in the text (WP5 description): Response (THL)
Task 5.2 International collaboration between authorities during crises – Expected Focus is on avoiding duplication of efforts. WP5 has identified
Result 3 some of the same legal issues to be solved as DG ECHO, here the
focus is on health services.
- Should be more oriented towards a public health perspective. At the moment,
focus appears more oriented towards civil protection mechanisms.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
20 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Task 5.3. Feasibility of using information from national and international exercises As a WHO Collaborating Centre for Preparedness, RIVM is
and after action reviews in assessing state of public health preparedness in the EU currently leading a systematic review of published exercises and
AAR. We have chosen not to include this activity as part of the JA
- - We suggest that this task includes a review of information on
in order to avoid duplication. However, we will use the results of
preparedness available from previous exercises/AARs.
the RIVM review to inform the activities described below and have
indicated this as part of the methods.
Please not that at EU level the reporting system is defined by implementing act, and The text has been formulated accordingly.
should be adopted under the Comitology Procedure (MS Committee).
Current reporting template: Commission Implementing Decision of 25 July 2014
implementing Decision No 1082/2013/EU with regard to the template for providing the
information on preparedness and response planning in relation to serious cross-border
threats to health
Task 5.3. Develop tools for compiling and sharing information on exercises and AAR ECDC has proposed the development of a tool for sharing
between countries information from exercises/AAR. However, to our knowledge this
has not yet been designed. This JA will support ECDC in the tool
- Please describe this tool, e.g., compendium allowing for updates, type of information
developing, including defining what will be collected and how the
included, and process to inform about follow up activities and updates, a sustainability
information will be disseminated.
of the tool?
Task 5.3. Outcome: Improved use of results from exercises and AAR as part of a This task will support the commission, ECDC and WHO in their
comprehensive monitoring and evaluation strategy for IHR (2005) core capacities and efforts to assess how this qualitative information from TTX and
implementation of Decision 1082/2013/EU at the European level. AAR can improve monitoring of the status of health preparedness
in the EU. It is not generally meant as a gap analysis per se, but
how this info can complement the annual self-assessment.
Please add deliverables supporting Member States in building capacities irrespectively Study visits and expert exchange have been transferred into WP8.
of GNI, or previous experience with JEE (i.e., voluntary assessment tool). E.g., visits or
expert exchange, looking at national action plans development/implementation.
Chafea /DG SANTE comments in the text (WP6 description): Response (THL)
- Laboratories are one sector of integrated preparedness planning. The WP6 description has been revised to include all sectors.
- The WP should have a focus on Article 4 of Decision 1082/2013/EU in terms of
interoperability of preparedness planning, approaches (generic an specific),
intersectoral work and business continuity planning, in particular with sectors
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
21 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
where gaps was identified by the 2018 Report on Preparedness and Response
Planning.
- Specific actions could be planned around mapping preparedness plans, exchange of
best practices, developing guidance on preparedness and response planning.
- Specific sectors where there’s a gap in intersectoral collaboration is also listed in
the report executive summary, the full report is available from MS national
authorities, based on which priorities for the WP participants could be established
(e.g., survey on priority list).
Disease X could be more oriented towards other aspects of preparedness (including Text revised as requested.
chemical) and public health rather than just labs
Task 6.4: Translation into best practices and sustainability to feed into WP4 and WP5 Text of task 6.4. revised accordingly.
- Please detail how best practices are intended to be collected? Methods, criteria,
format of the catalogue, possibility to update, sustainability and implementation?
- Consider using the methods/tools available under the SANTE Best Practices Portal
(https://webgate.ec.europa.eu/dyna/bp-portal/)
Chafea /DG SANTE comments in the text (WP7 description): Response (THL)
General comments WP7 Description has been updated. Response to DG SANTE and
- Low GNI? Not well reflected Chafea comments:
- As mentioned before, WP6/7: assessing lab preparedness. Clear delimitation - New elements in this SHARP JA (compared to the EMERGE JA)
to avoid confusion have been described
- JA EMERGE mentioned many times - Most of lower GNI partners are participating in this WP (over
Sustainability point. What do they expect from the EC? Should be clarified -> WP4 30% of the budget for lower GNI), special support to lower
GNI partners taken better into account
- Sustainability point discussed in the description
- Parts of the WP7 description have been moved according to
the DG SANTE and Chafea suggestions to the Methods and
Means and to the Introduction part.
Chafea /DG SANTE comments in the text (WP8 description): Response (THL)
Task 1. Assessment of the cross-sectoral training needs Described in Problem analysis chapter.
Please add reference to the 2018 Progress Report on preparedness and Response
Planning: One key gap identified is Human Resources.
Activities could be carried out to improve policy, collaboration and coordination
framework between sectors/training institutions (e. g, Availability-Distribution-
Competencies)
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
22 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Chafea /DG SANTE comments in the text (WP9 description): Response (THL)
WP9 Description has been updated. Response to DG SANTE and
Chafea comments:
- One process indicator (feasibility) added, according to the DG
SANTE comments.
- Parts of the WP9 description have been moved according to
the DG SANTE and Chafea suggestions to the Methods and
Means and to the Introduction part.
- Expected results moved to expected outcomes
- Collaboration with SCHEER Rapid Risk Assessment Working
Group for Chemical Threats and other relevant chemical
networks added to the text.
Chafea /DG SANTE comments in the text (WP10 description): Response (THL)
WP10 Description has been updated.
Changes done according to the recommendations of the Evaluation Report:
Criterion 1 - Contribution to public health in Europe
Recommendation by the evaluators – Evaluation Summary Report Response THL
(1 March 2019)
The IHR and the Decision No 1082/2013/EU deal with cross-border/internationally This has been addressed with the Partners and discussed
spreading threats. This proposal is a bit unclear about its scope: national, trans-national thoroughly. The scope of the project is indeed to improve both
or both? R1. We recommend that the applicants discuss the relationship between capacities for national threats and cross border threats. This is
preparedness and capacities for national threats versus cross border threats. simply because it is not really possible to directly separate the two:
no cross border threat can appear without it first being a local
threat.
Similarly, a threat that appears by crossing the border needs to be
addressed by national capacity, which needs to be available,
exercised and competent. Such capacity is dependent of
continuous operations, so most preparedness functions must
stand on the pillars of the regular/routine activities of a public
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
23 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
health and health service system.
Much of this was actually explained in the first submission, but it
has now been more clearly emphasized in the text. See for
example: Page 5, second paragraph under heading “Introduction
and state of play”.
In the introduction part, please start describing the current situation in the EU and All updated according to the suggestions
neighbor countries for the implementation of the Decision 1082/2013 and the IHR
2005, then includes the global health security. Please focus on what are the
gaps/challenges in the participating countries and define how you will address these
problems, in low and high GNI countries.
The Health Programme reference on page 11 is misleading, as there are several projects
(few examples, EPISOUTH, ECHMNET) and joint actions (SHIPSAN) funded on general
preparedness planning, not only related to the laboratory preparedness, please correct.
Several of your partners have contributed to the different actions and it will be useful
to map how they contribute to the 19 technical areas of IHR and maybe update and use
them, under SHARP.
1. Although the main starting point for this JA is clearly the Decision No 1082/2013/EU, This has now been addressed: we have added language explaining
the applicants may also consider the WHO’s recent document on implementation of the WHO IHR context on both the global level and in the WHO
the IHR and action plan to improve public health preparedness and response in the European region context. In addition, relevant reference has been
European Region. added to the latest WHA resolutions and the global and regional
Action plans as requested.
The added text is found in page 6, paragraphs 3-5 and in the
literature references in the end.
- Under the introduction the contribution to the implementation of the - Text revised accordingly
Decision 1082/2013 and the gaps identified in the monitoring reports is
not sufficiently addressed. Further, there is no reference to the role of - Reference and link to the EU and non EU countries
the EC and the HSC as responsible for the coordination of the serious participating in SHARP that participate have done or
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
24 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
cross border health threats to health in Europe. are on the process to perform JEE. (EU and non EU
- On page 7, where the JEE monitoring is mentioned, please make countries) has been added
reference to the countries (EU and non EU countries) participating in
SHARP that participate have done or are on the process to perform JEE.
- This has been discussed in the Introduction
- When making reference to the outbreak impact, please consider how a possible
major outbreak will impact the EU strained health systems.
2. The Work Programme point 2.2.1 stipulates that the JA will coordinate a reference The role of ECDC has been clarified in the WP7 description: “The
network of laboratories “in collaboration with” ECDC. The applicants should clarify close cooperation with ECDC and EVD-LabNet, established in the
whether the current management structure gives ECDC a proper role in the previous JA EMERGE, will be maintained and the agreed MoU will
coordination of the laboratory network, i.e. WP 7. also be effective for the upcoming JA. […]
See also WP1 description, page 1: “ECDC has been added as an
observer in the Steering Committee (SC). WHO has been invited to
join the Advisory Group of the JA”
Under the problem analysis and the prioritization of countries, the ECDC report is Country preparedness reports taken better into account
limited to the laboratory preparedness. Please consider taking into account the
country preparedness reports, to be used on WP 5 and WP 6; and acknowledging that
ECDC activities are much broader than the laboratory part, in particular on capacity
building for IHR core capacities (WP8).
3. The discussion of added value in point 4.2 should be expanded. For instance, we This has been extensively discussed in Chapter
believe that pooling of national expertise and experience, including to responding to “Added value at EU level in the field of public health”.
rare events, can lead to added value. Furthermore, with our open borders it is clear
that joint exercises and joint preparedness models are valuable. The applicants need
to demonstrate that the project gives value to EU citizens.
For the current proposal description it is not clear what will be the joint preparedness
model and how these will be test with joint activities, including exercises. How would
you contribute to the preparedness and response improvement for the participating
countries, low and high GNI.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
25 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
- The justification for improved preparedness should be presented more clearly, for This has been extensively discussed under Introduction.
instance by pointing to the economic impact, workload and political consequences
of recent large outbreaks. The main results of the “Article 4 monitoring” need to be
cited as well.
- Under the problem analysis, when given examples, please use real serious cross
border health threats, which have affected the EU MS, such as the E.coli 157:H7
Given examples discussed under Problem Analysis
outbreaks or the toxic sludge in the Danube, they are presented on the specific
WPs description and should be moved to the problem analysis.
4. In line with 2 and 3 above, we think the proposal lacks a clear description of how The objective of the JA is to help the WHO in multiple ways in
duplicative efforts with ECDC and WHO will be avoided and where synergies can be supporting the members states to achieve full IHR compliance.
identified in supporting and enhancing ECDC’s and WHO’s specific mandates in this
field of action. Also links to large EU research projects must be maintained. This JA
should build on, not repeat, what has already been done. It may be helpful to invite Objectives, tasks and activities of WP5 and WP6 have been revised
ECDC as an observer to the Steering Committee in order to make sure that there are to avoid duplications.
links to ECDC’s relevant networks of national focal points on preparedness and public
health reference laboratories.
Duplication of the WP5 and WP6 have been have also discussed
with WHO to avoid duplication of actions, and both work packages
Chafea: under the method, the specific WP description should present the use of will act to support member states to implement preparedness
relevant methods/tools from ECDC, WHO or previous Health Programme actions functions and development of core capacity. In addition, the joint
should be presented. action will support and encourage member states to volunteer for
both EU/ECDC and WHO external evaluations, after action reviews
and exercises.
Links to EU research projects and networks have been clarified and
described in the WP description, e.g. in WP5 and in WP10, and
especially WP7 which is well connected to EU research projects.
See the revised WP1 description.
ECDC has been added as an observer in the Steering Committee
(SC). WHO has been invited to join the Advisory Group of the JA.
5. We recommend that the preparedness measures considered should not only be on WP7: In WP description of work, the text concerning preparedness
chemicals and highly infectious diseases but also on other threats, such as epidemic- measures was added and adjusted: “The main focus of diagnostic
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
26 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
prone multidrug-resistant bacteria. capabilities will be on RG3 bacteria and RG4 viruses. In addition to
6. the previous JA EMERGE, the differential diagnoses of outbreak
Chafea: the WP 10 is not part of the integrated preparedness and response model causing RG2 bacteria and RG2/3 viruses will be included by “open
activities yet. The duplication on laboratory preparedness remain, with activities view” diagnostic tools like metagenomics and mass
planned mostly on WP 6, and WP 7 only focusing on detection and diagnostic spectrometry/proteomics. In case of detection of such pathogens,
improvement. including epidemic prone multidrug-resistant bacteria or pandemic
viruses, other appropriate networks will be engaged for
confirmation and outbreak management, if available. This will be
achieved in close interaction with WP6.” See also Criterion 1,
Comment 3.
Criterion 2 - Technical quality
Recommendation by the evaluators - Evaluation Summary Report Response
(1st Revisions, 28 January 2019)
S1. The JA is rather fragmented and the WPs heterogeneous; it looks almost like six The problem analysis chapter has been greatly expanded to add
almost unrelated projects or silos under one umbrella. The JA needs more homogenous much more clarity to the contents of the different work packages
description of problems and solutions, common terminology across WPs, and logical, and how they relate to each other. It is important to recognize that
horizontal linkage across all WPs. Describe the linkage and interdependence in a table IHR Core capacity is indeed a collection of different technical
or figure. functions, which nevertheless need to be connected to each other.
This is reflected in pages 10-14, under the heading “Detailed
problem analysis: addressing the challenges and gaps through the
SHARP core work packages”
Furthermore WP5 and WP8 are especially linked to the
connectivity of the different capacities.
S2. The WP descriptions, especially 4, 5, 6 and 8 are long and rich in jargon. Use WP4 will build a sustainability plan to ensure the uptake and
previous reports, surveys and projects (inc. Art. 4 Monitoring) to go directly to the main sustainability of the Joint Action outcomes from WP5 to WP10 at
questions: What are the gaps in Decision 1082/2013/EU and IHR implementation? EU, national, local and/or regional level, and enabling to sustain
activities that should fill the gaps in the implementation of the IHR
What do you plan to do to fill those gaps? What is the evidence that your activities will
(2005) and relating Decision 1082/2013/EU.
fill the gaps? What are the expected and ambitious outcomes and deliverables? Focus
on concrete outcomes, like SOPs, business continuity planning, interoperability, WP4 description has been simplified; WP4 will identify evidence-
intersectoral collaboration, protocols, and best practices – capacities that will be based best practices outcomes and recommendations to include a
SHARP sustainability plan.
available in a crisis – not only meetings, workshops and exercises.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
27 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
All WP descriptions have been revised.
The focus has been shifted to best practices and more concrete
actions and outcomes.
WPs have been also expanded to provide more consultation and
expert advice to support country preparedness planning.
- The WP 4 should include the implementation of the sustainability plan WP4 description has been revised accordingly.
and a sustainability report, to demonstrate how the SHARP activities
have been integrated on national policies.
- On WP 4 please define what is meant by evidence base outcomes and
how they will be selected? Are they best practices? The planning should
be revised, the workshop for drafting the guidance of sustainability is
very late at M12, then the selection is only carried at M24, thus there is The term “evidence-based outcomes” has been changed to best
no expected implementation/adoption of the "best outcomes". It is clear practices.
that EC is not interested on the production of recommendation for
sustainability, but rather on good examples of how the evidence base
outcomes were integrated in participating countries policies by M35.
The timing of activities has been revised.
- For every WP5 to WP10, the objective and description should clearly Described in the Problem analysis.
present what are the gaps on Decision 1082/2013/EU and on IHR core
capacities which will be addressed. And how the concrete outcomes are
expected to contribute to improve preparedness and response and IHR
core capacities.
Described in the Expected outcomes.
- There is no reference on how best practices will be identified (criteria) and how
they will be adopted and piloted in the participating countries, through the
different WPs.
Included into WP4 tasks.
WP 1 Could you reflect whether SHARP will be able to provide technical advice on WP1 description has been modified with an addition: “In case of
preparedness and response, in case of an outbreak? if yes, the WP 1 description should European cross-border outbreak, the SC can provide technical
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
28 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
include the outbreak response mode operation. This advice, if asked.”
S3. According to the IHR art. 4, the NFP is only the country’s contact point with the This text has been modified to reflect more accurately the NFP role
WHO; governments MAY delegate IHR-relevant tasks and responsibilities, including and challenges cost by delegation of IHR relevant tasks and
command and control, to the NFP or to other entities. responsibilities.
S4. The JA should seek to integrate the various parts of the health sector preparedness, WP5 and WP6 are addressing the questions on integration of IHR
including the laboratories (WP7), the public health/IHR/surveillance community core capacities.
(WP5,6), the hospital infection control specialists (WP10) and the chemical
Involvement of other sectors (e.g. animal and environmental
preparedness experts (WP9) as well as Animal health, Environment Health, and Civil
health) will happen on course of the JA.
Protection sectors. The robustness developed in EMERGE (e.g. SOPs and EQA) may be
an example to the other WPs.
Laboratory preparedness (WP7) is integrated in almost all of the
activities of this JA. Links from chemical preparedness (WP9) has
been consolidated especially to WP5 and WP8.
Chafea: Could you consider that WP 5 and WP 6 will be horizontal and will receive At the teleconference on 11 February, SANTE agreed that all WPs
contribution of the core WPs 7, 9, and 10? this could solve maybe the problem of should include preparedness, but it can be done otherwise and not
duplication and lack of coordination on laboratory preparedness, presented now in WP changing WP6 to be horizontal.
6, WP 7 and WP 9 and Wp 10?
WP 10 is still very much a single work, without identify interaction with WP 5, WP 6 There are links to WP5, WP6 and WP7 in the work of WP10.
and WP 8. It only relates to WP 7, on biorisk management, but limited to the
laboratory part, does not address biorisk management on clinical settings.
S5. Please ensure technical complementarity and avoidance of duplication with other Complementarity and avoidance of duplication of this JA actions
similar actions at EU level, including ECDC supported public health laboratory networks, with ECDC activities has been discussed and taken into account,
research and innovation projects such as PREPARE/ECRAIT, learned societies initiatives especially in case of WP7 (laboratory preparedness) and WP8
such as the ESCMID-led EUCIC and EID Task Force, and already developed (or planned) (Training and local exercises).
tools/methodologies/platforms/training material/repositories by ECDC and WHO. Close
consultation, during the development and finalisation of the proposal, with relevant
officers of the two agencies would certainly help clarifying potential redundancies and The avoidance of duplication of previous work has been taken into
account in WP descriptions.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
29 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
opportunities for synergies.
Both the ECDC and WHO has been consulted in detail, and there is
no intention to duplicate of their activities. However, the JA
expects to be able to multiply their impact by full utilisation of
ECDC and WHO products and protocols in the partnership
countries.
Chafea: please consider to ensure the collaboration with HEALHY GATEWAYS and avoid Healthy Gateways is included into the Advisory Board of SHARP.
any risk of double funding under WP 6 contact tracing activities.
Contact tracing has been removed from WP6.
S6. WP2. Dissemination activities should build on best practices to date and include WP2 description has been revised; chapter Methodology has been
actions on visibility and awareness, including use of social media. Linkage to WP8 needs added; task to develop a channel strategy which will include
to be developed. A blueprint of dissemination for future JAs is very positive but should actions on visibility and awareness, including use of social media
be reflected in the deliverables. has been added.
Collaboration with other WPs, especially WP8 has been added. The
latter will include work with WP8 to ensure coordinated
dissemination of toolkits and exchange of working practices.
A blueprint of dissemination for future JAs has been added as a
deliverable 2.4.
WP2 description revised.
Chafea: WP 2 is expected to be actively involved on the dissemination of all JA activities
across all WPs.
S7. WP3. The external evaluation should not finish half way through the project. The WP3 description has been modified according to the
Procurement and cost in WP3 may require more detail. The plan for the external recommendations. The external evaluation is changed to cover
component should be more specified. two phases: M18-M25 and M31-M36. The plan for external
evaluation has been further elaborated; see Task 3.3 External
Evaluation of the effect and impact of the JA.
A more detailed specification of the budget and procedures has
been made in both the WP3 Description and the budget
preparation.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
30 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Chafea: the monitoring and evaluation activities should be based on the agreed
objectives and indicators (2.2) and expected outcomes (6.) Presented on the technical
WP3 description revised.
annex.
S8. WP5. The work should build on and not repeat the considerable mapping and WP5 and WP8 have been thoroughly reworked taking into account
monitoring already done. Try to define what are the good practices on IHR core the comments by the evaluation report.
capacities gaps that can be multiplied across countries. There seems to be overlap WP5 and WP8: amount of workshops and the aims of workshops
between WP5 and WP8 concerning expert exchange. Workshops are expensive; are all have been cross-checked.
needed to achieve objectives? The best practice workshops would benefit from
Secondments are included in the WP8.
participation by high GNI countries to share experiences. Expert exchanges are useful,
but please quantify and ensure administrative support and budget. Secondments to
ECDC, WHO or high GNI countries institutions may be added as useful learning
experience for some countries.
Chafea: the role and involvement of high GNI countries is not mentioned on the core
WP descriptions. The preparatory work required for the high quality
workshops/training should be taking into account on the planning and resource
allocation. Working time has been allocated to high GNI country partners so
that they can act as trainers in workshops.
S9. WP8. Please make sure to address the gaps identified on IHR core capacities, is Training needs assessment will be based on a on the previously
aligned with ECDC’s competency handbook where relevant. Low GNI countries should conducted ECDC and WHO training needs assessments - see tasks
be prioritised. Close links across WP. 8.1, sub-task 8.1.1. in the WP8 description.
Tasks earlier allocated to high GNI countries will be performed by
partners from low GNI countries. In all tasks 8.1-8.4 the share of
low GNI countries has been increased.
S10. WP9. Please ensure close linkage to other WPs. See WP9 description, where specific collaborations have been
listed in the activities.
Criterion 3 - Management quality
Recommendation by the evaluators - Evaluation Summary Report Response
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
31 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
S1. The membership of the Advisory Board should be specified, at least in general In the WP1 description ECDC has been added as an observer, see
terms. Please consider ECDC as an observer in the Steering Committee. page 1.
The Steering Committee wishes to have some place for decisions
concerning members of the Advisory Board in the beginning of the
project, and will decide whom to invite at its first meeting. Possible
invitees are mentioned in WP1 description. EUPHA which does not
have a body and thus resources for AB membership, has been
replaced by the Public Health Agency, Canada . EFSA – the
European Food Safety Agency and World Organisation of Animal
Health (OIE) have been removed. SCHEER Rapid Risk Assessment
Working Group for Chemical Threats has been added.
The members of the Steering Committee participate at Advisory
Board meetings. See page 2 of the description.
S2. The risk analysis points to an overrepresentation of laboratory experts among The risk analysis has been revised in chapter “Critical risks”.
participants and a biased partner composition. This should be mitigated. The risk
related to the management of a large network and the potential impact of BREXIT
should be considered under the risk analysis. UK is leader in two work packages, in WP2 and WP9. In case of
Brexit (beyond March 2019) and if UK is unable to participate in
this JA, the mitigation measures are discussed in chapter:”Critical
Chafea: please update the risk analysis and mitigation measures as several of them Risks”. Briefly, the coordinator will take over WP2 and another JA
partner will take over part of the WP9.
might not be a risk anymore.
S3. With such a large project, the Steering Committee should meet more often, e.g. In addition to meeting face-to-face, the SC will discuss current
every second month (not necessarily face to face). A plan for conflict resolution should issues via phone/skype meetings at least every second month.
be developed. A quality control system and progress monitoring should be applied. A plan for conflict resolution will be developed having its basis in
the Consortium agreement between partners.
Monitoring of the progress of the action is the responsibility of the
coordinator, WP3 evaluation leadership and the Steering
Committee together.
A quality control system will be developed in the beginning of the
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
32 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
action by WP3, co-coordinators RKI and INMI will share
responsibilities in this.
WP1 description has been modified accordingly.
S4. Please describe partners 25 and 26. Descriptions of partners added.
The affiliated entities should be updated and their operational capacity mentioned. Description of affiliated entities has been added.
Now some are completed and others not.
(S5. – There is no Criterion S5 in the Evaluation Report)
S6. It might be good to look into Value Creation / Business Concept to identify possible Sustainability of the SHARP JA outcomes has been discussed in
additional ideas for achieving sustainability of the outcomes. WP4, see WP4 description. Deliverables include: 1) Guidance tool
to ensure that sustainability is taken into consideration by all WPs
Chafea: the sustainability plan proposed will only be available at M35. It is suggested throughout the Joint Action, and 2) Sustainability plan, which
that the sustainability plan should be available earlier and that the partners, maybe at includes priorities to be included into national plans and for
the first partnership forum already identify opportunities/ ways for integration of the regional organizations.
good/best practices in national preparedness plans/policies and the new deliverable
The coordinator will work in tight collaboration with WP4 and
sustainability plan report, will show the success of integration and sustainability of
other WP leaders in order to ensure sustainability of the results of
SHARP outcomes.
the action.
WP4 description and its timetable have been revised.
S7. Please harmonise the terminology for infectious agents of different threat levels The terminology has been harmonized in between WP6, WP7 and
(HID, RG, etc.) WP10.
Please check WP 10 as there is different terms, what are the pathogens under the - High Infectious Disease (HID) > high-
scope of the different WPs? Epidemic prone pathogens of high consequence, or will you consequence infectious diseases
- Risk Groups 3 and 4 (RG3 and RG4)
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
33 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
include tropical diseases? - Terminology has been unified
(Continued from criterion 2: Technical quality)
S11. WP6. Much of this WP seems to be redundant. Task 2 is rather to ECDC’s work WP5 and WP6 has been completely revised taking into account the
plan. Tools and indicators already exist or are under development. Gaps have been feedback from the evaluators, Chafea and DG SANTE. Please see
identified by Art. 4 Monitoring report. Explain “preparedness and response mechanism” the WP descriptions.
and “preparedness and response cycle”. Disease X scenario is promising. Delineation of
objectives- tasks between WP5 and WP6 is unclear. What number of countries is
participating in WP6? Avoid overlap on assessment of gaps in tasks 1.1 and 1.3.
The only lab network mentioned is the one in WP7; how will the JA contribute to lab
preparedness for other emerging pathogens; either within the JA or through
operational collaboration with other EU initiatives and laboratory networks. The lab
networking should be fully integrated in national surveillance and response structures.
The correct phrase is "the ECDC laboratory capacity and capability MONITORING
SYSTEM". Task 2 lacks a definition of the outcome/deliverable " integrated all hazards
e-learning EQAE scenario protocol" (p. 42).
Chafea: the definition of the concept of “preparedness and response mechanism” and
“preparedness and response cycle" is not given under the background, not under the
methods. It is as well not explained how the different WP activities will contribute to
the preparedness and response cycle.
It is still not clear why the Integrated IHR laboratory preparedness and response plan is
under WP 6, when there is WP 7 which is named Laboratory preparedness and
responsiveness?
Described in the background text.
Why task 1.1 and 1.2 does not involve the different IHR core capacities and all WPs (5-
10)?
S12. WP7. Which applicant laboratories are participating and person-months WP7: See the WP7 description.
allocated? Please explain the "diffuse biorepository for RG 4 viruses" and its relation to - Applicant laboratories and person months have
EVAg bio-banking services. Can the network collaboration be expanded beyond been updated accordingly. Person months have to
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
34 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
outbreak-prone RG 3 bacteria and RG 4 viruses? Please specify outbreak response be adapted according to the new budget.
mode operation, and how to ensure the cooperation with ECDC, public health - The sentence for “diffuse biorepository” clarified,
laboratory networks and national public health authorities. An MoU with ECDC and relation to EVAg has been added: “The existing
interoperability protocols seem necessary. Please explain the relation to lab-work in European repository of highly pathogenic bacteria
WP6. The outcome indicator is difficult to understand: “The biorisk for handling…” will be maintained for application in EQAEs and for
What is the target? 10% increase of what? The two WP7 Working Groups seem to evaluation of new methods. For the viral part, there
is a decentralized biorepository for RG4 viruses
focus more on development of new laboratory methods than to implementation of
partly located at different partners. Additionally, the
current preparedness and should be reconsidered.
ongoing collaboration with the the European Virus
Archive (EVAg) consortium ….” (continued)
- Network collaboration beyond RG3 bacteria and
Chafea: this has not been specified under WP description, "outbreak response mode RG4 viruses is taken into account, linked to WP6:
operation, and how to ensure the cooperation with ECDC, public health laboratory “The main focus of diagnostic capabilities will be on
networks and national public health authorities". RG3 bacteria and RG4 viruses. In addition to the
previous JA EMERGE, the differential diagnoses of
outbreak causing RG2 bacteria and RG2/3 viruses
will be included by “open view” diagnostic tools like
metagenomics and mass spectrometry/proteomics.
In case of detection of such pathogens, including
epidemic prone multidrug-resistant bacteria or
pandemic viruses….” (continued)
- Cooperation with ECDC and MoU clarified in the
text. See also response Criterion 1, Comment 3.
- Specific objective 4.2: Unclear outcome indicator
“The biorisk for handling…” has been clarified and
rephrased: “The biorisk for handling of RG3 bacteria
and RG4 viruses has been reduced by appropriate
and harmonized inactivation procedures, enabling
safe handling of inactivated pathogens under BSL2
conditions”.
- Specific objective 5: Unclear outcome indicator is
related to WP8. However, the outcome Indicator in
relation to laboratory training has been changed in
WP7: “At least 10 laboratories have increased the
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
35 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
diagnostic capabilities or laboratory biorisk
management”.
- The activities and aims of the WP7 two Working
Groups have been shifted to reply more to the
implementation of the current preparedness.
S13. WP10. Please reconsider the term Highly Infectious Diseases (HID) as this perhaps See the WP10 description. Term Highly Infectious Diseseas (HID) is
is not a good one. The reasons for giving certain diseases special attention are not only replaced by term High-Consequence Infectious Diseases, to reflect
their high infectiousness, but their high infectiousness in combination with high better the broader spectrum of diseases, including also e.g.
severity. This WP seems to be a resurrection of previous networks (EuroNHID, EUNID) measles and arboviruses.
and focuses on containment units and repeating previous work. The added value must WP10 will be built on the experiences gained in previous networks
be demonstrated. We recommend the applicants to refocus on more common cross- (EuroNHID, EUNID), recognizing the changes in the management of
border infectious threats, not only the very rare Ebola-type cases. This WP needs to be infectious diseases in the last 5 years. The recommendations
closely coordinated with other WPs. provided by the previous networks will be followed up.
Chafea: in particular the added value of the task 4 in the case management of cross Mapping of the current existing facilities and clinical capacities will
border infectious is not explained, the actual description is like a research proposal. This give added value to all European countries in case of exceptional
has been previously funded through the SIDARTHA network. Further it is not clear the cross-border infectious epidemics or threats.
relation with the workshop proposed by WP 5 task 2. The WP 10 remains isolated, WP10 linkages to other WPs have been reviewed and
without clear contribution to other WP. strengthened:
- Mapping and assessing the existing IPC facilities – links to WP5
and WP6, collaboration on preparedness
- Jointly conducted workshops with WP5 and WP6 to assure
international collaboration between authorities during crises
- WP10 task 4 - Workshops coordinated together with WP8
- Clinical capacity assessment (WP10) - Linked to WP6
assessment on preparedness, WP10 will benefit of the Disease
X scenario (WP6)
- Interaction with WP7 and laboratory networks, joint
participation to workshops and through the collaboration with
other WPs in the development of assessment tools.
Criterion 4 - Overall and detailed budget
Recommendation by the evaluators - Evaluation Summary Report Response
S1. We recommend increasing the budget allocated to countries with GNI less than 90 - Current, proposed budget frame has allocated 34%
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
36 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
% of EU average from 26 to at least 30 %, complying with the high exceptional utility of the budget to lower GNI countries
criteria. - Budget frame reaches the exceptional utility criteria
80-20%
S2. The requested grant per participant varies from 7 to 1111 thousand € and the Budget and person months has been revised
workload from 1 to 196 person-months. Almost 50% of the total requested is to be
shared by only four partners whilst 11 partners will receive less than 1% each of the
total requested. Six participants have less than 10 person-months of participation,
which may make meaningful participation difficult. Some affiliated partners are not in
the budget. Please consider revising the distribution of workload and budget.
S3. Some activities seem overly expensive: Very high travel budget in WP5. Expensive The entire budget has been completely revised .
workshops in WP5. Expensive external evaluation. Expensive expert exchanges.
Expensive laboratory network (WP7) with 25 % of the person-months. Expensive
laboratory equipment in WP7. Total travel budget is 11 %. Please consider WP7: The overall budget of has been substantially reduced. 39
reallocations. partners will participate in WP7 showing the great interest of MS
in these activities. All partners, willing to participate, has to be able
to participate at least with a minimum budget, and to carry out the
envisaged activities.
Travel budget of 11% for an extensive network with over 30
countries and 60 partners involved is quite realistic.
S4. The WPs 5, 6 and 8 are closely related, but the structure of the plan differs. It is Descriptions, structures and objectives of the WP5, 6 and 8 has
difficult to see the interactions and overlaps between the WPs and the coordination been revised. See the WP descriptions.
between them. Are there redundancies?
S5. In WP7, the distribution of person-months among partners is missing. It is unclear WP7: Distribution of person-months has been added. See also
how the biorisk equipment will be installed (partners 9, 20 and 21). In WP8 the Criterion 1, S12. Biorisk equipment (for partners 9, 20 and 21) have
education/ training equipment seems quite highly budgeted (partner 20). been reconsidered.
WP8: equipment has been reallocated.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
37 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
The participation of Switzerland as collaborating partner should be Switzerland has participated in the previous JA EMERGE and
reconsidered/explained. provided major added value by its highly qualified expertise in
both B and C laboratory diagnostics. In addition, the participation
of this collaborating partner (without funding) will further increase
the coverage of European countries.
Exceptional Utility
Recommendation by the evaluators - Evaluation Summary Report Response
(1st Revisions, 28 January 2019)
Status: No Current, proposed budget frame reaches the exceptional utility
criteria 80-20%.
The proposal does not fulfil the budget allocation criterion; only 26 % of the budget is
allocated to countries with GNI less than 90 % of EU average. The other criteria are
fulfilled.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
38 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.1. Problem analysis including evidence base
Introduction and state of play
Health threats can be caused by various factors, including internal or external (in terms of the
individual), but in the international context the term is mostly used for threats that are external to
the individual. In the global context health threats cover the threats caused by communicable
(infectious) diseases, exposure to chemicals, radioactive agents and environmental disasters.
Furthermore, the internal and external elements can be seen from the country perspective: is the
threat localized and most likely to cause negative effects only within the country border, or is it a
cross-border threat that can affect other countries as well? For infectious diseases, the latter, i.e.
cross-border relevance, is particularly relevant, as infectious diseases that are directly or
indirectly transmitted between humans are following population movements, and thus country
borders in general do not stop their spread.
The EU/EEA region has since a number of years been at the global forefront of coordinated
actions to address cross-border health threats, and has through a number of EU regulations
enabled both rapid and officially verified information sharing on health threats among Member
States (MS) and coordinated surveillance, risk assessment and response activities. Already in
1998 the early warning and response system and coordinated surveillance activities were
established by Decision No 2119/98/EC of the European Parliament and of the Council.
Furthermore, in 2004 the European Centre for Disease Prevention and Control (ECDC) was
established by Regulation (EC) No 851/2004 of the European Parliament and of the Council,
creating a common EU expert agency resource for coordinated surveillance and risk assessment.
The International Health Regulations, IHR (2005), of which the WHO is the global custodian,
comprises a legally binding international instrument governing global detection, prevention and
control of the international spread of disease (1). The IHR imposes obligations on Member States
to develop and maintain core public health capacities for surveillance and response at points of
entry, including early detection, assessment, notification and reporting to WHO about events
covered by the regulations (2). Yet globally many countries are behind in meeting all the
obligations of this treaty (3).
Within the European Union the Member States are all signatories to and thus bound by the IHR
(2005). In 2013 the Decision 1082/2013/EU of the European Parliament and of the Council
further strengthened EU regional coordination. The decision aims at ensuring adequate
coordination between EU Member States to achieve a consistent level of preparedness and the
highest level of interoperability between national preparedness plans. It is an instrument at EU
level to support the implementation of the IHR (2005).
A detailed report of the EU state of play in terms of Preparedness and Response planning to
address health threats (Article 4 of Decision 1082/2013/EU on serious cross-border threats to
health) has been prepared by the EU Commission Directorate General for Health and Food Safety
(DG SANTE) in collaboration with the ECDC. This report, prepared for the Health Security
Committee, presents data and analysis in four main chapters: (i) International Health Regulations
(IHR) capacities; (ii) Interoperability;
(iii) Business Continuity; (iv) Revision of National Preparedness Planning. This report is
available at country level through the Health Security Committee (HSC), but is not available for
public circulation (4). A summary of the reports main findings is however available.
The report mentions a number of areas of IHR core public health capacities where further
improvement can be made, i.e. training and exercises; sharing experiences and joint country
visits; technical support and expertise with preparedness and response planning; and
enhancement of inter-sectoral collaboration. Furthermore, the report suggests that cooperation
between EU agencies should be strengthened and cooperation and coordination with UN
programmes and agencies should be improved.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
39 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
In particular the report stresses the need to work across sectors on a local, regional and state level,
especially between health, food safety and the civil protection sectors. It emphasizes the need to
strengthen health systems capacities to detect, assess and respond to cross-border health threats.
By the end of the year 2016 most State Parties that have ratified the IHR (2005) in the year 2007
have reported to the WHO at least once on their core public health capacity under the IHR. In
accordance to WHA decisions, countries should report every year, but only approximately 1/3
actually does this. The self-reporting data is also used as a component of the reporting required
under Decision 1082/2013/EU Article 4 on preparedness and response planning. Since the entry
into force of the Decision, two rounds of reporting have been performed by the Member States to
the Commission.
Unfortunately, the Ebola epidemic in West Africa of 2014-2015 demonstrated that the world was
ill-prepared to detect, prevent and respond to emerging infectious disease outbreaks (5-7). This
outbreak resulted in more than 14000 cases and 9000 deaths in the main three affected countries.
Challenges were also identified in high-income level countries, particularly exemplified by a
substantial (over 150 cases) outbreak of imported MERS-Coronavirus infection in nosocomial
settings, causing severe acute respiratory syndrome with substantial mortality in South Korea
during the summer of 2015. These examples pointed to severe limitations in global IHR (2005)
implementation.
In response to lessons learned after the severe Ebola epidemic in Western Africa affecting
Guinea, Sierra Leone and Liberia, which also posed a threat of spreading regionally and causing a
several orders of magnitude larger epidemic, both the EU and WHO have subsequently enhanced
approaches to responding to health emergencies.
The EU Council Conclusions on the Ebola outbreak (8), the 2016 Special Report of the European
Court of Auditors: Dealing with serious cross-border threats to health in the EU: important steps
taken but more needs to be done (9), and the HSC Action plan for the Health Security Committee
2017-2019 (10) provide the way forward for the EU region action to improve preparedness and
IHR implementation. As part of these policy documents, the following priority areas for action
have been identified:
1. policy development (on vaccination and on infectious diseases threats) and adoption
of implementing acts
2. enhanced coordination with Member States through the HSC and working groups
3. cross-sectoral capacity building, exchange of knowledge and best practices
4. re-engineering the Early Warning and Response System
5. enhancing monitoring and evaluation of actions under Decision 1082/2013/EU in
alignment with the WHO IHR Monitoring and Evaluation Framework
6. improving the access to medical countermeasures and rapid deployment in case of
emergency
7. enhancing the health and security interface and preparedness and response to terror
attacks
8. improving risk and crisis communication
9. laboratory strengthening through a consolidated laboratory practice
10. enhancing preparedness and action at points of entry
Of the above priority areas the SHARP Joint Action (which is part of the HSC action plan area 3.
Cross sectoral capacity building for preparedness, response and recovery) will aim to address
especially points 3, 5 and 9 (and 7 to a certain limited extent). In addition, the Joint Action will
address gaps in basic IHR core capacity which have been identified through Member State
reporting in relation to Article 4 of Decision 1082/2013/EU on serious cross-border threats
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
40 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
to health. The other priority areas are addressed through other Joint Actions (points 1 and 10) and
commissioned and internal work by DG SANTE (points 2, 4, 6 and 8).
As part of the WHO reform the World Health Assembly (WHA) in 2016 and 2017 requested for,
and the WHO in 2018 subsequently developed a 5 year Action plan to improve public health
preparedness and response for the implementation of the IHR (11-14).
Based on these global commitments, the WHO European Region has in its Regional Committee
in 2018 adopted a resolution to welcome with appreciation an Action plan to improve public
health preparedness and response in the WHO European Region (15, 16).
The Action Plan aims to strengthen and maintain national capacities in the WHO European
Region to effectively prevent, prepare for, detect and respond to public health threats, and to
provide assistance to affected countries, when necessary, through three strategic pillars:
• Strategic pillar 1. Build, strengthen and maintain States Parties’ core capacities required
under the International Health Regulations (IHR) (2005);
• Strategic pillar 2. Strengthen event management and compliance with the requirements under
the IHR (2005);
• Strategic pillar 3. Measure progress and promote accountability.
Ensuring that the IHR (2005) implementation proceeds on a global level is dependent on member
states investing in, developing and maintaining the core capacities that are required under the
treaty. A reliable global monitoring system is needed to verify that this is actually taking place.
Already in 2010 the WHO developed a self-assessment questionnaire for annual reporting by
members states on the implementation of the IHR (2005), for the purpose of reporting back to the
WHA.
Subsequent assessment of the root causes of the failings of global level of prevention and control
revealed major challenges in the system of self-reporting of the core public health capacities in a
substantial portion of the submitted annual reports. For this reason, the WHO in collaboration
with several partners has developed a new process of voluntary Joint External Evaluation (JEE)
of IHR (2005) core capacity. Reports and data from the JEE’s are publicly available from the
WHO website and can be used for analytical purposes.
Comparing the external
evaluation data representing
the assessment of core public
health with the self-assessment
data supplied by the state
parties to the WHO reveals
major discrepancy between the
datasets (Figure 1).
While only a small number of
EU Member States have so far
been evaluated by the JEE
process, and the discrepancy
between JEE scores and
annual self-reporting scores is
smaller than among the
majority of the other assessed
countries and regions of the
Figure 1. Overestimation of Core Public Health capacity by annual self-
reporting only (compared to JEE scores). Blue markers represent individual
EU Member States
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
41 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
world, there is still cause for concern1.
These results, as well as other sources of information suggests, that the capacity for preparedness
and adequate responses within the EU, may not be at a level which is necessary for what is
needed to adequately prevent, detect and control outbreaks of serious infectious diseases, or
chemical and environmental hazards. This is a cause of concern, as cross-border health threats
can have an enormous negative impact not only on the human health sector but to much more
widely in society. Economic impacts from recent major outbreaks or the perceived risk of spread
have been estimated to be in the billion EUR range and have affected highly developed countries
in addition to less developed ones.
An outbreak of E. coli (STEC) O104:H4 linked to sprouted seeds originating from Germany
caused almost 4000 cases of severe gastrointestinal disease, with at least 55 deaths. Direct and
indirect economic losses in multiple EU Member States due to loss of vegetable exports and local
sales amounted to over one billion EUR (17). While the source of the infection was eventually
determined to be from German products, the impact affected multiple EU Member States,
particularly due to import restrictions placed on the entire EU or individual MS. The impact on
cucumber sales from Spain was over 350 million EUR alone, due to a mistaken claim of a link to
Spanish cucumbers. Even if this claim was very rapidly refuted, the damage had already been
done. These effects come primarily from the loss of trade and travel but also other measures and
are heavily dependent on the fear of the population and the approach taken to the response
measures (17).
In addition to the economic impact, uncontrolled outbreaks and health threats cause major
workload for health and public health professionals, adding to the indirect costs of the event.
They may also have political consequences if the response is perceived to have been handled
poorly.
The core public health capacities as laid down in the IHR (2005) comprise of a number of basic
societal functions that every country needs to have in place to ensure that it can adequately
prevent, detect and respond to internal and cross-border health threats. The WHO secretariat has
since 2010 elaborated these into a number of specific detailed functions which have since been
revised a number of times2. Originally 8 core capacities were identified, complemented by
capacity needed at borders (Points of Entry). In 2011 the list of core capacities was revised to
incorporate new hazards and it grew to 13. In the latest incarnation, used for the Joint External
Evaluation, 19 technical areas, loosely grouped into four main functions (prevention, detection
and responses + others) representing the core public health capacity for the IHR are specified 3
(Figure 2).
1
WHO EUROPEAN REGION: JEE MISSION REPORTS
https://www.who.int/ihr/procedures/mission-reports-europe/en/
2
http://www.who.int/ihr/procedures/monitoring/en/
3
http://www.who.int/ihr/publications/WHO_HSE_GCR_2018_2/en/
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
42 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Figure 2. Core public health capacities required by the IHR (2005) to be established and maintained by the state
parties that have ratified the regulations (196 countries). In accordance to the JEE process and tool (2nd ed. 2018).
The core public health capacities that are required by the IHR (2005) are by no means a new or
unique concept. These core capacities form an integral part of fundamental societal activities that
address the determinants of health.
Essential public health functions prevent and manage the major contributors to the burden of
disease. When in place they work to ensure that the population of the country is protected against
biological, chemical and infectious disease threats. They are part of the Essential Public Health
Functions (EPHF) which are a WHO concept of population targeted societal functions that need
to be in place to ensure attainment of a healthy population and resilient health systems (18, 19).
The EPHF are a key component of a fully developed health system, providing Universal Health
Coverage to the population (Figure 3).
The ultimate purpose
of public health
functions is to provide
the population with
measures that decrease
the burden of disease
and increase life
expectancy. However,
seen from a larger
perspective, the
determinants leading
to good health cannot
be seen in isolation.
There is equal
evidence that suggest
that by ensuring the
health of the
population, social Figure 3. The relationship of IHR core capacity, EPHF and UHC
development in general
and economic growth are boosted, as healthier populations can be more productive and spend
fewer resources on the basic needs and more on increased prosperity and education.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
43 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Figure 4 demonstrates
how the relationship
of the determinants
and outcomes form a
partially mutually re-
enforcing feedback
loop that is facilitating
societal development
and improved health
status of both society
and the individual.
As can be seen from
the list on figure 2,
IHR core capacities
cover quite a wide
area of public health
functions, all of which
are necessary for Figure 4. Feedback loop model of health determinants and health outcomes (© THL – MS)
maintaining a compre-
hensive preparedness and response function that can cover different eventualities and operate in
different scenarios.
It has been demonstrated that these functions work in a consorted fashion and there is not really
one or another which is more important than the other (18, 20). In terms of this proposal each of
the 19 core capacities are to be addressed, with the exceptions of “Immunisation”, “Antimicrobial
resistance” and “Points of Entry”, for which there are existing, dedicated Joint Actions (EU-
JAV4, JAMRAI5 and Healthy Gateways6) and “radio-nuclear emergencies,” which is not covered
by Decision 1082/2013/EU and it is addressed by the EURATOM community agreement7. Close
collaboration with the “points of entry” “Healthy Gateways” JA is planned, as this Joint Action is
most relevant for the area of work covered here. This collaboration will take place by attending
the partnership forum meetings of both JA:s as well as inviting the coordinator of Healthy
Gateways to the Advisory Group of the SHARP JA. In addition, collaboration between Healthy
Gateways and SHARP JA work packages 5, 6, 9 and 10 is envisioned.
It is important to realise that from the point of preparedness and health security, the IHR core
capacity functions are regular societal activities and not some kind of special functions which are
only needed in large scale events. On the contrary, it is necessary to maintain the activities on a
day to day basis and also operate in a cross-sectoral mode during normal times. A model of
preparedness that would not be used very often would rapidly decline in effectiveness and instead
potentially even cause confusion and harm in a large scale health threat situation.
This is not to say that there is no need to modify ways of working during times of special
circumstances or train for such events, on the contrary. In a crisis situation it is critical to have a
clear command-and-control structure, including communication channels, so that decisions are
consistent and clear to all partners involved and can be effectively executed. Thus preparedness
and IHR implementation needs to have a number of components in place to be effective.
First, the core capacities listed in figure 2 must be present. Secondly, as many of the functions are
multi-sectorial in nature (i.e. surveillance, laboratories, zoonotic diseases, food safety etc.), links
4
https://eu-jav.com/
5
https://eu-jamrai.eu/
6
https://www.healthygateways.eu/
7
https://ec.europa.eu/energy/en/topics/nuclear-energy
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
44 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
and cooperation between actors need to be built during normal times. Thirdly, a national
coordination and planning mechanism needs to exist, which makes plans and agrees on the
command and control and communications structure during times of crisis. This function needs to
be at a sufficiently high level of government and with sufficient authority to be able to bypass
regular sector wise line of command when the situation so demands. Fourth, regular exercises
need to test the operational factors and fifth, material and specialized function stockpiling and
service contracts need to be in place to avoid stock-outs or lack of capability for a very rarely
occurring situation. Finally, in situations of crisis, human and even material and facility resources
may be overwhelmed and some a for accessing surge capacity must be in place. This may in the
case of human resources involve shifting personnel from other tasks and in the case of other
resources stockpiles or repurposing of facilities.
In the WHO IHR model, it is sometimes assumed that the National Focal Point for IHR (IHR-
NFP) is the coordination body that takes the command and control function. This may work very
well if the NFP is an institution with sufficient powers and authority compared to other national
actors. In reality this is not always the case but the coordination tasks are delegated to multiple
institutions. In many countries the
NFP may be a single individual,
which mainly has been tasked with
annual reporting to the WHO and
possibly for monitoring early
warning and response messages
posted on the WHO Event
information site (EIS)8 and the EU
Early Warning and Response
(EWRS)9 systems10 This is not
uncommon especially if there has
been only few instances of serious
outbreaks or health emergencies
due to cross-border threats in
recent years. Also, in many Figure 5. Health Security – societal positioning
countries with highly decentralized
administrative structures, or a federal devolved power structure with strong regional state
governments and central governments with limited authority, it may be difficult or even
constitutionally impossible to follow such a scheme. Larger countries with multiple specialized
agencies may also suffer from coordination challenges and a difficulty of seeing the entire field
of sectors involved in preparedness and health security, especially when the topic traverses
multiple ministries and departments.
Figure 5 demonstrates the sectors that are and should be involved in maintaining IHR Core
capacity.
While the different sectors within the figure 5 are not shown to scale in accordance to their
proportion of responsibility, it still clearly shows the complex nature of maintaining a proper
level of health security preparedness through prevention, detection and response activities. A
very clear challenge is to develop preparedness plans where intersectoral collaboration and real
interoperability is ensured. Reasons for these are multiple, but mainly stem from the tradition to
work mainly within ones own legal remit in different sectors. There may be real legal obstacles
8
http://apps.who.int/ihr/eventinformation/
9
https://ewrs.ecdc.europa.eu/
10
note: both the above systems are accessible only to offically nominated National Focal Points and
Competent Authorities
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
45 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
for cooperation and practical ones stemming from different planning cycles and practices, system
incompatibility and data protection obstacles, to name a few.
This Joint Action aims at strengthening the Member States own internal activities for
preparedness and IHR implementation and to improve the coordination across sectors and across
countries of the EU/EEA and partner countries11.
The European Commission in partnership with Member States has over the last decade invested
substantial resources and efforts in developing preparedness and response capacity in the
EU/EEA. However, previous Joint Actions and projects funded from the EU Health
Programmes12 have mainly concentrated on the strengthening of individual components of
national Health Security system or IHR core capacities13. The innovative feature of the SHARP
JA is that it takes a system approach, i.e. aims to develop the integration of all necessary
preparedness and IHR core capacity functions in a holistic perspective. Ensuring that Member
States and partner countries have the necessary capabilities to prevent, detect and respond to
health threats creates synergistic added EU value, as any system is only as strong as its weakest
link. Preventing, or quickly detecting and controlling an outbreak or environmental spill in one
country efficiently prevents cross-border escalation and amplification of the problem at hand into
the other Member States. Thus it is in the direct interest of all Member States to ensure that not
only national but all Member State capacities are adequate.
Within the European Union, the Health Security Committee (as defined in Decision
1082/2013/EU), consisting of the European Commission DG SANTE and Member State
representatives forms the basis of coordination of actions aimed at both supporting Member
States but also providing mechanisms which are beyond the capability of any individual Member
State. Thus the Health Security Committee provides the forum for issues such as joint
procurement, coordinated risk and crisis communication and alignment of measures taken by
individual Member States.
A leading principle of comprehensive preparedness and response to crises and health threats is
the coordination of preparedness activities and a one response command and control function. In
case of health threats this system must be led from a comprehensive public health entity with an
overview of the different needs of society and with sufficient authority to act as a convener of
different sectors. This is often a national institute or ministry department.
Past experience has shown that independently led laboratory activities during times of crisis,
without a link to a comprehensive public health entity, may lead to substantial confusion among
stakeholders. Laboratory functions need to be fully integrated into the national command and
control structures. It is however important to recognize the role of specialized laboratories, both
through their research and development function in case of emerging novel health threats, and as
providers of diagnostic services for rare and highly pathogenic infectious agents. Such capacity is
not available in all Member States, and this is unlikely to change due to reasons of cost and
sustainability of expertise.
Several EU level projects have supported specialized microbiological laboratories with a vision
of possibly creating a European Reference Laboratory network dealing with highly pathogenic
infectious agents, and accessible to all Member States. The Commission has also performed a
cost-benefit analysis of such a network, which seems to suggest that it might be a cost-
effective solution14.
11
https://ec.europa.eu/health/preparedness_response/crisis_management_en
12
https://ec.europa.eu/health/funding/programme_en
13
EU Health Programme project database. https://webgate.ec.europa.eu/chafea_pdb/health/ examples of
relevant projects: EQADeBa, QUANDHIP, EMERGE, REACT, EPISOUTH, EPISOUTH PLUS,
SHIPSAN (TRAINET and – ACT), EU PH preparedness law, SIDARTHA, CLIMATRAP, HEALTH
THREATS, CRICORM, ORCHIDS, MASH, ASHT (I, II, III) and ECHEMNET.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
46 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
However, as health policy and service provision is a mainly Member State competence, the issue of
creating supranational EU clinical diagnostic laboratory services would require a consensus
decision by Member States and possible regulatory action. Thus establishment of any formal
permanent structures is beyond the scope of this Joint Action. However, the SHARP JA can
facilitate the establishment of bilateral and/or multilateral service agreements between Member
States, based on their own wishes.
Detailed problem analysis: addressing the challenges and gaps through the SHARP
core work packages
Challenges and gaps
The strengthening of health security at European and global levels is of paramount importance. In
a world where there is a constant and rapid movement of people, goods and services there is a
need to strengthen our ability to prevent, detect, and rapidly respond to public health threats
whether occurring naturally or due to deliberate or accidental events. These events may occur as a
result of chemical, biological, environmental or other hazards. While this Joint Action is not
addressing prevention of deliberate use of chemical or biological agents in a criminal or
terroristic manner, the tools for the management of the effects on human health are mostly the
same. Thus part of the preparedness activities will serve both purposes and in some countries may
be interlinked.
The main problem which this Joint Action aims to address is variation in EU Member State and
partner country implementation of the IHR (2005) and Decision 1082/2013/EU leading to likely
gaps in preparedness for responding and controlling cross-border health threats. Furthermore, the
lack of prevention of escalation of local health threats may lead to situations where they will
become cross-border threats. For example, a failure to detect a microbiological contaminant in
foodstuffs in one country may easily affect multiple countries (i.e. the previously mentioned 2011
E. coli outbreak linked to bean sprouts).
Events involving chemicals can have a significant impact on public health and affect more than
one country, for example give rise to transboundary pollution (i.e. the 2010 Ajka aluminum plant
waste spill into the Danube15; and the Sandoz chemical spill in 1986 which polluted the Rhine in
multiple countries). In addition, outbreaks of chemical aetiology may arise from imported goods
and consumer products (reformulated chemical sealant sprays, lead in toys, arsenic in children’s
magnetic putty, mercury in face cream; the Czech methanol outbreak 2012).
Sources of detailed and comprehensive information on the implementation of the IHR (2005) and
Decision 1082/2013/EU among EU Member States are limited, but some usable information
exists. The Commission’s “Draft Progress Report on Preparedness and Response Planning for the
Health Security Committee” provides a source of implementation information, of which publicly
available is the latest IHR self-assessment data submitted by Member States to the WHO (4).
This data is however also publicly available from the WHO (21). Another source is available
through the ECDC in the form of the “EU Laboratory Capability Monitoring System
(EULabCap) – Report 2016” (22).
These data were used by the steering SHARP planning committee (WP leaders) to produce a rank
of priority partners that can be used as a first approximation for the selection of support for
developing their capacities. The ranking was performed by producing a weighted score using
those IHR core capacity scores that were less than 70% in the latest submitted data, combined
with the aggregated EULabCap index. In addition, ranking was considered separately for partners
from countries with a Gross National Income (GNI) higher than 90% of the EU average (high
GNI) and those with a lower GNI (low GNI)16.
14 Study on cost-benefit analysis of reference laboratories for human pathogens.
https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/2016_laboratorieshumanpath
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
47 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ogens_frep_en.pdf
15 https://en.wikipedia.org/wiki/Ajka_alumina_plant_accident
16 2016 data provided by Eurostat
It is clear that there are several limitations to this approach to ranking the countries into a priority
order. First and foremost, as has been clearly demonstrated through multiple studies and our own
work, the data collected through the WHO IHR self-assessment scheme is not fully reliable as a
descriptor of true capability and capacity. Many countries have overestimated their capacity,
leading to a potentially too optimistic view of the actual situation.
Thus the partnership will over the course of the action (mainly in the early phases) conduct
further work and negotiations with partners to try to better understand where actual gaps are. It is
however necessary to have some form of baseline assessment as a starting point for initial
activities. Despite the caveats in the detailed data, it is likely that in an overall ranking the
countries with more challenges still stand out.
Using this methodology, the following rank list was produced:
Low GNI GNI as % of EU SHARP IHR Number of Priority Rank High GNI GNI as % of SHARP IHR Number of Priority
average Index low scoring Low GNI EU average3 Index4 low scoring Rank High
areas areas5 GNI
Croatia 35% 78,1 5 1 Iceland 131% 79,7 7 1
Malta 68% 79,4 5 2 Ireland 167% 86,2 3 2
Poland 37% 80,2 4 3 Belgium 130% 90,0 3 3
Bulgaria 23% 83,2 5 4 Denmark 171% 92,3 1 4
Estonia 54% 85,5 4 5 Italy 96% 93,1 2 5
Slovenia 66% 86,9 3 6 Luxembourg no data 94,1 1 6
Lithuania 45% 86,9 3 7 United Kingdom 123% 95,4 2 7
Cyprus 71% 90,2 3 8 Netherlands 140% 95,6 1 8
Romania 27% 92,2 3 9 France 117% 96,9 2 9
Hungary 37% 94,1 2 10 Germany 134% 97,4 1 10
Latvia 44% 95,0 2 11 Austria 139% 98,1 2 11
Slovakia 51% 96,1 1 12 Finland 136% 98,7 0 12
Czech Republic 54% 96,9 2 13 Norway 231% 99,4 0 13
Portugal 60% 96,9 1 14 Sweden 164% 100,0 0 14
Spain 83% 100,0 0 15
Serbia 16% no data
Greece 56% no data
It should be noted that Bulgaria, Cyprus, Iceland, Slovakia and Belgium are Collaborating, but
not Associated partners of the JA and thus cannot be funded. Switzerland does not participate in
the EU Health Programme and is therefore also not eligible for funding.
For the planning of the Joint Action, the Steering Committee jointly agreed to use the ranking in
the following manner when planning Work Package activities:
1) prioritise engagement (including resource allocation) of countries from the “Low GNI”
list (starting from the top of the list) in activities aimed to strengthen the country’s
capacity and capability
2) take into account those countries for which the data is unavailable (Serbia, Greece,
Bosnia-Herzegovina and Moldova)
3) Engage “High GNI” countries for development as appropriate, but as a second priority.
Relevant high GNI countries will support knowledge and good practice exchange.
Prioritisation does not mean that only high priority countries can participate in activities, all
partners may participate in all WP areas. However, in decisions on resource allocation, the needs
of the top priority ranked countries in the “Low GNI” category must be addressed first.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
48 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Work packages to address the gaps and support IHR and preparedness strengthening
Work packages 1-4 are mandatory components of all Joint Actions. Work packages 5-10 contain
the main activities that aim to strengthen the EU preparedness, capacity and capability to address
cross border threats to health. The management structure of the SHARP Joint Action can be seen
in figure 6.
WP1
Figure 6. SHARP JA management structure
The 2018 “Progress Report on Preparedness and Response Planning for the Health Security
Committee” highlights the following areas as existing gaps (4):
1. Human resources, Points of Entry (covered by existing JA Healthy Gateways),
Maintaining and developing all IHR core capacities.
2. Improving cross-sector interoperability and cooperation, as well as an all-hazards
approach, especially from a One Health perspective, but also other sectors
3. Business continuity, i.e. preparedness to not only deal with a health threat, but also
ensure that other essential societal functions can continue despite the crisis.
Contribution of the work packages to addressing the identified challenges and filling the
identified gaps
WP4 Sustainability
The work package is expected not only to address sustainability but as well integration in
national policies, thus potentially it can contribute to points 2 and 3.
WP5 IHR core capacity strengthening and assessment
The aim of this work package is to address gaps that exist in the IHR core capacities of countries,
i.e. those essential public health functions that each country needs to have in place to effectively
prevent, detect and control and manage health threats. These are basic functions such as legislation
and regulation, surveillance systems, water and food safety functions, outbreak investigation etc.
It is well recognized that the capacity to address cross-border threats requires that you first have
the capability and capacity to control local, regional or even national level health threats.
Work package 5 will support partners in building these capacities through the following
activities:
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
49 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
1. Supporting the countries in initiation of the evaluation process with regards to IHR
implementation and thereby aiding in evaluation of capacities and needs for capacity
building.
2. For low GNI countries that have already performed a JEE, participating countries will
through peer to peer exchange of knowledge and best practice, develop national plans to
address the common identified gaps
3. Improving capacity to send and receive public health assistance. Public health
emergencies might be of a magnitude that exceeds the national capacities. In these cases,
there are obstacles for effective international cooperation and support. The health sector
often underestimates the complexity of intersectoral cooperation. According to the EU
risk assessment report some scenarios could warrant the need to be able to move health
personnel, capacities, or medevac of patients in large scale emergencies. Establishment
of clear coordination and cooperation between the Civil Protection Mechanism and the
European Medical Corps would be essential. The above-mentioned challenges also
highlight the need for cooperation between national sectors and DG SANTE, DG ECHO
and WHO respectively.
4. Gaps in capacity are not always captured by evaluations and much information exists in
experiences gained through after action reviews and exercise reports. In cooperation with
ECDC, the WHO, and the Commission the possibility to collect and learn from these
sources will be explored.
WP6 Preparedness and response planning
The aim of the work is to support EU Member States in developing and testing operational
preparedness and response plans for serious cross-border health threats from a multisectoral
perspective. The focus of this WP is to improve the integration of multiple sectors (among
others specialized laboratory services, clinical sector) in the overall IHR response to public
health threats and incidents in the medical, biological and chemical sectors.
This will be achieved by:
1) Identifying core elements of an integrated multisectoral preparedness and response
plan. This identification will take place by several means: (1) review of international
and/or national tools and planning instruments for preparedness and response focused
on public health, laboratory services, the clinical and chemical sectors, (2) achieving
consensus among countries on the core elements of a multisectoral preparedness and
response plan, (3) inventory of the applicability of the core elements in low GNI
countries. The core elements will form the content of the plan, and countries can adapt
the core elements specific for their own country, (4) inventory of all multisectoral
networks (e.g. biological, chemical, veterinary) that are relevant for integrated
preparedness and response planning.
2) Supporting partners and Member States in development of an integrated Preparedness and
Response plan. The backbone of the plan will be the preparedness and response cycle and
the core elements identified in step 1. WP6 will support countries in developing their own
integrated Preparedness and Response plans.
3) Testing the multisectoral preparedness and response plan: a “Disease X” scenario will be
developed, i.e. a scenario for a novel disease or threat that is unknown and requires
multisectoral collaboration. The scenario will be developed in a step-wise approach, with
new situations that will emerge during a period of time, and which will require
involvement of new experts (e.g. in infectious diseases and chemical incidents) and
stakeholders. This scenario will be used to test the country specific integrated IHR
preparedness and response plans. In this scenario active collaboration with WP7, WP9 and
WP10 will be sought in order to provide the necessary technical input in the simulation.
4) The simulation of “Disease X” scenario will be used to develop, assess and test functional
capabilities and to describe procedures and mechanisms that compose the preparedness
plans. It will provide the most robust assessment of the strengths and weaknesses of the
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
50 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
multisectoral collaboration within a country in relation to the Preparedness and Response
cycle. These strengths and limitations will be revealed by translating the “Disease X”
scenario into flexible e-learnings and tabletop exercises for continuous learning and testing
of the different core elements in the national integrated multisectoral preparedness and
response plans.
5) Based on the lessons learned from applying the scenario, the plans will be adapted. This
process (using the scenario to test the plans, evaluate the plans based on the test and
applying the lessons learned) will be supported by the WP6 leaders.
In these e-learnings and tabletop exercises the different aspects of preparedness and
response plans will be simulated for different sectors in practical examples. These e-
learnings and tabletop exercises provide thus an accessible, flexible tool for simulating any
relevant scenario at any time in different countries and or geographic regions (e.g.
foodborne outbreak, syndromic airborne diseases investigation (chemical, microbiological),
zoonotic threat, vector-borne preparedness, etc.) for continuous evaluation of the integrated
multisectoral preparedness and response plans.
6) The inventories, simulations, evaluations and lessons learned will be used for development
of best practices catalogues and guidelines by the participating partners in order to provide
common and tailor-made standards for all hazard integrated IHR preparedness and response
planning in all participating countries.
WP7 Laboratory preparedness
The aim of the work is to address and mitigate the lack of sufficient quality assured
microbiological laboratory diagnostic services, preparedness and response in a part of the
Member States and participating neighbouring countries. In particular, capacity to detect and
reliably perform diagnostic testing of pathogenic infectious agents of Risk Group 3 (RG3)
Bacteria / Risk Group 4 (RG4) viruses with quality assured methods.
This will be achieved by:
1) Providing External Quality Assurance Exercises (EQAE) for agents not included in
commercial EQAE panel, building up on experience developed in EMERGE JA
including additional reference laboratories and new methodological approaches such as
serology, differential diagnoses of non-target pathogens, and antimicrobial susceptibility
testing.
2) Providing and evaluating specialized diagnostic services, evaluation of new advanced
diagnostic approaches, development of collaboration and consensus statements on
laboratory aspects including recommendations especially for partners with lower
capacities.
3) Supporting good biorisk management including procedures for inactivation for save
handling of diagnostic specimens, also under lower resource conditions.
4) Supporting bilateral cooperation and agreements of specialized laboratory services
between partners with the focus on new partners with lower resources and in sharing of
advanced diagnostic approaches.
WP8 Training and local exercises, exchange of working practices
The aim of the work package is to address one of the aspects of the gaps identified in the “Draft
Progress Report on Preparedness and Response Planning for the Health Security Committee”, i.e.
insufficient workforce (4). A partial problem is the lack of sufficiently trained competent staff.
The training activities coordination and implementation, the work package is cross-cutting in
relation to other work packages and thus coordination is key. This will be addressed by this work
package.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
51 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Activities planned include:
1) Assessment of the cross-sectoral training needs in EU, EEA and neighboring countries
related to preparedness and IHR implementation (utilizing work done by the ECDC)
2) Development of curricula for basic and advanced face-to-face and on-line Problem Based
Learning
3) Training implementation
Insufficiency of human resources is a major obstacle in IHR implementation worldwide. It is a
common finding in assessments regarding the state of IHR Implementation that the indicators for
human resources are amongst the weakest. The latest results of the annual reporting for IHR
implementation (2017) verifies, that the WHO EURO Region has with 45% implementation in
the capacity of human resources the lowest rate amongst all WHO Regions, where the average is
61%. While all other WHO Regions demonstrate a steady increase in their capacity in human
resources since 2010, the capacity in the WHO Euro region has even decreased in the recent
years (http://apps.who.int/gho//data/view.main.IHRREG07v?lang=en).
The recent reporting according to Art. 4 EU decision 1082/2013 demonstrated, that Human
resources is by far the weakest capacity (52%) and shows hardly any improvements compared to
the first reporting round 2015 (50%). Sophisticated plans, regulations or SOPs can not be
implemented, unless qualified and trained staff is available to fulfill this task.
Despite these worrying signals, it must be recognized that a severe lack of human resources
should be reflected in all other IHR core capacity scores, where the EU and European region
clearly has the highest global scores. This is a de facto paradoxical situation that needs to be
better understood.
It is possible that the perception of what constitutes sufficient human resources is highly
dependent on the expectations and perceived ambition level, and shows variation across the
globe.
WP9 Chemical safety and chemical threats
WP9 will develop a standardised approach to chemical preparedness and response through
increasing the level of exchange of information, best practice and promotion of existing
mechanisms, tools and resources produced in previous EU-funded projects (e.g. RASCHEM
tool, CERM sheets, Rapid Risk Assessment etc.) between and within EU Member States (MSs)
and participating SHARP JA countries.
A dedicated chemicals WP is required to strengthen IHR compliance in Europe and will work to
ensure that meeting the chemical obligations17 of the IHR has equal standing compared to other
hazards e.g. communicable disease, in line with the all-hazards approach of the IHR.
The approach on this substantial area of work will be the following:
1) improving implementation of chemical core capacities,
2) preparedness and response planning for chemical events,
3) strengthening gaps in IHR compliance in support of the prevention, detection, risk
assessment and response to chemical events.
4) standardisation of current procedures for preparing and responding to cross-border
chemical health threats.
WP10 Case management and infection prevention and control preparedness
The aim of the work package is to improve clinical and associated biorisk management of
infectious diseases, so called high-consequence infectious diseases (HCID), which could have
high clinical and public health impact in the EU. HCID are caused by pathogens that can
potentially cause epidemics or pandemics; infect/affect many people; spread rapidly in a short
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
52 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
time, and cause high cost to society and healthcare setting.
The outbreak of measles and the autochthonous cases of chikungunya in some of EU countries
are clear example of cross-border risk related to HCID. Defining the detailed list of HCID is one
of the tasks in this WP. Here the definition of HCID includes diseases with potential high public
health impact such as measles; new introductions with epidemic potential such as dengue,
chikungunya, MERS, EBOV; emerging diseases as consequence of AMR.
There are substantial differences in clinical expertise and experience in managing cases of HCID,
as well as many tropical severe infections that are rare in the EU region.
Preparedness and response in terms of hospital facilities varies greatly between the countries. At
the same time, the connectivity of the modern world ensures that a person with a high-
consequence infectious disease can appear in any of the cities of the EU or neighboring countries,
even before actual symptoms start. Thus preparedness and response capacities for such events
have to be in place in all member states.
The work package will address this in the following way:
1) Mapping of existing hospital preparedness for HCID, including high isolation clinical
facilities
2) Assessment of country hospital preparedness and capacity for HCID, including high
isolation clinical centers
3) Feasibility study for an expert clinical support service for HCID
4) Application of a “syndrome based” approach for clinical management of emerging
disease threats
17
WHO Manual: The Public Health Management of Chemical Incidents (2009)
https://www.who.int/environmental_health_emergencies/publications/Manual_Chemical_Incidents/en
References
1. World Health Organisation. International Health Regulations (2005). WHA58.3. 2005.
2. World Health Organisation. Assessment and Monitoring of implementation of the
International Health Regulations (2005): meeting the 2016 target. EM/RC62/8. 2015.
3. Gostin LO, Friedman EA. Global Health: A Pivotal Moment Of Opportunity And
Peril. Health Aff (Millwood). 2017 Jan 1;36(1):159-65.
4. European Commission DG Sante, European Centre for Disease Prevention and
Control. Draft Progress Report on Preparedness and Response Planning for the Health
Security Committee (Article 4 of Decision 1082/2013/EU on serious cross-border threats
to health). Luxembourg: European Commission; 2018.
5. World Health Organisation. First report of the Ebola Interim Assessment Panel.
A68/25. 2015.
6. Panel of independent experts. Report of the Ebola Interim Assessment Panel. Panel
report. 2015.
7. Moon S, Sridhar D, Pate MA, Jha AK, Clinton C, Delaunay S, et al. Will Ebola
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
53 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
change the game? Ten essential reforms before the next pandemic. The report of the
Harvard-LSHTM Independent Panel on the Global Response to Ebola. Lancet. 2015 Nov
28,;386(10009):2204-21.
8. THE COUNCIL OF THE EUROPEAN UNION. Council conclusions on ‘Lessons
learned for Public Health from the Ebola outbreak in West Africa — Health Security in
the European Union’. Official Journal of the European Union. 2015 17.12.:C 421/6.
9. EUROPEAN COURT OF AUDITORS. Special Report 28/2016: Dealing with serious
cross-border threats to health in the EU: important steps taken but more needs to be done.
Luxembourg: Publications Office of the European Union; 2016.
10. European Commission DG Sante. A technical action plan to strengthen preparedness
to cross-border health threats in the EU and support the use of the International Health
Regulations. Commission working document (drfat). 2018.
11. World Health Assembly. RESOLUTIONS AND DECISIONS: Decision
WHA69(14). WHA69/2016/REC/1. 2016.
12. World Health Assembly. RESOLUTIONS AND DECISIONS, Decision
WHA70(11). WHA70/2017/REC/1. 2017.
13. World Health Assembly. Decision WHA71(15) Implementation of the International
Health Regulations (2005): five-year global strategic plan to improve public health
preparedness and response, 2018–2023. WHA71(15). 2018.
14. World Health Organisation. DRAFT FIVE-YEAR GLOBAL STRATEGIC PLAN
TO IMPROVE PUBLIC HEALTH PREPAREDNESS AND RESPONSE, 2018–2023
(Annex 1/A71/8). Public health preparedness and response, Implementation of the
International Health Regulations (2005), A71/8. 2018.
15. World Health Organisation. Resolution on: Action plan to improve public health
preparedness and response in the WHO European Region. Resolution
EUR/RC68/R7. 2018.
16. World Health Organisation. Action plan to improve public health preparedness and
response in the WHO European Region. EUR/RC68/17+ EUR/RC68/Conf.Doc./5 Rev.1.
2018.
17. Dg Sanco. Lessons learned from the 2011 outbreak of Shiga toxin-producing
Escherichia coli (STEC) O104:H4 in sprouted seeds. COMMISSION STAFF
WORKING DOCUMENT. 2011:SANCO/13004/2011.
18. Kluge H, Martin-Moreno JM, Emiroglu N, Rodier G, Kelley E, Vujnovic M, et al.
Strengthening global health security by embedding the International Health Regulations
requirements into national health systems. BMJ Glob Health. 2018 January 20;3(Suppl
1):000656. eCollection 2018.
19. Bettcher DW, Sapirie S, Goon EH. Essential public health functions: results of the
international Delphi study. World Health Stat Q. 1998;51(1):44-54.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
54 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
20. Gupta V, Kraemer JD, Katz R, Jha AK, Kerry VB, Sane J, et al. Analysis of results
from the Joint External Evaluation: examining its strength and assessing
for trends among participating countries. Journal of Global health. 2018;8(2):1-9.
21. WHO Global Health Observatory data repository [Internet]. [cited August 15, 2018].
Available from: http://apps.who.int/gho/data/node.main.IHR?lang=en.
22. European Centre for Disease Prevention and Control. EU Laboratory Capability
Monitoring System (EULabCap) – Report on 2016 survey of EU/EEA country
capabilities and capacities. Stockholm: European Centre for Disease Prevention; 2018.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
55 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.2. Aims and objectives of the project
2.2.1. General objective of the project
The general objective of the SHARP Joint Action is to strengthen IHR implementation and
preparedness, to support capacity building and to contribute to a high level of protection of health
and security in EU Member States in line with the EU health security framework. This is reflected
through two overall objectives:
1. To support the implementation of Decision 1082/2013/EU on serious cross-border threats
to health
2. To strengthen the resilience and response capacities of health systems, and to ensure
coherence and interoperability for preparedness and response planning to health threats at
national, EU and regional level
This will be achieved by supporting the implementation of IHR in EU Member States, EEA and
neighbouring countries through improving preparedness and response planning for serious cross-
border threats and improving the core functions of public health laboratories, by the coordination,
(in collaboration with ECDC) of a reference network of European microbiology laboratories
specialised in highly pathogenic or newly emerging pathogens to improve laboratory capacity.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
56 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.2.2. Specific objectives of the project
Specific Objective 1 (WP4 Sustainability and policy development)
Number
Specific Objective Best practices on IHR and preparedness incorporated in national policies,
including improved cooperation mechanism between EU Member states
Process Indicator(s) Target
Best practices and recommendations engaged in the JA are selected Minimum 3 best
practices and
recommendations is
established and
validated by the
Steering Committee,
Advisory Board and
HSC M18
Output Indicator(s) Target
SHARP sustainability plan is developed One generic
sustainability plan is
presented to the
Steering Committee,
Advisory Board and
HSC for validation
M24
Outcome/Impact Indicator(s) Target
Evidence-based best outcomes and recommendations on IHR Minimum 2 best
implementation are integrated into EU/ national /regional policies and practices and
mechanisms recommendations are
integrated into national
policies and 1 best
practice is integrated
into mechanisms
(M24)
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
57 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Specific Objective 2 (WP5 IHR core capacity strengthening and assessment)
Number
Specific Objective Improved core capacity in EU member states as required by IHR and
Decision 1082/2013EU
Process Indicator(s) Target
Analysis of common gaps in IHR implementation in countries One agreed work plan including
that have conducted a JEE and selection of gaps to address in selected challenges agreed with
workshops. participating countries,
International workshops focused on low-GNI countries 3 workshops (with up to 12 low
GNI countries participating) by
Annual workshops jointly aimed to assist both countries that
month 36
have conducted a JEE and those who have not. One part
introducing and preparing for JEE and one part working on
identified gaps after JEE.
International workshop on cross border collaboration open for 1 workshop (up to 50
all member states participants) by month 24
Feasibility of using information from national and 1 feasibility study performed by
international exercises and after action reviews in assessing month 36
state of public health preparedness in the EU: study protocol
adopted
Output Indicator(s) Target
Number of countries participating in training in the JEE 5 countries out of 15 low GNI
process countries
Reports from the workshops (1. on external evaluation 3 workshop reports by M34
processes; 2. on strengthening of IHR core capacities and 3.
on international collaboration between authorities during
crisis)
Report on the feasibility study of using information from 1feasibility report by M36
national and international exercises and after action reviews in
assessing state of public health preparedness in the EU
Outcome/Impact Indicator(s) Target
Participating countries have increased their knowledge of the 5 countries
JEE process and best practices for preparing and performing a
JEE as measured by pre and post workshop evaluations.
Participating countries have greater understanding and are in a
better position to reduce weaknesses in selected core 5 draft action plans (1 per
capacities and have developed a draft action plan how to country addressing three
address the specified gaps. challenges)
Key challenges and possible solutions in national and Gaps identified and development
international collaboration between government authorities of policy recommendations
and relevant national authorities, European Commission (DG
ECHO, DG SANTE) and WHO identified.
Better use of data from exercises and AAR to assess status of Input to report on the state of
preparedness in the EU preparedness in the EU under
Decision 1082/2013/EU
More comprehensive picture of challenges in health
preparedness in EU
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
58 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Specific Objective 3 (WP6 Preparedness and Response planning)
Number
Specific Objective EU Member States and JA partner countries supported in
developing operational integrated preparedness and response plans
and mechanisms for serious cross-border health threats with an
integrated all hazards approach.
Process Indicator(s) Target
Expert meetings Two meetings with at least
1. Consensus meeting on core elements of integrated 10 experts from
multisectoral preparedness and response plans, most relevant to participating countries by
the “Disease X” scenario and the critical process steps for month 18
further development of the scenario
2. Consensus meeting to evaluate lessons learned and critical
steps needed to translate the tested plans into all hazard
multisectoral preparedness and response plans with particular
emphasis on applicability in low GNI countries.
Consultations Five (online) consultations
1. To assess the applicability of the selected core elements by month 33
in low GNI countries
2. on protocol development “Disease X” scenario
3. online survey to inventory outcomes and
recommendations from exercise “Disease X” simulation
4. protocol development all hazard e-learnings and tabletop
exercises
5. online survey to inventory outcomes and
recommendations from e-learnings and tabletop exercises
elements critical for improving implementation of the
integrated all hazards multisectoral preparedness and
response plans.
Workshops (cooperation with WP8) Four workshops by month
1. To collect relevant tools, instruments or core elements that 27
were not identified in the review, or may have different
meaning for different sectors/ countries
2. To clarify gaps, feasibility and barriers for participating
countries to develop a multisectoral preparedness and
response plan for high risk threats with particular focus on
low GNI countries
3. Translation of high risk plans into all hazards applicability
4. To collect best practices, fail and success factors, not
identified in the simulations, workshops and reviews, or
have different meaning or weight for different sectors or
countries.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
59 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Disease X-scenario simulation (in cooperation with WP7, WP9 At least 1 Disease X scenario
and WP10 ) evaluated and disseminated by Month 33
E-learnings and tabletop exercises (in cooperation with WP7, 2 e-learning tools and 2
WP9 and WP10) tested, evaluated and disseminated tabletop exercises by
Month 33
Output Indicator(s) Target
Literature reviews
1. Review of international and/or national tools and planning 2 reviews by month 9
instruments for preparedness and response focused on
multisectoral integration for the following sectors: public
health laboratory services, clinical and chemical sectors
2. Review of a selected recent threats with emphasis on
preparedness and response methods used, success and fail
factors.
Checklists Two checklists by month 27
1. For “Disease X” scenario, and
2. For e-learnings and tabletop exercise development.
Protocols Two protocols by month 27
1. “Disease X” scenario simulation
2. All hazard e-learnings and tabletop exercises
Catalogue of best practices on integrated multisectoral 1 by month 27
preparedness and response plan implementation
Guidelines of best practices on integrated multisectoral 1 by month 33
preparedness and response plan implementation
Outcome/Impact Indicator(s) Target
JA partners actively participated and know what barriers may 100% of the JA partners
hamper implementation of the integrated preparedness and
response cycle, and steps needed to achieve implementation
Member States participated in “Disease X”scenario simulation 80% of Member States
and/or applied at least one e-learnings and tabletop exercise
JA partners consulted and/or actively participated in the 100% of the JA partners
development of best practices guidelines on integrated
multisectoral preparedness and response plan implementation and
know how to use them
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
60 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Specific Objective 4. (WP7 Laboratory preparedness and responsiveness)
Number
Specific Objective 4.1. Improved laboratory preparedness in order to ensure the application
of best practices in detection and analyses of highly pathogenic infectious
agents
Process Indicator(s) Target
Number of rounds of EQAEs for viral and bacterial specimens reaching a 3 rounds of EQAE,
majority of partners reaching at least 25
laboratories, Mo
32
Number of participants assessing and implementing basic and advanced At least 20
diagnostic approaches laboratories will be
interested to
participate, Mo 18
Output Indicator(s) Target
Detailed report on EQAEs 3 reports, Mo 12,
24, 35
Report on assessment / evaluation of diagnostic capabilities and 2 reports, Mo 18,
approaches, integration of these data sets with WP6 Mo 35
Outcome/Impact Indicator(s) Target
Quality assurance of diagnostic methods has been improved by refinement 1 report indicating
of single steps in the diagnostic approaches, by improving validation that at least 5
procedures of previously adopted methods, introduction of new methods or laboratories have
consolidation of existing high quality standards improved diagnostic
methods and the
other participants
have maintained
and consolidated
their high diagnostic
quality, Mo 35
Laboratories have defined best diagnostic practices which will be assessed 1 report, Mo 35
together with WP6
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
61 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Specific Objective 4 (WP7 Laboratory preparedness and responsiveness )
Number
Specific Objective 4.2. Improved and consolidated biorisk management in laboratories
dedicated for the diagnostics of highly pathogenic infectious agents
Process Indicator(s) Target
Number of participants working on consolidation and improvement of At least 20
laboratory biorisk management especially with lower resources laboratories
confirmed, Mo 6
Number and quality of sample inactivation methods defined for handling At least 2 methods
under lower level of biosafety containment have been
evaluated for risk
group 3 bacteria
and risk group 4
viruses, Mo 24
Output Indicator(s)
Number of laboratories which have applied the revised and newly developed At least 5 reports
biorisk management recommendations by partners on
implementation of
the biorisk
management
recommendations,
Mo 30
SOP on best practice sample inactivation procedures considering 2 SOP, one each
applicability and effectiveness of procedures and reagents for bacteria and for
viruses reports, Mo
18, Mo 35
Outcome/Impact Indicator(s) Target
The biorisk management of RG3 and RG4 agents has been improved by an 1 report indicating
extended risk assessment and introduction of new/additional that at least 5
biosafety/biosecurity measures laboratories have
introduced new
measures for biorisk
management and
others have
maintained/
consolidated the
high standard of
biorisk
management;
Mo 35
The biorisk for handling of risk group 3 bacteria and risk group 4 viruses 1 report, Mo 35
has been reduced by appropriate and harmonized inactivation procedures
for handling under BSL2-conditions, offer of these procedures to clinical
laboratories associated with High Containment Units for patients’ care
(collaboration with WP10)
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
62 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Specific Objective 5 (WP8 Training and local exercises, exchange of working practices)
Number
Specific Objective Capacity of professionals in IHR implementation and preparedness for
serious cross-border health threats in the JA partner countries increased.
Process Indicator(s) Target
International trainings and meetings organized 10 workshops/
trainings (2X IHR
basic and 4 X
advanced
including chemical
trainings, 2X field
exercises, 2 X
laboratory and), 2
meetings
Assessment of the cross-sectoral training needs performed 1 by M15
Output Indicator(s) Target
Report on assessment of the cross-sectoral training needs across countries Training needs of
(at least) 15 low
GNI countries
Training materials for WP8 developed by M18
Report on the trainings provided by M36
Outcome/Impact Indicator(s) Target
IHR implementers across countries will achieve improvement of the 10% increase
knowledge in the area of prevention, preparedness, detection and response (based on the pre
to cross-border threats to health; and post-training
test results of
training
participants)
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
63 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Specific Objective 6 (WP9 - Chemical safety and chemical threats)
Number
Specific Objective Improved implementation of IHR chemical core capacities, strengthened
preparedness and response to cross-border chemical health threats within
MSs and across the EU
Process Indicator(s) Target
Gap analysis of country IHR chemical capacity implementation All MSs invited to
- Consult with relevant organisations, EC, MS authorities and undertake gap analysis
external stakeholders to determine current capacities with respect by month 5
to chemical incident response.
- Review of existing health protection mechanisms in the area of
cross-border chemical incidents and lessons learnt from previous
incidents.
EU-level workshops organised 2 workshops (with 1-2
- Consultations and meetings throughout the project to engage representatives from each
with project partner and relevant stakeholders/authorities to MS e.g. 60-80) by month
develop material that is used in workshops. 30
Training materials, guidance documents and SOPs to be produced Training materials
- Agreement at the project level of guidance documents and (including slides, case
resources tested during workshops and exercises. studies and exercise
scenarios), guidance
documents and SOPs to
be distributed amongst
all JA partner countries
(32) by month 36
Output Indicator(s) Target
- Reports detailing progress on: achieving gap analysis of 3 reports (to be delivered
chemical capacity implementation; surveillance strategy for EU M12, M24, M36).
MSs; outcomes of the workshops and exercise, to be
disseminated by the end of the Joint Action. A set of lectures (4-8),
case studies (3-5) and
- Training materials on improving preparedness to cross-border questions and activities
chemical health threats will be developed (reports, toolkit,), to promote discussion
tested in the workshops and disseminated by the end of the among participants (to be
action. delivered M16).
- Guidance and SOPs on improving implementation of IHR core SOP compendium (to be
capacities (such as surveillance and reporting of chemical events) delivered M36).
based on the country assessment of IHR capacities.
Outcome/Impact Indicator(s) Target
Improved implementation of IHR chemical core capacities within EU At least 70% of the MSs
MSs and partner countries, to support the timely detection of and to have utilized the
effective response to potential chemical health risks/events. In advice documents
particular, those partner countries who identified the need to provided by WP9 in their
strengthen capacity to respond to chemical events. planning, preparedness,
risk assessment and
response to chemical
events
Workshop attendees have improved their knowledge of chemical By 60% according to pre
hazards and IHR core capacity requirements for chemical events and post questionnaires
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
64 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Specific Objective 7 (WP10 Case management and Infection Prevention and Control
Number Preparedness )
Specific Objective Improved clinical and biorisk management; improved hospital
preparedness and response to high-consequence infectious diseases
(HCID)
Process Indicator(s) Target
Four workshops organised: 4 workshops
- Workshop 10.1 – Presentation of the Map (Mapping and assessing (minimum one
the existing facilities and country clinical preparedness); participant for each
Definition of methodology and recommendation for assessment country of the JA)
- Workshop 10.2 – Dissemination and discussion of the assessment by month 30
results
- Workshop 10.3 – Identification of the list of HCID , case definition
of each HCID; systematic identification of major disease drivers
and threats; evaluation of validated severity scores (involving all
SHARP partners)
- Workshop 10.4 – Dissemination and discussion of the obtained
results from the Task 4.
Map and survey of clinical capacities, including high isolation clinical units Map covering at
available least 80% of
existing units
Assessment of clinical and biorisk management capacities, including high 90% of countries
isolation clinical units assessed by month
23
Syndrome based clinical protocol implemented at country level in selected Implemented in at
clinics least one clinic in
3 countries of the
JA by M32
Output Indicator(s) Target
Map (existing hospital preparedness for HCID, including high isolation 1 Map including
clinical facilities) 20 countries
Feasibility study for an expert clinical support service for high-consequence 1 report by M18
infectious diseases
Protocol for syndrome-based approach for prompt and early clinical 1 protocol for
management of high-consequence infectious diseases each of the three
involved pilot
countries by M18
Outcome/Impact Indicator(s) Target
50% of partner
Increase in assessed and improved hospitals with isolation facilities countries assessed
Participating hospitals have utilized the JA guidance on biorisk management 80% of
participating
hospitals
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
65 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.3. Target groups
The final beneficiaries of the Joint Action is ultimately the EU citizens of the member states, as
the sole purpose of the activities undertaken under the premise of the project seek to improve the
health security in the region and thus contribute to a safer and healthier environment and a
resilient public health system.
However, the immediate target groups though which the action needs to operate and whose work
it aims to support are the following.
A. Global policy level
1) World Health Organisation – (WHO)
2) WHO European Regional Office
3) EU Commission and ECDC
4) International Association of Public Health Institutes (IANPHI)
5) Food and Agriculture Organisation of the UN (FAO)
B. The national policy and coordination levels
1) Health and health security policy makers
2) National Focal Points for the IHR (2005)
3) Health Security Committee representatives
4) ECDC preparedness and response NFPs
5) National Public Health Agencies (as relevant)
6) Food safety authorities
7) Chemical safety authorities
C. The operational levels
1) Health provider organisations
2) Local and regional public health officers
3) Public health laboratories
4) Local and regional outbreak investigation teams
2.4. Political Relevance
2.4.1. Contribution to meeting the objectives and priorities defined in the annual work
programme
The policy expectations for this SHARP JA have been described in detail in the Health
Programme 2014-2020 Annual Work Programme 2018.
The overarching goal is to strengthen IHR implementation and preparedness, to support capacity
building and to contribute to a high level of protection of health and security in EU Member
States in line with the EU health security framework. Gaps identified in the Draft Progress Report
on Preparedness and Response Planning for the Health Security Committee under Article 4 of
Decision 1082/2013/EU will be addressed through the SHARP Joint Action.
The core Work Packages in this SHARP JA are designed to meet the priorities and fulfil the
objectives defined in the Health Programme 2014-2020 Annual Work Programme 2018. The
eight priorities given in the Annex for the Joint Action to be funded are listed here:
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
66 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
- Strengthening the scientific evidence base on effective actions to prevent and respond to
cross-border health threats of biological, chemical, environmental and unknown origin;
- Exchanging of information and sharing of best practices within and among Member
States;
- Strengthening preparedness and the implementation of IHR core capacities, supporting
Member States in developing standard operating procedures, business continuity plans,
and promoting the interoperability of national preparedness planning;
- Improving methods, tools and criteria for monitoring, assessment and reporting under
Decision 1082/2013/EU;
- Improving EU Member State coordination as regards different global initiatives, and in
particular the WHO’s IHR Monitoring and Evaluation Framework under the Health
Emergencies Programme;
- Improving the core functions of public health laboratories, including biosafety and
biosecurity to ensure systems for the safe referral of clinical specimens for early
detection and monitoring of outbreaks, transport in-country and international shipment,
which key capacities required under the IHR;
- The coordination, in collaboration with the European Centre for Disease Prevention and
Control (ECDC), of a reference network of European microbiology laboratories
specialised in highly pathogenic or newly emerging pathogens to improve laboratory
capacity;
These objectives cover the overall objectives, strengthening preparedness and the implementation
of all IHR core capacities, which are within the scope of this JA. The IHR core capacities and
areas which are not covered here, are covered by other on-going JA, e.g. JA “Healthy Gateways”
which covers Points of Entry, the JA on Vaccination covers Immunization, and JA Antimicrobial
Resistance (JAMRAI) and Healthcare-Associated Infections, which covers issues on AMR. This
SHARP Joint Action will collaborate with and follow the results achieved in these JAs, and
especially with the JA “Healthy Gateways”. The objectives of the SHARP JA aim at improving
methods, tools and criteria for monitoring, assessment and reporting under Decision
1082/2013/EU as well as improving EU Member State coordination as regards different global
initiatives, and in particular the WHO’s IHR Monitoring and Evaluation Framework under the
Health Emergencies Programme, most notably the WHO European Regions activites, as well as
the ECDC’s activities
Other EU policy frameworks which may be relevant for cross-sectoral preparedness and response
planning: 1) DG SANTE: Frameworks for food safety and animal health and for pharmaceutical
products; 2) DG ECHO: EU Civil Protection Mechanism, European Medical Corps, European
Voluntary Aid Corps; 3) DG HOME: European Agenda on Security, Security Union; EU CBRN
Action Plan; 4) DG GROW-EEAS: EU Joint Framework on countering hybrid threats; 5) DG
RTD: EU Framework Programme for Research and Innovation Horizon 2020; 6) DG DEVCO:
Bilateral programmes - IHR implementation within health systems strengthening and promoting
universal health coverage; 7) DG ECHO-JRC: EU Action Plan on the Sendai Framework for
Disaster Risk Reduction 2015-2030; 8) DG EEAS: Strategy on Foreign and Security Policy
The SHARP Joint Action will strive to engage actors from different sectors involved in work
under the related policy frameworks listed above, as will be deemed relevant.
2.4.2. Added value at EU level in the field of public health
The SHARP Joint Action will strive to provide European added value by several approaches: 1)
by spreading good practices across the Members States so that different solutions to resource and
coordination challenges can be propagated from country to country, 2) by offering models for
potential sharing of resources across borders in accordance to national policies and opportunities.
Such resources could be specialized health containment facilities, evacuation capacity, cross
border consultations, specialized diagnostic laboratory capacity, cross-border exercises and
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
67 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
preparedness scenarios, etc. 3) by increasing awareness among relevant actors from differing
sectors on the obligation under the IHR (2005) and Decision 1082/2013/EU on serious cross-
border threats.
Although many countries in the region have developed IHR capacity and capability and clear
preparedness and response plans (partly with support from earlier EU funded projects), gaps in
the collective EU capacity still exist, especially among the lower GNI member states and the
neighbouring countries.
Therefore, the major EU added value from the SHARP JA comes from working towards a goal
that all member states can adequately ensure that a health threat in one country does not get out
of hand and spread to the neighbors. In a union where barriers do not exist for the free movement
of people and goods, the statement that infectious diseases do not respect borders is exceptionally
relevant. In addition, an introduction of a high consequence infectious disease from outside of the
EU needs to be controlled irrespective of which country it happens to land in.
Only by working together for this goal can we ensure the protection of all EU citizens from high
consequence health threats, be they infections, chemical or environmental threats.
2.4.3. Pertinence of geographical coverage
This SHARP Joint Action covers the majority of the European countries.
Out of the 28 EU Member States, 22 are engaged as Associated partners in this SHARP JA, listed
here in alphabetical order: Austria, Croatia, Czech Republic, Denmark, Estonia, Finland, France,
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland,
Portugal, Slovenia, Spain, Sweden and the United Kingdom. In addition, EEA member Norway,
as well as Bosnia-Herzegovina, Moldova and Serbia are also Associated Partners of this JA
(totally 26 Associated partners).
EFTA member Switzerland, EEA member Iceland, and EU Member States Belgium and Bulgaria
have agreed to join and contribute as Collaborating partners, which makes the total number 30
countries participating in the Joint Action (including collaborating partners). Thus only Slovakia,
Romania, Luxemburg and Cyprus out of the EU member states are not at all engaged in the Joint
Action. Using the 2018 national estimates from Eurostat the SHARP JA covers 94,8 % of the EU
population18.
2.4.4. Consideration of the social, cultural and political context
The aims and outcomes of this JA, to strengthen preparedness and the implementation of IHR,
will ultimately benefit all the EU citizens of the Member States, although the main actions will be
implemented in and targeted to the policy and national coordination levels in the health security
field. While many countries in Europe have achieved a high level of preparedness and have
implemented many or even most parts of the IHR, this has not been fulfilled in several European
countries.
To take into account and to respond to the specific needs of the different Member States, this JA
will first provide information on existing IHR implementation gaps and tailored support to
strengthen core capacities and cross-sectoral capacity building, especially to the less prepared
Member States.
This JA aims to achieve efficient and effective visibility, awareness and acceptance of the project
to internal and external stakeholders and to the broader European public, to improve the health of
EU citizens and reduce health inequalities across Europe.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
68 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
This will be realized by identifying the language needs – including which countries have
statutory duties to communicate in particular languages, and by tailoring and translating
messages where appropriate, and by adapting messages to suitable channels, and by identifying
long-term, sustainable ownership for these channels. The outcome will be long term, sustainable
benefits with a particular focus on Member States where more assistance may be needed.
This JA proposal does not comprise studies involving humans. Therefore specific ethical aspects
or personal data issues do not need to be considered. The General Data Protection regulation
(GDPR), the data protection law enforcement directive and other rules concerning the protection
of personal data will be strictly followed in the execution of the project.
18
https://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tps00005&plugin=1
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
69 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.5. Methods and means
The methods and means to achieve the expected objectives and outcomes of this SHARP JA will
be implemented through the following actions within the management activities (WP1-WP3:
Coordination, Dissemination and Evaluation), and through the work and activities within the core
Work Packages (WP4-WP10).
Management activities: Coordinator (THL) will monitor that the action and it’s financial
management is implemented properly, and will submit the deliverables and reports to the
Agency. This will be implemented e.g. by arranging a Kick-off meeting, two Partnership Forums,
seven Steering Committee meetings and four Advisory Board meetings. A closing conference
will take place in the end of the JA. The progress and outcomes of the JA will be monitored
through reporting, Interim report and Final report. Through a specific and appropriate
communications and dissemination strategy the visibility and awareness of the project and its
outcomes will be ensured. The means for implementing evaluation includes questionnaires and
round table meetings.
Methods and means to achieve the objectives of the Work Packages include such activities, as:
- Developing guidance tools to ensure sustainability, reports on sustainability strategy,
assessing the gaps in current IHR capacities, and assessing the key priorities and current
best practices;
- Arranging workshops, through producing reports on feasibility study, through expert
exchanges;
- Engaging more partners from other sectors, e.g. including food safety, zoonotic
veterinary public health, environmental health and civil protection in the course of time
in this JA.
- Providing direct consultation and expert assistance to partner countries;
- Assuring high quality of diagnostics for highly infectious pathogens by conducting
annual EQAEs, through assessment of and recommendations for application of novel
diagnostic methods;
- Development and application of an assessment tool for laboratory biorisk management;
- Reporting on assessment of the cross-sectoral training needs and trainings provided
within this JA, and through delivering recommendations for risk management and risk
reduction in diagnostics of highly pathogenic agents; and
- Producing fact-finding reports and surveillance strategic reports.
The detailed methods and means for the execution of the Joint Action can be found below, and in
the description of the activities under the specific work packages.
WP2 – Communication and Dissemination
Public Health Wales has an established Communications and Dissemination methodology which
will be used to undertake each of the phases. This methodology can be adapted to meet the needs
of project and programme communications, as well as internal communications.
WP3 – Evaluation of the action
The methods and means of evaluation the action are described in detail in the WP3 description.
The evaluation will be carried out through following tasks:
Task 3.1 Evaluation plan development.The evaluation plan will examine the process, outputs
and outcomes of the WPs of the project through systematic review in terms of results, as well as
in terms of quality standards met. The common evaluation plan will be designed based on the
information regarding the finalized tasks of each WP and planned milestones.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
70 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Task 3.2 On-going internal evaluation. Internal evaluation procedures will be applied
throughout the duration of the project and will emphasize on the efficacy of WP tasks.
Task 3.3 External Evaluation of the effect and impact of the JA. The external evaluation will
ensure the objectiveness in the evaluation process. Independent evaluator will concentrate on the
impact of the JA and will determine the relevance, effectiveness, outcome and impact of the JA
activities. It will focus on whether the stated objectives and related indicators have been
achieved, measuring the level of the target group’s satisfaction through quantitative and
qualitative methods. It will be performed by independent external evaluators procured by the WP
leader. The activities of the external evaluation are summarized as following phases:
0) Preparatory phase; 1) Desk Phases; 2) Field phase; 3) Synthesis phase; and 4) Dissemination
and follow up phase.
The evaluation outcomes (report, executive summary, article and/or presentation) will be
disseminated to the relevant project stakeholders.
Evaluation tools to be utilised:
- - Evaluation surveys (to random sample and/or preselected target group representatives)
- - Participation in selected project meetings.
- - In-depth interview with all WP leaders.
- - Development of a tool to monitor results and outcomes during the project but also for
evaluating impact and sustainability.
All partners will be mobilized during its activities, especially the leaders of all WPs. WP4,
sustainability and policy development will be particularly involved, as one key desired outcome
of the project would be the establishment of sustained IHR core capacity in all partner countries.
WP4 – Integration in National Policies and Sustainability
Key activities carried out by the different WPs of this JA are expected to improve preparedness
and response planning. The purpose of this WP is to build a sustainability plan, to ensure uptake
and sustainability of the JA outcomes from WP5 to WP10 at EU, national and/or regional level,
and enabling to comply with the implementation of the IHR (2005) and relating Decision
1082/2013/EU.
Task 4.1. Guidance tool. To develop a guidance tool aiming at ensuring that all core WPs take
into account the sustainability of their outcomes within their work and reports. WP4 task leaders
will follow-up and contribute to the work done by other WPs through participation at meetings,
iterative process of deliverables, observation and guidance on other WP’s outputs.
- Workshop 1 will be organized with the Steering Committee (SC) members to draft the
guidance frame.
Task 4.2. Selection of best practices. To select best practices for integration into sustainability
plan. Pilot actions supporting a sustainable integration of best practices will be developed based
on the interim internal evaluation report in collaboration with WP3, and based on the review of
the existing IHR and laboratory preparedness and response tools and mechanisms done by WP6.
Identified actions will be included into the sustainability plan. This selection will be developed in
close collaboration with the Health Security Committee (HSC), during its bi-annual meeting.
- Workshop 2 will be organized with the SC, the Advisory Board and the HSC to review
those selected outcomes and confer about the next steps, to be included in the
sustainability plan and national policies.
Task 4.3. Development of the SHARP sustainability plan. To develop a generic sustainability
plan to foster long term integration of selected WP outcomes into EU/ national / regional policies
and mechanisms and to define the conditions for operationalization. It will include a selection of
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
71 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
priorities and best practices, the identification of required resources (budget, training, HR) and
partners to be involved, an advocacy strategy on identified priorities in coordination with WP2
and WP3, and a sustainable communication and coordination between MS. This sustainability
plan will be developed in close collaboration with WP1 and WP5 and the HSC members, to
ensure optimal uptake. It is expected to contribute to the objectives and indicators related to
national legislations, policy and financing, as outlined in particular in WHO Joint External
Evaluation (JEE) tool.
- Workshop 3 involving SHARP Steering Committee and Advisory Board as well as the
EC HSC members will be organized to present a final draft of the sustainability report.
WP5 – IHR core capacity strengthening and assessment
IHR core capacities will be strengthened and assessed mainly through different
workshops.Workshops are targeted to participating partner low GNI countries that have not
performed a WHO JEE as well as those that have. This supports MS in their preparation to
undertake a JEE and thereby making a structured and thorough evaluation of core functions that
simplifies the capacity building required to fulfill the requirements of IHR and EU Decision
1082/2013/EU2013/EU.
Up to twelve selected lower GNI countries will be funded for participation in the planned
workshops and teleconferences/webinars and for preparatory work in between. The activities will
be divided into four main parts; the first part focusing on increasing knowledge about the
evaluation process and best practice in preparation it, the second part focusing on post-evaluation
follow up of joint identified weaknesses in core capacities, the third part focusing on cross country
collaboration in emergencies, the fourth part on assessing the usefulness of including exercises and
after action reviews in evaluations of preparedness.
Task 5.1 – Improving IHR implementation
Workshops will be hosted together to further enable exchange of knowledge between countries.
Partners from low GNI-countries included in this WP will participate in all workshops.
- Subtask 5.1.1 Increasing knowledge about the practicalities and added value of external
evaluation processes (Workshops 1, 3 and 6).
- Subtask 5.1.2 Facilitating strengthening of selected core capacities (Workshops 2,4 and
6). For selected countries that who have already performed a JEE.
Task 5.2 International collaboration between authorities during crisis
Two workshops will be arranged:
- 5.2.1 Workshop on international collaboration between authorities during crisis. To find
out if there is a need for an agreement of intention between neighboring countries to
assist each other in the event of large scale emergencies; and to define what are the main
obstacles against receiving help or assisting. A table-top exercise will be organized as
part of the workshop.
- 5.2.2 Workshop on cooperation between public health and civic protection and on
clinical consultation. The objective of the workshop is to identify key challenges in
national and international collaboration between governments and national authorities,
and to elaborate on measures for the operationalization of obligations related to response
from health systems, cross-sectoral efforts and effective assistance between MS when
needed. The workshop will also propose a legal framework for trans-country medical
consultations as outlined in WP10 task 10.3
Task 5.3. Feasibility of using information from national and international exercises and after
action reviews in assessing state of public health preparedness in the EU
- To support efforts and initiatives from ECDC, WHO and their collaborating centre
RIVM, and building on exercises and after action reviews conducted as part of the JA
(especially linked to WP8).
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
72 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Both IHR annual monitoring and reporting to the EU Commission, as required under Article 4 in
Decision 1082/2013/EU, is done through standardized questionnaires. However, the responses to
the questions in the current reporting templates are dependent on subjective interpretation by the
respondents, and scores may vary depending on the interpretation of those completing the
questionnaires. Although the updated Monitoring and Evaluation Framework for the IHR (2005)
includes use of After Action Reviews and Simulation Exercises in order to better document the
functional capacity in existing systems, this aspect of preparedness is not successfully captured in
the annual monitoring of preparedness.
In order to assess the status of the functional capacity of public health preparedness in the EU, the
structured reporting system can potentially be improved by collecting information on the results
of exercises and after action reviews from Member States in order to map the key challenges in
detection and response in Europe. This Joint Action task will support ongoing efforts by the
European Commission, WHO, ECDC and RIVM (the WHO Collaborating Center for
Preparedness) to better document capacity level through exercises and ARR, as well as support
the development of tools for sharing information about exercises and AAR between countries.
Method:
Contribute to the ongoing processes of WHO and ECDC, to 1) review information on
preparedness available from published exercises and AAR, 2) prospectively collect data
on use of exercises and AAR in Europe to document preparedness capacities, and 3)
develop tools for compiling and sharing information on exercises and AAR between
countries
Assess how exercises that will be conducted as part of the JA (e.g. WP8) can be used to
inform use of exercises to document preparedness capacity at the European level.
Consider focus group discussion during JA workshops to discuss possibilities and
challenges in data sharing from exercises and AAR
WP6 – IHR core capacity strengthening and assessment
Preparedness and response activities in emergencies and serious cross-border health threat
situations relies on re-alignment of existing public health, healthcare and other necessary
resources under a single command and control structure. Public health emergency preparedness is
a continuous, evolving process, using the preparedness cycle with appropriate evaluations,
exercises and after-action reviews to strengthen the system (See figure WP6). It is essential that
plans for different scenarios and types of threats are developed in advance and are appropriately
tested and exercised engaging all relevant sectors (among others public health, laboratory,
clinical, chemical). A specific issue identified in the planning of the JA is the lack of a clearly
identified business model on how to ensure access to rarely needed diagnostic laboratory
services. These include diagnostic capacity for high-consequence infectious diseases (HCID) or
unknown agents that need level 3 or 4 containment facilities, or highly specialised chemical agent
analytical services. Many countries do not have these resources, and a model for access through
bilateral and/or multilateral agreements in emergency situations will be developed.
A limitation of preparedness planning is that emerging health threats frequently do not behave in
predictable ways. Thus well-defined preparedness plans may be of limited use in the actual
emergency situation. WP 6 will focus on developing and testing cross-sectoral preparedness and
response plans using “Disease X” scenario.
First step aims to identifying core elements of an integrated multisectoral preparedness and
response plan. In the second step, a cross-sectoral preparedness and response plan will be
developed. The basis for this plan will be the preparedness cycle, since all steps describe in this
cycle are essential for cross-sectoral preparedness and response. In the third step, a generic hazard
scenario, “Disease X” scenario, will be developed. The aim of this scenario is to introduce
uncertainty and unpredictable pathways of evolution, mimicking a real live event.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
73 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Such a scenario will be useful for developing flexible preparedness plans and testing these
through simulations and exercises, such as e-learnings and tabletop exercises. Laboratory input in
these scenario’s will come from WP7 and WP10.
These scenario’s will be discussed with countries to test their cross-sectoral preparedness and
response plan. Based on the lessons learned, the plans will be adapted. Assessing the actual
national capacity to ensure operational preparedness and response capability is a non-trivial task,
especially if multiple sectors are necessary to include for the optimal response. Various
international tools do exist but each of them has their own weaknesses and biases
As output, core elements, catalogues, guidelines and models for intersectoral collaboration will
be developed. WP6 aims to that organizations and networks have access to and are capable of
using the integrated preparedness and response planning cycle, and to recognize how it fits
within their activities and how it supports achieving and maintaining IHR compliance.
WP6 actions interface with WP4 - WP10, and are meant to provide an integrated preparedness
planning base relying on all the necessary IHR core public health capacities.
Source: Health Emergency Preparedness Self-Assessment Tool
(ECDC TECHNICAL DOCUMENT HEPSA)
https://ecdc.europa.eu/sites/portal/files/documents/Technical-Doc-HEPSA-tool.pdf
The specific objective of the WP6 will be achieved through the following tasks, described in
detail in the WP description:
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
74 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Task 6.1: Identifying core elements of an integrated multisectoral preparedness and response
plan
Subtask 6.1.1: Review of international and/or national tools and planning instruments for
preparedness and response focused on multisectoral integration for the public health
laboratory services, clinical and chemical sectors
Workshop 6.1.1: A workshop will be organized with the aim to collect relevant tools,
instruments or core elements that were not identified in the review. Outcome should be
mutual understanding and agreement of terms, tools, instruments and core elements.
Subtask 6.1.2 Achieving consensus among countries on the core elements of a multisectoral
preparedness and response plan.
Task 6.2: Supporting partners and Member States in development of a draft for an
integrated multisectoral Preparedness and Response plan
Based on the selected core elements, a draft multisectoral plan will be developed. The backbone of
the plan will be the preparedness and response cycle.
Workshop 6.2.1: Based on inventories of minimum level of expertise necessary, the agreed set of
core capacities, a workshop will be organized to further clarify gaps, feasibility and barriers for
participating countries to develop a multisectoral preparedness and response plans, with particular
focus on low GNI countries
Task 6.3 Testing the multisectoral Preparedness and Response plan: “Disease X”scenario
“Disease X” scenario , i.e. a scenario for a novel disease that is unknown and requires
multisectoral collaboration, will be developed with the ingredients from tasks 6.1 and 6.2
and will be simulated to test the country specific multisectoral IHR preparedness and
response plans. Through consultations, the “Disease X” scenario will be adapted into
several subversions so that it applies to all included sectors.
Subtask 6.3.1. Development of the scenario
Subtask 6.3.2 Applying the disease X” scenario
Subtask 6.3.3 Survey among lower GNI countries three months after the simulation
exercise
Task 6.4: Learning from Disease X: testing the multi-sectorial preparedness and response
plan in e-learnings and tabletop exercises
The simulation of “Disease X” scenario provides the most robust assessment of the
strengths and weaknesses of the multisectoral collaboration within a country in relation to
the Preparedness and Response cycle. These strengths and limitations will be addressed in
flexible e-learnings and tabletop exercises.
Subtask 6.4.1. Inventory of best practices by using a selected amount of recent threats, to serve
as input into the all-hazards e-learning and tabletop protocols (with WP4 and WP5)
Task 6.5 Supporting partners and Member States in development of an integrated all hazards
multisectoral Preparedness and Response plan
Workshop 6.5.1: Lessons learned from the high-risk preparedness and response plans
tested will form the base for this workshop. The workshop will focus on the translation of
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
75 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
these plans into all hazards applicability.
Subtask 6.5.2 Development of integrated all hazards e-learning and tabletop exercise protocols
and testing for operability
Subtask 6.5.3 Survey among lower GNI countries to inventory outcomes and country specific
recommendations from the e-leanings and tabletop exercises.
Task 6.6: Translation into best practices and sustainability (with WP4 and WP5)
Subtask 6.6.1 Analysis of performance of best practices from “Disease X” scenario simulation
and available all hazards e-learning and table topexercise scenarios
Workshop 6.6.2 Multisectorial collaboration: The aim of this workshop is to collect
relevant best practices, fail and success factors that were not identified in the simulations,
workshops and reviews. Outcome should be mutual understanding and agreement of best
practices to be translated into best practices catalogues and guidelines applicable to all
MS and participating countries and relevant for the different sectors.
WP7 - Laboratory preparedness and responsiveness
This work package focuses on actions undertaken for laboratory preparedness and responsiveness
to detect outbreaks caused by highly pathogenic infectious agents in close interaction with the
Public Health sector and other networks. The specific objective is to ensure the application of
best practices and quality assured methods in detection and analyses of highly pathogenic
infectious agents in laboratories of Member States (MS) and JA participating countries. The WP
responds to the Core Capacities of IHR implementation given in the “Checklist and Indicators for
Monitoring Progress in the Development of IHR Core Capacities in States Parties”
(https://apps.who.int/iris/bitstream/handle/10665/84933/WHO_HSE_GCR_2013.2_eng.pdf).
It is a major goal of WP7 and the entire JA that laboratory services are part of every phase of alert
and response, including detection, investigation and response, with laboratory analysis of
samples. The WP is based on the outcomes of the previous JA EMERGE - “Efficient response to
highly dangerous and emerging pathogens at EU level”. The existing laboratory network will be
further consolidated and extended by new partners, which will be enabled to conduct high quality
microbiological analyses and to establish supportive collaborations.
One long-term goal will be to further develop recommendations and a plan for setting up a
sustainable cross-sectoral reference laboratory network for highly pathogenic infectious agents at
European level, which will be proposed to the European Commission and European Agencies
like ECDC for further discussion and implementation. The WP7 consortium together with WP5
and WP6 will further discuss and propose possible approaches for maintenance of the network
emphasizing and considering the outcomes of the “Study on cost-benefit analysis of reference
laboratories for human pathogens” (2016, European Commission B-1049 Brussels). There will be
a need to discuss and develop plans for maintenance together with the EC and ECDC.
External Quality Assurance Exercises (EQAE) are a major element of the quality management
system of microbiological diagnostic laboratories. It is mandatory for accreditation and also
needed for re-accreditation of laboratories. The EQAEs will enable partners to self-evaluate their
applied approaches and methods.
There are no other EQAEs for highly pathogenic agents provided in this complexity, than those to
be conducted here, based on the experience of the JA EMERGE. RKI/ZBS2, as provider of
EQAEs, is accredited as proficiency test provider according to DIN EN ISO 17043. This offers
the usage of official certificates and the possibility to assess the performance of the participating
laboratories if this will be agreed among the participants.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
76 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
In order to continue these EQAEs, which are important for the partner country laboratories, other
possibilities for sustainable, self-maintaining funding will be checked together with WP4 and the
EC which will be part of the general discussion on the maintenance of the laboratory network as
described above.
The existing European repository of highly pathogenic bacteria will be maintained to be used for
the EQAEs and for evaluation of new methods. For the viral part, there is a decentralized
biorepository for RG4 viruses partly located at different partners. Additionally, the ongoing
collaboration with the European Virus Archive (EVAg) consortium will be continued utilizing,
on request, the decentralized biorepository and supply with appropriate reference material.
The main focus of diagnostic capabilities will be on RG3 bacteria and RG4 viruses. In addition to
the previous JA EMERGE, the differential diagnoses of outbreak causing RG2 bacteria and
RG2/3 viruses will be included by “open view” diagnostic tools like metagenomics and mass
spectrometry/proteomics. In case of detection of such pathogens, including epidemic prone
multidrug-resistant bacteria or pandemic viruses, other appropriate networks will be engaged for
confirmation and outbreak management, if available. This will be achieved in close cooperation
with WP6. The close cooperation with ECDC and EVD-LabNet, established in the previous JA
EMERGE, will be maintained and the agreed MoU will also be effective for the upcoming JA.
As in EMERGE, in outbreak situations, ECDC will be consulted and engaged in the outbreak
management. Furthermore, ECDC is invited to become part of both Steering Committee and the
Advisory Board of SHARP in order to advise also on the laboratory network activities and their
implementation in IHR.
For highly pathogenic agents, there are open questions in regard to safe and cost-effective basic
diagnostic approaches. Point of Care Diagnostics (POCD) is increasingly used and might be a
diagnostic solution for both less equipped laboratories and high containment facilities. A broad
range of rapid hand held test kits (HHTK) is available for “field diagnostics” in outbreak
situations. Various partners have experiences in POCD and HHTK, also applied in international
outbreak response (WHO-GOARN) and in endemic countries. This knowledge will be shared
between partners at WP7 meetings and practical applications will be exercised and/or trained in
framework of EQAE or training courses (WP8).
New and innovative methodical approaches will be considered for high-quality detection and
characterisation of pathogens. This will include metagenomic approaches, spectroscopic,
multiplex molecular and immunological methods and, in case of RG3 bacteria, antimicrobial
susceptibility testing (AST) to ensure successful antimicrobial therapy even in genetically
modified multi-resistant bacteria. The aim of this task is to evaluate existing methods, including
new developments which are close to be implemented. This allows to assess and decide whether
these methods should be applied in routine diagnostics. The common approach substantially
saves resources for those countries not yet having implemented these modern methods.
Furthermore, all laboratories will have the opportunity to exchange and obtain knowledge by
mutual training coordinated by WP8.
During the JA EMERGE, the need for supported self-evaluation of biosafety and biosecurity
approaches in high containment laboratories was identified. This self-evaluation is a continuous
issue for established and approved laboratories, but, especially, for those laboratories which are
either newly constructed or which do not have to fulfil standardized requirements at national
level. A special issue is the decontamination of workplaces and instruments in POCD but also in
routine laboratories for which appropriate recommendations will be developed. In agreement with
the MS, self-evaluation will be supported on-site by advanced and specialized partners, and
recommendations for further capacity building will be developed.
In specific situations, diagnostics can be applied on inactivated instead of native samples.
Therefore, the JA will evaluate appropriate procedures and provide recommendations on
adequate procedures for inactivation. Furthermore, in order to harmonize biosafety and
biosecurity procedures for BSL4 laboratories involved in research projects, collaboration with
ERINHA AISBL Infrastructure will be developed.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
77 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Finally, common exercises for outbreak management, involving Public Health authorities and
laboratory networks, will ensure the interoperability between epidemiological and laboratory
investigation for a fast and efficient response.
In case of unknown or all hazards CBRN threats, the laboratory network on highly pathogenic
infectious agents will be part of the public health response as long as biological threats are not
excluded and will participate to the close interaction between relevant agencies, organizations,
and networks will be established. Further, the network can provide support in regard of biological
threats to EU MS without adequate CBRN diagnostic capabilities.
There are strong links with other WPs of this JA:
- Interaction with other relevant agencies, organizations, and networks for microbiological
investigation (e.g. ECDC, WHO, GOARN, EVD-LabNet, GHSAG, UNODA, ESCMID
relevant Study Groups) – WP4
- Interaction with Public Health authorities for laboratory support of IHR implementation
(to be identified in this JA, interaction with JA "Healthy Gateways on preparedness and
action at points of entry") – WP4, 5, 6, 10
- Continuous threat assessment, including identification of most relevant highly pathogenic
bacteria and viruses having the potential of causing outbreaks in European MS – WP4, 5,
6
- Support in clarification of the role and interaction of medical and veterinary
microbiological laboratories in outbreaks among humans and/or animals (interaction with
OIE) – WP6
- Interaction with other relevant agencies, organizations, and networks in case of chemical
threats – WP9
- Common exercises for outbreak management by Public Health authorities and laboratory
networks – WP6
- Laboratory training, including modern diagnostic approaches as well as laboratory
biosafety and biosecurity, and interactive training of Public Health/IHR activities and
laboratory support – WP8
- Interaction with high isolation facility team in Infectious Diseases Clinical Unit (a
separate task in this WP and in WP10) and interaction with laboratory supporting clinical
high isolation facilities – WP10
- Interaction on Core Capacities 3-8 given by IHR Checklist
Tasks in WP7:
Task 7.1 External Quality Assurance Exercise (EQAE)
The number and nature of samples will be agreed with the participants in advance of each EQAE.
Samples should allow culturing of bacteria, molecular and immunological detection,
metagenomic approaches and full genome analyses, application of POCD and HHTK. The aim of
the exercises will be the direct detection and characterization of the pathogens and indirect
confirmation of an infection by the detection of specific serum antibodies. The samples will
consist preferentially of RG3 bacteria and RG4 viruses (inactivated), but will also include
relevant RG1/2 bacteria and RG2/3 viruses for differential diagnoses. All sample sets will be
accompanied by a scenario to assess the medical relevance of the data
- The provision of data will be realized by several steps: (1) rapid preliminary data by
single laboratories, (2) confirmed data by single laboratories, (3) confirmed data agreed
at national level reflecting the idea of primary diagnostic and reference confirmatory
diagnostic. This allows the assessment of diagnostic capabilities at national and European
level for identification of needs for improvement.
- Data collection and statistical analyses will be conducted by a specialized subcontractor.
The evaluation of data and provision of certificates will be performed by the EQAE
provider.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
78 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Task 7.2 Diagnostic approaches
- Ensure that nationally relevant laboratory institutions have access to communication
channels to interact with the IHR national focal point (IHR-NFP); this will be exercised
by linkage with WP4, 5, 6.
- Improve and implement new diagnostic approaches, also by topical working groups
(Working Group 7.2.1 “NGS approaches for detection, tracking and tracing of highly
pathogenic infectious agents”; Working Group 7.2.2 “Basic diagnostics”, Working
Group 7.2.3 “Antimicrobial susceptibility testing (AST)”;).
- Sample sharing will mainly be coordinated by the WP7 leaders and will be realized by
the participants, following official regulations and recommendations, like transport
regulations for dangerous goods, Nagoya protocol and others. The Consortium
Agreement, including a Material Transfer Agreement (MTA), will regulate sample
sharing within and outside the network.
Working Group 7.2.1 “NGS approaches for detection, tracking and tracing of highly pathogenic
infectious agents”
Indeed, to better understand and characterize the pathogens responsible for cross-border
outbreaks, the improvement of the European laboratories’ capacity of detection and
investigation also goes by the metagenomics approach. In addition to other approaches
(i.e. Illumina Miseq, Ion Torrent), Nanopore Sequencing (MinION) is one of the
currently most promising approaches, experience should be created and exchanged
collectively among JA partners, including also training workshops and exchange
programmes. Under this task, standard reference material will be exchanged between the
participants and analyzed by different or similar technical platforms and approaches. The
aim is to identify best methodological approaches to draw recommendations for future
applications and for MS and partner countries not having yet implemented these
upcoming technologies. Partially, the reference material developed in Task 1 can be
applied for evaluation of technical platforms under this task.
Working Group 7.2.2 “Basic diagnostics”
In addition to technically high advanced approaches targeted by Working Group 7.2.1,
the implementation of basic diagnostics of highly pathogenic infectious agents would be
a minimal requirement in designated partner country laboratories, especially in those with
lower resources.
The identification of cost-effective diagnostic methods under low financial and
infrastructural resources including mobile laboratories, the availability of high-
containment laboratory facilities, and diagnostics in high-containment clinical facilities
(Point of Care Diagnostics, POCD) will be carried out. Access of partners from lower
GNI countries to high-containment facilities by cooperative agreements will be further
fostered. Relevant methodological approaches will be identified and assessed by the
working group. Recommendations of best practice will be developed. There is a strong
link with Task 7.1 wherefrom partially the reference material for EQAE can be used for
the evaluation of the identified methods.
Working Group 7.2.3 “Antimicrobial susceptibility testing (AST)”
The participants of the AST group will test their strain collections and isolates from
actual cases and outbreaks, ending up in a European wild type antibiotic sensitivity
distribution to determine epidemiological cut-off values (ECOFFs) and give
recommendations on breakpoints to European Committee on Antimicrobial
Susceptibility Testing (EUCAST). A major part of validation and testing will be done by
the Greek partner which had one of the largest strain collections on B. melitensis isolates.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
79 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
The wild type distribution will be measured for B. anthracis, Francisella tularensis ssp.
holarctica, and Brucella melitensis. Collaboration with EUCAST during EMERGE
enables the AST group to implement the methods into European guidelines.
Task 7.3 Laboratory biorisk management
The tool will prove guidance on how to use and combine the Checklist for Laboratory Biorisk
Management (developed in a previous JA), the soon to be ISO-standard Laboratory Biorisk
Management, CWA15793 (and the self-assessment tool “Secure biorisks” developed by
PHAS (www.sakrabiorisker.se/en) and the JEE-tool. Hence, the tool to be used here will
address biorisk management capacity from both a system perspective as well as from an
applied (operational) risk management perspective. The outputs from ERINHA should also
be considered to be included. PHAS and PHE will form an expert team that will provide
assistance to MS/partners, both for assisting in the self-evaluation process (and usage of the
tool) as well as aiding in the subsequent address of gaps/capacity building according to the
needs of the individual laboratory organization. Results from the evaluation will be treated
confidentially if required. Activities planned for the address of gaps are workshops and other
means of transfer of knowledge such as sharing of best practice, methods and SOPs.
Educational tours of various BSL3/4 facilities will be organised for less experienced
members to showcase established methods available within different partner institutes. As an
example, such tours could be organised to the PHE BSL3/4 facilities including the mock-up
Ebola / Lassa deployment training laboratory at PHE.
On-demand laboratory verifications of the prioritized inactivation methods will be performed.
A survey of current best practices and supporting evidence will be gathered and a priority list
will be generated. Participating partners will be asked to contribute to this Task by sharing
standard protocols or report from validated inactivation/decontamination experiments.
WP8 – Training and local exercises, exchange of working practices
This work package (WP8) will ensure synergies with other EU and global level activities related
to strengthening the IHR implementation involved in training and exchange of work practices, for
example HSC Action plan on preparedness and IHR implementation, WHO Action Plan to
Improve Public Health Preparedness and Response in the WHO European Region, Health
Programme actions and activities, such as the ongoing Healthy Gateways, JAV, JA AMR
Commission frameworks; and on a global level with WHO and global health security
frameworks and initiatives. All countries with GNI less than 90% of EU average are expected to
participate at training activities.
WP8 will focus on applied activities:
- A kick-off meeting between all countries involved in WP will initiate the activities of the
project
- Meeting after finalisation of cross-sectoral training needs assessment to agree on the
agenda and methodology of the advanced trainings.
Task 8.1. Assessment of the cross-sectoral training needs in JA partner countries related to
preparedness and IHR implementation
Subtask 8.1.1 An assessment of the cross-sectoral training needs of countries will be
conducted, building on the previously conducted ECDC and WHO training needs
assessments, followed by analysis of results.
Subtask 8.1.2 An inventory of existing IHR-related training activities and materials
available will be compiled. A survey amongst partners of possible training offers might
be helpful for further definition of training activities.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
80 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Task 8.2. Development of curricula for basic and advanced face-to-face and on-line training
The aim of the training will be to strengthen the IHR (2005) core capacities according to country
needs. WP8 will develop a training curriculum and generic module-based basic IHR-training
package which can be adapted for different priority regions based on country needs with special
emphasis to capacity building of low GNI countries. Training will comprise of both face-to-face
trainings and on-line problem-based learning delivered on a learning platform with field exercises
and simulations. Guidelines for face-to-face and on-line exercises will be developed.
Task 8.3. Training implementation
Within this task, workshops, trainings, exercises (national and international), laboratory trainings
and trainings for chemical hazards will be implemented according to findings of training needs
assessment.
Subtask 8.3.1. Implementation of basic and advanced trainings
- 2 basic IHR-workshops. (year 1)
- 4 advanced (years 2 and 3) three-day workshops (including international field exercises with
multi-sectoral involvement, lab and chemical trainings). Each of these four thematic
workshops will be provided at two different locations in order to enable all interested parties
the opportunity to participate.
Contents of advanced trainings, laboratory trainings for participants involved in WP7 and
trainings for chemical hazards will be performed according to the results of the training needs
assessment (Task 1).
Subtask 8.3.2 Secondments, study tours or internships to supranational organizations
or other countries. Participating countries might allocate training budget distributed to their
country under WP8 for secondment of staff to WHO, ECDC or high GNI-partner countries.
ECDC and WHO have been asked to host such individuals.
Subtask 8.3.3 National exercises implementation. In all low GNI countries will be
organized multi-sectorial exercises with participation of all institutions responsible for IHR
implementation.
Task 8.4. WP8 activities coordination and implementation
WP leader and co-leader will coordinate, organize and monitor the activities that are included in
this WP. It will be done by tele/skype conferences with WP8 participants and face-to-face
meetings
- 2 meetings, in Serbia and in Portugal.
WP9 – Chemical safety and chemical threats
Desktop-based evaluations of EU MSs chemical capacities could be undertaken using, for
example, the WHO Joint External Evaluation (JEE) tool as a guide, or semi-structured
questionnaires to assess existing business continuity plans, SOPs etc. Execution of WP9 tasks
and activities is described here:
Task 9.1 Gap analysis
In collaboration with WP5, a fact-finding/gap analysis will be conducted to determine which
areas require further action, with a view to strengthen chemical core capacity implementation
under IHR. Desktop-based evaluations of EU MSs chemical capacities could be undertaken
using, for example, the WHO Joint External Evaluation (JEE) tool as a guide, or semi-structured
questionnaires to assess existing business continuity plans, SOPs etc. This would highlight the
chemical capacities that require strengthening under IHR. Analyse possible approaches to foster
information sharing and strengthen best practice among MSs will be explored, for example
partnering and mentoring.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
81 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Task 9.2 Strengthening existing mechanisms
In collaboration with WP4 and WP5, existing mechanisms for chemical incident preparedness,
risk communication and operational response will be identified and where necessary
strengthened, to promote their uptake by all EU countries. Relevant chemical networks funded
under the Heath Programme will also be updated. This could include awareness raising,
guidance, support, training and exercising of tools and mechanisms including the RASCHEM
platform and other resources developed by previous EC-funded projects (e.g. ASHT I-III,
ECHEMNET, CELESTE). WP9 will also work with the EC Scientific Committee on Health,
Environment and Emerging Risks (SCHEER) Rapid Risk Assessment Working Group (RRA
WG) for chemical threats, to strengthen their activities and promote their work and outputs to
other organisations and MSs. It could also include the provision of advice in emergencies from
relevant authorities (e.g. use of the Rapid Risk Assessment for cross-border chemical health
threats). It is also expected that this WP will work closely with the Healthy Gateways Joint
Action. In addition, WP9 will collaborate with WP6 to include chemical laboratory capacity in
their preparedness and response planning activities. The desirability of a chemical laboratory
response network will also be explored.
Task 9.3 Surveillance of chemical incidents
Under IHR, tested surveillance systems are required for the detection, verification and risk
assessment of chemical events of (potential) international health concern as part of a multi-hazard
surveillance strategy. As a first step, the benefits of chemical event surveillance, in relation to
public health preparedness will be reviewed, and used this as a baseline to inform subsequent
activities. We will also look at methods to strengthen the link between relevant national
authorities e.g. Poison Centres (PCs) and chemical surveillance (potentially using the
RASCHEM platform), as PCs are an extremely useful resource in the medical management of
chemical exposures and surveillance and reporting of chemical incidents. We would look to
further develop chemical surveillance activities in MSs, for example, taking account of Event-
Based Surveillance (EBS) methodology and environmental public health tracking activities. We
will work with WP5 to survey the capacity for surveillance, examine methods for the collection
of existing chemical exposure data and developing proposals for best practice of surveillance
capability, SOPs and facilities, relating to chemical incidents. Based on this capacity, existing
material from e.g. WHO, EC, ECDC and the International Network on Public Health and
Environment Tracking (INPHET), would be utilised to develop resources on conducting
chemical surveillance. The above activities would support MSs awareness of and preparedness
to, emerging chemical health threats. This work would be done in close collaboration between
WP5 and WP6. The use of existing data on chemical exposures and environmental hazards is
under-utilised for the purposes of IHR. In addition, comparing surveillance approaches with other
MSs could increase consistency between European countries.
Task 9.4 Training program and materials
In association with other WPs as required, materials will be devised and developed to identify
and assess best practices, gaps, bottlenecks and lessons learned from previous events. These will
include workshop material and chemical incident exercise scenarios, to be held on areas such as:
- Preparedness of EU MSs to cross-border chemical health threats (according to IHR and Dec
1082/2013) including e.g. continuity planning, intersectoral collaboration
- Surveillance, alerting and notifying of cross-border chemical health threats
- The rapid risk assessment of chemical health threats
- Public health response and safety when dealing with/responding to potential chemical health
threats
- Improving access to information on roles and responsibilities of the Commission and other
EU organisations
The training program will be aimed at a broad cross-section of participants from all EU Member
States and countries in the European Economic Area (EEA). Awareness raising and networking
opportunities provided by the training program are aimed to encourage the exchange of
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
82 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
information and foster collaboration between EU countries. Approaches to encourage sharing of
best practice on preparedness and response to cross-border chemical health threats will be
explored, which could develop into sustainable working relationships beyond the life of the Joint
Action.
Material will be prepared for two workshops, to be integrated with existing WP5 and WP8
activities. For example, one will be used to invite MS representatives and test preparedness to
cross-border chemical health threats, as well as seek feedback on the prepared materials. The
second workshop will be held toward the end of the project and will be used to refine the
materials, to ascertain the level of preparedness and to see if the training materials, guidance and
surveillance information have helped MSs to improve their IHR capacity implementation and
increase their level of preparedness against cross-border chemical health threats. This would
involve working closely with WP5 in addition to WP8. The developed materials may also be
used in other workshops/training activities in the Joint Action to cover chemical threats.
Task 9.5 Exercises
In collaboration with WP5 and WP8, WP9 will contribute exercise material to existing WP
activities. This will enable WP9 to test current preparedness and response arrangements to a
serious cross border threat to health involving chemical and environmental hazards within the
scope of IHR and EU Decision 1082/2013/EU. This material would also work towards improving
the sharing of experiences and lessons learned from chemical events and managing risks of
national and international concern. This approach could foster increased collaboration,
intersectoral communication and interoperability between MSs.
Task 9.6 Standard Operating Procedures (SOPs)
To ensure a baseline competency among EU MSs on their approach to cross-border chemical
health threats and promote sustainability of the outputs of this Joint Action, SOPs will be
produced, based on findings from the workshops and the best practices, gaps and bottlenecks
identified previously.
Specific topics for the development of SOPs may include:
- Surveillance/monitoring of potential cross-border chemical health threats, e.g. the current
methods available and the involvement of Poison Centres
- Methodologies for the response to cross-border chemical health threats (including operational
response and risk communication)
- Further development of the EU-level advice on the public health response and medical
management of chemical incidents.
This task promotes the uptake of existing procedures, mechanisms and the harmonisation
between EU MSs/EAA countries, including but not limited to:
- Detection, alerting and notification of cross-border chemical health threats
- Risk assessment of cross-border chemical health threats
- Safely responding to a cross-border chemical health threat
- Inter-country collaboration/communication during the event of a cross-border chemical
health threat
- Incident trigger levels (for response or cross-border exercises).
WP10 - Case management and Infection Prevention and Control Preparedness
The focus of this WP10 is on health care professionals. Clinicians play a key role in public health
interventions to reduce the risk of transmission and to control the spread of the diseases. This
includes a diagnosis of suspect cases; establishing the best strategy to perform differential
diagnosis of potential high-consequence infectious diseases; alerting public health services with
information to identify a possible introduction/importation in the country; and performing
immediately proper isolation and IPC procedures.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
83 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
One of the IHR key core capacity indicators is that the Infection Prevention and Control (IPC)
measures are established at national, regional and community level, and in hospitals. Over the
last 20 years, a number of clinical institutions and projects, partly funded by SANTE (such as
EUNID and EuroNIHD on ID clinical networks; ETIDE for multidisciplinary training;
EuronetP4, ENP4Lab, QUANDHIP and EMERGE) on advanced diagnostic for support clinical
activities, has been effectively tested as they have received patients with high-consequence
infectious diseases for treatment in their clinical facilities.
In the hospital setting the primary objective is to reduce the nosocomial exposure to the suspected
infectious agent (often still unknown in most cases of the early phase of the outbreak) to health
care workers, and to other patients. A better coordination of public health approaches will lead to
standardization of interventions and protocols, such as the prompt isolation within structures with
adequate technical and logistic features, to the development of a common core-curriculum, and
substantial improvement in the application of IHR.
Task 10.1 Mapping of existing facilities
Existing Infection Prevention and Control (IPC) facilities will be mapped. Interactive maps will
link the geography of communities with availability and accessibility of health services, or
disease prevention and control services. The map aims to evaluate the presence and availability
of identified clinical facilities for isolation of suspected high-consequence infectious diseases
(HCID). These facilities will be evaluated for presence of specialized intensive clinical care
facilities (including e.g. continuous renal replacement therapy), biocontainment units, high
biocontainment level laboratories, and patient referral systems.
The map will provide a comprehensive picture of the expertise for management of HCID. This
interactive map will be used by Member States to locate, contact and consult different expertise
across Europe. Moreover, the task aims to evolve a system whereby such information is updated
on a regular basis by the countries.
Task 10.2 Assessment of country hospital preparedness and capacity for HCID, including high
isolation clinical centers
Based on the Map (Mapping of existing facilities, Task 1), an electronic follow-up by self-
assessment questionnaire will be developed and filled by each MS and JA partners, using also the
previous tool developed by EUNID and EuroNHID. The assessment will explore also:
availability of a specific chapter of National Preparedness Plan on the case management;
physical, procedural and clinical capabilities (personal protective equipment, occupational issues
such as vaccination, infection control, and training). The follow-up assessment will serve also to
measure the level of implementation of the recommendations previously released by EUNID and
EURONHID and to identify technical and organizational bottlenecks. Different tools will be used
to assess the facilities; these will include the use of classical self-administered questionnaire, in
combination with table top exercise and mock exercise.
After the assessment, a new set of recommendations focused on HCID, requirements for
infrastructure and personnel will be released. The recommendations will reflect a consensus
developed in the course of international meetings attended by experts on clinical management
infectious diseases, epidemiology, as well as by representatives of governmental public health
and civil protection organizations.
Task 10.3 Feasibility study for an expert clinical support service for HCID
This task aims to define the characteristics of an expert clinical consultation and support service.
The service should function as support for clinical management of difficult cases of possible
epidemic-prone diseases. A protocol for the utilization of the service will be also developed and
an inventory of existing electronic platforms for teleconsultation will be explored. This will result
in a set of technical recommendations which would be part of the evaluation in WP5 where
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
84 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
identification of key challenges in national and international collaboration between governments
and national authorities will be conducted in a dedicated workshop/exercise. During this exercise,
legal frameworks for patient referral, for medical consultation between MS and for clinical
information exchange will be explored.
Task 10.4 Application of a “syndrome based” approach for prompt and early clinical
management of HCID
Good clinical management of infectious diseases and the prompt application Infection Prevention
and Control (IPC) are both vital elements in implementing IHR. First, developing and
maintaining a core capacity for excellence in the provision of clinical care will improve outcomes
for individual patients. Experience has also shown that frontline clinicians are often the first to
recognize and alert their colleagues to the presence of a novel threat.
A timely clinical or epidemiological suspicion and an early detection of HCID is difficult. The
suspicion can be raised by the epidemiological awareness of the risk assessment and by the
clinical knowledge of the specific disease. In order to guide the clinical and biorisk management
of HCID cases, a triage strategy based on syndromic approach is proposed not for surveillance
purpose, i.e. as in SIDARTHA EU project, (SIDARTHA EU Project:
https://webgate.ec.europa.eu/chafea_pdb/health/projects/2007208/summary), but for prompt and
early clinical and biorisk management.
The implementation of this task will be carried out through different phases:
- identification of the list of HCID ,
- case definition of each HCID with acceptable ratio between sensitivity and specificity;
- systematic identification of major disease drivers of, and threats associated with the
occurrence of the diseases;
- piloting of the syndrome based approach in single institutions of few member countries by
the implementation of a proof of concept network based on referral centers;
- identification of protocols to determine the clinical priorities for the HCID management,
based on already validated severity score.
Each country will select the clinics and areas for implementing this approach. Protocols and
procedures will be adapted based on the workshops conducted. Under Task 10.4, two workshops
will be organized:
- Workshop 10.4.1 – This workshop will involve all SHARP partners and will be focused
on the identification of the list of HCID, case definition of each HCID; systematic
identification of major disease drivers and threats, and; evaluation of validated severity
scores. (WS arranged by INMI in Italy).
- Workshop 10.4.2 – This workshop will involve the dissemination and discussion of the
obtained results. (WS arranged by SSI in Denmark)
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
85 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.6. Expected outcomes
The project aims to contribute to the following outcomes (long term EU-wide overall objectives):
- To support the implementation of Decision 1082/2013/EU on serious cross-border threats
to health
- To strengthen the resilience and response capacities of health systems, and to ensure
coherence and interoperability for preparedness and response planning to health threats at
national, EU and regional level
Through the SHARP Join Action the expectation is that the participating EU member states and
partner countries, representing almost 95% of the EU population, have gained substantial
improvements in their preparedness and capability to respond to cross-border health threats,
effectively ensuring Decision 1082/2013/EU and IHR (2005) implementation. Through this
project the ability of the entire EU is anticipated to have been raised to such a level that the risk
posed by any cross-border health threat can be mitigated and that the possibility of an EU-wide or
multi-member state major crisis been substantially diminished, providing a major EU added
value through concerted action.
The main innovation of the Joint Action is that it aims to address preparedness and responses to
health threats is based on a system-wide approach instead of addressing just one part of the
essential public health core capacities needed to ensure an all-hazards response. The Joint Action
will first help partners to identify specific gaps in their systems (utilizing and deepening
previously collected information), then provide support to build capacity to fill the gaps and
provide concrete tools to ensure that existing good practices can be replicated and learned from.
The Joint Action will help Member States and partners to enhance collaboration to share
specialized services which may not be available in all individual countries (such as very
specialized diagnostic laboratory services and possibly clinical services).
Legal barriers or lack of procedures for the provision of cross border health service assistance
and coordination with the civil protection mechanisms will be mapped and solutions proposed,
both on a national and European level. Innovative preparedness planning models will be
developed and tested in exersizes and simulations. A specific training programme for tailored
IHR and cross-border health threat reduction and control will be executed based on the exact
need of the participants and countries.
Finally, to ensure that the work performed through the planned three years of the project will not
stop after the project ends, special attention will be given to building sustainability of the
activities on a government and EU level right from the initiation of the project. Care will be taken
to ensure interoperability and continuity with the activities of EU institutions such as the Health
Security committee, the ECDC, the WHO European regional office and the national
governments.
To achieve the expected outcomes, work is divided into manageable work packages. The specific
expected outcomes per work package are outlined in detail in the following section:
WP4 – Integration in National Policies and Sustainability
Expected outcomes: Best practices on IHR and preparedness incorporated in national policies,
including improved cooperation mechanism between EU Member States and JA partner
countries.
1) Sustainability plan is developed to foster sustainability of identified best evidence-based
best practices outcomes and recommendations engaged by the JA WPs;
2) Improved / enhanced information sharing and communication within the EU and with
neighboring countries;
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
86 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
3) Strengthened coordination and advocacy on Preparedness and IHR implementation
across the existing global and European initiatives and strengthened existing coordination
mechanisms across EU MS and strengthen already existing coordination mechanisms
(ECDC, HSC, WHO EURO, WHO Lyon office, etc.);
4) Both at EU and international level, evidence-based best outcomes and recommendations
to inform and help sustain coordinated EU positions during negotiations on IHR-related
legal texts (resolutions, decisions, implementing acts).
WP5 – IHR core capacity strengthening and assessment
Expected outcomes: Improved core capacity in EU Member States and participating JA partner
countries as required by IHR and Decision 1082/2013/EU/.
5) Participating lower GNI countries who have not conducted a Joint External Evaluation
(JEE) supported to get prepared for an external assessment of their IHR Core Capacity,
i.e. JEE or other agreed standardised external evaluation process; countries helped in the
assessment of capacity for future development and sustainability of necessary core
capacity as required by IHR and Decision 1082/2013/EU;
5) Participating lower GNI that have conducted a JEE; assisted by addressing problem areas
identified in the post JEE country reports;
6) Challenges in national and international collaboration between governments and national
authorities identified, and measures elaborated for the operationalization of obligations
related to response from health systems, cross-sectoral efforts and effective assistance
between Member States when needed;
7) The usefulness of using information from national and international exercises and after
action reviews in assessing the state of public health preparedness in the EU evaluated.
WP6 – Preparedness and response planning
Expected outcomes: EU Member States and JA partner countries supported in developing
operational integrated Preparedness and Response plans and mechanisms for serious cross-border
health threats with an integrated all hazards approach.
1) Review of and preparation of an integrated multisectoral preparedness and response plan
2) Scenario for “Disease X” developed, simulated and evaluated;
3) All hazard e-learnings and tabletop exercise protocols, using different methods for
multisectoral collaboration developed, tested and evaluated
4) Best practices guidelines based on analysis of performances from “Disease X” scenario
simulation and available all hazards e-learnings and tabletop exercises to provide common
and tailor-made standards for all hazard integrated preparedness and response planning in
all participating countries.
WP7 – Laboratory preparedness and responsiveness
Expected outcomes: Strengthened laboratory preparedness and responsiveness to detect highly
pathogenic infectious agents of Risk Group 3 (RG3) bacteria / Risk Group 4 (RG4) viruses with
quality assured methods in laboratories of MS and SHARP JA partner countries, and evaluating
new diagnostic approaches and improving biosafety procedures.
1) Performance of annual External Quality Assurance Exercises (EQAE) and consolidation
or improvement of a high quality in diagnostic of highly pathogenic bacteria and viruses
documented by reports and certificates provided to the participants;
2) Assessment of modern and new diagnostic approaches and provision of evidence based
recommendations for implementation of best practice diagnostics;
3) Development, provision and application of tools for self-evaluation of biorisk
management in high containment microbiological diagnostic laboratories and provision
of evidence based SOP for proper inactivation of highly pathogenic infectious agents.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
87 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
The major interests and requirements of laboratories participating in EQAEs for assessment of
their diagnostic quality are fulfilled. Individual certificates and overall reports on the diagnostic
performance of participating laboratories allow the assessment of laboratory preparedness at
European level. Conclusions on improvement are part of the reports. A sustainability plan for the
European repository of highly pathogenic bacteria is implemented. The biorepository for RG4
viruses is consolidated and synergies with the European Virus Archive are developed. A forum
for discussion has been established and evidence-based recommendations are developed for basic
and advanced diagnostic approaches considering economic requirements. This is documented by
reports and scientific publications. The AST for highly pathogenic bacteria is further evaluated
and implemented as well as documented by Standard Operational Procedures (SOP) and reports
in collaboration with EUCAST. Collaboration between laboratories is established to ensure a
sustainable mutual support and appropriate laboratory response to highly pathogenic infectious
agents at national and European levels which is documented by reports and publications. SOPs
for diagnostic methods are exchanged. An applicable tool for self-evaluation of the biorisk
management in BSL3 and BSL4 laboratories is developed and applied in participating
laboratories. Reports will illustrate the consolidation and improvement of the biorisk
management. Agreed and harmonized SOPs are developed for proper and validated inactivation
of RG3 bacteria and RG4 viruses allowing the diagnostic under BSL2, also supporting clinical
laboratories in charge of patient treatments in high containment clinical units. These procedures
consider the different capacities of high containment laboratories in MS and simplify sample
sharing. The laboratory network has participated as one core element of IHR in exercises planned
by WP 5, 6, and 10 which is documented in reports. The role of reference laboratories as core
element of the IHR and the interaction with clinical and epidemiological sectors is consolidated.
WP8 – Training and local exercises, exchange of working practices
Expected outcomes: Strengthened capacity of professionals in IHR implementation and
preparedness for serious cross-border health threats in the MS and JA partner countries.
1) The level of IHR capacities to prevent, prepare, detect and respond to cross-border
threats to health improved
2) Practices related to IHR capacity building exchanged with the special emphasis to
strengthening the capacities of countries with GNI less than 90% of EU average ;
3) Cross-sectoral capacities for detection, preparedness and response to emerging public
health threats built and scaled-up.
WP 8 of the Joint Action SHARP aims to improve the capacity of professionals in regards to IHR
implementation in the EU and neighboring countries. First, we hope to better understand the
actual gaps in the capacity of human resources, including regional differences. For this, the
available results of existing assessments will be analyzed and efforts of single countries as well
as supranational organizations such as WHO, EC DG SANTE or ECDC will be collected and
mapped. Based on this inventory, basic and advances IHR trainings well be developed for
different target audiences, including face-to face and online courses. WP 8 will ensure that all
trainings conducted during SHARP will be able to use common training material on generic IHR
aspects. This training material will be complementary to but in-line with WHO training material.
After the Joint Action, we hope that the capacities in human resources in regards to IHR will be
improved, at least in some countries/ regions. While the JA cannot overcome obstacles in
regional/ national workforce employment, the JA SHARP can assist countries in IHR specific
trainings for existing staff.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
88 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
WP9 – Chemical safety and chemical threats
Expected outcomes: Improved implementation of IHR chemical core capacities, strengthened
preparedness and response to cross-border chemical health threats within MSs and across the EU.
1) Gaps or areas requiring further action in the implementation of IHR core capacities, with
respect to chemicals, at the EU- and MS-level determined;
2) The use of existing tools and mechanisms to respond to cross-border chemical health
threats promoted, providing guidance where required. Where gaps exist, MSs supported
in the development of guidance, SOPs, plans and tools to respond to cross-border
chemical health threats;
3) Resources to promote and to support the implementation of core capacity requirements
for surveillance for chemical and environmental hazards developed;
4) Materials for workshops developed, and for the purpose of training and exercising to
address and promote interoperability of preparedness and response planning and sharing
best practice.
The expected outcomes from WP9 include: the production of a training and exercise materials,
which will be used in workshops and training during the JA, also suitable for future use beyond
the life of the project; the consolidation, refinement and promotion of existing mechanisms for
cross-border chemical health threat preparedness; Guidance on conducting chemical surveillance,
including relevant protocols and a compilation of relevant available resources, detailed in a
surveillance strategy report. The above outcomes will work towards the strengthening of
preparedness and IHR chemical core capacities of European countries.
Outcomes from WP9 include the uptake and/or improvement of chemical surveillance practice in
JA participating countries, along with closer linkages between Poison Centres and chemical
surveillance. The combination of awareness raising by the guidance document, improved
surveillance capacity and networking opportunities provided by the training program, will
encourage the exchange of information and foster collaboration between EU countries against
cross-border chemical health threats, which could develop into sustainable working relationships
beyond the life of this JA.
WP10 – Case management and Infection Prevention and Control Preparedness
Expected outcomes: Improved clinical and biorisk management, hospital preparedness and
response to high-consequence infectious diseases (HCID)
1) The level of hospital preparedness and response to high-consequence infectious diseases
improved and clinical approach standardised in order to facilitate collaboration and joint
management of these cross-border health threats.
2) New tools for early detection and timely clinical management of emerging disease threats
evaluated, such as the establishment of at-distance expert support systems in case of
patients admitted in place with no adequate capabilities.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
89 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.7. Timetable / Gantt Chart
WP name and number, Activities MONTH
JOINT MEETINGS FOR SEVERAL WPs 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
WP1 Kick-off meeting
WP1 Seven Steering Committee
meetings
WP1 Four Advisory Board meetings
WP1 Two Partnership Forums
(M12, M24)
WP1 Thematic meeting on
preparedness and IHR during
Finnish Presidency of EU
WP1 Closing conference
WP2 Dissemination planning with
WP leaders
WP3 Evaluation planning with WP
leaders
WP4 Workshop 1. Guidance tool on
sustainability
WP4 Workshop 2. Review selected
actions
WP4 Workshop 3. Present draft
Sustainability plan
WP9 Joint meeting with
partners and other WPs
WP1 Coordination (THL)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
1. Kick-off meeting MS1
2. Establishment of Steering
Committee and Advisory Board MS2
3. Seven Steering Committee
meetings
4. Consortium agreement MS3
3. Four Advisory Board meetings
5. Two Partnership Forums (M12,
M24) MS4
6. Interim report D.1.1
7. Thematic meeting on
preparedness and IHR during
Finnish Presidency of EU
8. Closing conference
MS5
9. Final report D1.2
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
90 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
WP2 Dissemination
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1 19 20 21 22 23 24 25 26 27 28 29 30 31 3 33 34 35 36
8 2
1. Leaflet D2.1
2. Stakeholder analysis MS6
3. Website D2.2
MS7
4. Communications plan
5. Channel strategy MS8
6. Layman report D2.3
7. Blueprint of dissemination for
future Joint Actions D2.4
8. Communication and
dissemination report D2.5
WP 3 Evaluation
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1 19 20 21 22 23 24 25 26 27 28 29 30 31 3 33 34 35 36
8 2
1. Meeting with WP leads MS9
MS10
2. Evaluation plan D3.1
D3.2 D3.2
3. Interim internal evaluations
D3.3
4. Final internal evaluation
5. Presentation of internal
MS12 MS12
evaluation results
MS11
5. External evaluation mobilised
D3.4
6. First external evaluation report
D3.5
7. 2nd External evaluation report
WP 4 Sustainability and
policy development 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1 19 20 21 22 23 24 25 26 27 28 29 30 31 3 33 34 35 36
8 2
Workshop 1. Guidance tool on MS13
sustainability D4.1
Workshop 2. Review selected
actions MS14
Workshop 3. Present draft
Sustainable plan MS15
Sustainability report D4.2
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
91 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
WP 5 IHR core capacity
strengthening and assessment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Workshops 1 and 2 organised MS16
Workshops 3,4 and 7 organised MS18
Workshops 5 and 6 organised MS19
D5.1 Work plan with selected
challenges/ gaps D5.1
MS17 Table-top exercise
MS17
D5.2 Report on knowledge and
practices and added value of external
evaluation processes and facilitating
strengthening of selected core
capacities in the EU and neighboring
countries
D5.2
D5.3 Report on international
collaboration during crisis D5.3
D5.4 Report on the use of exercises
and AAR as part of monitoring for IHR
(2005) core capacities and
implementation of decision
1082/2013 D5.4
WP 6 Preparedness and response
planning 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Review of integrated evidence-based
tools and indicators for preparedness
and response cycle D6.1
Literature reviews MS20
Disease X scenario simulation MS21 D6.2
All hazards scenario-based e-learning
tool MS22
WP6 workshops MS23
Tabletop exercises MS24
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
92 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
WP 7 Laboratory
preparedness 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Assurance of high quality of
diagnostics for highly infectious
pathogens applied in
MS25 MS25 D7.1
microbiological laboratories of MS MS25
by conducting annual EQAEs.
Assessment of and
recommendation for application D7.2
MS26 MS26
of modern molecular diagnostic
methods.
Development of
recommendations for risk
management & reduction in
diagnostics of highly pathogenic
MS27 MS27 D7.3
agents.
WP 8 Training and local
exercises 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Activity 1. Assessment of the cross-
sectoral training needs in JA
partner countries related to
preparedness and IHR MS28 D8.1
implementation
Activity 2. Development of
curricula for basic and advanced MS29 MS30
face-to-face and on-line learning
Activity 3. Training implementation
Activity 4. WP8 activities
coordination and implementation MS31 MS31 D8.2
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
93 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
WP9 Chemical safety
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
MS32: Joint meeting with all
partners and other relevant WPs MS32
MS33: Stakeholder consultation and
gap analysis MS33
D9.1: Fact-finding report
D9.1
MS34: Production of training and
exercise materials MS34
MS35: Surveillance strategy report
(M24) MS35
D9.2. Chemical laboratory
response network - scoping report D9.2
MS36: Two workshops conducted MS36 MS36
MS37: Consolidate, refine and
promote existing mechanisms for
cross-border chemical health
threat preparedness MS37
MS38: Training and exercises
outcome report MS38
D9.3: Final report
D9.3
WP 10 Case management 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
1.Assessment of existing facilities
D10.1
2. Data collection on hospital MS39
preparedness
MS40
3. Protocol and report for feasibility
study MS41 D10.2
4. Application of a “syndrome
based” approach for clinical
management of imported
emerging diseases threats MS42 D10.3
5. Workshops
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
94 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.8. Project management structure
The exact project management structure is partly defined in the contract to be signed. Further details will be
included in the Consortium Agreement, which will lay down specific responsibilities in detail regarding the
coordinator and partners, including ways of resolving conflicts and the possibility of default or breach of contract
duties of one of the consortium partners. In short the management structure will be the following:
The projects decision making body is the Steering Committee (SC) which consists of the Work Package leaders that
have been selected by the partners; the Coordinator, who will chair and lead the meetings. WP co-leads can attend
SC meetings. SC meetings may be conducted face-to-face or by telecommunication means. The decisions will be
taken by consensus, or exceptionally by vote if consensus cannot be reached. Each WP has one vote, which is given
by the WP lead. WP co-leads do not have a separate vote but should strive to agree with the WP lead on the voting.
In the case of a draw vote, the Coordinators vote will be decisive. Co-coordinators do not have a vote (except as a
WP lead, if applicable). The Commission representatives may participate as observers (one representing DG
SANTE and one representing CHAFEA).
Work package leaders have a similar role to the coordinator within their own work package.
The SC will be supported by an Advisory Board (AB) of wich the structure is described in Work package 1. The AB
shall advice the project SC on matters in which they have expertise but it will have no decision making power. The
AB shall elect a chair and the coordinator will act as the secretariat of the AB. SC members may attend AB
meetings.
The partnership forum (PF) is the main platform where all partners meet and discuss the progress and results of the
project. It shall consist of one representative from each partner and shall meet at least 4 times (kick-off meeting, 2
annual meetings and a closing conference) during the project period. The PF will be Chaired by the coordinator but
can elect a vice chair. The partnership forum shall be consulted for SC decisions affecting more than 20% of JA
total budget either at PF meetings or by silent procedure. Associated partners (competent bodies) have one vote per
country in PF meetings, whereas affiliated partners can attend the PF and have speaking, but not voting rights.
Collaborating partners can attend the partnership forum on their own cost and have speaking, but not voting rights.
The coordinator has the right and responsibility to request reports on actions and finances to work package leaders
(or any partner if deemed necessary) according to a schedule laid down in the Consortium Agreement.
A minimum of biannual financial reporting will be required. Work package leaders have similar rights of requesting
reports from the partners participating in their Work Package.
Bi-monthly teleconferences on progress will be held among WP leaders and the coordinator. Other partners can also
be invited.
Funding provided by the Commission will be distributed to partners through the coordinator in accordance with the
rules and timelines that the Commission regulations require. The Coordinator cannot distribute funds in advance of
receipt from the Commission.
2.8.1. Quality of the partnership
The partnership consists of almost exclusively highly experienced government and public institutions that have been
designated by national governments to participate in the Joint Action. It covers the priority regions almost
completely.
The partnership includes public health institutes, infectious disease institutes, universities, ministries of health and
social affairs, ministry of defence, ministry on internal affairs, laboratories, hospitals, food safety authorities,
veterinary institute and institute on nuclear and chemical protection. The majority of partners come from human
health sector, but during project execution special attention will be paid to involving relevant other sectors in
workshops and other activities of the JA.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
95 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.8.2. Capacity of the staff
1 - THL – The National Institute for Health and Welfare, Finland
The National Institute for Health and Welfare (THL) is a governmental research institute and a public health agency
under the Finnish Ministry of Social Affairs and Health. The main mission of THL is to promote health and welfare
in Finland and to provide reliable, evidence based information for the government, decision-makers and other actors
in the social welfare and health sectors.
The Department of Health Security at THL is in charge of preventing, combating and monitoring infection and
environmental threats on a national level. The Department maintains preparedness to diagnose and control
infectious diseases, and it directs, supports and develops national monitoring and surveillance systems for infectious
diseases and the national vaccination programme. THL is part of international networks (ECDC, WHO), and it
serves as national IHR and EWRS focal point. THL has been key partner in development of WHO Joint External
Evaluation (JEE) process for IHR assessment and THL has participated and led several JEE missions globally. THL
has participated in several Joint Actions and has experience in successful JA coordination.
Coordinator: Professor Mika Salminen, Ph.D. Professor Salminen is Director of the Department of Health Security
at the National Institute for Health and Welfare (THL) in Finland. He has over 25 years of experience in biomedical
and public health research and implementation of public health programmes. The Department he leads has a wide
responsibility for national level infectious disease surveillance, preparedness, prevention and control and
environmental health protection. It has the National Focal Point functions for the IHR (2005) and the European
1082/EU/2013 decision and runs the national vaccination programme, surveillance system for infectious diseases as
well as reference laboratories and has a staff of 160 people.
Professor Salminen has led multiple EU-funded cooperation and research projects, taught and lectured in
international courses and conferences and has served as a consultant to the European Commission, UNAIDS,
UNODC and WHO. He has supported the Ministry of Social Affairs and Health and Ministry of Foreign Affairs for
the WHO WHA and Executive Board as well as UNGA high level meetings.
During recent years, professor Salminen has been intimately evolved in Global efforts to improve implementation of
the International Health Regulations, IHR (2005). As part of the Finnish team participating in the Global Health
Security Agenda programme (which the Ministry of Social Affairs and Health chaired in 2015) he was personally
involved in developing, together with the WHO and multiple other international partners, a new process and tool
(Joint External Evaluation – JEE) for peer-to-peer evaluation of countries multisectoral capacities as required by the
IHR treaty. This has since been used to assess 80+ countries in one-week missions of which Professor Salminen has
lead eight international expert team missions (Portugal, Pakistan, Jordan, Sudan, Afghanistan, Oman, Korea,
Switzerland and Australia). He also was in charge of the national team organizing the JEE for Finland in 2017.
Professor Salminen has managerial experience since the late 1990s. He has held positions in the US, in Sweden (for
the European Union) and in Finland. Most recently 2009 he took up the position as head of the Section for the
Evidence Base for Prevention and Control at the European Center for Disease Prevention and Control (ECDC)
where he later also managed the Sections for HIV, STIs and Hepatitis and the Section for Health Impact. He also
served a period as Crisis Manager during the 2009-2010 Influenza Pandemic when the agency operated at its highest
level of crisis mode for over one year. In January 2012 Professor Salminen re-joined THL and since June 2013 he
has been Director of the Department of Health Security. Professor Salminen is an Adjunct Professor of Virology at
the University of Helsinki.
Vice-Coordinator: Dr Taneli Puumalainen, Ph.D., Chief Physician, Head of Infectious Diseases Control and
Vaccinations Unit, Department of Health Security, THL. Dr Puumalainen is paediatric infectious diseases
consultant with specialist degrees on tropical medicine and hygiene as well as international health. His research
activities have focused on vaccines, infectious diseases, child health and migrant health issues. Dr Puumalainen has
over 20 years’ experience in international health and management from both governmental and private sectors.
He is currently a member of several multi-sectoral committees and expert groups on infectious diseases control,
vaccines and health security. He has been the Alternate Member for Finland in the Management Board of ECDC
since 2012. Dr Puumalainen has led 4 WHO-IHR JEE missions and also covered several JEE/GHSA technical
areas including immunization programs, infectious diseases surveillance, anti-microbial resistance, IHR
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
96 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
coordination and reporting, biosafety/-security and national laboratory systems.
Expert on Microbiology and Biosecurity: Dr Anna Katz, Ph.D., is a project coordinator and senior researcher at the
Department of Health Security at THL. Katz is a specialist in microbiology, virology, and molecular biology and
she’s experienced in biosecurity, biosafety and working with highly pathogenic microbes. Katz has worked as senior
researcher at the Centres for Biothreat Preparedness and for Military Medicine, Finnish Defence Forces during
2012-2018, where she coordinated several domestic and international projects related to biothreats, including a
bilateral capacity building project on strengthening health and biosecurity in Tanzania. Katz has joined the
Department of Health Security at THL in 2018.
IHR Specialist: Dr Jussi Sane, Ph.D., is a Chief Specialist at the National Institute for Health and Welfare (THL),
Finland. Dr Sane in an epidemiologist and virologist by training and a graduate from the European Programme for
Intervention Epidemiology Training (EPIET). Dr Sane leads a team responsible for communicable disease
preparedness and response. The team is developing and updating disease prevention and control guidelines,
coordinating and leading outbreak investigations, maintaining situational awareness and performing operational
research. He is an adjunct professor (docent) of Infectious Disease Epidemiology, research activities focusing on
vector-borne and vaccine-preventable infections and global health. Dr Sane has been actively involved in Finland’s
contribution to the Global Health Security Agenda (GHSA) and WHO Joint External Evaluation (JEE) process. He
was involved in the GHSA/JEE Tool development, has participated in several JEE missions and the JEE Team Lead
training.
Biosafety and Biosecurity Specialist: Susanna Sissonen is a senior specialist at the Department of Health Security
at the THL and at the Centre for Biothreat Preparedness. She has a Master´s degree in microbiology from the
University of Helsinki. Sissonen works as a biosafety and biosecurity officer and has a Professional Certification in
Biorisk Management (International Federation of Biosafety Associations). She is also one of the founding members
of The Finnish Biosafety and Biosecurity Network. Sissonen is experienced in working with highly pathogenic
microbes, laboratory preparedness and managing a BSL-3 laboratory.
Chemical Expert: Hannu Kiviranta, Ph.D., Research professor at the THL. Dr Kiviranta directs the Chemical
Risks team at THL working with the analyses of persistent organic pollutants (POPs). He has a broad, over 20 years,
background in POP exposure assessment including environmental analytical chemistry and epidemiological studies.
He is a member of the Finnish center of know-how on serious chemical threats in where he acts as a member of
steering group as well as duty officer. Dr Kiviranta is also a chief of preparedness in THL.
Public Health Expert: Outi Lyytikäinen, research professor at the THL, is a medical doctor specialized in
infectious diseases and has special expertise in healthcare-associated infections and hospital hygiene and a graduate
of the European Program for Intervention Epidemiology Training (EPIET), assigned to Robert Koch Institute,
Berlin, Germany. She has led the Finnish National Hospital Infection Program (SIRO) since the beginning 1998 and
has been involved in several public health actions including preparedness plans and national guidelines since SARS
with special focus in surveillance, isolation facilities and personal protective equipment (PPE). She also took part in
the European Network in Emerging Infectious Diseases (EUNID). Her research interests include healthcare-
associated infections, invasive bacterial infections, and antimicrobial resistance.
Project Manager: Outi Karvonen, MA, Development Manager at the International Affairs and Research Support
Office of THL. Ms. Outi Karvonen has 22 years of experience in managing and coordinating international health
and development projects funded by various national and international donors such as the Finnish Ministry for
Foreign Affairs, European Union and UNAIDS. Her expertise in project management covers project assessment,
planning, monitoring and evaluation, financial management, budgeting and reporting to international partners and
donors.Ms. Karvonen worked as International Technical Advisor (ITA) of the Expert Group on HIV/AIDS and
Associated Infection of Northern Dimension Partnership in Public Health and Social Well-being (NDPHS) as
well as Coordinator of the Barents HIV/AIDS Programme during 2006-2015. Since 2015 she has been Project
Manager of the Joint Action on HIV and co-infections prevention and harm reduction (HA-REACT).
Financial Officer: Pirre Talponen (BBA) Coordinator of EU funding at THL (Financial issues) and over 10 years’
experience in EU funded projects (finance and administration), for example HA-REACT Joint Action. Will be
responsible for financial reporting of the JA.
Other staff of THL involved in the Joint Action includes assistant with extensive experience in project
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
97 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
management, administration, logistics and coordination of bilateral projects. Communication Officer with an
excellent command of English will contribute to WP1 and WP2 Dissemination.
Affiliated to THL: The Finnish Food Authority
The Finnish Food Authority works for the good of humans, animals and plants, supports the vitality of the
agricultural sector, and develops and maintains information systems.
The Finnish Food Authority began its operations on 1 January 2019 when the Finnish Food Safety Authority
(Evira) was merged with other agencies into one single Authority. The Authority operates under the Ministry of
Agriculture and Forestry, and the Authority employs almost one thousand experts and professionals in nearly 20
locations.
The Finnish Food Authority
- promotes, monitors and studies the safety and quality of food; the health and wellbeing of animals; plant
health; fertiliser products, animal feeds and plant protection products that are used in agricultural and forestry
production; and propagating materials i.e. seeds and planting materials.
- is responsible for the use of the funds provided by the European Union’s agricultural guarantee and rural
development funds in Finland, operates as the EU’s paying agency and monitors the implementation of EU
and national grants
- In addition, the Finnish Food Authority develops and maintains the information systems used in rural business
administration, develops online services, maintains and develops the registers used in the field, and also
produces information management services.
https://www.ruokavirasto.fi/en/about-us/what-is-the-finnish-food-authority/
Key staff of the affiliated entity
Professor Janne Nieminen, Doctor (Ph. D.), Physical Chemistry, is the Director of the Laboratory and Research
Department and Deputy Director General of the Finnish Food Authority (Ruokavirasto) since 1 January 2019. His
previous task was the Head of the Chemistry and Toxicology Research Unit in Evira starting in 2015.
Dr Annika Pihlajasaari, DVM, Food Hygiene Veterinarian. Senior Officer in Microbiological Food Safety Unit of
Finnish Food Authority since 2010. Main tasks: directing of food borne outbreak investigations and
microbiological food safety at national level, including international co-operation.
2 - RKI – Robert Koch Institute, Germany
Associated partner
The Robert Koch Institute (RKI) is German government’s public health institute with 1,200 employees from 90
different fields. It is a scientific institution in the field of biomedicine and safeguarding public health in Germany.
RKI main tasks include identification, surveillance and prevention of diseases, especially infectious diseases;
epidemiological and medical analyses and evaluation of highly pathogenic, highly contagious diseases of great
significance for the public; executive tasks defined by special laws, in particular protection from infections,
legislation on stem cell research, and attacks using biological agents.
The Centre for Biological Threats and Special Pathogens, Division of Highly Pathogenic Microorganisms (ZBS2) at
the RKI is the co-coordinator of the Joint Action SHARP and to lead the WP on laboratory networking, and is
responsible for the analysis of suspected high threat samples. It currently coordinates the Joint Action EMERGE
(2015-2019).
The RKI is equipped with several BSL3 laboratories and a BSL4 laboratory. Regarding the BSL3 labs, three are
for handling of viral and bacterial agents, one for mycotic and parasitic agents, and, in addition an animal facility
which can be upgraded up to BSL3. Therefore, ZBS2 provides all instruments for a conventional and advanced
rapid detection and identification of high threat samples. ZBS2 is accredited as Proficiency Test provider,
according to DIN EN ISO 17043, since May 2018.
Key staff of the associated partner
Prof Dr Roland Grunow, MD, is the Head of ZBS2. He has long experience with BSL3 pathogens. Guest
researcher at Karolinska Institute, Sweden and Inselspital, Switzerland. Dr Grunow has previously led the National
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
98 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Consulting Laboratory for Tularemia in Munich, and the Department for Immuno-Biotechnology at the Charité in
Berlin. Coordinator of the Joint Actions EMERGE (2015-2018) and QUANDHIP (2011-2014). Current lead of the
National Consultant Laboratories for Tularemia and B. anthracis, as well as for the reference lab of V. cholerae at
the RKI.
Dr Daniela Jacob is Group leader at ZBS2. Classical and molecular detection methods of BT agents. Routine
diagnostic in clinical microbiology for over 20 years. Deputy head of the Consultant Laboratories for Tularemia
and Reference Laboratory of Vibrio cholerae in the human sector. Responsible for the organisation of BT sample
analysis at RKI and running of the BSL3 laboratory. Professional expertise for the bacterial BSL3 laboratory.
Deputy coordinator of the Joint Actions QUANDHIP and EMERGE.
Dr Silke Klee (Biologist/Microbiologist), Group leader in ZBS2. Experience in molecular biology and classical
microbiology in respect to high threat pathogens. PhD in molecular biology. Deputy lead of the National
Consultant Laboratory of B. anthracis. Current special field is anthrax in Africa. Participation in wetlabs and
EQAE on BT-samples. Quality management officer at ZBS2.
Dr Sandra Appelt (PhD human pathologies and infectious disease), scientist in charge for the organization and
performance of proficiency tests on identification of highly pathogenic bacteria (projects: EMERGE, RefBio).
Classical and molecular detection methods of BT agents. Deputy Quality Management Officer at ZBS2.
Anna-Maria Rohleder (Master in language and literature studies), project manager in ZBS2 since 2008 with
experience gained in several projects, three of which at the RKI, previously at the Technical University of
Berlin as project manager and network coordinator.
Nathalie Fiedler, Silke Becker, Sabine Howaldt (Technical Assistants), state licenced to work as
technicians or equivalently experienced.
Dr Ute Rexroth (MD, MPH, MSc), Head of unit for surveillance, Department for Infectious Disease
Epidemiology; long-term experience, e.g., in IHR implementation, IHR National Focal Point activities, early
warning and response systems, crisis management, simulation exercises, and after action reviews.. Dr Maria an der
Heiden (DVM), Deputy head of unit for surveillance, Department for Infectious Disease Epidemiology; long-term
experience, e.g., in IHR implementation, IHR National Focal Point activities, early warning and response systems,
crisis management, simulation exercises, and preparedness and response.
Ulrike Grote (Teacher, MPH), working as scientist and trainer in the unit for surveillance, Department for
Infectious Disease Epidemiology, since 2016; experienced, e.g., in crisis management, simulation exercises, after
action reviews, preparedness and response, and risk communication.
Affiliated to RKI:
1. Philipps Universität Marburg (UMR), Institute of Virology
The Philipps-University Marburg was founded in 1527 and homes today more than 20.000 students. Infection
biology is a scientific focus of the University. The Institute of Virology is responsible for the routine virus
diagnostics of the Marburg University Hospital, for diagnostics of imported tropical diseases and for the
investigation of suspected bioterror samples as international reference laboratory for Filoviruses. Moreover, the
seven research groups of the Institute of Virology investigate replication and pathogenesis of highly pathogenic
viruses.
The Institute of Virology has a long tradition in research with highly pathogenic viruses that goes back to the initial
outbreak of Marburg virus in 1967. Since then, the Institute focused its research on filoviruses and other viruses
causing hemorrhagic fevers like arenaviruses and Nipahvirus. During the SARS outbreak in 2003 the Institute of
Virology was involved in the outbreak investigations and contributed to the identification and characterization of the
new coronavirus. The development of surrogate systems as iVLP and recombinant VSV at the Institute of Virology
allowed and accelerated the research on the highly pathogenic viruses under BSL1-2 conditions. In the modern
BSL-4 laboratory of the Philipps-University, recombinant viruses are generated and analyzed to understand all virus
replication steps. The BSL-4 laboratory of the Philipps-University Marburg is a partner of the emerging-infection
unit in the German Center for Infection Research (DZIF). The research field “Emerging Infections” aim to
accelerate biomedical research on emerging viruses and to be prepared for emerging infectious diseases in the
future.
Key staff of the affiliated entity
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
99 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Dr Markus Eickmann is head of the BSL-4 facility and has lasting experience with diagnostics of high pathogenic
virus. He is responsible for duties of the national reference centre for Filoviruses.
Katharina Kowalski (technician) is in charge for the production and testing of EQA material.
2. Bernhard-Nocht-Institut für Tropenmedizin (BNITM), Virology
Affiliated entity
BNITM is a public research institute governed by the German Ministry of Health and State authorities. It is
"National Reference Center for Tropical Infectious Agents" appointed by RKI. Due to this appointment, BNITM is
the national institution responsible for the diagnostic service for tropical pathogens including RG4 pathogens. To
accomplish this task, BNITM is running a 24/7 accredited diagnostic service in the legal framework of a Medical
Care Center (MVZ) and an Outpatient Department. Research is dedicated to infectious diseases that are of particular
relevance to the tropics. BNITM offers assistance to hospitals, medical practices and laboratories worldwide in
diagnostics of exotic and rare infectious agents (viruses, helminths, protozoa, and bacteria) and conducts research in
the fields of microbiology, immunology, and human genetics. BNITM is a partner of RKI in government-funded
programs such as GHPP and SEEG based on institutional Agreements. The Department of Virology is a WHO
Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research (DEU-115). Research of the
Department of Virology is dedicated to applied and basic aspects of arenavirus biology, in particular the
investigation of the virus life cycle, pathogenesis and immunology by the use of reverse genetics and structural
biology techniques. Major focus of clinical virology is molecular epidemiology of arenaviruses and the development
of novel diagnostic tools for the detection of known and unknown arenaviruses. This includes metagenomic analysis
of specimen and cultures based on data generated by next generation sequencing techniques in the field and in
laboratory settings.
Experience of the team relevant to the project:
- Operation of a BSL4 laboratory to investigate and diagnose highly pathogenic viruses such as Lassa and Ebola
virus for more than 30 years.
- Routine diagnostic service for 50+ tropical viruses for patients returning from tropical countries with
>5000 samples tested per year.
- Outbreak investigations in Africa, European Mobile Lab (http://www.emlab.eu/)
- Performing research programmes on identification and characterisation of emerging viruses; e.g. identification
of SARS coronavirus in 2003, Ebola virus Guinea in 2014, and various arenaviruses.
Key staff of the affiliated entity
Prof. Dr. Stephan Günther (MD) is the Head of Department of Virology, the Biosafety level 4 laboratory, and
WHO Collaborating Centre for Arboviruses and Hemorrhagic Fever Reference and Research at the Bernhard-
Nocht-Institute for Tropical Medicine in Hamburg, Germany, and adjunct professor at the University of Hamburg.
Dr. Lisa Oestereich, (PhD) is Research Group leader in the Department of Virology. She is leading research on
diagnostic evaluation in Africa as well as immunological studies in Africa and the BSL-4 laboratory.
3. Bundesministerium der Verteidigung, Bundeswehr Institute of Microbiology (BwIM)
Affiliated entity
The Bundeswehr Institute of Microbiology (BwIM) governed by the Federal Ministry of Defense is the scientific
centre of competence for biological medical defence of the Bundeswehr and represents the German Armed Forces
in research, teaching and training. It provides state-of-the-art procedures for investigations of unusual outbreaks of
infectious diseases and for the identification and verification of a suspected use of biological agents. BwIM’s
scientific focus is on research and development as well as studies on the pathogenesis, recognition, treatment and
prevention of health disorders which may be caused
by exposure to biological agents. The institute works in close cooperation with Germany’s public health
organisations and is cooperation partner of the German Biosecurity Programme together with RKI, FLI and BNI
under the Federal Foreign Office. The diagnostic unit is accredited according to DIN EN/ISO 15189 for highly
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
100 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
pathogenic bacteria and viruses up to risk group 4 since 2012 and provides diagnostic testing for infectious disease
agents that are considered as either differential diagnostics or possible co-infections to the civilian and military
sector and it is back-up lab for RKI in regard of suspected bioterrorism samples. In Germany, the network of
Consultant and Reference Laboratories in Germany is led by the RKI. BwIM is holding the National Consultant
Laboratories for Yersinia pestis, Brucella and Tick-Borne Encephalitis. To fulfil its tasks even beyond Germany’s
borders, the institute developed modular, rapidly deployable, mobile field laboratories which are adapted to be
operated abroad in low resource settings (http://www.emlab.eu/). Currently, BwIM leads the working group for
antimicrobial susceptibility testing in the EMERGE project (2015-2019).
Key staff of the affiliated entity
Dr. Sabine Zange, MD & DTMH, specialist in medical microbiology, virology and epidemiology of infectious
diseases; specialist training at the Ludwig Maximilian University of Munich; since 2009, head of the Central
Diagnostic Unit for highly pathogenic bacteria and viruses up to risk group 4 and lead of the diagnostic for the
National Consultant Laboratory for Yersinia pestis, Brucella and Tick-Borne Encephalitis at BwIM; long-term
experience in antimicrobial susceptibility testing of multi-resistant as well as of highly pathogenic bacteria; lead of
the working group for antimicrobial susceptibility testing in the Joint Actions EMERGE (2015 – 2019) and
QUANDHIP (2011 – 2014).
Enrico Georgi, specialist in medical microbiology, virology and epidemiology of infectious diseases; member of
the Microbial Forensics and Bioinformatics group at BwIM and deputy head of Central Diagnostic Unit;
experienced in medical informatics, data analysis and programming (e.g. SQL, R, Python).
Christin Hinz (Technical Assistant), state licenced to work as technician; experienced in bacteriological and
molecular diagnostics of highly pathogenic bacteria.
Biotechnologist - Scientist experienced in handling of data from partners and bioinformatic evaluation, data analysis
with respect to virulence and resistance genes in microbial genomes; in charge for molecular biological and
phenotypic diagnostic testing, validation and training of scientists from member states;
4. Friedrich Loeffler Institut - Bundesforschungsinstitut für Tiergesundheit: Institute of Bacterial Infections
and Zoonoses and Institute of Novel and Emerging Infectious Diseases (FLI)
Affiliated entity
As a federal research institute and an independent Higher Federal Authority, the FLI focusses on farm animal health
and welfare and on the protection of humans from zoonoses, i.e. infections which can be transmitted from animals
to humans. These tasks are defined in the Animal Health Act. The FLI does basic and applied research in different
scientific fields. Their aims are the prevention of diseases through improving rapid diagnostics, improving
prophylactic measures and providing the background for modern control strategies for animal diseases and
zoonoses.
As a federal research institute and independent higher federal authority under the Federal Ministry for Food and
Agriculture, the FLI has a consultative function which helps provide the scientific basis for political decision-
making. The FLI also works as national Licensing Authority for in vitro diagnostics for detection of notifiable and
reportable animal diseases (obtained from FLI website: https://www.fli.de/en/about-us/the- fli/).
The Institute of Novel and Emerging Infectious Diseases at the FLI (FLI INNT) has its core mandate in the
characterisation and identification of novel and/or emerging viral diseases, including VHFs. For the past decades
and years, a large number of diagnostic assays for VHF members have been developed, tested and established. The
Institute of Bacterial Infections and Zoonoses (FLI IBIZ) has its core mandate in the characterisation and
identification of highly pathogenic bacteria.
FLI constitutes the back-up lab for the RKI from the veterinary side, thereby realizing the One-Health- Approach.
All National Reference Laboratories for infectious animal diseases are run by FLI, including Anthrax, Brucellosis,
Coxiellose, Glanders, Tularemia as well as for BSE, West-Nile-Virus, Japanese Encephalitis Virus,
Western/Eastern/Venezuelian Equine Encephalitis Virus, Rift valley Fever Virus, Filo
(Ebola/Marburg) Virus, Crimean-Congo Hemorrhagic Fever Virus and Hanta Virus infections. FLI constitutes OIE
Collaborating Centre for Zoonoses in Europe and the OIE-Reference Laboratories for Brucellosis and Glanders. In
terms of infrastructure FLI is running BS3 and BSL4 laboratory and animal facilities for biosafe work with these
bacteria and viruses.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
101 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Key staff of the affiliated entity
Dr Mandy Elschner is FLI project leader and will organize the interactions with /contributions of all FLI
collaborators (incl. virologists). She is working group leader at FLI, Jena for “BSL3-Agents”. Head of the National
Reference laboratories for anthrax and glanders. Classical microbiological and molecular detection methods
experience for over 10 years. Professional expertise for the bacterial BSL3 laboratory. Local management for Joint
Actions QUANDHIP and EMERGE.
5. Universitätsklinikum Frankfurt, Medizinische Klinik II, Isolation Unit for Highly Pathogenic Infectious
Diseases
Affiliated entity
Public university medical center (the university medical center Frankfurt is a public institution)
- Clinical isolation unit for Hesse, Rhineland-Palatinate and Saarland
- 24/7 emergency service for consultation in case of infectious disease emergency
- Leading role in German network of Clinical Competence and Treatment Centres for highly pathogenic infectious
diseases (STAKOB) – close interaction with the RKI
- Clinical Research Centre with expertise in the field of HIV clinical studies, fungal infections, antibiotic
stewardship.
Key staff of the affiliated entity
PD Dr Timo Wolf (MD), Consultant Physician for Internal Medicine and Infectious Diseases, University Hospital
Frankfurt Medical Center II, Infectious Diseases & HIV Dept. Head of Isolation Unit for Highly Pathogenic
Infectious Diseases; experienced in HIV, Lassa fever, Hep C, Influenza, Staphylococcus aureus; Ebola Virus
Disease, general Infectious Diseases and Tropical Medicine, Outbreak management. Clinical study experience as
deputy PI for Frankfurt HIV Center.
3 - INMI – The National Institute for Infectious Diseases “L. Spallanzani” (INMI) Rome, Italy
Associated partner
INMI is a National public research and care institution operating since 1936 in the field of infectious diseases (IDs).
Recognized as a leader in IDs, INMI ranks as a top level institution for publication impact in this field. It has been
designated as the Italian National Referral Centre for highly transmissible infectious diseases. INMI is member of
the GOARN (WHO), and is “WHO collaborative center for clinical care, diagnosis, response and training on
HIDs”. INMI’s research agenda is mainly focused on emerging/re- emerging infections, blood-borne pathogens,
tuberculosis and tropical diseases, covering basic, pathogenetic, diagnostic, epidemiologic, care/treatment and
prevention aspects. The Institute has an experienced team in managing national and international projects, and has
coordinated the European BSL4 laboratories for a very long time.
Key staff of the associated partner
Prof. Dr. Giuseppe Ippolito, Scientific Director of INMI, has over 20 years of experience in the study of
emerging and re-emerging infections and management of outbreaks. He has served as an expert to numerous
organizations including the EU, WHO and the Italian Ministry of Health, and has been project and program
manager or partner of numerous projects.
Dr Antonino Di Caro is the Director of Microbiology Laboratory and Infectious Diseases Biorepository at INMI.
He has extensive experience in diagnostic virology, on training activity on viruses, involving diagnostic,
pathogenetic, molecular, and biosafety aspects. Dr. Di Caro participates to numerous projects on Emerging
Infectious Diseases.
Dr Maria Rosaria Capobianchi is the Director of the Laboratory of Virology and Biocontainment Laboratories
at INMI, where she is in charge of diagnostic and research activity on viral diseases. She has extensive experience
in virology. She has been project and program manager or partner of numerous projects.
Dr Emanuele Nicastri is the head of the Clinical Unit of Infectious and Tropical Diseases and of the Clinical Unit
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
102 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
of Highly Infectious Diseases at INMI. His first clinical interest is the clinical management of patients with
emerging and re-emerging diseases. He participates to numerous EU project and he is involved in WHO-GOARN
and EDCARN activities.
Dr Francesco Vairo, infectious disease physician and epidemiologist. His main interest is in outbreak
preparedness and response and epidemiology of emerging infectious diseases. He participates to national research
programs and to European research project on Emerging Infectious Diseases and he is involved in WHO-GOARN
and EDCARN activities.
Dr Barbara Bartolini is virologist at INMI. She is involved in several projects on emerging infectious diseases,
particularly on laboratory capacity and preparedness aspects. She has experience in the study of viral diversity,
pathogen detection, metagenomics.
Affiliated to INMI:
5. Ministry of Health – General Directorate for Health Prevention
Affiliated entity
The MoH is the central body of the National Health Service. The DG for Health Prevention has competencies, inter
alia, in international health, prevention, preparedness, surveillance and response to threats related to infectious
diseases, early warning system, implementation of International Health Regulations, border health
Key staff of the affiliated entity
Dr Claudio D’Amario, MD, specialist in Public Health, Laboratory Medicine and Internal Medicine; Director-
General for Health Prevention, he has several years of experience in the field of Management of Health Services and
laboratory Medicine
Dr Francesco Maraglino, MD, specialist in Epidemiology (Health statistics); Senior Medical Officer of the MoH,
Director of Unit 5 (Prevention of Communicable Diseases), he has more than 20 years of experience in IHR, border
Health, prevention, preparedness, surveillance and response to threats related to infectious diseases, early warning
system
Dr Patrizia Parodi, Veterinary, specialist in Epidemiology (Health statistics); Veterinary Officer of the MoH, Unit
5 (Prevention of Communicable Diseases), he has prevention, preparedness, surveillance and response to threats
related to infectious diseases (zoonoses and arboviroses in particular).
6. ISS – Istituto Superiore di Sanità, Rome, Italy
Affiliated entity
The ISS is the Italian National Institute of Health, a public institution founded in 1931. The Institute is under the
supervision of the Italian MoH and is the technical-scientific structure of the Italian National Health Service. The
ISS performs scientific research in a wide variety of fields producing publications with a high level of impact factor
in different topics. In particular, the activities of the Department of Infectious Diseases of the ISS (DMI-ISS) are
focused on research, diagnostic, surveillance and epidemiologic aspects for pathogenic agents. In recent years, the
DMI-ISS has contributed to the implementation of regional laboratory surveillance. The diagnostic confirmation for
class A pathogens is always active in the department and the diagnostic protocols have been verified by the
continuous participation in the external EQAs organized by projects and JA (EQADeBa, QUANDHIP, Emerge).
Key staff of the affiliated entity
Dr Giovanni Rezza, MD, specialist in Epidemiology and Infectious Diseases. Director of DMI-ISS, has over 20
years of experience in the study of emerging and re-emerging infections and management of outbreaks. He has
served as an expert to numerous organizations including the EU, WHO and the Italian Ministry of Health, and has
been project and program manager or partner of numerous projects.
Dr Alessandra Ciervo, Ph.D, specialist in Microbiology and Virology. She is the scientific coordinator of the
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
103 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Reference Laboratory for Human Leptospirosis and the Laboratory for atypical pathogens. She has extensive
experience in molecular diagnostic of fastidious bacteria including vector-borne and bioterrorism agents. She
participates to numerous projects on Emerging Infectious Diseases.
Dr Fabiola Mancini, Ph.D, specialist in Microbiology and Immunology. Her main interest is in diagnostic and
research activity on emerging and re-emerging infections, including vector-borne and bioterrorism agents. She
participates to numerous projects on Emerging Infectious Diseases.
Dr Monica Monaco, Ph.D, specialist in Microbiology. Her main interest is in diagnostic and research activity on
antimicrobial resistance. She is the Italian National focal point for Diphtheria. She participates to numerous projects
on Infectious Diseases and antimicrobial resistance.
7. IZSLER-Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna
Affiliated entity
IZSLER is an Italian regional governmental institution that focuses its activities on the diagnosis of infectious and
parasitic diseases of animals, including zoonoses, the detection of microbiological and chemical contaminants in
food commodities, and research. The IZSLER laboratory of Pavia in the Lombardy region has extensive experience
in the diagnosis of tularaemia, chlamydiosis, brucellosis, yersiniosis, glanders, Q fever, cat-scratch disease, anthrax
and legionellosis. The laboratory hosts 3 reference laboratories, namely the National Reference Laboratory for
Tularaemia, the National Reference Laboratory for Chlamydiosis and the Regional Reference Centre for the rapid
detection of highly pathogenic bacteria with potential bioterrorism use. The laboratory closely supports the
firefighter NBCR nucleus in Lombardy for the detection of highly pathogenic bacteria in suspected biological
samples, and participates in the international Wet Lab within the United Nations Office for Disarmament Affairs in
the context of collaboration and support to the UN Secretary-General's Mechanism for the Investigation of Alleged
Use of Chemical, Biological or Toxin Weapons (UNSGM).
Key staff of the affiliated entity
Dr Massimo Fabbi, DVM, specialist in Veterinary Public Health. Head of the IZSLER-Pavia Dept. Director of the
National Reference laboratory for Tularemia from 1999 until 2018 and Director of the Regional Reference Center
for rapid detection of highly pathogenic bacteria from 2013 until 2018. He has extensive experience, in diagnostic of
infectious disease of animals, zoonoses, foodborne diseases, highly pathogenic bacteria and biosafety aspects. He
participates to different National Research Projects and to European Projects on Emerging Infectious Diseases.
Dr Nadia Vicari, Biologist, is the head of both the Molecular Biology Laboratory and the Regional Reference
Laboratory for the rapid detection of highly pathogenic bacteria with potential bioterrorism use since 2018. She has
experience on the research and detection of bacterial pathogens. She participates to National Research Projects and
to European Projects on Emerging Infectious Diseases as well as to the UNSGM Wet Lab
Dr Paola Prati, DVM ,is the head of the National Reference Laboratory for Tularemia since 2018 and she is
responsible for the Microbiology Laboratory. Her activity is focused on the diagnosis of infectious diseases (mainly
zoonoses)
Dr Simone Magnino, DVM, is responsible for the serological diagnosis of infectious and parasitic diseases of
animals. During his secondment to WHO Headquarters in Geneva from 2009 to 2013 he provided support for the
development of programmes and activities for the reduction of the incidence and prevalence of major zoonotic
infections.
8. IZSPB- Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata
Affiliated entity
The IZSPB is a specialized Italian government funded institution mainly involved in diagnostics and research. The
main tasks of the institute are the diagnosis of animal infectious diseases, zoonotic diseases and food borne diseases.
The institute is also involved in the diagnosis and control of highly pathogenic agents. The IZSPB takes part to
national and international research programs, with regard to health, prevention, surveillance and response to threats
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
104 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
related to infectious diseases.
Key staff of the affiliated entity:
Antonio Fasanella is the General Director of the IZSPB and Head of the Anthrax Reference Institute of Italy. He
has a very long experience in the study of infection diseases and management of outbreaks, in particular of anthrax.
He has been manager and partner of numerous national and international projects.
Domenico Galante is actually executive of the Anthrax Reference Institute of Italy. He has ten years’ experience in
the field of infectious diseases diagnostics in particular in bacteriology, mostly anthrax, and virology.
Luigina Serrecchia is a biologist. She has a very long experience in the field infectious diseases diagnostics, in
particular of anthrax. She took part to many national, international research projects.
4 - BMASGK - Federal Ministry of Labour, Social Affairs, Health and Consumer Protection, Department of
Communicable Diseases, Crisis Management, Disease Control, Austria
Associated partner
The Health scope of the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection in Austria
covers among others: general health policies, protection against dangers to the general state of health of the
population including national health crisis management, structural policy and planning, the development of the
health care system, procedure- and diagnosis-based financing of health care services, information and
classification systems in the health care system, health reporting, quality in the health care system, healthcare
information technology and health telematics, monitoring and combating infectious diseases.
Key staff of the associated partner
Dr Bernhard Benka, medical doctor, specialized in international public health and communicable diseases and
head of Department for Communicable Diseases, Crisis Management, and Disease Control. He was active and has
a vast experience in low and middle income countries. He is responsible for many international activities related to
ECDC and WHO, e.g. for IHR/EWRS monitoring and implementation; furthermore he is responsible for national
preparedness and response of public health events.
Martina Brix, natural scientist and deputy head of department, has a university degree in nutritional sciences and
is involved in the development and advancement of infectious diseases prevention and control policies. She has
experience in research and scientific publications on the topic of food safety and is also involved in IHR
monitoring and implementation.
Alina Rusu is referee with a university degree in International Relations and specialized in conference
interpreting. For the last four years she has been assisting the department for Communicable Diseases, Crisis
Management, and Disease Control in financial and administrative operations as well as communication
activities.
Affiliated to BMASGK:
1. Austrian Agency for Health and Food Safety (AGES)
The Austrian Agency for Health and Food Safety (AGES) is a government owned agency attached to the Federal
Ministry of Labour, Social Affairs, Health and Consumer Protection and to the Federal Ministry of Sustainability
and Tourism.
The business of AGES is to promote a holistic approach to food security, food safety, animal health and public
health issues in Austria by integrating different disciplines along the human food chain in order to
achieve synergy effects and to concentrate all relevant capacities. AGES was formed upon a Federal law (Health
and Food Safety Act) as a private company with limited liability, with a public service mission.
AGES executes federal state tasks in the areas of agriculture, food and feed safety control, control of infectious
diseases, veterinary medicine, radiation protection, medical devices and pharmaceuticals.
AGES operates the federal laboratories related to food safety (food and feed analysis, water analysis, residues
analysis) and radiation protection, the main diagnostic laboratories related to food safety and human health, animal
health and plant health. AGES’s laboratories serve as National Reference Laboratories according to Regulation No.
(EC) 882/2004, as reference centres for infectious diseases.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
105 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
AGES is responsible for integrated risk assessment and conducts research in the areas above mentioned. Regarding
research AGES is classified as non-profit research organisation.
Key staff of the affiliated entity
Daniela Schmid is head of the department Surveillance and Infection-Epidemiology at the Institute for Medical
Microbiology and Hygiene Vienna at the Austrian Agency for Health and Food Safety in Vienna, Austria. After
attending medical school at the University Vienna, she became qualified to teach hygiene, microbiology and
preventative medicine, receiving the title Privatdozent from the Medical University Vienna. She is a supervisor
within the ECDC Fellowship Programmes EPIET and EUPHEM. PubMed lists 40 peer reviewed publications.
PD Dr med. Alexander Indra is head of the Institute for Medical Microbiology and Hygiene Vienna at the Austrian
Agency for Health and Food Safety in Vienna, Austria. After attending medical school at the University Vienna, he
became qualified to teach hygiene, microbiology and preventative medicine, receiving the title Privatdozent from
the Paracelsus Private Medical University Salzburg. As head of the Viennese AGES-biosafety level 3 facility, he is
the nominated contact person in charge of diagnosis of highly pathogenic microorganisms in Austria. PubMed lists
36 peer reviewed publications.
2. Vienna Hospital Association (VHA), Kaiser Franz Josef Hospital Vienna, Department of Medicine IV
Sole beneficiary member
The Department of Medicine IV is the largest infectious diseases department in Austria and in charge of the
treatment of highly pathogenic infectious diseases in Vienna and other parts of eastern Austria. It has the capacity to
treat up to 3 patients in separate isolation facilities in an intensive care setting. Staff is regularly trained for this
purpose. A point of care laboratory ensures timely detection of relevant pathogens within the facility.
Key staff of the sole beneficiary member
Dr. Christoph Wenisch, head of the department of Medicine IV has over 20 years’ experience in treating
patients with infectious diseases including patients with high consequence infectious diseases (HCID) including
MERS-CoV.
Dr. Alexander Zoufaly, coordinator of the EU grant activities, is a senior physician with longstanding
experience in treatment and diagnosis of infectious diseases including HCID. He is currently heading the point
of care laboratory for infectious diseases within the department and actively involved in several research studies.
5– MCA - Ministry of Civil Affairs of Bosnia and Herzegovina (Ministarstvo civilnih poslova Bosne i Hercegovine)
Associated partner
The Ministry of Civil Affairs’ (MCA) Department for Health is responsible for coordinating activities,
harmonizing authorities’ plans and defining the international level strategy in the field of health care. MCA is the
focal point for reporting on communicable and non-communicable diseases and other health-related matters to
WHO, ECDC and other international partners. It coordinates the work of the Commission for Implementation of
International Health Regulations (IHR WHO 2005). Primary Responsible Person for IHR (available 24/7) was also
nominated by MCA.
Key staff of the associated partner
Dr Dušan Kojić, is a medical doctor with seven years of experience in public health programs in the Ministry of
Civil Affairs. As the national correspondent for ECDC he is in charge of preparing reports on communicable and
non-communicable diseases for WHO and ECDC. He is also a member in a number of expert bodies incl. the
Commission for Implementation of IHR, Commission of Experts for Poliomyelitis, Commission for Verification
of Rubella and Measles Elimination in BiH as well as the Working Group for reporting on avian surveillance in
BiH.
Prim.dr Draženka Malićbegović, is a medical doctor with specialization in pediatrics with 19 years of experience
in the leadership/management, monitoring and evaluation of health projects e.g. on reforming the Primary and
Secondary Health Care systems, Communicable and Non-communicable Diseases, Public Health, and
International Health Regulation funded by EU, WB, GFATM, WHO, SDC, CDC, etc. The Chairperson of the
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
106 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Commission for Certification of Poliomyelitis Eradication in BiH and Commission for Implementation of IHR,
she is also the Primary Responsible Person for IHR. She is a member of the Coordination Body of Bosnia and
Herzegovina for Protection and Rescue, and the Working Group for Monitoring the Vaccination Program in BiH.
She is experienced in multi-sectoral exercises.
Jasna Džemić, is the Head of Department for EU Integrations and International Cooperation with extensive
experience in the preparation and management of EU funded projects and international cooperation. She holds a
university degree in technical science and has a high command of English.
Snježana Brčkalo, a graduated economist, is an advisor for EU integration and International Cooperation, She has
many years of experience in health project development and implementation as well as in the field of promotion
and dissemination.
6 – CIPH - Croatian Institute of Public Health (Hrvatski Zavod za Javno Zdravstvo)
Associated partner
Croatian Institute of Public Health (CIPH) plans, promotes and implements measures for the enhancement of
population health and reduction of health problems. CIPH carries out epidemiological surveillance and proposes,
organizes and undertakes preventive and counter-epidemic measures. It also plays a crucial role in planning,
supervision and evaluation of immunization. CIPH performs duties concerned with the analysis and evaluation of
water safety and the impact of environmental factors on human health. It maintains national public health registries,
supervises data storage and coordinates the work of other health registers. The CIPH proposes national anti-
epidemic measures, supervises compulsory immunisations and oversees the work of the network of public health
institutes. CNIPH has been also identified as the institution acting in roles required by the EU acquis
communautaire in the area of communicable diseases. These are representation in Community Network on
communicable diseases surveillance, EWRS, Health Security Committee. The Microbiology Division of CIPH is
composed of five departments including 10 specialists of medical/clinical microbiology and two residents of clinical
microbiology.
Key staff:
Dr Bernard Kaić, MD, is a Senior epidemiologist, expert in vaccinology, immunisation and epidemiology of
communicable diseases, and Head of Division for Epidemiology of communicable diseases in Croatian Institute of
Public Health (CIPH). Prim. Kaić is also National Program Immunisation Manager, ECDC National
Coordinator (Coordinating Competent Body), NFP for Surveillance, and Alternate NFP for Scientific Advice
Coordination and Contact point for IHR.
Dr Goranka Petrović, MD, is a Senior epidemiologist, Head of Department for Travel Medicine, Early Warnings
and Cross-Border Threats at CIPH, Division for Epidemiology of communicable diseases. Dr. Petrović is also a
ECDC National Focal Point for Threat Detection, EWRS and IHR and NFP for influenza and tuberculosis. Dr
Petrović was a national leader for project CARE (Common Approach for Refugees and other migrants' health, 2016
– 2017), funded by European Commission. Part of IHR Country Team.
Dr Vesna Višekruna Vučina, MD, epidemiologist, Head of Unit for coordination, monitoring and evaluation of
Immunisation programme and Registry of adverse events following immunization at CIPH, Division for
Epidemiology of communicable diseases. ECDC National Focal Point for preparedness and response and NFP for
Vaccine preventable diseases (VPD Programme). Dr Višekruna Vučina is a national coordinator for I-MOVE+
project (HORIZON 2020) since 2015/2016. Part of IHR Country Team.
Dr Zvjezdana Lovrić Makarić, MD, resident in epidemiology at Division for Epidemiology of communicable
diseases at CIPH. Dr. Lovrić Makarić is European Programme for Intervention Epidemiology Training alumni and
NFP alternate for Emerging and vector-borne disease, NFP alternate for tuberculosis and NFP alternate for
preparedness and response.
Dr Vedrana Marić, MD, resident in epidemiology at Division for Epidemiology of communicable diseases at
CIPH. Dr. Marić is alternate national focal point for Vaccine preventable diseases (VPD Programme).
Bojana Raičković, Head of Department for Programme and Project Management, representative of the project
unit of the Croatian Institute for Public Health.
Dr Irena Tabain, PhD, MD is a Head of Enterovirus and Respiratory Viruses Laboratories at CIPH, Zagreb, and
an associate lecturer at School of Medicine, University of Split. She is also the Head of National WHO Polio
Laboratory. She is a Head of Reference Centre for diagnostics of viral respiratory and gastrointestinal infections
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
107 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
and a member of Reference Centre for diagnostics and surveillance of zoonotic viral infections of the Croatian
Ministry of Health.
Dr Ljiljana Zmak, MD, PhD is the Head of the National/Supranational TB Reference Laboratory, Zagreb,
Croatia. She has extensive TB laboratory expertise and knowledge in the implementation of WHO
recommendations for new TB diagnostics, biosafety and laboratory maintenance. Along with having substantial
practical TB laboratory experience, she is also an ECDC TB laboratory support expert. Dr.
Zmak participates in creating public health strategies in TB control.
Dr Nenad Andrić, MD, Specialist of Clinical Microbiology is Head of Units for Respiratory Infections and General
Bacteriology, and for Bacterial Serology. He is also Head of National reference laboratories for Leptospirae,
Corynebacterium diphteriae, Borreliae, Legionellae, and Bordetellae. He is consultant in many hospitals and
President of the Commission for the Infection Control in two hospitals. He has a BSL3 laboratory experience and
extensive AST experience.
Affiliated to CIPH:
1. Ministry of Health, Directorate for Sanitary Inspection, Service for Border Sanitary Inspection
The main goal of the Ministry of Health (MoH) is to protect, improve and preserve health. One of the specific goals
is protection of public health interests which is the main role of sanitary inspection. Border sanitary inspection (BSI)
is part of the Directorate for Sanitary Inspection of the MoH. BSI is conducting inspection surveillance at the border
crossings in order to protect population from the introduction of communicable diseases. Surveillance is conducted
according to IHR at ports, airports and ground crossings. Within the competence of BSI are measures for the
prevention and control of communicable diseases which include early detection of the source of infection and the
routes by which infection is transmitted, surveillance of means of transport and supervision over general measures
of disinfection, disinsectisation and deratisation.
BSI has participated in EU SHIPSAN ACT Joint Action “The impact on maritime transport of health threats due to
biological, chemical and radiological agents, including communicable diseases”, 2013-2016. BSI is involved in The
Joint Action EU Healthy Gateways.
Key staff of the affiliated entity:
MSc, Koraljka Knezic is Head of Service for Adriatic coast of Border Sanitary Inspection. She has experience in
conducting, organising and management inspection surveillance in relation to public health issue. She is national
SHIPSAN inspector, conducting inspection in Croatia on cruise ships. Expert and contact point for Croatia in EU
SHIPSAN ACT Joint Action, 2013-2016. Experience in organization, coordination and implementation of EU
funded projects.
Marko Markušić, MSc (Techn), is Head of Service for continental Croatia of Border Sanitary Inspection. He has
experience in conducting, organising and management inspection surveillance in relation to public health issues. He
is experience in inspections related to airports and ground crossings.
2. University Hospital for Infectious Diseases (UHID)
Affiliated entity
University Hospital for Infectious Diseases, Zagreb, Croatia (UHID), has a long tradition in the control,
management and research of infectious diseases including highly infected pathogens (HIDs), and is the leading
institution for the treatment of infectious disease patients in Croatia. It was founded in 1893 and it is a tertiary care
provider treating over 15,000 inpatients and up to 45,000 outpatients per year, not only from the Zagreb area, but
also patients from other regions in Croatia that are referred to the hospital, but also from the neighbouring
countries. It is affiliated with the University of Zagreb Medical School and consists of different clinical, laboratory
and administrative Departments and Units. Capacities for clinical management and treatment of patients with
infectious diseases include Central Diagnostic Laboratory building (CDL), providing modern laboratory diagnostics
of infectious diseases and research infrastructure and including the new BSL3 laboratory, and Cell Culture Unit.
There are different clinical departments for adults and kids, including intensive clinical care facility for adults and
children and Isolation Department with 6+6 beds capacity (no negative room pressure). There are also cabinets,
lecturing rooms, and training sites and library as well.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
108 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Key staff of the affiliated entity:
Professor Alemka Markotić, MD, PhD, is director of the University Hospital for Infectious Diseases, Zagreb
Croatia. She is head of the Department for Research which include Biosafety Level 3 Laboratory and head of the
Clinical Department for Urinary Tract Infections. She is also full professor at the Medical School, University of
Rijeka and Catholic University Zagreb, Croatia and associate member of the Croatian Academy of Sciences and
Arts. Her specializations are in Clinical Immunology (1997) and Infectious Diseases (2007). For many years, she is
involved in research and clinical and laboratory medical management in the field of emerging and re-emerging
infectious diseases with special focus on zoonoses and vector-borne diseases and is member of many national and
international boards in the field. She established the first Croatian BSL-3 laboratory and the Croatian Society for
Biosafety and Biosecurity.
Professor Adriana Vince, MD, PhD, is former director of the University Hospital for Infectious Diseases, Zagreb
Croatia. She is head of the Department for Gastrointestinal and Hepatal Infectious Diseases with Isolation Unit. She
is also full professor at the Medical School, University of Zagreb. Her specializations are in Cytology and
Infectious Diseases. For many years, she is involved in research and clinical and laboratory medical management in
the field of different infectious diseases with special focus on hepatitis viruses diseases and is member of many
national and international boards in the field. She established the first Croatian Isolation Unit for patients infected
with quarantine pathogens.
Assistant professor Rok Čivljak, MD, PhD, is Deputy Director of the University Hospital for Infectious Diseases,
Zagreb Croatia. He is head of the Department for Respiratory Tract Infections. He is also assistant professor at the
Medical School, University of Zagreb. His specializations are in Infectious Diseases and Children Infectious
Diseases. For many years, he is involved in research and clinical management in the field of different infectious
diseases with special focus on respiratory tract infections and influenza and is member of different national and
international boards in the field.
Ivan-Christian-Kurolt, BSc, PhD, is scientist at the Department for Research and currently manage BSL-3
laboratory. He established and developed many molecular in-house methods for the detection of zoonotic and vector
–borne diseases. His research is focus on emerging and re-emerging infectious diseases with special focus on
zoonoses and vector-borne diseases as well and is member of several national and international societies and
working groups in the field.
7- SUJCHBO - National Institute for Nuclear, Chemical and Biological Protection, Czech Republic
Associated partner
SUJCHBO is a public research institution established by the State Office for Nuclear Safety for the purpose of the
development and research in the field of chemical, biological and radioactive agents, and the provision of technical
support to the supervisory and inspection activities carried out by the aforementioned Office in radiological
protection and in the verification of the prohibition of chemical and biological weapons.
Key staff of the associated partner:
Michal Drevinek, RNDr., Ph.D. works as a Head of Department of Biological Protection, with research focus on
instrumental techniques in analysis of high risk biological agents and toxins, mass spectrometry and combination
of immunological methods with electrochemical detection. During his employment at SUJCHBO, Michal
Drevinek was actively involved in several international and national research projects (IMPACT, QUANDHIP,
EMERGE).
Martina Grochová, MSc. obtained her degree in specialization on molecular mechanisms in plant organogenesis.
She is a part of the Biology Protection Division as a molecular biologist. Simultaneously, she is a Ph.D. student at
the University of South Bohemia in České Budějovice with the specialization in the field of infectious biology.
Being experienced at the molecular biology, she is aimed at various molecular biology techniques as a detection
system.
Hana Andělová holds a Master degree in Analysis of Biological Materials. Her work is focused on development of
methods for rapid detection of microbial agents in environmental samples, using molecular biology methods, PCR,
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
109 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Sanger sequencing, work with cell lines, fluorescent microscopy.
8– SSI - Statens Serum Institut, Denmark
Associated partner
Statens Serum Institut (SSI) is internationally acclaimed as the Danish National Public Health Institute for
Infectious Diseases. The SSI is responsible for research-based health surveillance and analysis, as well as the
prevention and control of infectious diseases, biological threats and congenital disorders.
Key staff:
Dr Øystein Angen, Senior researcher, PhD, DVM, is a trained bacteriologist with long experience in handling of
BSL3-bacteria. He has participated in earlier EU projects dealing with high pathogenic agents, including the
QUANDHIP and EMERGE. Participates in WP 7 and WP 8.
Dr Anders Koch, Senior researcher, MD, PhD, MPH, is a professor and specialist in infectious diseases and tropical
medicine, and a medical epidemiologist. Participates in WP 8 and WP 10.
Mikkel Lyndrup, Int. M.Sc. in Economics and Business Administration, part of SSI´s Executive Office, which
supports researchers with external funding issues and Grant Management. His role will be to support the allocated
staff in Administrative matters.
9 - MSAE - Sotsiaalministeerium - Ministry of Social Affairs of Estonia
Associated partner
MSAE is responsible for developing strategies and coordinates the implementation of strategies in the field of
health. It covers also preparedness and response to the serious cross-border health threats in policy- making level
for what excellent cooperation is needed between different institutions and partners in health sector as well as with
other sectors, but cross-border cooperation is also crucial aspect it. Its competencies include the leading role in
coordination of prevention and control of communicable diseases and development of respective strategies.
Key staff:
Ms Kärt Sõber is Adviser of the Public Health Department of the Ministry of Social Affairs of Estonia on
prevention of communicable diseases and AMR. Her competences include coordination of the implementation of
IHR at policy level, coordination of policies and strategies in the field of prevention and control of communicable
diseases and AMR.
Affiliated to MSAE: Terviseamet – Health Board (HB)
One of the key government bodies in the area of governance of the MSAE in case of the serious cross- border
health threats is Health Board who is the key partner in the practical implementation of the international health
regulations in Estonia. Health Board is a Governmental agency within the MSAE, providing leadership in the
degree specified in the legislation and performing surveillance and enforcement functions to assure compliance
with legal requirements including Health Protection in communicable diseases; environmental health; chemical
Safety; poisoning information centre; laboratories
Key staff of Affiliated Entity:
Mrs Külli Rae is Head of the National Laboratory on communicable diseases. Competences include
coordination of the work of the laboratory and its participation in the national communicable diseases
prevention and control system.
10 - MoH-FR - Santé publique France
Associated partner
The Ministry of Solidarity and Health (MoH-FR) leads across health, social affairs, solidarity and social cohesion
by leading national policies and legislation, providing the cohesion by leading ambition to meet current and future
challenges, putting health and solidarity at the heart of government. Within the MoH, the Directorate General for
Health (DGH) is responsible for the elaboration of Public Health policies, disease prevention and health promotion,
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
110 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
including the protection from public health hazards, preparing for and responding to public health emergencies. Two
units will be involved in the joint action within the DGH: the Department of European and International Affairs and
the Surveillance and Health Security Division.
Key staff of the associated partner:
Coralie Giese, MA, MSc, is a policy advisor on international affairs at the Department of European and
International Affairs of the Ministry of Solidarities and Health in France. She has worked as a public health
epidemiologist with extensive international experience with CDC, WHO, EU, GOARN in outbreak investigation,
emergency response, surveillance, rapid assessment among others. She has experience in IHR implementation,
cross-border alerts and epidemic intelligence, as well as advanced level of statistics, communication and scientific
writing.
Christine Berling, is head of European and International affairs department. She has actively contributed to various
European projects, of which Joint Actions. M.Sc. in Physics, PhD in Biophysics, C. Berling has over 15 years’
experience of working in public-private partnership and technology licensing, initially with the INSERM, and
subsequently at the European Commission, DG RTD Health Directorate, during the setting up of the Innovative
Medicine Initiative Joint Undertaking.
Jérôme Weinbach - Adviser for European Affairs, Directorate General for Health, French Ministry of Solidarities
and Health, National Focal Point of DG SANTE. In charge of liaising with all EU institutions and Member States,
on Joint Actions and notably on specific topics such as AMR and vaccine coverage. Jérôme is an engineer in genetic
microbiology applied to health from the National Institute of Applied Sciences in Toulouse. He holds a PhD from
the University of Paul Sabatier (adenoviral vectors applied to gene therapy of cancer). He was subsequently
Scientific Attaché for Life Sciences, health and biotechnology at the French Embassy in Germany for 2 years and at
the French Embassy in the UK for 3 years. He completed his knowledge of France’s neighbouring countries
working for 3 years at the Leiden University Medical Center, where he built and led European projects of the 5th
Framework Programme (FP7), aiming to develop vaccines against the Hepatitis C virus.
Affiliated to MoH-FR:
1. Agence Nationale de Santé Publique (SpFrance)
Santé publique France (SpFrance) is the French national public health agency. Its responsibilities include providing
evidence-based guidance and recommendations; producing analysis on the determinants of health and risk factors;
proposing measures to health authorities to protection population from health threats; and developing evidence-
based interventions for prevention and health-promotion. It contributes to preparedness and management of health
crises and provides support for the implementation of response plans. SpFrance manages the health reserve corps
and operates a pharmaceutical facility under the control of the MoH. In addition, it is responsible for the stockpiling
for emergency response. It has regional offices covering all regions of France including the overseas territories (in
the Indian Ocean and the Caribbean).
Key staff of the affiliated partner
Dr Philippe Magne is the deputy director of the Division of Alert and Crisis. Dr Magne has more than 20 years
of experience in the area of emergency medicine. He has worked in the MoH in the emergency management and
alerts in the area of public health (10 years) and in the area of health care (organization, quality and security).
2. Institut National de la Santé et de la Recherche Médicale (INSERM)
Since 2004, INSERM holds the Inserm Jean Mérieux BSL4 Laboratory, which was built in 1999 in Lyon.
Organized as a big infrastructure open to the whole national and international scientific community that needs to
handle risk group 4 (RG4) infectious pathogens, the laboratory is the only one in France empowered to receive and
study samples infected by RG4 pathogens. This infrastructure provides cutting edge facilities and proposes the
largest Animal Biosafety Level 4 facility in Europe, allowing performing experimentations with animal models
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
111 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ranking from small rodents to Non‐Human Primates (NHP).
The Inserm Jean Mérieux BSL4 Laboratory meets the most drastic international biological safety standards enabling
to play a key role in the early warning and surveillance of epidemics. As such, the laboratory is actively involved in
international and European-funded programs related to diagnosis and biological resources management.
Key staff of affiliated entity:
Dr Hervé Raoul is the Research Director of the INSERM. He was appointed as the Director of the French BSL4
Inserm Jean Mérieux laboratory in Lyon in 2005. In this framework he made the laboratory a research
infrastructure open to national and international research teams, and currently around ten different research teams
use the laboratory on a daily basis. Dr Raoul has also developed diagnosis activities at the national level but also
through initiation of collaboration with foreign countries in Eastern Europe, Asia and Africa. He has also been the
coordinator of the ESFRI BMS research infrastructure of the ERINHA project dedicated to the creation of a Pan
European BSL4 infrastructure. Dr Raoul has been General Director of ERINHA AISBL since July 2017 when it
was created.
Further, he participates in numerous EU funded projects dedicated to research on RG4 pathogens (Reaction,
Evident, EbolaT_x) or to networking activities (ENP4Lab, Quandhip, Emerge, Enivd, EVDLabnet) either as a PI or
partner.
Dr Caroline Carbonnelle is the Deputy Director of the INSERM Jean Mérieux BSL4 laboratory since 2009, and is
involved in the definition and coordination of all activities related to the BSL4 laboratory. She is also in charge of
the supervision of all various and large collaborative national, international and European-funded programs. She is
also the deputy general director ERINHA AISBL created in July 2017.
Dr Delphine Pannetier is responsible for the diagnostic of the viruses of the risk 4 group at the INSERM Jean
Mérieux BSL4 laboratory and of the management of the in vitro experiments that are performed in the laboratory
with collaborative teams since 2010. Since 2012, she is also the deputy director of the national reference center for
viral haemorrhagic fevers, designated by Santé publique France. She is also responsible for the management of the
training of the new workers inside the BSL4 laboratory.
Sabine Godard is an engineer of the Inserm Jean Mérieux BSL4 laboratory involved in the in vitro team
(diagnostic, EQAE, metagenomics working group activities linked to the EMERGE project) since 2016.
Eve Chevillard is responsible of the administrative, financial and monitoring of the European projects in which the
INSERM Jean Mérieux BSL4 Laboratory is involved since 2015. She supervises the contractual maturity of each
project (deliverables, milestones, progress reports) and monitors the budget (financial reports). She insures the
interaction with the European Commission and the European partners.
3. Ministry of Defense (MOD)
DGA CBRN Defense is one of the entities of the Ministry of Defense (MOD) participating in the project SHARP.
DGA CBRN Defense is an expertise site of the DGA belonging to the Ministry of the Armed Forces. Its expertise
focuses mainly on the analysis and control of risks caused by biological and chemical agents. An essential sovereign
mission is working with governments to assess biological and chemical risks. DGA CBRN Defense provides
expertise services for all CBRN equipment projects for the benefit of the forces
(protective clothing for example) and for other organizations (Ministry of Foreign Affairs). It also applies its
expertise to the destruction of old chemical ammunition and within the framework of treaties on the non-
proliferation of chemical and biological weapons. It participates in the government plan for protection against
biological and chemical terrorism.
DGA CBRN has a comprehensive technical platform enabling experimentation to be carried out in maximum
security conditions. DGA CBRN is the national reference establishment in the area of biological and chemical
defense, working for the armed forces as well as for the benefit of the national security.
Key staff of affiliated entity:
Dr Marie-Pascale Petit, Service de Santé des armées. Chief of the Office, Division Opérations NRBC (nuclear,
radiological, biological and chemical risks).
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
112 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
4. Institut Hospitalo-Universitaire (IHU) “Mediterranee Infection”
The IHU MI was created in 2012 with a support of the French “Grand Emprunt” program amounting to 72.3 million
Euros following an international Grand Jury favourable evaluation. It gathers research laboratories with the aim of
condensing French fundamental and clinical researches to fight infectious diseases. Its strategy can be divided into
four key-activities:
Developing specialized and innovative clinical departments: research in clinical activities is performed
using the best innovative equipment available on the market. This includes 75 full hospitalisation beds,
including 25 beds in high-level isolating units (BSL3). An epidemiological team implements every
week a surveillance of all epidemics that affect the French South-East region (PACA).
Attracting international top-level scientists: the IHU brings together four excellent research units.
Converting knowledge into innovations: the IHU is bridging public and private sectors and welcomes, in
its building, representatives from the major French private medical players. It is also hosting 8 startups
that were created to value innovations conducted within the research units.
Transmitting knowledge by conducting university training sessions, welcoming national and
international PhD and Master students and broadcasting Massive Open Online Courses (MOOC).
Key staff involved in the project:
Dr Jean-Christophe Lagier, M.D., Ph.D., who specializes in infectious diseases, is a full professor at the Faculty
of Medicine of Marseille, Aix-Marseille University, since 2013. He is directing the research unit MEPHI
AMU/IRD. His clinical medical activity occurs at the University Hospital Institut Mediterranée Infection in
Marseille. His research interests include gut microbiota diversity, which he has specifically explored by culture
on the D. Raoult team. By January 2019, Dr. Lagier had coauthored more than 239 publications indexed in
PubMed.
Dr Philippe Brouqui, M.D., PhD., is the Medical Director of the IHU Méditerranée Infection. Pr Brouqui leads
one of the research teams of the MEPHI unit headed by Pr Lagier and whose theme is: "Innovative approaches to
understanding and controlling contagion in the hospital". He has benefited from several State aids; PHRC (14),
APRF (2), Amidex (1), ANR (1) and European (ERDF) all carried out and which have led to the publication of
376 articles, H-index 51. His research led to several patents and copyright and to the creation of the startup
MediHandTrace SAS which pursues the research and development of the team's inventions and markets their
products.
Dr Hervé Tissot-Dupont, M.D., PhD. Specialist in public health as well as in infectious and tropical diseases,
Hervé Tissot Dupont is a doctor at the Assistance Publique-Hôpitaux de Marseille in a department specifically
dealing with patients with HIV or osteo-articular and nosocomial infections. Holder of a thesis in Life Sciences
and Health on the epidemiology of Q fever, he has carried out many missions in the South, mainly in Africa.
Since 2015, he has been a researcher in epidemiology of infectious diseases at the IHU Méditerranée Infection
and is in charge of a network for the diagnosis and epidemiological surveillance of emerging infectious diseases
in West Africa and North Africa.
11 - HCDCP- Hellenic Center for Disease Control and Prevention, MoH, Greece
Associated partner
The Hellenic Center for Disease Control and Prevention (HCDCP) is a Governmental Organization with tasks that
include formulating national strategy to prevent disease transmission; assessment and response to public health
emergencies including risk communication as well as epidemiological surveillance of communicable diseases and
environmental epidemiology; preparedness and response to serious cross border health threats; monitoring analysis
and dissemination of surveillance data to coordinate responses to and ensure prevention and control of
communicable diseases and events with public health impact. It is the National Focal Point of IHR, EWRS and has
a representative in the Executive Board of ECDC and Health Security Committee. The HCDCP has experience in
coordinating various EU programmes like PHILOS, Care, EPISOUTH and programs funded by the EU for the
Migrants.
Key staff:
Dr Eleonora Hadjipaschali is a biologist and senior management expert with over 30 years professional experience
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
113 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
in pharmaceutical industry, health care, public care in private and public sector. She is a member of Scientific
Advisory Office of HCDCP President and experienced in coordinating international and national projects.
Lamprini Pappa holds anMSc degree in Health Crisis Management and is working in the Emergency Operation
Centre.She has experience in the field and public health emergencies.
Gerasimos Gerolymatos (RN, MBA, PhD) has over 10 years of experience in emergency public health
operations and has participated in numerous national epidemiological outbreak investigations and epidemic
intelligence activities (RAS/ECDC/EUROCADET),as well as in national and international level exercises and
workgroups.
Sole beneficiary partners of HCDCP:
1. National and Kapodistrian University of Athens (NKUA), Medical School, Dept. of Microbiology The
Dept. of Microbiology, Medical School, National and Kapodistrian University of Athens (NKUA) has a functional
Biosafety Level III (BSL-III) Containment Unit for diagnostic and research purposes. It provides diagnostic tools
for various pathogens, including tick-borne, vector-borne and zoonotic ones, such as Brucella spp., Leptospira spp.,
Borrelia burgdorferi, Coxiella burnetii, Rickettsia spp., Bacillus anthracis, Yersinia pestis and Francisella
tularensis (using conventional culture, PCR and sequencing).
The Unit serves as the sole National Reference Point for investigation of cases of deliberate release of bacterial
pathogens. A total of 251 probable cases have been investigated during the period 2001-2018, in collaboration with
the Hellenic Ministry of Health and the Hellenic Center for Disease Control and Prevention.
The Unit has also specialized on Brucella and hosts a National Collection of more than 350 clinical isolates, one of
the largest of its kind for this pathogen in Europe, containing all main species affecting humans, as well as vaccine-
type isolates, isolated from human cases of brucellosis after animal vaccination.
The facilities of the Unit include Biological Safety cabinets type IIA and type III, equipment certified for BSL-III
use (centrifuges, autoclave, conventional and CO2 incubators, etc.), PCR and sequencing equipment (BioRad
thermal cyclers, Applied Biosystems Real Time PCR systems, Thermo Fisher Ion Torrent NGS platform, Thermo
Fisher 3500 Capillary Genetic Analyzer, etc.).
The Microbiology Dpt. has been accredited according to ISO17025 and ISO15189.
Key staff:
Joseph Papaparaskevas, (MD, PhD), Associate Professor, Dept. of Microbiology, Medical School,
National and Kapodistrian University of Athens.
2. Aristotle University of Thessaloniki (AUTH), A' Department of Microbiology, Medical School Aristotle
University of Thessaloniki (AUTH) comprises 9 faculties organized into 39 Schools. The Department of
Microbiology in the Medical School of AUTH, leaded by Prof. Anna Papa-Konidari, houses 3 National Reference
Centres: for Arboviruses and Hemorrhagic Fever Viruses (NRC for AHFV), for HIV/AIDS and for influenza. The
NRC for AHFV runs a BSL-3 laboratory and performs diagnostics and research on arboviruses [viruses transmitted
by mosquitoes (such as West Nile virus, ticks and sandflies)] and on viruses causing hemorrhagic fever, such as
Crimean-Congo hemorrhagic fever virus and Hantaviruses. Several novel viral strains have been identified in the
Centre. The NRC for AHFV performs also diagnostics for imported viral diseases, while the diagnostic part covers a
wide range of pathogens included in the differential diagnosis of the syndromic approach in humans. The NRC for
AHFV has close collaboration with all neighbouring Balkan countries. The AUTH NRC for AHFV is member of
EVD- LabNet (European expert laboratory network for emerging viral diseases), and Prof. A. Papa is member of the
EVD-LabNet management team. The Centre participates in several EU projects like COMPARE and EMERGE and
bilateral European programs. The Centre participated successfully in all External Quality Assurance (EQA)
programs performed by EVD-LabNet and EMERGE.
Key staff
Prof. Anna Papa – Konidari (MD, PhD), head of the Department of Microbiology.
3. University of Thessaly, Laboratory of Hygiene and Epidemiology (UTH)
The University of Thessaly (UTH) is a body incorporated under public law with complete autonomy. It is
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
114 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
supervised and granted by the State through the Ministry of Education. The Department of Hygiene and
Epidemiology of Medical School, UTH runs a certified public health laboratory. Except for teaching medical
students, it operates a post graduate master course in applied Public Health focusing on food and water safety. The
Department consists of the following sectors: epidemiology, biostatistics, occupational health, environmental
hygiene and runs the certified Laboratory of Hygiene and Epidemiology conducting both microbiological (including
molecular techniques) and chemical (HPLC, GC-M, Atomic Absorption) analysis of environmental samples. The
Department is acting as the Peripheral Public Health Laboratory of Thessaly that is accredited in accordance to ISO
17025. A total of 30 persons work in the department (full- time or part–time) (epidemiologists, microbiologists,
chemists, statisticians, biochemists, public health officers, environmental engineers). Moreover, as of 17 February
2014, the Laboratory of Hygiene and Epidemiology of UTH was appointed as WHO Collaborating Centre for the
International Health Regulations: points of entry (WHO Reference Number GRE-27). The Laboratory of Hygiene
and Epidemiology of the UTH has long experience in coordinating, managing and acting as an associating partner
of many Projects and Joint Actions funded by private, National, European and International funds. In particular the
Laboratory of Hygiene and Epidemiology is currently the coordinator of the European funded Joint Action
HEALTHY GATEWAYS (2018-2021) and in the past was the coordinator and manager of the European funded
SHIPSAN ACT Joint Action (2013-2016), the EU funded projects Ship Sanitation Training Network-SHIPSAN
TRAINET (2008-2011) and SHIPSAN project (2006-2008). It also has experience in designing, implementing and
coordinating national programmes (e.g. public health surveillance during 2004 Olympics, and “Integrated
surveillance and control programme for West Nile virus and malaria in Greece”). The Director and staff of the
Laboratory of Hygiene and Epidemiology of UTH has the following expertise: leading, managing and coordinating
a project team; identification of best practices on crisis management and to analyse conditions to transfer to various
areas; drafting reference guidelines on how to manage a crisis including logistic aspects for managing a crisis, such
as setting up crisis teams, and mechanisms of coordination during a crisis; promotion of modelling schemes and
techniques for health emergency planning; training and supporting staff to deal with the unexpected, including
development of curricula; Management of information (including IT services) and risk/crisis communication
towards professionals, media and public; Information exchange between experts and policymakers.
Key staff
Dr Barbara Mouchtouri (PhD), public health expert
Mrs Elina Kostara, environmental chemist.
4. National Health Operations Centre (EKEPY/ NHOC)
The National Health Operations Centre (EKEPY/ NHOC), is a Ministry Department, which comes directly under
the Minister of Health and operates 24/7. It was founded in 2004 in preparation of the Athens 2004 Olympic Games
and ever since, it serves as the major supervising and coordinating operational body for the Greek health system.
EKEPY has an extended field of actions, including management of emergency medical services, Public Health,
humanitarian approach to victims of natural or manmade disasters, telemedicine provision, health coverage of major
events and European cooperation. EKEPY, designs, conducts and participates in national and international Public
Health Emergency Preparedness Exercises and is also responsible for training health care professionals for
emergency management.
Key staff
Konstantinos Gogossis, MSc, PhD(c) – healthcare operation manager
Panagiota Mandi, BA (Hons), MSc in Sociology of Health.
12 – NPHC- National Public Health Center, Hungary - Nemzeti Népegészségügyi Központ (NNK)
Associated partner
National Public Health Center is a government institute in Hungary with national competence, and is responsible for
developing and controlling the national public health programs. In order to fulfil the public health goals, such as
environmental and settlement health, child and young health, radiohygiene and chemical safety, epidemiology,
microbiology, health development and occupational health, home for many of the country’s reference laboratories,
and WHO national reference laboratories, NPHC is working with a wide range of microorganisms, including BSL-3
and BSL-4 pathogens. A significant collection of medical microorganisms and a national serum bank is also
operated by NPHC. NPHC is involved in training of health care professionals specializing in medical or clinical
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
115 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
microbiology, epidemiology, or preventive medicine, and under-graduate and postgraduate training. Because of
their extended diagnostic spectrum, the
national reference laboratories of NPHC perform confirmatory and complementary diagnostic analysis for the
regional laboratories.
Key staff of the associated partner
Dr Zoltan Kis, head of the National Biosafety Laboratory, virologist, experience in the working of BSL4 level,
molecular virologist, scientific associate at Semmelweis University, Member of Decision Preparatory Committee
for Identifying and designating the essential infrastructure in health sector at the Ministry of Human Capacities,
Hungary.
Bernadett Palyi, key staff member of National Biosafety Laboratory. She has broad experience working on BSL3
and BSL4 level with viruses and bacteria, field experience. She is experienced working with animals
(immunization experiment), molecular biology, immunology, cell cultures, MALDI-TOF. She has experience in
running EU funded projects (professional, administrative and financial part). Biosecurity officer at National Public
Health Center.
Judit Henczkó, key staff member of the National Biosafety Laboratory. She has broad experience working with
dangerous bacteria on BSL3 and trained for working on BSL4 level. She has broad experience in molecular
biology, MALDI-TOF, AMR.
13 - SEMS – State Emergency Medical service, Latvia
Associated partner
SEMS (State Emergency Medical service) is national institution under Ministry of Health. SEMS provides function
of disaster medicine preparedness planning and coordination as well maintains the IHR NFP function and is focal
point for preparedness at ECDC. The SEMS has an experience of organising implementation of IHR at country as
well SEMS have an experience working in emergency preparedness at multidisciplinary dimension.
Key staff of the associated partner
Indra Linina (Master degree in Public Health) is a Deputy Head of Department of Disaster Medicine Preparedness
Planning and Coordination. Indra has an EPIET fellowship experience at Belgium Scientific Institute of Public
Health and experience of giving lectures about Public Health at Riga Stradins University. Dita Heiberga (Master
degree in Public Health) is an experienced expert in Public Health and has a great experience in Disaster Medicine
preparedness. Dita has an experience of organizing and leading trainings at local and national level and she has
been involved in EU level exercise planning.
Sintija Mūrniece is Project manager at State Emergency Medical service. Sintija has various experience in project
management, such as European Commission Interreg V-A Latvia-Lithuania program for 2014-2020,
U.S. European Commands Civil Engagement Program, as well European Union programs for planning years
2014-2020.
14 – MOHLT - LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA – Ministry of
Health of Republic of Lithuania), Lithuania
Associated partner
MOHLT - The Ministry of Health of the Republic of Lithuania carries out State administration functions
established by the laws and other legal acts and implements State policy in the health care sector. MOHLT is
responsible for legislation and coordination in the field of preparedness and reponse as well as implementation of
IHR in Lithuania. MOHLT coordinates the activities of institutions under the Ministry of Health, such as National
Public Health Surveillance Laboratory (affiliated partner), Health Emergency Situation Centre, National Public
Health Centre under The Minstry of Health.
Key staff of the associated partner
Dr Loreta Asokliene (PhD in public health) is an epidemiologist with a university degree in public health and
over 15 years of professional experience in epidemiology, preparedness and response. She leads an
Epidemiology division, which is responsible for surveillance, preparedness and response as well as IHR
implementation in Lithuania. L. Asokliene also is a contact person for WHO IHR JEE in Lithuania.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
116 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Affiliated to MOHLT: National Public Health Surveillance Laboratory – NVSPL
The State Budget Institution National Public Health Care Laboratory (NPHCL/NVSPL) was established in July 1,
2003.
On the public authorities, municipalities, private and public legal and natural persons, residents requests, NPHCL
conducts laboratory tests on living and working environment air, sewage, bathing and drinking water, food, non-
food, cosmetic and personal hygiene products, materials and articles intended to come into contact with food,
biocide, detergents, household chemicals and other laboratory tests for personal and public health.
NPHCL conducts microbiological, virologic, parasitological, immunological, immuno-enzymatic, serological,
haematological, chemical, toxicological, physical, molecular, co-clinical and other environmental and clinical
diagnostic laboratory tests needed for personal and public health.
NPHCL conducts measurements of electromagnetic radiation, noise and vibration. NPHSL is accredited by the
National Accreditation Bureau under the Ministry of Economy. NPHSL Quality Control and Microbiological
Nutrition Media Production Division IS certified according to quality standard LTS EN ISO 9001:2008. The
Quality Control Unit conducts quality control of microbiological nutrient media.“
NPHCL is owned by the State and the institution implementing the rights and obligations of the owner is the
Ministry of Health of the Republic of Lithuania.
Key staff:
Mrs. Migle Janulaitiene, Head of Rare and High Threat Pathogens Sub-department
15 - MFH (DEH) - Ministry for Health, Environmental Health Directorate - Health Regulations, Malta
Associated partner
The Ministry for Health is responsible for the strategical leadership, development of a sustainable, resilient and
responsive health system that ensures a competent, high quality and efficiency health care services in Malta. The
Environmental Health Directorate-Health Regulations fulfils the mandate of the Ministry by ensuring health
security and safeguarding the well-being of the population through the enforcement of national public health
legislation and implementation of its obligations under the International Health Regulations.
Key staff of the associated partner
Dr Martin Anthony Williams has expertise and experience in public health and general medicine, and
competencies include policy analysis, public health program planning and implementation, risk governance,
communicable disease outbreak investigation and control. His responsibility includes the implementation of core
capacities in line with International Health Regulations at designated points of entry in Malta.
16 – RIVM - National Institute for Public Health and the Environment, the Centre for Communicable Disease
Control (CIb), the Netherlands
Associated partner
National Institute of Public Health and the Environment (RIVM – Netherlands) will lead work package 6
'Preparedness and Response'. The National Coordination Centre for Communicable Disease Control (LCI) of
RIVM has a large body of knowledge and expertise on preparedness. This includes preparedness and response
(including EWRS contact point and NFP/IHR); emergency and crisis planning; international surveillance;
implementation of International Health Regulations (2005)/ Decision 1082/2013/EU; national coordination of
outbreak response; risk communication (general public, Ministry of Health); development and conduct of exercises
of infectious diseases (including planning and response); development of guidelines (for professionals,
multidisciplinary); development of a handbook and self-assessment tool on preparedness for EU Member States;
research into preparedness and response, risk communication; associate partner/work package leader in Joint
Action Healthy Gateways; associate partner/work package leader/collaborative partner in international EU projects
(AIRSAN, RAGIDA, REACT, SHIPSAN, AsiaFluCap); WHO Collaborative Center for Infectious Disease
Preparedness and IHR monitoring and evaluation.
The Centre for Infectious Diseases Research, Diagnostics and laboratorySurveillance (IDS) is responsible for
availability of complete and well-arranged diagnostic capacity in the Netherlands, including first response and up-
scaling to (re)emerging pathogens and outbreaks; an in-house reference laboratory on
highly pathogenic bacteria, both for natural occurrence and bio-terroristic activities; in-house reference laboratory
for unknown bacteria; in-house reference laboratories for e.g. Mycobacteria, polio, Zika-virus, vaccine
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
117 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
preventable diseases, influenza; laboratory surveillance of public health relevant organisms including Salmonella,
MRSA, Bordetella pertussis and Influenza; changes in organisms included in the national vaccination plan;
continuous improvement of state of the art techniques used for the above; 24/7 Advising medical laboratories,
ECDC, WHO, sister institutes and universities; guaranteeing complete medical microbiological diagnostics for the
Netherlands, including high intensive, low volume diagnostics and those of public health relevance (e.g. C.
diphteriae toxin detection).
Key staff of the associated partner:
Dr Aura Timen, professor and senior consultant of communicable disease control with specialization in community
medicine, management of infectious control teams, expertise in infectious disease preparedness, IHR monitoring
and implementation and in preparedness and response of public health events.
Dr Corien Swaan, medical doctor, senior consultant communicable disease control with medical specialization in
community medicine, experience on IHR monitoring and evaluation, ao JEE participation. WP leader EU projects
Airsan, Shipsan.
Dr Bettie Voordouw, MD, medical microbiologist, MPH, PhD, specialization in virology, vaccinology and public
health microbiology; alternate member National Focal Point Microbiology. Management experience and extensive
exposure in different international public health and policy (eg. WHO, EMA, EU, ECDC).
Acting microbiologist for clinical diagnostics at RIVM.
Dr Evelien Belfroid, researcher and project manager, specialized in high quality preparedness and response for
outbreaks with several publication of scientific papers on this topic and experience on the development of
guidelines for strategic preparedness planning and a self-assessment tool on preparedness for EU Member States.
Currently project manager of a WP JA Healthy Gateways.
Dorothee Rosskamp, policy advisor on preparedness. Background: MSc Healthcare Policy, Innovation, and
Management and BSc European Public Health. Contributed to several ECDC projects on preparedness (a.o. the
Handbook on Strategic Planning), Followed WHO ToT course for IHR M&E (Amman August 2017).
Dr Maaike de Vries, senior scientist with laboratory expertise on (molecular) detection of highly pathogenic
bacteria who has contributed to the JA EMERGE, Quandhip and EQADeBa.
Dr Johan Reimerink, senior scientist with particular expertise in emerging viral infections, including serology of
arboviral infections and development of point of care tests for outbreak situation and low capacity areas. Part of
RIVM team, involved in sharing best practices and recommendations on diagnostics and logistics in support of the
IHR implementation in overseas territories and in remote areas.
Dr Chantal Reuskens, top expert emerging virology with extensive experience in different international
projects, including JA’s, EMERGE, WHO projects etc. Editor of several journals on virology.
Three technicians with high-level expertise on identifying unknown and highly pathogenic bacteria
including on bsl3-level laboratories.
16 Sole beneficiary with RIVM: Erasmus Medical Center
Erasmus MC is the largest university medical centre in the Netherlands. The Department of Viroscience at Erasmus
MC (see www.virosciencelab.com) employs more than 135 persons of different disciplines and runs an extensive
research program on viral infections of humans and animals, with specific interests in viral zoonoses, pathogenesis and
transmission and natural and vaccine-induced immunity.
There are 5 principal investigators at the professor level, each representing an essential skill in infectious diseases,
including professors in 1) General Virology; 2) Molecular Virology & Immunology; 3) Pathology; 4) Epidemiology; 5)
Clinical Virology, as well as assistant/associate professors specialized in specific virus fields. The department houses
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
118 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
the National Influenza Centre, the national reference centre for emerging viral diseases, and the international reference
centres for viral haemorrhagic fevers and measles & rubella for WHO. The department has built up an extensive track
record in the identification of several novel human viruses, including Middle Eastern Respiratory Syndrome (MERS)
coronavirus, human metapneumovirus (HMPV), human H5N1 infection in Hong Kong, SARS-CoV, hCoV-NL63 and
MERS-CoV.
The department of Viroscience is the co-coordinator of the H2020 project COMPARE, coordinator of the H2020 Marie
Skłodowska-Curie Innovative Training Network INITIATE and EVDLabNet, European Network of Laboratories for
early detection and surveillance of (re)emerging vector-borne viral diseases, and participates in numerous other
FP7/H2020 projects of relevance to emerging disease preparedness, like ZikAlliance, a global alliance for Zika virus
control and prevention, EMERGE, RECODID, Integrated human data repositories for infectious disease-related
international cohorts to foster personalized medicine approaches to infectious disease research, PREPARE, Platform
foR European Preparedness Against (Re-) emerging Epidemics, and ECRAID, European Clinical Research Alliance on
Infectious Diseases.
Prof. Dr. Marion Koopmans focuses her research on unravelling the modes of transmission of human and animal
viruses, by developing genomic and serum profiling techniques for assessing exposure and infection to unravel these
pathways, and to signal changes in transmission or disease impact. She focuses on global population level impact of
rapidly spreading zoonotic virus infections, with special emphasis on foodborne transmission. She is co-coordinator of
COMPARE, and coordinates a worldwide collaborative network of laboratories specialized in enteric viruses, funded
through the European Commission. She holds grants from NWO, ZonMw, EU, ECDC, CDC US, FDA, and Dutch
ministries and received the NWO Stevin prize, the highest award in Dutch science.
Building from the norovirus work and molecular epidemiological expertise, she has expanded her research into
emerging viral diseases that are recognized with increasing frequency. As Head of the Virology Reference Laboratory
of the National Public Health Laboratory, a position she held from 2001 to 2014, she has been responsible for emerging
disease preparedness, and coordination of the national laboratory response to such disease outbreaks, including SARS,
pandemic influenza H1N1 2009, avian influenza, MERS and West Nile virus. Building from those experiences, she
developed an academic emerging disease preparedness research agenda at Erasmus MC as Head of the Department of
Viroscience, combining basic laboratory science and tools with epidemiology to unravel causes, pathogenesis, sources
and transmission routes of emerging viral diseases at the human-animal interface, and to translate these into
diagnostics, and tools for tracking of infection and early warning. She has (co)authored > 400 publications.
Dr. R. Molenkamp
Dr. Richard Molenkamp has a long history of working in Virology. He defended his Ph.D. thesis in 2000 at Leiden
University, The Netherlands. Subsequently he worked as post-doctoral fellow on Yellow Fever Virus (YFV)
replication and on recombinant vaccine development for Lassa virus and Hepatitis C Virus. In 2005 he started as
molecular biologist in clinical virology at the Academic Medical Center Amsterdam, The Netherlands, where he
became head of molecular diagnostics in 2007. He was responsible for assay development, validation and
implementation as well as routine detection and genotyping of clinically relevant viruses. He has been a board member
of the Dutch working group for molecular diagnostics of infectious diseases for eight years. In April 2018 he moved to
the Erasmus MC, department of Viroscience where he is heading the molecular diagnostics. He has a strong interest in
emerging viruses in general and arboviruses specifically, quality management and innovative technologies. He has
(co)authored > 80 publications.
17 – HD - Helsedirektoratet (Norwegian Directorate of Health)
Associated partner
The directorate is an executive agency and professional authority under the Ministry of Health and Care
Services.
Key staff of the associated partner
Dr Svein Høegh Henrichsen, MD, senior adviser Department of Health Care Services - responsible for
infectious diseases preparedness and crisis management
Dr Andreas Skulberg, MD, Head of Department of Health Care Services - responsible for infectious
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
119 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
diseases preparedness and crisis management
Bente Lund, Senior adviser Dep of Health Law and Biotechnology- responsible for legal framework of The
infectious diseases act.
Bengt Skotheim ( Senior adviser, Master of int. politics and security -Department of Global Health and Health
Intelligence
Affiliated to HD -The Norwegian Institute of Public Health (NIPH)
Affiliated partner
The Norwegian Institute of Public Health (NIPH) acts as a national competence institution reporting directly under
the Ministry of Health and Care Services. The NIPH has national responsibility for conducting surveillance of
infectious diseases, carrying out epidemic intelligence activities for national events and international events, and
providing support to local and national authorities and health care institutions during outbreaks. The NIPH is the
IHR (2005) National Focal Point and the contact point for EUs early warning and response system (EWRS). The
NIPH performs microbiological laboratory analysis, including diagnostics and method development, and maintains
a high containment laboratory with a 24/7 preparedness function for national microbiological diagnostics of high-
consequence infectious agents. Since 2015, the NIPH has supported the implementation of the IHR (2005) in four
Low and Middle Income Countries through a range of twinning activities including strengthening surveillance,
outbreak investigation and laboratory preparedness.
Partner Key Staff
Karin Nygård , DVM, PhD. Head of the preparedness programme, Division for Environmental health and
Infectious Diseases, Norwegian Institute of Public Health. Extensive experience in epidemic intelligence
activities, preparedness and response to infectious disease outbreaks. National focal point for ECDC in
preparedness and threat detection.
Siri L Feruglio, MD, PhD, Senior Medical Officer, Department for Zoonotic, Food- and Water-borne Infections,
Division for Environmental health and Infectious Diseases. Broad experience in the field of laboratory
preparedness, medical microbiology and infectious diseases. Working with infection prevention and control, IHR
implementation, high risk pathogens detection and prevention.
Line Vold, DVM, PhD. Director, Department for Zoonotic, Food- and Water-borne Infections, Division for
Environmental health and Infectious Diseases, Norwegian Institute of Public Health.
Emily MacDonald, Senior Advisor, Department for Zoonotic, Food- and Water-borne Infections. Extensive
experience in training, epidemic intelligence, infectious disease control, preparedness and response
Pawel Stefanoff, MD, MS, Medical Officer, Department for Zoonotic, Food- and Water-borne Infections,
Division for Environmental health and Infectious Diseases. Extensive experience in Public Health surveillance,
teaching and international health.
18- NIPH-NIH (NIZP-PZH) - National Institute of Public Health – National Institute of Hygiene - Department of
Sera and Vaccines Evaluation, Poland
Associated partner
National Institute of Public Health - National Institute of Hygiene (NIPH – NIH) (Narodowy Instytut Zdrowia
Publicznego - Państwowy Zakład Higieny) was established in 1918. Its mission is to protect health of the Polish
population through expertise, research work, monitoring and analysis of health and its determinants as well as
activities in the field of health promotion and education. The Institute deals with epidemiology and prevention of
infectious and non-communicable diseases with Polish and international partners. It has developed a diagnostic
division, including BSL–3 laboratory and laboratories accredited by WHO, Polish Centre for Accreditation (PCA)
and European Directorate for the Quality of Medicines (EDQM).
Key staff of the associated partner
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
120 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Prof. Aleksandra Anna Zasada (PhD in medical science) is the Head of Department of Sera and Vaccines
Evaluation in National Institute of Public Health - National Institute of Hygiene, Poland. Among her research
interests is rapid detection of highly dangerous pathogens such as Bacillus anthracis, Yersinia pestis and Francisella
tularensis. Prof. Zasada is experienced in molecular biology techniques and genotyping. She is also interested in
biosafety and biosecurity in microbiological laboratories. She has participated in international projects concerning
biothreat agents (EQABeBa, QUANDHIP, EMERGE) for several years.
Dr Katarzyna Zacharczuk (PhD in medical science) is a scientist in Department of Department of Bacteriology and
Biocontamination Control in National Institute of Public Health - National Institute of Hygiene, Poland. Her
scientific interests focus on differentiation and antimicrobial susceptibility of Yersinia species. She also performs
microbiological diagnostics of human infections. Dr. Zacharczuk is experienced in work with highly dangerous
pathogens under BSL3 conditions. She participated in QUANDHIP and EMERGE.
MSc Kamila Formińska (MSc in biotechnology) is a researcher in Department of Sera and Vaccines Evaluation in
National Institute of Public Health - National Institute of Hygiene, Poland. She is involved in tularemia diagnostics
and genotyping. She is experienced in molecular methods and in work with highly dangerous pathogens under
BSL3 conditions. MSc Formińska participated in QUANDHIP and EMERGE.
Janusz Janiec, Medical doctor with specialization in epidemiology, with main duties of operational coordination of
IHR NFP activities related to cross border public health events, and experience in participating in European Union
funded projects in the area of public health threats of international concern (AIRSAN, Healthy Gateways)
Paulina Maria Nowicka – Medical doctor during the last year of the specialization training in public health at the
Medical University of Warsaw, with a master degree in international relations (security and strategic studies
specialty), focused on global health and international threats to health security.
Affiliated to NIPH-NIH: The National Veterinary Institute in Puławy (NVRI)
NVRI carries out tasks in connection with the Veterinary Inspection (GIW) and reports the results directly to the
Minister of Agriculture. The major mission of the Institute is applied research in veterinary medicine, particularly
concentrating on the diagnosis and prophylaxis of infectious diseases of animals, hygiene and toxicology of food of
animal origin and feeds, protection of the environment, and development of the production technology of veterinary
biologicals and diagnostic kits. Additionally, the Institute runs postgraduate training and professional specialisation,
evaluates the quality of biologicals, participates in drug and vaccine licence process, and provides the expertise and
consultancy service for the veterinary administration. The Institute acts as the National Reference Laboratory
responsible for the diagnosis of infectious diseases of animals, surveillance of epidemiological situation in the
country, and monitoring of xenobiotics in food of animal origin and feeding stuffs.
The Institute is authorised to confer the degrees of doctor of science (ScD) and doctor of philosophy (PhD) in
veterinary sciences.
Key staff of the affiliated entity
Prof. Marcin Weiner, (DVM, PhD, ScD) is the Deputy Head of the Department of Microbiology in the National
Veterinary Research Institute, Pulawy, Poland. He has almost twenty years’ experience in detection and detailed
identification of highly dangerous and zoonotic pathogens such as Brucella spp., Francisella tularensis, Yersinia
pestis, Y. enterocolitica, Mycobacterium tuberculosis and VTEC/STEC in humans, food of animal origin and
animals. He also has an experience in serological, bacteriological and molecular techniques including MST, MLVA,
MST, PFGE, MALDI-TOF and NGS. He is also a supervisor of BSL3 Bacteriological Unit in NVRI, Poland. He
also participated in many national and international civilian or military projects, concerning biological BSL2 and
BSL3 agents identification (NCN, NCBiR, EMERGE) for over 10 years.
Prof. Monika Szymańska-Czerwińska (PhD in veterinary science) is the Head of Laboratory of Serological
Diagnosis in National Veterinary Research Institute in Pulawy, Poland. Among her research interests is rapid
detection of highly dangerous and zoonotic pathogens such as Coxiella burnetii. Prof. Szymańska- Czerwińska is
experienced in serology techniques and molecular biology and genotyping including MST, MLVA, MST and NGS.
She is also interested in biosafety and biosecurity in microbiological laboratories and have experience in laboratory
work under BSL3 conditions. She has participated in international projects concerning biological threat agents
(QUANDHIP, EMERGE) for several years.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
121 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Agnieszka Kedrak-Jablonska, DVM, PhD, is an assistant professor in Department of Microbiology in National
Veterinary Research Institute, Pulawy, Poland. Her scientific research focuses on zoonotic bacteria such as Bacillus
anthracis and Listeria monocytogenes. She has experience in diagnostics of bacterial diseases, i.e. glanders,
melioidosis, pasteurellosis and salmonellosis. She is responsible for National Reference Laboratory for anthrax,
glanders and listeriosis. She participated in international projects QUANDHIP and EMERGE. She is also involved
in batch release and sterility testing of immunological veterinary medicinal products.
19 - MS (DGS) - Directorate-General of Health, Ministry of Health (MoH) – Portugal
Associated partner
The DGS is a public body and competent institution of the MoH responsible for ensuring the Public Health
Essential Operations at national level and a technical reference for whom operates in the healthcare field. Its main
areas of activity are: to guide and develop programmes of Public Health, improved healthcare and clinical and
organizational quality management; to coordinate and assure national epidemiological surveillance; to prepare and
publish health statistics; to coordinate the public health emergencies system; to regulate and monitor the compliance
with safety and quality standards of blood, tissues and organs and to coordinate the European and International
relations of the Ministry of Health.
DGS defines the development of health programs and the surveillance of health determinants, supporting evidence-
based policies and decision taking at MoH. It coordinates the early detection of public health hazards, and the
preparedness and response of public health emergencies at national level and the respective contribution at
international level. Hosts the National Public Health Authority and its functional as national focal point for IHR,
EWRS, ECDC networks and other international representations in public health functions and coordinates the
nationwide networks of the health authorities at regional and local level. DGS has developed several initiatives in
the frame of assessing capacities and capabilities for the implementation of IHR (2005) and under the frame of
Decision 1082/2013/EU.
DGS has been participating in the technical and financial management of national and international initiatives as EU
action projects and WHO projects. Recently DGS is participating on the JA related to Physical Activity, Tobacco,
Cancer, AMR, Chronical Diseases and Healthy Gateways.
Key Staff
Dr Cristina Abreu Santos: Head of Unit, Senior expert in management, specialist in information technologies and
with experience in preparedness and response for PH Emergencies, coordinates the Portuguese Public Health
Emergencies Operations Centre at DGS. Is member of the Health Security Committee and focal point for threat
detection at international level. Also supports the Director-General of Health/National Health Authority on the
management of the network of PH Officers and on the implementation of IHR core capacities. Is also National
focal point for ECDC on Threat Detection, EWRS and IHR.
Dr Paula Vasconcelos: MD, Senior expert in PH working on public health emergencies at national and international
levels. Head of the Office for Preparedness and Public Health Support at Portuguese Public Health Emergencies
Operations Centre at DGS, involved in activities with ECDC and WHO. Supports the implementation of IHR,
assessing capacities and capabilities, also in the frame of JEE and Decision 1082/2013/EU. Coordinating and
contributing for capacity building of health professionals through training and simulation exercises. Experienced on
engaging different sectors contexts and building up collaboration and cooperation planning of preparedness and
response.
Nurse Ana Firme: Epidemic intelligence officer in the Portuguese Public Health Emergencies Operations Centre at
DGS. Supports the National Focal Point for IHR and EWRS on threat detection.
Dr Telma Gaspar: Technical expert, responsible for the procurement area in the Division of Management Support
at DGS. She is Bachelor in Financial Management with a Master of Business Administration in International
Finance and Negotiation. Has experience in administering EU grants, both from the partner and the coordinator
perspective.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
122 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Diana Fernandes: Assistant responsible to support logistics and organizational activities related to meetings,
workshops and other initiatives with external partners.
Affiliated to MS: Portuguese National Institute of Health Dr. Ricardo Jorge (INSA)
The (INSA) develops its activity as State Laboratory of the health sector, National Reference Laboratory and
National Health Observatory. Its main mission is to contribute to public health, either in the laboratory area or
through specialized health care, to provide the Ministry of Health with the adequate data for knowledge-based
decision-making essential to define the national health policy, to follow the guidelines defined by the Ministry of
Health and to answer the questions raised by the scientific community and society. INSA ensures its mission
through research and technological development, epidemiological and health services research, laboratory quality
assurance through external evaluation, diffusion of scientific culture, fostering capacities, knowledge and skills
through training programs and by providing specialized services in several domains including the prevention of
genetic diseases. INSA develops several R&D activities on the health sciences domain, with a special focus on
epidemiology, environmental health, food and nutrition, genetics, proteomics, health services, infectious diseases,
chronic diseases and health promotion. INSA has five BSL-3 laboratories, two dedicated to tuberculosis, one to
emergent diseases and two dedicated to vector-borne diseases, one of which allows animal manipulation
(Mosquitoes, ticks and mice) and experimentation. INSA also coordinates the Portuguese Network of BSL-3 labs
(LabPTBionet).
Key Staff
Maria Sofia Núncio, PhD. Head of the Unit for Emergence Response and Biopreparedness, Department of
Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Portugal. Extensive experience in the field
of laboratory preparedness, surveillance activities, preparedness and response to infectious disease outbreaks. She is
also interested in biosafety and biosecurity in microbiological laboratories. She has participated in international
projects concerning biothreat agents (EQABeBa, QUANDHIP, EMERGE, ERINHA) for several years. National
focal point for GOARN.
Isabel Lopes de Carvalho, PhD, Researcher at the Biopreparedness and Emergence Response Unit and at the Center
for Vectors and Vector-Borne Diseases, National Institute of Health Doutor Ricardo Jorge. Her main areas of
activity are Biosafety and Biosecurity, vector-borne diseases, emergency response and detection of highly
pathogenic organisms. Expertise in Biosafety and Biosecurity; experience in detection of emerging agents used as
biological weapons of class A and B and field investigation of human samples.
Ana Pelerito, Scientist at the Biopreparedness and Emergence Response Unit, Infectious Diseases Department,
National Institute of Health Doutor Ricardo Jorge, with Master’s Degree in Clinical Microbiology and Degree in
Biotechnological Engineering. Expertise in Biosafety and Biosecurity; experience in detection of emerging agents
used as biological weapons of class A and B and field investigation of human samples.
Rita Cordeiro, Scientist at the Biopreparedness and Emergence Response Unit, Infectious Diseases Department,
National Institute of Health Doutor Ricardo Jorge, Master’s Degree in Clinical Microbiology and Degree in
Biotechnological Engineering. Rita has extensive experience in the areas of Biopreparedness and Emergency
Response, Biosafety/Biosecurity, Emerging and Reemerging Infectious Diseases and Detection methods of highly
pathogenic agents in BSL-2 and BSL-3 conditions.).
Jorge Machado, PhD, Coordinator of Department of Infectious Diseases, National Institute of Health Doutor
Ricardo Jorge, Portugal. He leads the Reference and Epidemiological Surveillance Unit and is responsible of one
National Reference Laboratory. He was the responsible for basic laboratory training in microbiology, diagnostics
and molecular biology. He has led training courses across Portugal and Angola. He is the Portuguese National
Microbiological Focal Point for European Centre for Disease Control and Prevention (ECDC).
20 - IPHS - Institute of Public Health, Republic of Serbia "Dr Milan Jovanović Batut"
Associated partner
Institute of Public Health of Serbia "Dr Milan Jovanović Batut" provides advice, expertize, support and guidance for
the Serbian government and all public health institutions in all aspects of public health. The activities of the Institute
are directed towards fulfillment of public interest by developing conditions for the sustainable health and wellbeing
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
123 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
through comprehensive activities of the society, to preserve physical and mental health, to protect environment and
to prevent and control diseases, risk factors and injuries. It conducts independent researches on issues of public
health concern in Serbia.
In addition, Institute of Public Health of Serbia is National Focal Point for IHR and one of the main its tasks is
related to coordination of preparedness and response of the health system to public health emergencies, performing
together with a network of 24 district public health institutes.
Key staff of the Associated partner
Dr Verica Jovanovic, MD, Specialist in Social Medicine, Master in Health Management, PhD, Associate Professor,
Acting Director of the Institute of Public Health of Serbia, WHO National focal point for IHR, more than 20 years
of extensive experience in Public Health and Project Management.
Dr Milena Vasic, DMD, Specialist in Social Medicine, Master in Health Management, PhD, Associate Professor,
Head of Department for International Cooperation and Project Management, more than 20 years of extensive
experience in Project Management, Public Health capacity building and Human Resources Planning and
Development.
Dr Maja Stosic, MD, MPH, PhD Candidate, resident in Epidemiology, National Tuberculosis Program Coordinator,
WHO/ECDC focal point for TB Surveillance, more than 8 years of progressive experience in Project Management
and Public Health.
21 - NIJZ - National Institute of Public Health, Slovenia
Associated partner
The National Institute of Public Health (NIJZ) is the central Slovenian institution for public health practice,
research and education working on epidemiology of communicable and non-communicable diseases, health
promotion, health protection, health system research and national coordination of preventive programmes in
primary health care.
NIJZ's main activities include national health statistics and research; identifying health threats and designing
measures for their control; designing health promotion programmes; and preparing a scientific background for
health-friendly policies, programmes and measures for disease prevention.
NIJZ/ Center for communicable diseases is the National Focal point for IHR and EWRS. In 2017 the experts from
NIJZ, together with the MoH, were responsible for the preparation and implementation of the WHO JEE for
Slovenia. NIJZ has successfully coordinated and participated in various EU projects. NIJZ is currently the WP
leader in the ongoing JA Healthy GateWays.
Key staff of the associated partner
Nuška Čakš Jager, MD, Specialist in Public Health, is responsible for Planning and Preparedness activities in the
Centre of Communicable Diseases, NIJZ. She has broad experience in planning, preparedness and response on PH
threats. She is involved in many international activities linked with ECDC and WHO. She coordinates the IHR
implementation in the country working on multi-sectoral approach and responsible for preparing and carrying out
simulation exercises in PH field.
Assoc. Prof. Maja Sočan, M.D., Ph.D. is specialist in public health and internal medicine and the head of
Communicable Diseases Centre. She dedicates her research work to communicable diseases surveillance and
response. She is country representative in European networks and expert groups coordinated by ECDC (ELSNET,
EISN, Vector and Emerging Diseases, RSV) and WHO influenza network.
Tatjana Frelih is a medical doctor, and a Senior Epidemiologist at NIPH of Slovenia. She has worked as a field
epidemiologist at one of Regional Institutes of Public Health as well as a Director and a Professional Director at
the Regional Institute. For the past 10 years, she has worked at the National Institute of Public Health of Slovenia
mainly in the field of outbreaks investigation and Epidemic Intelligence.
Peter Otorepec, is a medical doctor, a specialist of hygiene and occupational medicine and the Head of
Environmental Health Centre. Having worked in the field of environment and health for almost 30 years, he has
been involved in various EU projects on development of environment – health indicators and on the impact of
exposure to air pollution and in developing method for Health impact assessment. He is the project coordinator at
NIJZ, WP8 leader for SHIPSAN ACT JA, and also WP2 leader and WP8 Co-leader for JA Healthy GateWays.
Boris Kopilović is an epidemiologist with a university degree in medicine and 19 years of professional experience
in infectious disease epidemiology on regional level. He participated as an expert in Shipsan Act JA and on Taiex
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
124 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
mission on International Health Regulations (IHR) applicable to sea transport with a view of increasing
preparedness and response capacity to serious cross-border threats to health. He is actively involved in JA Healthy
GateWays.
Ana Hojs is a public health specialist with a university degree in medicine and 20 years of professional
experience in environmental medicine. She participated in the Shipsan Act JA, and is involved also in JA
Healthy GateWays.
Claudia Adamič is a project officer with a university degree in economics. She has over 20 years of professional
experience. For the last eight years she has been working as financial and administrative officer for European
projects at the Research and Project Management Centre in NIJZ. She has been involved in almost 50 European
funded projects including SHIPSAN TRAINET, JA SHIPSAN ACT and JA Healthy GateWays.
Affiliated to NIJZ:
Laboratory for diagnosis of zoonoses, Institute of microbiology and immunology, Faculty of medicine, University of
Ljubljana (UL-IMI)
The Laboratory for Diagnosis of Zoonoses of the University of Ljubljana is involved in the clinical diagnostics
and research of zoonotic vector-borne diseases, mainly arboviruses and viral haemorrhagic fevers (Hantaviruses,
Tick-borne encephalitis virus and other Flaviviruses, Crimean-Congo haemorrhagic fever, Chikungunya virus,
Arenaviruses) and zoonotic bacteria (Coxiella burnetii, Anaplasma phagocytophillum, Bartonella sp. Francisella
tularensis, Brucella sp. etc.). The laboratory has the role of reference centre at the national and international
level, for hantaviruses, TBE and CCHF viruses. The Laboratory for Zoonoses, which manages the BSL-3
laboratory, conducts research on genetic variability and pathogenesis studies of the above mentioned pathogens
with the relation to their host-vector-man relationship. The laboratory staff is trained for working in field
(collecting rodents and ticks as natural sources of viruses), working with viruses under BSL-2 and BSL-3
conditions (virus isolates from patients and from natural hosts) and molecular detection and genetic
characterization of viruses.
Key staff of the affiliated entity
Prof. Tatjana Avšič-Županc, head of the laboratory, has 30 years of experiences in the clinical diagnostics and
research of zoonotic vector-borne diseases, mainly arboviruses and viral hemorrhagic fevers. She was principal
investigator on numerous national and international research projects and is also the head of research activity at the
Institute of Microbiology and Immunology at the Faculty of Medicine in Ljubljana. Dr Miša Korva is a PostDoc,
involved in clinical diagnosis, pathogenesis research and isolations of vector- borne pathogens. She is highly
involved in field work and have been working on several European and national projects.
Dr Nataša Knap is PostDoc involved in research of ecology and epidemiology of zoonotic pathogens. She is
highly involved in field work and have been working on several European and national projects.
22 - ISCIII - The Instituto de Salud Carlos III
Associated partner
ISCII is the main Public Research Entity in funding, managing and carrying out biomedical research in Spain. The
Institute has been conducting research and providing key services in the life and health sciences for over 20 years. It
is also the body responsible for managing Spain's Health Research and Development Strategy within the framework
of the National R+D+I Plan. It has as its main mission to support the development of scientific knowledge in the
health sciences and to contribute to innovation in healthcare and the prevention of disease. The ISCIII Centres and
Units, of national and international reference, develop research activities in biomedicine, environmental health and
public health fields. Their thematic priorities mainly include research towards infectious, chronic, rare,
neurodegenerative, tropical and occupational diseases, in telemedicine, environmental health, epidemiology, and
public health and healthcare. For this end it counts with specific centres such as the National Centre for
Microbiology and the National Centre for Epidemiology.
In November 2005, the ISCIII Office for EU and International Research Projects was created as part of a global
plan to encourage participation in health related European and International Projects. ISCIII actively participates in
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
125 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
research projects funded by the EU Framework Programmes and the CHAFEA. As an example, So far in H2020,
ISCIII participates as partner in 23 projects, and as coordinator in 3 of them.
ISCIII also acts as international representative in Health Research Fora and Programmes. ISCIII has been awarded
the Logo “Human Resources Excellence in Research” by the EC for its participation on the Human Resources
Strategy for Researchers towards the implementation of the principles contained in the European Charter for
Researchers and Code of Conduct for the Recruitment of Researchers.
Key staff:
Dr Carmen Varela-Martinez has PhD in Pharmacy, specialist in Microbiology and MS in field epidemiology.
She is epidemiologist scientist at the Spanish National Centre of Epidemiology since 2002, coordinating the
management of outbreaks of national relevance. She is the ECDC National Focal Point (acting as alternate) for
food and waterborne diseases. She has participated in different European projects and Joint Actions.
Elena Vanessa Martínez Sánchez, MD, is epidemiologist at the Spanish National Centre of Epidemiology. She is
responsible of the Spanish Surveillance System of infectious diseases database (mandatory diseases and outbreaks).
She is part of the surveillance of food and waterborne diseases team. She has participated in different projects.
Raquel Escudero has PhD in Biology. She has been a scientist at the Spanish National Center of Microbiology
(Institute of Health Carlos III) since 1995. She shares the head of the Laboratory of Reference and Research on
Special Pathogens. She has participated in different European projects including QUANDHIP and EMERGE.
Isabel Jado is PhD in Biology. She has been working in the Spanish National Center of Microbiology since 1994
and she became part of the scientific staff in since 2006. She shares the head of the Laboratory of Reference and
Research on Special Pathogens. She has participated in different National and European Projects and Joint Actions.
Mari Paz Sanchez-Seco, is working in the Arbovirus and imported viral diseases laboratory in the National
Microbiology Center that is the National Reference Laboratory for zoonoses. She is working in the center as
a researcher from 2006 and as the head of the laboratory from 2012. She was part of the scientific advisory board
of the ENIVD and now of the EVDLabNet.
Ana Vázquez is PhD in Biology, specialist in Virology. She is working at the Spanish National Center of
Microbiology since 2003, in the Arbovirus and imported viral diseases laboratory. She has participated in
different European projects.
Affiliated to ISCIII:
1. Servicio Vasco de Salud-Osakidetza/ Health Research Institute Biocruces-Bizkaia
Osakidetza is the Basque Public Health System provider of health care to more than 2 million inhabitants living in
the Basque Country - a region located in the north of Spain, formed by three provinces: Bizkaia, Araba and
Gipuzkoa. Along with its clinical facilities, like Basurto University Hospital, Osakidetza holds 4 research institutes
such as the BIOCRUCES BIZKAIA Health Research Institute (BIOCRUCES BIZKAIA HRI).
BC - BIOCRUCES BIZKAIA is the Health Research Institute of the Health Organizations of Osakidetza in
Bizkaia, with a consolidated teaching and research trajectory, whose objectives are the promotion of biomedical,
epidemiological, public health and healthcare research, as well as the scientific basis of the programs and policies of
the health system and, the promotion of translational research, understood as research aimed at accelerating the
transfer of scientific knowledge to clinical practice, according to international recommendations. Their thematic
priorities mainly include research towards infectious, chronic, rare and neurodegenerative diseases, in telemedicine,
public health and healthcare.
BIOCRUCES BIZKAIA HRI actively participates in research projects funded by the EU Framework Programmes,
e.g. in H2020, BIOCRUCES BIZKAIA participates as partner in 7 projects.
BIOCRUCES BIZKAIA HRI has been awarded the Logo “Human Resources Excellence in Research” by the EC
for its participation on the Human Resources Strategy for Researchers towards the implementation of the principles
contained in the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers.
The Clinical Microbiology and Infection Control Service of the Basurto University Hospital has a Level 2
laboratory and a Biosafety laboratory. In this Service, all patient samples are processed, both admitted to the
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
126 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
hospital itself, as well as from the Emergency Department and all the primary care centers belonging to the OSI
Bilbao Basurto. It has a team of 12 clinicians and 35 laboratory technicians trained in the microbiological diagnosis
of infectious diseases and the development of all types of microbiological techniques.
Key staff:
Dr. Jose Luís Díaz de Tuesta: Principal Investigator. Head of the Unit of the Clinical Microbiology and Infection
Control Service of the Basurto University Hospital.
Dr. Maria Carmen Nieto: Researcher. Responsible of the Molecular Microbiology Section of the Clinical
Microbiology and Infection Control Service of the Basurto University Hospital.
Dr. Mikele Macho: Researcher. Responsible of the Infection Control Section of the Basurto University Hospital.
Mikel Urrutikoetxea: Researcher. Medical resident of the Clinical Microbiology and Infection Control Service of
the Basurto University Hospital.
2. SERMAS/IDIPAZ-FIBULP
Affiliated entity
SERMAS constitutes the Public Health System for the Madrid Autonomous Region, Spain. Along with its clinical
facilities, like La Paz University Hospital – HULP, SERMAS also holds several research institutes such as the
Hospital La Paz Institute for Health Research – IdiPAZ.
HULP is the referral hospital for an area with a population of 750,000. This prestigious hospital is widely
recognised for its range of specializations such as oncology, immunology and infectious diseases (HIV), hepatology,
cardiology, paediatrics and neonatology, neurology and neurodegenerative diseases, digestive diseases and nutrition,
rheumatology, ophthalmology, maxillofacial, surgery and trauma.
IdiPAZ concentrates the clinical, translational and experimental research of the University Hospital La Paz (HULP).
The institute harbours 55 research groups distributed in six main research areas: neurosciences; cardiovascular;
infectious diseases and immunity; organ system pathologies; cancer and human molecular genetics; and surgery,
transplant and health technologies. Their groups have an active participation in European Projects such as H2020 or
CHAFEA and coordinates one of the European Reference Network – ERN in Paedriatic Transplantation.
Within IdiPAZ, SIDA and Infectious Diseases research group includes all the research in this field with an extensive
experience in managing health emergencies, such as the EBOLA one in 2014 and the Crimean- Congo hemorrhagic
fever in 2018. IdiPAZ has a High Level Isolation Unit for treating this kind of patients.
Key staff:
José Luis Narro Villanueva, Institutional Projects Manager.
23 – FoHM - Folkhälsomyndigheten (Public Health Agency of Sweden)
Associated partner
Folkhälsomyndigheten is the national agency for public responsible for both epidemiological and microbiological
surveillance of communicable diseases. The agency is the national contact point for IHR as well as EWRS and
coordinates the national implementation of actions to strengthen health security. The agency has a national
responsibility for the laboratory preparedness for high consequence pathogens and for this purpose has both BSL3
and BSL4 laboratories.
Key staff of the associated partner
Dr Anders Wallensten (MD, PhD) is the deputy state epidemiologist working at the Unit for Preparedness and
Crisis Management, Department of Communicable Disease and Health Protection.
Dr Andreas Bråve (PhD) is a senior advisor at the Department of Microbiology. Andreas has been involved in
several previous Joint Actions and is currently leading the work package on Training in the JA EMERGE.
Dr Kim Ribacke Brolin (PhD) is an analyst at the Unit for Preparedness and Crisis Management, Department of
Communicable Diseases and Health Protection. Her main tasks is national and international coordination of IHR,
representing the NFP for IHR.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
127 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
John Angrén is an analyst at the Unit for Preparedness and Crisis Management, Department of Communicable
Diseases and Health Protection. His main tasks is national and international coordination of IHR, specifically of
designated Points of Entry. Project manager for the agency, and co-lead, for WP6 (Air Transport) in EU Joint
Action “Healthy Gateways”.
24 - DH/PHE - Public Health England, United Kingdom
Associated partner
Public Health England (PHE) is an executive agency of the UK Department of Health and is the expert national
public health agency of the UK. PHE exists to protect and improve the public’s health and wellbeing and reduce
health inequalities and undertakes a range of evidence-based activities that span the full breadth of public health,
working locally, nationally and globally. PHE employs around 5000 members of staff and has a wide range of
skills and expertise. As such PHE has bid for, led and executed large numbers of multi-agency projects including
previous contributions to Joint Actions and the coordination of other EU projects which have been successfully
delivered. In addition, the UK IHR National Focal Point (NFP) is within PHE and as such, PHE is well established
to participate in the Joint Action on IHR implementation.
Key staff of the associated partner
Prof. Raquel Duarte-Davidson (PhD), a scientist and Head of Department with over 10 years’ relevant experience.
Provides chemical specialist input to a large number of Government and EU contracts involving multi-partners
across Europe on topics ranging from public health risks associated with environmental exposures to chemicals and
poisons, planning, preparedness, response and recovery from chemical incidents and alerting and notification of
cross boundary chemical incidents. Commissioner of the UK National Poisons Information Service (NPIS).
Ms Eirian Thomas (MSc), a principal scientist and project manager with a postgraduate Master’s degree in Public
Health with over 10 years’ relevant experience. Contributes to a variety of EU projects and applied research
focussing on IHR and cross border chemical health threats.
Dr Tom Gaulton (PhD), a public health scientist and project manager with 3 years of experience working on
previous Joint Actions and applied research focussed on IHR and cross border chemical health threats. Dr
Charlotte Hague (PhD), a public health scientist and project manager with over 3 years’ relevant experience.
Contributes to a variety of EU projects and applied research focussing on IHR and cross border chemical health
threats.
Dr Richard Vipond (PhD) is the Operational Manager for the PHE Rare and Imported Pathogens Laboratory
(RIPL), the UK diagnostic laboratory for imported fevers, and has been involved with several previous EU
projects (EQADeBa, Quandhip and EMERGE) and has 20 years experience of working with high containment
pathogens, diagnostic development and diagnostic service delivery.
Prof. Roger Hewson (PhD) is the Scientific Leader for Virology and Pathogenesis at the PHE Porton Down
facility and co-lead of the WHO Reference and Research Collaborating Centre for Viral Haemorrhagic Fevers and
Special Pathogens (which also includes RIP). With 20 years in this field he leads the virology and pathogenesis
team work on interventions testing, development and implementation, including with collaboration with research
institutes in endemic countries.
Affiliated to DH/PHE:
1. Public Health Wales NHS Trust (WP2 Lead)
Public Health Wales is the national public health agency in Wales and exists to protect and improve health and
wellbeing and reduce health inequalities for people in Wales. We are part of the NHS and report to the Cabinet
Secretary for Health, Well-being and Sport in the Welsh Government. We provide advice,
expertise and specialist services to Welsh Government, seven health boards, two NHS Trusts, 22 local authorities,
other agencies and to the population of Wales. We provide the public health knowledge, scientific expertise and
intelligence to lead transformational change and to drive a focus on ensuring that we deliver tangible improvements
in health and wellbeing outcomes and reduce health inequalities in Wales.
Public Health Wales, health boards and local authorities work closely together to promote public health in their
areas and jointly identify and set the local strategic agenda in partnership with communities, housing, education,
police, fire and rescue and the voluntary sector.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
128 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Key Staff
Dr Giri Shankar is the Professional Lead Consultant for Health Protection at Public Health Wales. His role
involves overseeing the operational delivery of health protection services across Wales. He is the consultant lead for
health protection programmes including sexual health, substance misuse and health & justice. Prior to joining Public
Health Wales, Giri worked for Public Health England as the Deputy Director for Health Protection. Giri obtained
his basic medical degree and masters in community medicine from India and subsequently moved to the UK. He
trained in the West Midlands obtaining both his Masters in Public Health from the University of Birmingham and
higher specialist public health training certification from the West Midlands Deanery. He is also a fellow of the
Faculty of Public Health.
Leah Morantz is the Head of Communications for Public Health Wales and has extensive experience across a
variety of internal communications, marketing and PR roles for the financial services and regulated utilities sectors.
Leading the Communications function for the organisation, Leah acts as a strategic advisor helping internal
stakeholders to meet their business objectives through planning and execution of internal and external
communications strategies. Accustomed to managing complex change across a large, matrix organisation, Leah is a
skilled project manager with the ability to balance priorities in a fast-paced, demanding environment. A leader in
her field, Leah employs a collaborative approach to her work and enjoy coaching others. Outside of work, Leah has
been the co-Vice Chair of the Women’s Network of the Royal College of Obstetricians and Gynaecologists (RCOG)
where her focus was on ensuring that the voice of women remains central to the design and provision of women’s
healthcare. She is past Chair of the Maternity Services Liaison Committee for Cardiff and Vale University Health
Board where she set the strategic direction of the committee to focus more on public and patient involvement.
2. RFH – Royal Free London NHS Foundation Trust
Affiliated partner
Royal Free London NHS Foundation Trust (RFH) runs three hospitals in London; Barnet Hospital, Chase Farm
Hospital and Royal Free Hospital. Across these hospitals, our vision is clear: to deliver world class expertise and
local care. We combine globally recognised clinical expertise with local and friendly hospital care to represent the
NHS at its best. Our mission is to be world class in terms of healthcare treatment, clinical research and teaching
excellence. We aim to deliver and develop leading local healthcare in all three of our hospitals, to improve lives
and help people thrive. Infectious Diseases is a key strategic specialty for our organisation and we deliver a
comprehensive specialist service, including the UK High Level Isolation Unit for management of viral
haemorrhagic fevers.
Key staff of the affiliated partner
Dr Michael Jacobs, is a consultant and internationally recognised expert in infectious diseases at the Royal Free
Hospital, who has received a knighthood for his work in Ebola.
25 – HSE – Health Service Executive, Ireland
Associated partner
The Irish Partner organisation is the Health Service Executive (HSE) part of which is the Health Protection
Surveillance Centre unit (HSE-HPSC). The HSE-HPSC is Ireland's specialist agency for the surveillance of
communicable diseases. It is part of the Health Service Executive and works in partnership with health service
providers and sister organisations in Ireland and around the world, to provide the best possible information for the
control and prevention of infectious diseases. HSE-HPSC strives to protect and improve the health of the Irish
population by providing timely information and independent advice, and by carrying out disease surveillance,
epidemiological investigation and related research and training.
As the overarching health service body, the Health Service Executive is responsible for the provision of health and
personal social services for everyone living in Ireland, with public funds. The Executive was established by the
Health Act, 2004 and came into official operation on 1 January 2005. The Minister for Health has overall
responsibility for the Executive in Government.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
129 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Key staff of the associated partner
Dr. Jeff Connell PhD FRCPath, is the Assistant Director of the National Virus Reference Laboratory (NVRL),
Ireland and has over 35 years’ experience in diagnostic virology. He is a member of EVD-LabNet, and is the NVRL
lead for the CL3 laboratory and WHO influenza, measles/rubella and polio programs.
Dr. Mary O’Riordan, MRCPUK, MPH, MFPHI, Specialist Public Health Medicine, Health Service Executive
(HSE) - Health Protection Surveillance Centre (HPSC). As part of my role, I am the nominated alternate IHR and
EWRS focal point and work in in the area of emergency preparedness.
26 – NAPH - National Agency for Public Health, Moldova
Associated partner
National Public Health Agency was established in September 2017, when duties earlier taken care by the National
Public Health Centre, National Council for Health Assessment and Accreditation, National Center for Health
Management, and inspection functions of Transplant Agency, Medicines and Medical Devices Agency and Standing
Committee on Drugs Control were transferred to the new institution.
The Agency performs its functions in the following areas: state surveillance, promotion and protection of public
health; state inspection in health; monitoring and assessing the health status of the population; accreditation of
medical and pharmaceutical providers and occupational safety.
The National Public Health Agency is responsible for most core public health functions at the national level and
focuses on health promotion and disease prevention by overseeing activities in preventive field medicine and
sanitation, public health surveillance, preparedness and response to public health emergencies and capacity building
and policy development. The Agency monitors and assesses the public health and the healthcare systems, and gives
expert health policy advice. It provides data and reports on principal health indicators; prepares programmes and
measures for the prevention of disease; works on the professional development of public health experts, and
performs public health research.
The institution is responsible for quality of medicines, para-pharmaceutical products and their circulation, controls
medical devices, including their radiological and nuclear safety, services provided by medical institutions and
circulation of narcotic drugs, psychotropic substances and precursors.
The NAPH also monitors threats to health and draws up measures for their mitigation; provides technical and
methodological support to territorial Centres of Public Health; assesses and reports on implementation of national
public health policies, and serves as a training centre.
Key staff of the associated partner
Dr Nicolae Furtuna, Director of the National Agency for Public Health (NAPH).
Natalia Caterinciuc, PhD, Head of the Department of Prevention and Control of Communicable Diseases.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
130 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.8.3 Financial management
A dedicated main financial officer is allocated to the financial management of the project by the coordinator
institution. Each of the partners will be required to provide a similar point of contact to work with the coordinator.
Internal financial reporting will be demanded from beneficiaries every 6 months in order to monitor the project’s
financial situation.
The coordinator will receive and distribute prepayments and subsequent activity and deliverable based payments to
the partners in accordance to the rules and payments schedules specified by the programme and CHAFEA rules.
Detailed rules will be specified in the contract and a consortium agreement to be agreed among the partners prior to
project kick off.
2.9. Budget
2.9.1. Content description and justification
Exceptional Utility status and funding model: 26 partners and 33 affiliated entities from 26 countries (out of which
15 are low GNI countries) have agreed to participate in the SHARP Joint Action which corresponds to the Health
Programme requirement “Bodies from at least 14 participating countries participate in the action, out of which at
least four are countries whose GNI per inhabitant is less than 90% of the Union average”. In addition, 34% of the
budget is used in low GNI countries as defined for the purpose of this call (30% required). Thus the proposal clearly
fulfills and substantially exceeds the requirements to receive the status of exceptional utility, and we respectfully
request to be allowed to follow a funding model of 20% member state self-funding and 80 % EU funding.
The budget is built from a strictly for-purpose basis, allocating the funding in accordance to the responsibilities of
the partners for different activities. All partners that had been designated as Associated Partners were invited to the
Commission Health Program kick-off meeting in Luxemburg, and WP leaders and co-leaders were invited to the 2nd
preparatory meeting hosted by Italy in Rome, September 4, 2018. Another planning meeting with the same group
was held in Helsinki, Finland January 14-15.
Budgeting has been done in parallel with the Work Package content development, and negotiations have been
primarily led by each WP leader. The coordinator has assisted in negotiations as needed and has both facilitated
consensus building and decision making in cases where it has been necessary. However, all major decisions have
been made with agreement from the partners. The overall budget plan has been maintained and developed by the
Coordinator.
Each work package has its own budget, which is divided among partners that participate in one way or another in
the Work Package. Each Associated partner therefore has their own partner budget split according to the
participation in the different work packages and is fully responsible for its use under the guidance of the WP leads.
Collaborating partner will participate using their own funds. The partner from Switzerland will also fully self-fund
all their activity, as Switzerland is not participating in the EU Health Programme.
The Coordinator will monitor both the WP budget execution and the Associated partner budget execution and has
the right to suggest changes in accordance to the commission budget rules. The Coordinator will also have the right
and responsibility to raise potential issues for decision to the Steering Comittee where the workplan for any reasons
cannot be executed. A consortium agreement will be developed and agreed among partners for more detailed rules
of procedure in addition to following the terms of the project contract between partners and the EU commission.
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
131 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
2.9.2 Detailed budget
Applicant Number/
Short name: 01 – THL
(If affiliated entity: Affiliated to which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Project Director (MS) 13 671,00 4,40 60 152,40
Project Coordinator (OK) 6 615,00 33,00 218 295,00
Project Coordinator (AK) 6 909,00 33,00 227 997,00
IHR Specialist 1 (JS) 7 056,00 5,00 35 280,00
IHR Specialist 2 (HK) 9 481,50 2,85 27 022,28
IHR Specialist 3 (TP) 10 143,00 2,00 20 286,00
IHR Specialist 4 (SS) 6 909,00 4,00 27 636,00
Financial Officer (PT) 5 586,00 10,00 55 860,00
Communication officer 6 615,00 6,00 39 690,00
Project Assistant 4 704,00 15,00 70 560,00
Public health expert (OL) 9 114,00 2,00 18 228,00
Total Person-months Total Costs (€) for (A)
117,25 801 006,68
Justification
WP1 lead - Coordination team consist of project director, 2 project coordinators, financial officer, project assistant and
communication officer. Coordination team will contribute to all work packages. In addition to coordination team IHR
specialists and public health expert will participate in WP4,5,6,7,8,9 and 10.
WP2: communications officer WP3
project coordinator (OK)
WP4: project director and IHR Specialist (JS) WP5:
project director and IHR Specialist (JS) WP6:
project coordinator (AK)
WP7: project coordinator (AK), IHR Specialist (SS) WP8:
project coordinator (AK)
WP9: IHR Specialist (HK)
WP10:Public health expert (OL)
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 40 000,00 WP10 Clinical experts on infectious diseases
20 000,00 WP1 expert on IHR monitoring and evaluation
Total costs (€) of (B) 60 000,00
Justification
External expert to support EU presidency meeting planning and execution.
For activities of theWP10 clinical experts from a Finnish infectious diseases hospital will be subcontracted.
( C) Other direct costs
(C.1) Travel Costs (€) Justification
84 202,24 WP1 Steering Committee meeting ‐ 1 per year (4 persons). Outside of annual meetings
WP1 Consortium Annual and advisory board meetings
WP1 Invited Experts'
WP1 Relevant conferences and thematic meetings
WP3 meetings and events
WP4 meetings and events
WP5 meetings and events
WP6 meetings and events
WP7 meetings and events
WP8 meetings and events
WP9 meetings and events
WP10 meetings and events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
201 000,00 WP1 Steering Group meetings ‐ meeting costs (2‐3 meeting per year)
WP1 Consortium Annual meetings and advisory board ‐ meeting costs (1 meeting per
year/80 persons)
WP1 EU presidency meeting in Helsinki ‐ organising meeting
WP1 Conference fees
WP1 CFS costs
WP2 dissemination materials and services (translation, interpretation, printing,
domain/URL)
WP7 Laboratory consumables EQAE and delivery of samples
Total Costs (€) of ( C) 285 202,24
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 80 234,62
TOTAL ESTIMATED ELIGIBLE COSTS 1 226 443,54
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
132 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 01A1 - FFA
(If affiliated entity: Affiliated to which Applicant number/Short
name) 1 - THL
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Head of research unit 7 767,84 2,50 19 419,60
Senior inspector 5 738,05 1,00 5 738,05
Total Person-months Total Costs (€) for (A)
3,50 25 157,66
Justification
Ruokavirasto (Finnish Food Authority) will contribute and offer it´s specialists to participate in work packages
WP1, 6 and 9.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
4 800,00 WP1 general meetings, 2 meetings and 1 participant (travel)
WP6 meetings and events
WP9 meetings and events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 4 800,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 097,04
TOTAL ESTIMATED ELIGIBLE COSTS 32 054,70
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
133 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 02 - RKI
(If affiliated entity: Affiliated to which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
WP7 Technician 5 163,65 18,00 92 945,70
Project Manager 5 528,12 9,00 49 753,07
Scientist WP7 7 608,26 9,00 68 474,38
Scientist IHR 7 838,80 18,00 141 098,33
SHARP Co coordinator, WP7 lead 8 610,89 1,80 15 499,60
WP7 task lead 8 403,26 3,50 29 411,42
WP7 scientist 8 403,26 1,80 15 125,88
IHR Scientist 7 274,96 3,60 26 189,84
Co -lead WP8, Scientist 8 721,49 3,60 31 397,37
WP7 technician 5 761,66 3,64 20 992,95
Total Person-months Total Costs (€) for (A)
71,94 490 888,53
Justification
1 scientist: coordinator WP7, co-coordinator JA and support, advisor contribution to task 1, carry out
serological ananlysis, supervising EQAE including evaluation, reporting ;
3 scientists: lead task 1 EQAE, organisation and evaluation of EQAE, sample preparation, quality assurance, meeting
for definition of best practices, reporting;
1 project manager: logistics and legal issues of EQAE, correspondence with EQAE participants, reporting;
3 technicians: sample preparation, testing quality assurance, conducting EQAEs, lab work under BSL3 conditions;
3 scientists WP 8,4,5,6 (line 48,76,83): conduct training needs assessment, compile inventory on training material,
develop and implement generic IHR-trainings, including e-learning components, compile an overview over
training activities in the JA and provide a generic module on IHR core elements to be added on the specific
trainings, e.g. on laboratory issues, cross-sectional coordination of trainings within SHARP
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 65 000,00 WP7 For a company to establish online data entry masks and to perform statistical
57 300,00 WP7 For consultant senior scientist
Total costs (€) of (B) 122 300,00
Justification
Support for at least 6 EQAE, development of data entry masks, data collection, statistical analysis of EQAE results,
templates for reporting, special IT hardware and software will be applied, this activity cannot be carried out by
participants, outsourcing is in compliance with EQAE‐schemes.
Senior scientist: coordinator WP7, co‐coordinator JA SHARP, expert consultant.
( C) Other direct costs
(C.1) Travel Costs (€) Justification
26 300,00 WP1 general meetings to 8 meetings, 1-2 participants
WP7 3 technical meetings, four persons for two days
WP8 Training of lab personnel
WP8 Local exercises and training
WP10 3 working meetings, one person
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
14 000,00 WP7 Laboratory materials (DNA extraction kits, PCR reagents, agar‐plates, biobank
reagents) for preparation of EQAE samples and the bacterial repository
WP7 publication open access
Total Costs (€) of ( C) 40 300,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 45 744,20
TOTAL ESTIMATED ELIGIBLE COSTS 699 232,73
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
134 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant
Number/ Short 02A2 – UMR
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name) 2-RKI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Scientist, WP7, Task 1 viral 7 584,74 1,08 8 191,52
Total Person-months Total Costs (€) for (A)
1,08 8 191,52
Justification
Scientist participating in WP7
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
7 100,00 WP1 general meetings to 5 meetings, 1 participant
WP7 3 technical meetings, (one person for two days)
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
21 000,00 WP7 Shipment viral EQAE samples
WP7 Laboratory consumables (DNA/RNA extraction kits, PCR reagents) for the
production and analysing of EQAE samples
Total Costs (€) of ( C) 28 100,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 540,41
TOTAL ESTIMATED ELIGIBLE COSTS 38 831,93
Applicant
Number/ Short 02A3 – BNITM
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name) 2 – RKI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Postdoc 6 667,30 12,00 80 007,60
Head Department 8 918,20 1,05 9 390,86
Group leader 6 667,30 1,08 7 200,68
Technician 3 660,00 2,52 9 223,20
Total Person-months Total Costs (€) for (A)
16,65 105 822,35
Justification
Personnel is required for performing the activities of Task 2.3 in WP7. This includes the work on near patient
diagnostics for BSL-4 pathogens.
Personnel is also needed to participate in other activities, such as EQA, NGS workshops etc. Head department will
lead the activities and attend the meetings.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
7 100,00 WP1 general meetings to 5 meetings and one person
WP7 3 technical meetings, (one person for two days)
WP8 Lab training of personnel
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
8 000,00 WP7 Laboratory consumables (DNA/RNA extraction kits, PCR reagents) for
analysing of EQAE samples
WP7 Shipment of EQAE samples (inactivated material)
Total Costs (€) of ( C) 15 100,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 8 464,56
TOTAL ESTIMATED ELIGIBLE COSTS 129 386,91
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
135 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant
Number/ Short 02A4 – BwIM
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name) 2 – RKI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Scientist E14 WP7 task 2.3 7 198,00 12,00 86 376,00
Senior scientist 6 954,00 0,72 5 006,88
Senior scientist 6 222,00 1,80 11 199,60
Technician 3 721,00 2,88 10 716,48
Total Person-months Total Costs (€) for (A)
17,40 113 298,96
Justification
WP1: participation to meetings
WP7
task 1: participation to EQAs; task 2: co-lead; task 2: lead of AST working group and participation to other
working groups; task 3: participation
WP8
Training offers and participation to trainings; AST-work of NN scientist in charge of the project: phenotypic AST
testing of isolates, test-optimization and validation, handling of data from partners and bioinformatic evaluation,
whole genome sequencing of isolates and bioinformatics, training of scientist from MS, organization of meetings,
shipment of material
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
7 100,00 WP1 general meetings to 5 meetings and one person
WP7 3 technical meetings; one person for two days
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
10 000,00 WP7 Consumables (DNA/RNA extraction kits, PCR reagents) for analysing of EQAE
samples
WP7 Shipment of EQAE samples (living material)
Total Costs (€) of ( C) 17 100,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 9 127,93
TOTAL ESTIMATED ELIGIBLE COSTS 139 526,89
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
136 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant
Number/ Short 02A5 – FLI
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name) 2 – RKI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
PostDoc 1 7 990,00 0,36 2 876,40
PostDoc 2 4 770,00 0,36 1 717,20
PostDoc 3 6 260,00 0,36 2 253,60
PostDoc 4 6 161,00 0,36 2 217,96
Total Person-months Total Costs (€) for (A)
1,44 9 065,16
Justification
Scientists group working for EQAE samples (WP7 and 8)
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
7 200,00 WP7 FLI‐Jena (Bact.): 3 technical meetings (one person for two days)
WP7 FLI‐ Riems (Vir.): 3 technical meetings (one person for two days)
WP8 Training of participants lab vir
WP8 Training of participants lab bact
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
19 000,00 WP7 Laboratory consumables (DNA extraction kits, PCR reagents, agar plates) for
analysing of EQAE samples
WP7 Shipment of EQAE samples
Total Costs (€) of ( C) 26 200,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 468,56
TOTAL ESTIMATED ELIGIBLE COSTS 37 733,72
Applicant
Number/ Short 02A6 – UKF
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name) 2 – RKI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Head of the isolation unit, Senior consultant 7 270,32 9,00 65 432,89
Total Person-months Total Costs (€) for (A)
9,00 65 432,89
Justification
Senior consultant participating in WP10 Case study
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
3 500,00 WP1 general meetings to 5 meetings, 1 participant
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
3 000,00 WP10 workshop organisation
Total Costs (€) of ( C) 6 500,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 5 035,30
TOTAL ESTIMATED ELIGIBLE COSTS 76 968,19
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
137 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 03 – INMI
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Scientific Director 16 900,00 2,00 33 800,00
Laboratory Director 12 220,00 2,80 34 216,00
Diagnostic Department Director 13 130,00 0,50 6 565,00
Clinical Unit Director 11 700,00 1,50 17 550,00
Head of Biocontainment laboratories 5 980,00 1,10 6 578,00
Epidemiologist 5 980,00 1,70 10 166,00
Epidemiologist 5 980,00 29,00 173 420,00
Virologist/Microbiologist 4 940,00 29,00 143 260,00
Total Person-months Total Costs (€) for (A)
67,60 425 555,00
Justification
WP10 leader, WP1 Co-leader and WP7 Co-leader
1 scientist: coordinator WP10, co-coordinator JA and support, advisor contribution to WP7; 1
scientist: co-coordinator JA and support, support WP3, co-coordinator WP7;
1 scientist: support WP7 ;
1 clinicians: support WP10, including development and implementation of protocols for task 2, 3 and 4 of WP10; 2
researchers: conducting EQAEs, lab work under BSL3 conditions, carry out serological analysis;
1 epidemiologist: coordination WP10;
1 epidemiologist to be hired: support development and implementation of protocols and assessment tools for task 2, 3
and 4 of WP10;
1 virologist/microbiologist to be hired: support WP7 activities, reporting
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
30 500,00 WP1 General meeting 8 meetings and 1‐2 participants
WP3 Evaluations meetings
WP6 working meeting for evaluation laboratory capabilities
WP8 Trainings for scientist
WP10 working meetings (Task1 and 4)
WP10 assessment visits and workshops (Task 2)
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
28 000,00 WP7 shipment of EQAEs ,
WP7 Laboratory consumables for EQAEs and laboratory activities ,
WP10 workshop (for example meeting rooms rent, catering etc.)
Total Costs (€) of ( C) 58 500,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 33 883,85
TOTAL ESTIMATED ELIGIBLE COSTS 517 938,85
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
138 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 03A7 – MoH
(If affiliated entity: Affiliated to which Applicant number/Short
name) 3 – INMI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior Expert 10 400,00 2,00 20 800,00
Total Person-months Total Costs (€) for (A)
2,00 20 800,00
Justification
Specialist participating in work packages WP5 and WP6
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
7 200,00 WP1 General meetings, 5 meetings and 1 participant
WP5 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 7 200,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 960,00
TOTAL ESTIMATED ELIGIBLE COSTS 29 960,00
Applicant Number/
Short name: 03A8 – ISS
(If affiliated entity: Affiliated to which Applicant number/Short
name) 3 – INMI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Microbiologist and molecular biology 2 990,00 1,10 3 289,00
Molecular biology 1 950,00 1,20 2 340,00
Medical doctor and infectious diseases specialization 6 500,00 0,10 650,00
Microbiologist 2 080,00 0,40 832,00
Total Person-months Total Costs (€) for (A)
2,80 7 111,00
Justification
Specialist participating in work packages WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
1 000,00 WP1 General meetings
WP8 meetings and training
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
12 000,00 WP7 Laboratory consumables (DNA extraction kits, molecular biology kits, primers and probes,
reagents, sequencing kits, disposable materials for molecular biology, bacterial grothw and P3
facilities)
WP7 Shipment EQAE samples
Total Costs (€) of ( C) 13 000,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 407,77
TOTAL ESTIMATED ELIGIBLE COSTS 21 518,77
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
139 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 03A9 – IZSPB
(If affiliated entity: Affiliated to which Applicant number/Short
name) 3 – INMI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Veterinarian - Supervisor and coordinator, data analysis 3 666,00 1,00 3 666,00
Biologist - Execution of the tests 1 841,50 1,00 1 841,50
Total Person-months Total Costs (€) for (A)
2,00 5 507,50
Justification
Specialist participating in work packages WP7 and WP8. Veterinarian ‐ Supervisor and coordinator, data analysis. Biologist ‐
Execution of the tests.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
16 880,00 WP1 general meetings
WP7 working meetings
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
9 500,00 WP7 Laboratory consumables for EQAE (PCR reagents, extraction KITs, primers, probes,
disposable materials)
WP7 Shipment of EQAE samples
Total Costs (€) of ( C) 26 380,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 232,13
TOTAL ESTIMATED ELIGIBLE COSTS 34 119,63
Applicant Number/ Short
name: 03A10 – IZSLER
(If affiliated entity: Affiliated to which Applicant number/Short
name) 3 – INMI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Head Veterinary 11 063,91 0,70 7 744,74
Biologist 5 985,45 1,20 7 182,54
Total Person-months Total Costs (€) for (A)
1,90 14 927,28
Justification
Specialist participating in work packages WP7 and WP8.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
9 400,00 WP1 General meetings
WP7 Working meetings
WP8 Training meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
9 500,00 WP7 Laboratory consumables for EQAE
WP7 Shipment of EQAE samples
Total Costs (€) of ( C) 18 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 367,91
TOTAL ESTIMATED ELIGIBLE COSTS 36 195,19
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
140 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 04 – BMASGK
(If affiliated entity: Affiliated to which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
MD, Head of Department 5 482,26 1,34 7 346,23
Deputy Head of Department 5 482,26 0,82 4 495,45
Project officer 5 482,26 0,82 4 495,45
Total Person-months Total Costs (€) for (A)
2,98 16 337,13
Justification
Specialists participating in work package WP8.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
13 300,00 WP1 5 general meetings x 1 participant
WP8 3 workshops x 3 participants
WP8 2 working meetings
WP8 Laboratory training
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 13 300,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 074,60
TOTAL ESTIMATED ELIGIBLE COSTS 31 711,73
Applicant Number/ Short
name: 04A11 – VHA
(If affiliated entity: Affiliated to which Applicant number/Short name)
4 – BMASGK
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Speicialist physician Intensive Care Unit (Medical ICU) 5 200,00 1,50 7 800,00
Specialist Physician Infectious Diseases 5 200,00 1,50 7 800,00
Specialist Nurse ICU 3 250,00 1,00 3 250,00
Assistant for Hygiene, Risk management, psychosocial support 3 900,00 1,00 3 900,00
Total Person-months Total Costs (€) for (A)
5,00 22 750,00
Justification
Specialists participating in WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
4 000,00 WP10 Workshop 1
WP10 Workshop 2
WP10 Workshop 3
WP10 Workshop 4
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 4 000,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 872,50
TOTAL ESTIMATED ELIGIBLE COSTS 28 622,50
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
141 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 04A12 – AGES
(If affiliated entity: Affiliated to which Applicant number/Short
name) 4 – BMASGK
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Head of Department, clinical Scientist 7 442,50 0,36 2 679,30
Technician 3 965,00 1,08 4 282,20
Head of department 8 242,00 0,60 4 945,20
Total Person-months Total Costs (€) for (A)
2,04 11 906,70
Justification
Specialists participating in work packages WP6, WP7 and
WP8. Laboratory and Scientific work within Working on EQA
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
9 400,00 WP1 General meetings
WP6 Expert meetings and workshops
WP7 Technical meetings (3), (one person for two days)
WP8 Training of participants lab
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
9 500,00 WP7 Laboratory materials (DNA extraction kits, PCR reagents, agar plates) for analysing of
EQAE samples
WP7 Shipment of EQAE samples
Total Costs (€) of ( C) 18 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 156,47
TOTAL ESTIMATED ELIGIBLE COSTS 32 963,17
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
142 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 05 – MCA
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Project Coordinator 1 070,40 6,80 7 278,72
IHR Adviser 2 154,99 3,50 7 542,47
Project Assistant 1 663,09 5,00 8 315,46
Project Officer 1 384,00 5,80 8 027,20
Total Person-months Total Costs (€) for (A)
21,10 31 163,85
Justification
Project coordinator will coordinate project activities and be involved in WP5, WP6,WP7 and WP8.
IHR Adviser will be involved as a consultant in WP5 and WP8 .
Project Assistant will be involved as Technical Expert in the WP5, WP6 and WP8. Project
Officer will participate in WP1, WP2, WP3, WP4, WP6, WP7 and WP8.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 14 000,00 WP7 Laboratory expert, Sarajevo
14 000,00 WP7 Laboratory expert, Mostar
Total costs (€) of (B) 28 000,00
Justification
Experts from a high-level laboratories will be subcontracted to participate in WP7 EQAE
( C) Other direct costs
(C.1) Travel Costs (€) Justification
46 400,00 WP1 Participation in the general meetings, 5 meetings 1 participant
WP4 3 events (workshop, meeting), 1 participants per event
WP5 4 workshops (2 participants per workshop, internal or external experts)
WP6 4 events (workshops/advanced trainings/meetings), 2 internal or external experts
WP7 4 working meetings (2 staff member, 2 external experts)
WP8 2 working meetings, 2 participants per meeting
WP8 International/regional secondment/internship (2 staff members/2 weeks or 1 staff
member/4 weeks)
WP 8 - 3 external trainings (1 basic training, 2 advanced trainings), 3 participants/training
from other relevant institutions
WP8 3 external trainings (1 basic training, 2 advanced trainings), 3 participants/training
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
16 400,00 WP2, WP5 and WP8 ‐ Printing costs for promotion and dissemination materials
WP8 Organization of one sub‐regional workshop (catering, venue etc.)
WP8 Organization of a national exercise (catering, supplies etc.)
Total Costs (€) of ( C) 62 800,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 8 537,47
TOTAL ESTIMATED ELIGIBLE COSTS 130 501,32
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
143 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 06 – CIPH
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
MEDICAL RESIDENT 1 745,92 2,80 4 888,57
HEAD OF UNIT, spec., prim. 1 3 629,24 2,15 7 802,86
HEAD OF UNIT, spec. 1 2 775,10 1,25 3 468,87
HEAD OF UNIT, spec. 1 2 356,04 1,30 3 062,85
MEDICAL RESIDENT 1 771,49 2,80 4 960,17
HEAD OF UNIT, spec., PhD 1 3 583,30 0,45 1 612,48
HEAD OF UNIT, spec., PhD 1 3 005,43 0,50 1 502,71
HEAD OF UNIT, spec. 1 2 731,46 0,40 1 092,59
Total Person-months Total Costs (€) for (A)
11,65 28 391,10
Justification
Specialists participating in WP5, WP7, WP8 and WP10
Experts in the field, covering epidemiology, microbiology, sanitary inspection and clinical infectology.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
28 100,00 WP1 General meetings, 5 meetings and 1 participant
WP5 Workshops participation (travel)
WP6 Simulation & exercise
WP6 Workshops and meetings
WP7 working meetings (travel)
WP8 working meetings, workshops and field exercise;
WP10 working meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
19 900,00 WP7 Laboratory consumables ‐ laboratory reagents
WP8 Laboratory training for participants in WP7
WP8 Workshop organization
Total Costs (€) of ( C) 48 000,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 5 347,38
TOTAL ESTIMATED ELIGIBLE COSTS 81 738,48
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
144 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 06A13 – UHID
(If affiliated entity: Affiliated to which Applicant number/Short name)
6 – CIPH
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
DIRECTOR 3 947,34 1,55 6 118,38
DEPUTY DIRECTOR 3 470,37 1,65 5 726,12
HEAD OF DEPARTMENT, PhD 1,2 1 886,93 2,00 3 773,86
HEAD OF DEPARTMENT, PhD 1,2 3 160,56 1,40 4 424,78
Total Person-months Total Costs (€) for (A)
6,60 20 043,14
Justification
Specialists participating in WP6, WP7, WP8 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
15 300,00 WP6 Simulation & exercise
WP6 Workshops and meetings
WP7 working meetings
WP8 working meetings, workshops and field exercise
WP8 External national experts to training;
WP8 Secondment (1 personX1month)
WP10 working meetings ‐ 4 trips
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
6 000,00 WP 7 Consumables - laboratory reagents
Total Costs (€) of ( C) 21 300,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 894,02
TOTAL ESTIMATED ELIGIBLE COSTS 44 237,16
Applicant Number/ Short
name: 06A14 - MH-BSI
(If affiliated entity: Affiliated to which Applicant number/Short name)
6 – CIPH
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
HEAD OF UNIT, NON-HEALTH DIVISION 3 2 024,08 2,50 5 060,20
HEAD OF UNIT, NON-HEALTH DIVISION 3 2 362,74 2,00 4 725,48
Total Person-months Total Costs (€) for (A)
4,50 9 785,68
Justification
Specialist participating inWP5
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
4 100,00 WP5 Workshops participation
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 4 100,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 972,00
TOTAL ESTIMATED ELIGIBLE COSTS 14 857,68
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
145 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 07 – SUJCHBO
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Dept. Head, analytical chemist 3 400,00 9,00 30 600,00
Molecular biologist 2 312,00 5,90 13 640,80
Immunologist 1 849,60 7,40 13 687,04
Total Person-months Total Costs (€) for (A)
22,30 57 927,84
Justification
Participation in WP1, WP2, WP3, WP4 and WP6; Laboratory activities in WP7; Training in WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
18 100,00 WP1 General meetings, 5 meetings and 1 participant
WP6 Workshops, expert consensus meeting
WP7 technical meetings
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
17 400,00 WP7 Laboratory consumables ‐ EQAE reagents
WP7 Shipment EQAE samples
WP7 Organization of technical meeting ‐ venue, catering etc.
WP8 Training of participants ‐ consumables (reagents, PPE, etc.)
Total Costs (€) of ( C) 35 500,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 6 539,95
TOTAL ESTIMATED ELIGIBLE COSTS 99 967,79
Applicant Number/
Short name: 08 – SSI
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior researcher 8 550,00 3,50 29 925,00
Senior researcher 10 004,40 5,25 52 523,10
Chief advisor, executive office 8 550,00 0,50 4 275,00
Total Person-months Total Costs (€) for (A)
9,25 86 723,10
Justification
Specialists to participate in WP1, WP7, WP8 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
21 400,00 WP1 general meetings, 5 meetings and 1 participant
WP7 working meetings
WP8 Training of participants
WP10 working meeting
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
6 000,00 WP7 Laboratory consumables
WP7 Shipment EQAE samples
Total Costs (€) of ( C) 27 400,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 7 988,62
TOTAL ESTIMATED ELIGIBLE COSTS 122 111,72
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
146 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 09 – MSAE
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Adviser 2 613,00 0,50 1 306,50
Adviser II 2 814,00 0,20 562,80
Total Person-months Total Costs (€) for (A)
0,70 1 869,30
Justification
Specialists participating in WP1 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
6 500,00 WP1 General meetings, 5 meetings and 1 participant
WP8 external experts to IHR trainings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 6 500,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 585,85
TOTAL ESTIMATED ELIGIBLE COSTS 8 955,15
Applicant Number/
Short name: 09A15 – HB
(If affiliated entity: Affiliated to which Applicant number/Short name)
9 – MSAE
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Assistant 3 077,40 0,70 2 154,18
Senior Scientist 2 274,60 10,00 22 746,00
Scientist 2 007,00 12,00 24 084,00
Scientist 2 007,00 2,80 5 619,60
Total Person-months Total Costs (€) for (A)
25,50 54 603,78
Justification
Specialists participating in WP1, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
19 400,00 WP1 General meetings
WP7 Working meetings
WP7 Training of participants
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
9 500,00 WP7 Laboratory consumables for EQAE
WP7 Shipment of EQAE samples
Total Costs (€) of ( C) 28 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 5 845,26
TOTAL ESTIMATED ELIGIBLE COSTS 89 349,04
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
147 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 10 - MoH-FR
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Policy advisor 8 000,20 8,95 71 601,79
Policy advisor 8 000,20 0,50 4 000,10
Policy advisor 8 000,20 3,50 28 000,70
Health security officer 8 000,20 2,80 22 400,56
Health security officer 8 000,20 1,50 12 000,30
Health security officer 8 000,20 0,50 4 000,10
Projet officer 4 065,10 29,75 120 936,73
Total Person-months Total Costs (€) for (A)
47,50 262 940,28
Justification
WP4 lead
Specialists participating in WP1, WP2, WP3, WP4, WP5, WP6 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
23 800,00 WP1 General meetings, 8 meetings 1‐2 participants
WP4 workshop (workshop2)
WP5 meetings
3 workshops x 2 participants
1 workshop 7 x 2 participants
WP8 training
1 basic workshop x 2 participants
2 advanced workshops x 2 participants
WP6 meeting for task 1.2
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 23 800,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 20 071,82
TOTAL ESTIMATED ELIGIBLE COSTS 306 812,10
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
148 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 10A16 – INSERM
(If affiliated entity: Affiliated to which Applicant number/Short name)
10 - MoH FR
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Director of the Inserm BSL4 Laboratory 8 121,00 1,20 9 745,20
Total Person-months Total Costs (€) for (A)
1,20 9 745,20
Justification
Specialist participating in WP7
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
4 900,00 WP1 general meetings
WP7 meetings and events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
6 475,00 WP7 Laboratory consumables for EQAE (inactivation experiments, diagnostic tests etc.)
WP7 shipment of EQAE samples
Total Costs (€) of ( C) 11 375,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 478,41
TOTAL ESTIMATED ELIGIBLE COSTS 22 598,61
Applicant Number/
Short name: 10A17 – SPF
(If affiliated entity: Affiliated to which Applicant number/Short name)
10 -MoH FR
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Deputy director of the Division of Alert and Crisis 9 149,06 0,70 6 404,34
Total Person-months Total Costs (€) for (A)
0,70 6 404,34
Justification
Specialist participating in WP5
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
2 340,00 WP5 workshops on cross border cooperation 3 meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 2 340,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 612,10
TOTAL ESTIMATED ELIGIBLE COSTS 9 356,44
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
149 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 10A18 - MOD – FR
(If affiliated entity: Affiliated to which Applicant number/Short name)
10 -MoH FR
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
CBRN expert DOD GL 7 150,00 1,00 7 150,00
CBRN expert DOD LB 5 200,00 0,40 2 080,00
CBRN expert DOD SR 5 200,00 0,80 4 160,00
CBRN expert DOD FR 5 200,00 0,70 3 640,00
CBRN expert DOD ME 5 200,00 0,40 2 080,00
CBRN expert DOD VL 5 200,00 0,40 2 080,00
DOD PHC President of biotox piratox network scientific board 8 450,00 0,40 3 380,00
DOD MC HIA 8 450,00 0,20 1 690,00
DOD MC HIA 8 450,00 0,20 1 690,00
DOD PHA 7 150,00 0,20 1 430,00
Total Person-months Total Costs (€) for (A)
4,70 29 380,00
Justification
Specialists participating in WP7, WP8, WP9 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
15 900,00 WP1 general meetings
WP2 dissemination meetings
WP3 evaluation meetings
WP7 working meetings
WP8 meetings and events
WP9 meetings and events
WP10 meetings and events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
5 000,00 WP8 Samples transportation
Total Costs (€) of ( C) 20 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 3 519,60
TOTAL ESTIMATED ELIGIBLE COSTS 53 799,60
Applicant Number/
Short name: 10A19 – IHUMI
(If affiliated entity: Affiliated to which Applicant number/Short name)
10 -MoH FR
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Epidemiologist/clinician 7 000,50 13,00 91 006,50
Total Person-months Total Costs (€) for (A)
13,00 91 006,50
Justification
Specialist participating in WP1 general meetings, WP2, WP3 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
5 900,00 WP1 general meetings
WP10 working meetings and workshops
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
3 000,00 WP10 organising workshop
Total Costs (€) of ( C) 8 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 6 993,46
TOTAL ESTIMATED ELIGIBLE COSTS 106 899,96
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
150 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 11 – HCDCP
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
WP Lead 3 451,66 14,00 48 323,18
Project Manager 2 863,87 11,50 32 934,55
Internal Evaluation Officer 2 413,66 16,50 39 825,36
Internal Evaluation Officer 2 207,31 10,00 22 073,09
Project Assistant 2 107,26 8,00 16 858,09
Project Assistant 1 813,37 9,00 16 320,33
Project Coordinator 3 170,27 7,00 22 191,90
Total Person-months Total Costs (€) for (A)
76,00 198 526,50
Justification
WP3 lead: monitoring project processes
Project Manager: management of WP3 activities
Senior Internal Evaluation Expert: management of WP3 Internal Evaluation activities, participation in WP8 Internal
Evaluation Office+ 3 Project Assistants: implement and support WP3 and WP8 activities
Project Coordinator: planning and coordinating WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 74 000,00 WP3 External evaluation
Total costs (€) of (B) 74 000,00
Justification
The external evaluation will be subcontracted to an independent entity with relevant experience in the field of health and
specifically in evaluation of health programmes. The external evaluation team will perform the impact and outcome
assessment in midterm and finalising phase of the project. Apart from the external evaluation services the cost will
include the travel and subsistence cost for the external evaluation team for participating in the project meetings.
( C) Other direct costs
(C.1) Travel Costs (€) Justification
55 700,00 WP1 General meetings, 8 meetings, 1‐2 participants
WP3 evaluation meetings and events
WP5 Participation at Workshop
WP8 Participation at WP8 kick off meeting, Basic workshop, advanced workshops for
trainers
WP10 Participation at Workshops
(C.2) Equipment Costs (€) Justification
5 000,00 WP3 Statistical software package
(C.3) Other goods and services Costs (€) Justification
41 500,00 WP3 organizing meetings
WP8 large scale international field exercise (consumables, catering, optic acoustical media
for command post)
WP8 National exercises
WP8 External national experts to trainings
WP8 Secondment/ internship
Total Costs (€) of ( C) 102 200,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 26 230,85
TOTAL ESTIMATED ELIGIBLE COSTS 400 957,35
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
151 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 11A20 – AUTH
(If affiliated entity: Affiliated to which Applicant number/Short name)
11 – HCDCP
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Head of the Department 9 870,00 2,04 20 134,80
Biologist 1 092,50 9,00 9 832,50
Total Person-months Total Costs (€) for (A)
11,04 29 967,30
Justification
Specialists participating in WP1 general meetings and WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
5 800,00 WP1 general meetings
WP7 3 technical meetings
WP8 Participations in workshops
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
25 500,00 WP7 Laboratory consumables for preparation of EQAE samples and optimizing protocols
WP7 shipment of EQAE samples
WP8 Participation on lab training: organization of training
Total Costs (€) of ( C) 31 300,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 4 288,71
TOTAL ESTIMATED ELIGIBLE COSTS 65 556,01
Applicant Number/
Short name: 11A21 – NKUA
(If affiliated entity: Affiliated to which Applicant number/Short name)
11 – HCDCP
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Principal Investigator 7 138,93 3,12 22 273,46
Technician 1 089,65 18,50 20 158,53
Total Person-months Total Costs (€) for (A)
21,62 42 431,98
Justification
Specialists participating in WP1 general meetings and WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
5 300,00 WP1 Participation in general meetings
WP7 2 technical meetings
WP8 participation in lab training workshops and meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
45 000,00 WP7 Consumables for preparation of EQAE samples and MIC measurements
WP7 Shipment of EQAE samples and infectious material between laboratories
WP7 Organization of a technical meeting for WP7 for two to three days for ~ 50 persons
(catering, and room rent etc.)
Total Costs (€) of ( C) 50 300,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 6 491,24
TOTAL ESTIMATED ELIGIBLE COSTS 99 223,22
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
152 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 11A22 – EKEPY
(If affiliated entity: Affiliated to which Applicant number/Short name)
11 – HCDCP
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior Expert 4 377,10 2,00 8 754,20
Expert 3 126,50 2,00 6 253,00
Total Person-months Total Costs (€) for (A)
4,00 15 007,20
Justification
Specialists participating in WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
0,00
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 0,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 050,50
TOTAL ESTIMATED ELIGIBLE COSTS 16 057,70
Applicant Number/
Short name: 11A23 - UTH Thessaly
(If affiliated entity: Affiliated to which Applicant number/Short name)
11 – HCDCP
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior Expert 4 377,10 2,00 8 754,20
Expert 3 126,50 2,00 6 253,00
Total Person-months Total Costs (€) for (A)
4,00 15 007,20
Justification
Specialists participating in WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
0,00
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 0,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 050,50
TOTAL ESTIMATED ELIGIBLE COSTS 16 057,70
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
153 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 12 – NNK
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Principal Investigator 2 794,80 4,85 13 554,78
Scientist 1 441,85 7,20 10 381,31
phd student 1 366,67 5,25 7 175,01
phd student 1 366,67 3,40 4 646,67
phd student 1 800,00 9,00 16 200,00
Total Person-months Total Costs (€) for (A)
29,70 51 957,76
Justification
Specialists participating in WP1 general meetings and WP3, WP6, WP7, WP8 and WP9
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
23 400,00 WP1 general meetings, 5 meetings and 1 participant
WP7 meeting (bacterial and viral, 2 laboratories, 3EQA=3 meetings)
WP7 AST, NGS and biorisk management meetings
WP8 working meetings (2 meetings)
WP8 Training of participants (2 trainings)
WP9 working meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
26 500,00 WP7 Laboratory consumables (laboratory materials for EQA and working group: AST,
NGS, HHTK (molecular enzymes, primers, probes, culture plates, media, serological assays,
etc.)
WP7 Shipment EQAE samples (bacterail and viral)
WP8 training material (laboratory consumables for training: molecular enzymes, primers,
probes, culture plates, media, PPE)
Total Costs (€) of ( C) 49 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 7 130,04
TOTAL ESTIMATED ELIGIBLE COSTS 108 987,80
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
154 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 13 – SEMS
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Project director 1 637,50 23,50 38 481,25
IHR Specialist 1 572,00 22,00 34 584,00
Project Manager 1 231,40 4,00 4 925,60
Total Person-months Total Costs (€) for (A)
49,50 77 990,85
Justification
Specialists participating in WP1 general meetings and WP5, WP6 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
22 800,00 WP1 General meetings, 5 meetings and 1 participant
WP5 Meetings and workshops
WP8 Meetings, workshops and events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
35 825,00 WP5 Organising workshop in Latvia (e.g. venue, catering)
WP6 Organising workshop in Latvia (e.g. venue, catering)
WP8 Organising training Latvia (e.g. Venue, catering)
WP8 Internship for expert at EU or WHO institution 1 month
Total Costs (€) of ( C) 58 625,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 9 563,11
TOTAL ESTIMATED ELIGIBLE COSTS 146 178,96
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
155 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 14 – MOHLT
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Public servant 2 185,54 3,50 7 649,39
Public servant 2 185,54 2,50 5 463,85
Public servant 2 185,54 2,50 5 463,85
Total Person-months Total Costs (€) for (A)
8,50 18 577,09
Justification
Specialists participating in WP1 general meetings and WP5, WP6 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
28 500,00 WP1 General meetings, 5 meetings and 1 participant
WP5 working meetings
WP8 working meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 28 500,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 3 295,40
TOTAL ESTIMATED ELIGIBLE COSTS 50 372,49
Applicant Number/
Short name: 14A24 – NVSPL
(If affiliated entity: Affiliated to which Applicant number/Short name)
14 – MOHLT
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior scientist 1 285,56 2,00 2 571,11
Scientist 1 285,56 1,00 1 285,56
Scientist 1 285,56 1,00 1 285,56
Scientist 1 285,56 0,80 1 028,45
Scientist 1 285,56 0,50 642,78
Total Person-months Total Costs (€) for (A)
5,30 6 813,45
Justification
Specialists participating in WP1 general meetings, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
10 571,00 WP1 General meetings
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
15 000,00 WP7 Laboratory consumables for participation in EQAEs (reagents, plastics for EQAE,
personal protective equipment and etc.)
WP7 Shipment of EQAE samples and repository material
Total Costs (€) of ( C) 25 571,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 266,91
TOTAL ESTIMATED ELIGIBLE COSTS 34 651,36
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
156 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant
Number/ Short 15 – MFH
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Project Lead 3 479,67 5,00 17 398,35
Head , IDCU or Alternate 4 253,34 1,50 6 380,01
Head, Path or PH Laboratory or alternate 4 253,34 0,25 1 063,34
Expert Infectious Disease/ Infection Control 4 253,34 0,25 1 063,34
Total Person-months Total Costs (€) for (A)
7,00 25 905,03
Justification
Specialists participating in WP1 general meetings, WP2, WP3, WP4, WP5, WP6, WP7, WP8, WP9 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
27 600,00 WP1 General meetings, 5 meetings and 1 participant
WP4 Workshops (x2)
WP5 Workshops (x4)
WP5 and WP6 Workshops - transportation & fuel expense
WP6 Workshop/ expert consultations
WP6 Simulation Exercise Pre/Post‐ meeting
WP8 Exchange visits/ training x4 participants
WP9 Workshop
WP10 Workshop (x 1 participants)/ expert meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
55 000,00 WP5,6 and 8 Training materials
WP2,3,4,5,6 and 8 Internet & multimedia
WP6 Hosting Simulation Exercise
WP6 Hosting Expert Consultation meeting
Total Costs (€) of ( C) 82 600,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 7 595,35
TOTAL ESTIMATED ELIGIBLE COSTS 116 100,38
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
157 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant
Number/ Short 16 – RIVM
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Project leader 12 110,00 1,00 12 110,00
Project manager 11 378,00 9,30 105 815,40
IHR project manager 10 358,00 6,30 65 255,40
Laboratory expert 5 686,00 10,50 59 703,00
IHR Project planning and operations 5 671,00 12,85 72 872,35
Junior operations managers 4 021,00 33,00 132 693,00
Senior expert in WP 9 8 557,00 2,70 23 103,90
Senior expert in WP 9 8 896,00 3,00 26 688,00
Total Person-months Total Costs (€) for (A)
78,65 498 241,05
Justification
WP6 leader
Specialist participating in WP1, WP2, WP3, WP4, WP5, WP6, WP7, WP8 and WP9
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
20 300,00 WP1 General meetings, 8 meetings and 1-2 participants
WP3 evaluation meetings
WP4 working meetings
WP6 Working meetings and events
WP8 Working meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
23 700,00 WP6 preparatory costs meetings (including training materials, shipment to venues) ,
WP6 e-learning/ table top protocol development, scenario preparations
WP6 costs e-learning/table top exercise tool development costs, simulation preparation
costs, instructions for use etc.
WP7 participation in EQAEs (mostly consumables, reagents for different EQAE etc.)
Total Costs (€) of ( C) 44 000,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 37 956,87
TOTAL ESTIMATED ELIGIBLE COSTS 580 197,92
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
158 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant
Number/ Short 16A25 – EMC
name:
(If affiliated entity: Affiliated to which Applicant number/Short
name) 16 – RIVM
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
PI 16 554,00 3,90 64 560,60
Manager 10 555,50 0,98 10 344,39
Postdoc 6 045,00 28,00 169 260,00
Total Person-months Total Costs (€) for (A)
32,88 244 164,99
Justification
Specialists participating in WP1 general meetings, WP3, WP4, WP6, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
12 600,00 WP1 General meetings
WP6 Preparedness and response cycle meetings
WP6 operational feasibility analysis need for further development expert group dynamics
and international consultation and consensus
WP7 working meetings
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
39 000,00 WP6 Disease X simulations
WP7 Laboratory consumables and materials
WP7 Shipment EQAE samples
WP7 Organising meeting
Total Costs (€) of ( C) 51 600,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 20 703,55
TOTAL ESTIMATED ELIGIBLE COSTS 316 468,54
Applicant Number/
Short name: 17 – HD
(If affiliated entity: Affiliated to which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
WP Coordinator NO 10 753,60 7,00 75 275,20
Analyst 10 910,90 4,00 43 643,60
Analyst 8 855,60 6,50 57 561,40
Analyst 8 789,30 3,00 26 367,90
Analyst 14 285,70 1,50 21 428,55
Analyst 7 857,20 3,00 23 571,60
Project assistant 8 000,20 1,50 12 000,30
Total Person-months Total Costs (€) for (A)
26,50 259 848,55
Justification
Co-lead WP5
Specialists participating in WP1, WP3, WP4, WP6, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
23 600,00 WP1 General meetings, 8 meetings and 1-2 participants
WP5 working meetings and workshops/events
WP7 working meetings
WP10 working meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 23 600,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 19 841,40
TOTAL ESTIMATED ELIGIBLE COSTS 303 289,95
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
159 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 17A26 – FHI
(If affiliated entity: Affiliated to which Applicant number/Short name)
17 – HD
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior Adviser - Preparedness Team Leader 9 921,80 4,40 43 655,92
Director - Epidemiologist 10 738,42 1,50 16 107,63
Senior Medical Officer - Laboratory Preparedness Expert 11 289,04 1,50 16 933,56
Senior Adviser - Epidemiologist 7 299,04 6,50 47 443,76
Medical Officer - Epidemiologist 9 464,28 2,25 21 294,63
Engineer Bacteriologist 6 098,05 1,50 9 147,08
Senior Adviser - Chemical Preparedness Expert 7 477,26 3,00 22 431,78
Total Person-months Total Costs (€) for (A)
20,65 177 014,36
Justification
Specialists participating in WP1, WP2, WP3, WP5, WP7, WP8 and WP9
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
24 300,00 WP1 General meetings; 8 meetings, 1 person
WP5 workshops and advanced trainings; National trainings/ meetings; 6 trips, 1 person
WP7 meetings: bacterial, viral, AST and biorisk management meetings; 2 persons (travel)
WP8 meetings: three meetings, training of participants and local excercises meetings and events,
attending 2 persons
WP9 Joint Meeting with all partners and other relevant WPs (2 person), First Workshop (1
person), Second Workshop; 1 person
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
12 500,00 WP7 shipment for EQAE
WP7 Laboratory materials (i.e. PPE, reagents for PCR analysis of EQUE analysis)
WP8 BSL‐3 laboratory training
Total Costs (€) of ( C) 36 800,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 14 967,00
TOTAL ESTIMATED ELIGIBLE COSTS 228 781,36
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
160 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 18 - NIZP-PZH
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Microbiologist; Molecular biologist 2 148,84 3,50 7 520,94
Scientist 1 432,56 2,50 3 581,40
Scientist 1 432,56 2,50 3 581,40
Epidemiologist 2 148,84 6,00 12 893,04
Public Health Specialist 2 148,84 6,00 12 893,04
Project Assistant 1 432,56 8,00 11 460,48
Epidemiologist 1 432,56 29,00 41 544,24
Total Person-months Total Costs (€) for (A)
57,50 93 474,54
Justification
Specialists participating in WP1, WP5, WP6, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
37 100,00 WP1 general meetings, 5 meetings and 1 participant
WP5 working meetings and workshops/events
WP7 working meetings
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
36 200,00 WP5 Arranging workshops (venue, catering, workshop materials etc.)
WP5 Training materials
WP6 Support e‐learning (preparing materials, graphics, pictures, short movies, etc.)
WP6 Arranging workshop (disposable office materials, laboratory consumables and disposable
personal protection equipment for demonstrations)
WP7 Laboratory consumables (for example primers and probes, reagents and kits for molecular
biology, disposable personal protection equipment)
WP7 Shipment of EQAE samples
WP8 Training consumables ‐ for example disposable office materials, laboratory consumables
and disposable personal protection equipment
Total Costs (€) of ( C) 73 300,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 11 674,22
TOTAL ESTIMATED ELIGIBLE COSTS 178 448,76
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
161 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 18A27 – NVRI
(If affiliated entity: Affiliated to which Applicant number/Short name)
18 - NIZP-PZH
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior Scientist 2 200,00 3,50 7 700,00
Senior Scientist 2 200,00 3,50 7 700,00
Scientist 2 000,00 3,50 7 000,00
Technician 1 000,00 3,50 3 500,00
Total Person-months Total Costs (€) for (A)
14,00 25 900,00
Justification
Specialists participating in WP1 general meetings, WP6, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
24 500,00 WP1 general meetings
WP6 working meetings
WP7 working meetings
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
27 500,00 WP6 Workshop e‐learning /EQAE
WP7 Laboratory consumables and shipment of EQAE samples
WP8 Training costs
Total Costs (€) of ( C) 52 000,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 5 453,00
TOTAL ESTIMATED ELIGIBLE COSTS 83 353,00
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
162 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 19 – MS
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Head of Unit 3 476,14 4,50 15 642,62
MD Senior Expert 5 346,00 7,00 37 422,00
Technical Expert 1 487,48 1,50 2 231,21
Technical Expert 1 487,48 5,50 8 181,11
Project assistant 1 231,94 1,50 1 847,92
Total Person-months Total Costs (€) for (A)
20,00 65 324,86
Justification
Specialists participating in WP1, WP2, WP3, WP5, WP6 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
32 920,00 WP1 General meetings, 5 meetings and 1 participant
WP3 Evaluation meetings
WP5 Meetings for the preparation of the workshop
WP5 - Organizing workshop on cross-border threats (2 from each low GNI countries)
WP8 Basic workshop for 3 participants
WP8 Advanced workshop for 3 participants
WP8 Field exercise for 3 participants
WP8 3 WP meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
46 470,00 WP1 EU presidency meeting
WP6 Organizing workshop expert meeting (venue rent, meals, refreshments, conference
services, gadgets, support materials)
WP8 Organization workshop and consumable
Total Costs (€) of ( C) 79 390,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 10 130,04
TOTAL ESTIMATED ELIGIBLE COSTS 154 844,90
Applicant Number/
Short name: 19A28 – INSA
(If affiliated entity: Affiliated to which Applicant number/Short name)
19 – MS
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior Researcher 5 414,06 2,75 14 888,67
Researcher 5 027,96 3,00 15 083,89
Technician 1 893,38 3,00 5 680,13
Technician 1 893,38 3,00 5 680,13
Head of Department 5 038,12 0,50 2 519,06
Total Person-months Total Costs (€) for (A)
12,25 43 851,87
Justification
Specialists participating in WP1 general meetings, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
25 800,00 WP1 General meetings
WP7 working meetings
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
53 000,00 WP7 Laboratory consumables and shipment of EQAE samples
WP8 Organising workshop and meeting
Total Costs (€) of ( C) 78 800,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 8 585,63
TOTAL ESTIMATED ELIGIBLE COSTS 131 237,50
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
163 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 20 – IPHS
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Assoc. Prof. 2 000,00 15,73 31 460,00
Assoc. Prof. 2 000,00 11,60 23 200,00
Public Health Expert 1 600,00 7,90 12 640,00
Senior researcher 1 800,00 7,50 13 500,00
Junior researcher 1 400,00 6,50 9 100,00
Dissemination specialist 1 800,00 2,30 4 140,00
Professor 2 000,00 15,00 30 000,00
Microbiologist 1 800,00 6,00 10 800,00
Epidemiologist 1 800,00 13,00 23 400,00
Project officer 1 400,00 9,00 12 600,00
Total Person-months Total Costs (€) for (A)
94,53 170 840,00
Justification
WP8 leader
Specialists participating in WP1, WP2, WP3, WP4, WP5, WP6, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
57 900,00 WP1 General meetings ‐ 8 meetings and 1‐2 participants
WP4 Sustainability workshops; 3x 1 participant
WP5 expert group meetings and workshops
WP6 expert group meetings; 3x 2 participant
WP7 meetings ‐ 3 meetingsX2participant
WP8 working meetings, workshops and field exercise
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
50 500,00 WP6 National exercise organization
WP6 Exercise
WP7 Reagents, laboratory materials and protective equipment, shipment of EQA
WP7 Training participation within WP8
WP8 Training materials
WP8 Organising meeting and workshop
WP8 Publications of scientific articles
WP8 Participation at national and international conferences to disseminate WP results
WP8 Translation and printing
Total Costs (€) of ( C) 108 400,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 19 546,80
TOTAL ESTIMATED ELIGIBLE COSTS 298 786,80
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
164 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 21 – NIJZ
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
National coordinator-Senior expert 1 5 600,00 6,50 36 400,00
Senior expert 2 6 020,00 4,50 27 090,00
Senior expert 3 5 740,00 1,50 8 610,00
Co-leader, national coordinator-Senior expert 4 5 740,00 12,50 71 750,00
Senior expert 5 5 600,00 7,00 39 200,00
Senior expert 6 5 600,00 3,60 20 160,00
Senior expert 7 5 600,00 3,60 20 160,00
Senior expert 8 4 760,00 4,00 19 040,00
Researcher 3 299,80 24,00 79 195,20
Project assistant 3 700,20 8,00 29 601,60
Junior Researcher 2 100,00 32,00 67 200,00
Total Person-months Total Costs (€) for (A)
107,20 418 406,80
Justification
Co-leader WP9
Specialists participating in WP1, WP2, WP3, WP4, WP5, WP6, WP8, WP9 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
55 800,00 WP1 General meetings; 8 meetings and 1‐2 participants
WP2 Stakeholder annual workshops; 3x 1 participant
WP3 evaluation meetings; 2x 1 participant
WP4 Sustainability workshops (3x 1 participant)
WP5 expert group meetings; 3x 3 participants
WP6 3 workshops (Portugal, Poland, Latvia) and expert Consensus meeting in Malta
WP8 meetings, 3x 1 participant and 1 advanced workshop, 3 participants
WP9 working meetings (3x 3 participants), workshops (M18, M30); 2x 2 persons
WP10 - participation in 4 workshops (4x 1 participant)
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
36 168,00 WP5 2‐days Workshop in Ljubljana: hosting expenses for 35 participants (room rental, 2 coffee
breaks/day, 1 lunch/day, 1 dinner)
WP5 WP8, WP9 Translation costs
WP5 WP8, WP9 Printing materials and brochures
WP9 expenses for 2‐ days Workshop in Ljubljana, ca. 35 participants (room rental, 2 coffee
breaks/day, 1 lunch/day, 1 dinner etc.)
WP8 expenses for organizing 1 workshop and 1 field exercise in Slovenia (room rental, coffee
breaks, lunch, dinner, consumables)
WP6 2‐days Workshop in Ljubljana: hosting expenses for 20 participants (venue, catering, hotel
costs for 2 nights)
Total Costs (€) of ( C) 91 968,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 35 726,24
TOTAL ESTIMATED ELIGIBLE COSTS 546 101,04
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
165 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 21A29 - UL-MF
(If affiliated entity: Affiliated to which Applicant number/Short name)
21 – NIJZ
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Scientist 1 4 060,00 2,50 10 150,00
Scientist 2 4 060,00 1,50 6 090,00
Total Person-months Total Costs (€) for (A)
4,00 16 240,00
Justification
Specialists participating in WP1, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
12 380,00 WP1 General meetings
WP7 Annual meetings (3x)
WP8 Training meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
13 500,00 WP7 Reagents, laboratory materials and protective equipment and shipment of EQAE
WP8 Reagents, laboratory materials and protective equipment for organising of training
Total Costs (€) of ( C) 25 880,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 948,40
TOTAL ESTIMATED ELIGIBLE COSTS 45 068,40
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
166 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 22 – ISCIII
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Researcher 4 422,00 1,50 6 633,00
Researcher 4 422,00 1,50 6 633,00
Researcher 4 422,00 1,50 6 633,00
Researcher 4 422,00 1,50 6 633,00
Technician 2 640,00 20,00 52 800,00
Technician 2 640,00 1,00 2 640,00
Technician 2 640,00 1,00 2 640,00
Researcher 4 422,00 7,25 32 059,50
Researcher 3 168,00 24,00 76 032,00
Total Person-months Total Costs (€) for (A)
59,25 192 703,50
Justification
Co-lead WP6
Specialists participating in WP1, WP2, WP3, WP5, WP6, WP7 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
35 400,00 WP1 General meetings; 8 meetings and 1‐2 participants
WP5 4 workshops (2 participants per workshop, internal or external experts)
WP6 working meetings
WP7 working meetings Bacteriology and Virology group
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
41 000,00 WP7 laboratory materials and Shipment of EQAE samples ,
WP8 organising workshop
Total Costs (€) of ( C) 76 400,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 18 837,25
TOTAL ESTIMATED ELIGIBLE COSTS 287 940,75
Applicant Number/
Short name: 22A30 ‐ SERMAS
(If affiliated entity: Affiliated to which Applicant number/Short name)
22 ‐ ISCIII
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person‐month Sum Cost (€)
Physician 5 500,00 6,10 33 550,00
Total Person-months Total Costs (€) for (A)
6,10 33 550,00
Justification
Scientist participating in WP1 general meetings, WP8 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
4 600,00 WP1 general meetings
WP10 project meetings and other events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
3 000,00 WP8 PPE ‐ Personal Protection materials
Total Costs (€) of ( C) 7 600,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 2 880,50
TOTAL ESTIMATED ELIGIBLE COSTS 44 030,50
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
167 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 22A31 ‐ FIBHULP
(If affiliated entity: Affiliated to which Applicant number/Short name)
22 ‐ ISCIII
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person‐month Sum Cost (€)
Physician Expert 5 500,00 2,00 11 000,00
Total Person-months Total Costs (€) for (A)
2,00 11 000,00
Justification
Specialists participating in WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
900,00 WP8 meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 833,00
TOTAL ESTIMATED ELIGIBLE COSTS 12 733,00
Applicant Number/
Short name: 22A32 ‐ OSAKIDETZA
(If affiliated entity: Affiliated to which Applicant number/Short name)
22 ‐ ISCIII
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person‐month Sum Cost (€)
Senior Researcher 7 298,79 0,20 1 459,76
Researcher 4 359,30 0,40 1 743,72
Researcher 5 550,84 0,20 1 110,17
Researcher 2 916,77 0,20 583,35
Total Person-months Total Costs (€) for (A)
1,00 4 897,00
Justification
Specialists participating in WP1 general meetings and WP7.
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
0,00
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 0,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 342,79
TOTAL ESTIMATED ELIGIBLE COSTS 5 239,79
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
168 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 22A33 ‐ BC
(If affiliated entity: Affiliated to which Applicant number/Short name)
22 ‐ ISCIII
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person‐month Sum Cost (€)
Researcher 4 300,00 0,25 1 075,00
Total Person-months Total Costs (€) for (A)
0,25 1 075,00
Justification
Specialist participating in WP1 general meetings and WP7
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
3 725,00 WP1 Participation in general meetings
WP7 working meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
10 000,00 WP7 consumables and shipment EQAE samples
Total Costs (€) of ( C) 13 725,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 036,00
TOTAL ESTIMATED ELIGIBLE COSTS 15 836,00
Applicant Number/
Short name: 23 – FoHM
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Senior advisor (AW) 11 440,66 12,75 145 868,42
Senior advisor (AB) 8 947,40 8,50 76 052,90
Analyst (KBR) 6 598,90 4,50 29 695,05
Analyst (JA) 5 721,10 3,50 20 023,85
Project Assistant (KJ) 5 134,36 1,50 7 701,54
Senior advisor (ÅB) 8 503,88 3,50 29 763,58
Laboratory staff (TW) 5 573,26 5,50 30 652,93
Laboratory staff (TB) 5 132,82 4,00 20 531,28
Analyst (JB) 5 867,40 3,00 17 602,20
Total Person-months Total Costs (€) for (A)
46,75 377 891,75
Justification
WP5 leader
Specialists participating in WP1, WP3, WP4, WP5, WP7, WP8 and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
57 400,00 WP1 general meetings; 8 meetings and 1‐2 participants
WP4 workshops
WP5 Workshop in Slovenia
WP5 Workshop in Poland
WP5 Workshop in Latvia
WP5 Workshop in Portugal
WP5 invited speakers for meetings and events
WP5 Expert exchange. Expert team for site visits for supporting evaluation and development of
biorisk management
WP10 working meetings
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
39 800,00 WP7 Expert exchange. Expert team for site visits for supporting evaluation and development
of biorisk management.
WP7 Laboratory consumables
WP8 Swedish lab training
Total Costs (€) of ( C) 97 200,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 33 256,42
TOTAL ESTIMATED ELIGIBLE COSTS 508 348,17
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
169 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 24 – DH
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Head of Department (RDD) 13 049,40 1,70 22 183,98
Senior researcher (ET) 9 009,00 4,55 40 990,95
Researcher (TG) 7 708,40 13,40 103 292,56
Researcher (CH) 7 348,60 13,20 97 001,52
Project assistant (JK) 5 087,60 2,00 10 175,20
Senior researcher (HC) 10 697,40 1,00 10 697,40
Researcher (Epi) 7 708,40 0,85 6 552,14
Consultant (GL) 15 538,60 0,30 4 661,58
Senior researcher (KF) 8 324,40 0,80 6 659,52
Researcher (EHE/CRCE Wales) 7 348,60 0,80 5 878,88
RIPL project manager (RV) 12 371,80 0,50 6 185,90
Researcher (RIPL) 7 397,60 9,00 66 578,40
Exercise manager (DR) 10 991,40 1,00 10 991,40
Researcher (VP) 7 397,60 2,80 20 713,28
Exercise manager (CT) 10 108,00 1,50 15 162,00
Total Person-months Total Costs (€) for (A)
53,40 427 724,71
Justification
WP9 Leader
Specialists participating in WP1, WP2, WP3, WP4, WP5, WP6, WP7, WP8 and WP9
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 3 370,00 WP9 surveillance and potential medical management activities (task 3)
Total costs (€) of (B) 3 370,00
Justification
Contribution from experts on poisons and toxicology, for the surveillance and potential medical management activities
( C) Other direct costs
(C.1) Travel Costs (€) Justification
41 242,00 WP1 General meetings; 8 meetings and 1‐2 participants
WP5 Working meetings gap analysis workshop to cover chemical components
WP7 RIPL group meetings
WP8 Training and exercise events to deliver chemical components
WP9 Working meetings
WP9 Stakeholder and expert travel costs ‐ additional experts to contribute to chemical material
(e.g. WP5 and WP8)
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
48 743,00 WP7 and WP8 Laboratory consumables e.g. sequencing reagents for WP7 Task 3
Total Costs (€) of ( C) 89 985,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 36 475,58
TOTAL ESTIMATED ELIGIBLE COSTS 557 555,29
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
170 / 174
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 24A34 – PHW
(If affiliated entity: Affiliated to which Applicant number/Short name)
24 – DH
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Professional Lead for Health Protection 14 540,23 2,51 36 423,28
Head of Communications 10 481,31 2,51 26 255,68
Communications Manager 5 915,00 14,65 86 713,90
Assistant 3 810,52 3,56 13 574,98
National Clinical Director, Microbiology services, Public Health Wales 3 825,00 1,00 3 825,00
Total Person-months Total Costs (€) for (A)
24,23 166 792,84
Justification
WP2 leader
Specialists participating in WP1, WP2 and WP8
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
15 561,96 WP1 Participation in general meetings
WP2 Communications workshops
WP8 Training of participants
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
32 770,12 WP2 Visual design of the joint action
WP2 SHARP JA Website
WP2 Delivery of other channels as identified under channel identification work during phase 4; e.g.
newsletters, posters, leaflets
WP2 Co‐ordination with communication leads though a series of workshops; organizing costs.
WP8 Consumables for training offer
Total Costs (€) of ( C) 48 332,08
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 15 058,74
TOTAL ESTIMATED ELIGIBLE COSTS 230 183,66
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
171 / 172
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/ Short
name: 24A35 – RFL
(If affiliated entity: Affiliated to which Applicant number/Short name)
24 – DH
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Infectious Diseases Specialist 6 100,00 3,10 18 910,00
Total Person-months Total Costs (€) for (A)
3,10 18 910,00
Justification
Specialists participating in WP1 general meeting and WP10
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
6 900,00 WP1 General meetings
WP10 meetings and events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 6 900,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 1 806,70
TOTAL ESTIMATED ELIGIBLE COSTS 27 616,70
Applicant Number/
Short name: 25 – HSE
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Project coordinator 5 850,00 1,00 5 850,00
Total Person-months Total Costs (€) for (A)
1,00 5 850,00
Justification
Specialist participating in WP1
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
4 500,00 WP1 general meetings, 5 meetings and 1 participant
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of ( C) 4 500,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 724,50
TOTAL ESTIMATED ELIGIBLE COSTS 11 074,50
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
172 / 172
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Applicant Number/
Short name: 26 – NAPH
(If affiliated entity: Affiliated to which Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Person-months Sum Cost (€)
Project coordinator 1 000,00 16,00 16 000,00
Total Person-months Total Costs (€) for (A)
16,00 16 000,00
Justification
Specialist participating in WP1 general meetings, WP5, WP7, WP8 and WP9
(B) Direct costs of subcontracting Costs (€) Task(s)/Justification
(please repeat line for each subcontract foreseen) 0,00
Total costs (€) of (B) 0,00
Justification
( C) Other direct costs
(C.1) Travel Costs (€) Justification
20 100,00 WP1 general meetings; 5 meetings and 1 participant
WP5 working meetings and workshops/events
WP7 meetings
WP8 working meetings, training and events
WP9 working meetings and events
(C.2) Equipment Costs (€) Justification
0,00
(C.3) Other goods and services Costs (€) Justification
10 000,00 WP7 Laboratory materials
WP7 Shipment of samples
Total Costs (€) of ( C) 30 100,00
(D) Indirect costs Total Costs (€)
(Max. 7 % on A, B and C) 3 227,00
TOTAL ESTIMATED ELIGIBLE COSTS 49 327,00
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
173 / 172
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Previous and current grants relevant to the programme
(Limited to the last 3 years)
Year Name of EU Title of the project
programme
2017 HP-JA-2017 eHAction: Joint Action to Support the eHealth
Network
2017 HP-JA-2017 JA-HEE: Joint Action on Health Inequalities
2017 HP-JA-2017 EU-JAV: European Joint Action on Vaccination
2016 HP-JA-2016 EMERGE: Joint Action on Efficient response to
highly dangerous and emerging pathogens at EU
level
2016 EU-EFSA 2016 INNUENDO: A cross-sectorial platform for the
integration of genomics in surveillance of
foodborne pathogens
2.10. Collaborating stakeholders
Institution Contact person City & Country
(First name and last
name)
Federal Public Service Health, Luc Tsachoua Belgium
Food Chain Safety and
Environment
Sciensano Marcella Mori Belgium
Sophie Quoilin
Agence pour une Vie de Qualité tbd Belgium
(Aviq)
Ministry of Health Angel Kunchev Bulgaria
Public Health Institute of the Daniela Maestro Bosnia and Herzegovina
Federation of Bosnia and
Herzegovina
Institute of Food Safety and Adela Berisa Fazlagic Bosnia and Herzegovina
Health Zenica
Directorate of Health Thorolfur Gudnason Iceland
Ministry of Health Berta Suárez Spain
SPIEZ Laboratory Nadia Schürch Switzerland
SHARP JA N:o 848096 – Call: HP-JA-2018 [June 24 2019]
174 / 174
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
ESTIMATED BUDGET FOR THE ACTION Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Estimated eligible1 costs (per budget category) EU contribution Action's estimated receipts
Financial
B. Direct D. Indirect Reimbursement Maximum EU Maximum Income contributions
A. Direct C. Other Action’s
costs of Total costs generated given by third
personnel costs direct costs costs2 rate %3 contribution4 grant amount5 total receipts
subcontracting by the action parties to the
beneficiaries
A.1 Employees C.1 Travel
(or equivalent)
C.2 Equipment
A.2 Natural
persons under C.3 Other goods
direct contract and services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7 7%
d=
a b c e = a+b+c+d f g=e*f h i j k=i+j
0.07 * (a+b+c)
1. THL 801 006.68 60 000.00 285 202.24 80 234.62 1 226 443.54 n/a n/a 981 154.83 0.00 0.00 0.00
- FFA 25 157.66 0.00 4 800.00 2 097.04 32 054.70 n/a n/a 25 643.76 0.00 0.00 0.00
Σ beneficiary 826 164.34 60 000.00 290 002.24 82 331.66 1 258 498.24 n/a n/a 1 006 798.59 0.00 0.00 0.00
2. RKI 490 888.53 122 300.00 40 300.00 45 744.20 699 232.73 n/a n/a 559 386.18 0.00 0.00 0.00
- UMR 8 191.52 0.00 28 100.00 2 540.41 38 831.93 n/a n/a 31 065.54 0.00 0.00 0.00
- BNITM 105 822.35 0.00 15 100.00 8 464.56 129 386.91 n/a n/a 103 509.53 0.00 0.00 0.00
- BwIM 113 298.96 0.00 17 100.00 9 127.93 139 526.89 n/a n/a 111 621.51 0.00 0.00 0.00
- FLI 9 065.16 0.00 26 200.00 2 468.56 37 733.72 n/a n/a 30 186.98 0.00 0.00 0.00
- UKF 65 432.89 0.00 6 500.00 5 035.30 76 968.19 n/a n/a 61 574.55 0.00 0.00 0.00
Σ beneficiary 792 699.41 122 300.00 133 300.00 73 380.96 1 121 680.37 n/a n/a 897 344.29 0.00 0.00 0.00
3. INMI 425 555.00 0.00 58 500.00 33 883.85 517 938.85 n/a n/a 414 351.08 0.00 0.00 0.00
- MoH 20 800.00 0.00 7 200.00 1 960.00 29 960.00 n/a n/a 23 968.00 0.00 0.00 0.00
- ISS 7 111.00 0.00 13 000.00 1 407.77 21 518.77 n/a n/a 17 215.02 0.00 0.00 0.00
- IZSPB 5 507.50 0.00 26 380.00 2 232.13 34 119.63 n/a n/a 27 295.70 0.00 0.00 0.00
- IZLER 14 927.28 0.00 18 900.00 2 367.91 36 195.19 n/a n/a 28 956.15 0.00 0.00 0.00
Σ beneficiary 473 900.78 0.00 123 980.00 41 851.66 639 732.44 n/a n/a 511 785.95 0.00 0.00 0.00
Page 1 of 6
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
ESTIMATED BUDGET FOR THE ACTION Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Estimated eligible1 costs (per budget category) EU contribution Action's estimated receipts
Financial
B. Direct D. Indirect Reimbursement Maximum EU Maximum Income contributions
A. Direct C. Other Action’s
costs of Total costs generated given by third
personnel costs direct costs costs2 rate %3 contribution4 grant amount5 total receipts
subcontracting by the action parties to the
beneficiaries
A.1 Employees C.1 Travel
(or equivalent)
C.2 Equipment
A.2 Natural
persons under C.3 Other goods
direct contract and services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7 7%
d=
a b c e = a+b+c+d f g=e*f h i j k=i+j
0.07 * (a+b+c)
4. BMASGK 16 337.13 0.00 13 300.00 2 074.60 31 711.73 n/a n/a 25 369.38 0.00 0.00 0.00
- AGES 11 906.70 0.00 18 900.00 2 156.47 32 963.17 n/a n/a 26 370.54 0.00 0.00 0.00
- VHA 22 750.00 0.00 4 000.00 1 872.50 28 622.50 n/a n/a 22 898.00 0.00 0.00 0.00
Σ beneficiary 50 993.83 0.00 36 200.00 6 103.57 93 297.40 n/a n/a 74 637.92 0.00 0.00 0.00
5. MCA 31 163.85 28 000.00 62 800.00 8 537.47 130 501.32 n/a n/a 104 401.06 0.00 0.00 0.00
6. CIPH 28 391.10 0.00 48 000.00 5 347.38 81 738.48 n/a n/a 65 390.78 0.00 0.00 0.00
- UHID 20 043.14 0.00 21 300.00 2 894.02 44 237.16 n/a n/a 35 389.73 0.00 0.00 0.00
- MH-BSI 9 785.68 0.00 4 100.00 972.00 14 857.68 n/a n/a 11 886.14 0.00 0.00 0.00
Σ beneficiary 58 219.92 0.00 73 400.00 9 213.40 140 833.32 n/a n/a 112 666.65 0.00 0.00 0.00
7. SUJCHBO 57 927.84 0.00 35 500.00 6 539.95 99 967.79 n/a n/a 79 974.23 0.00 0.00 0.00
8. SSI 86 723.10 0.00 27 400.00 7 988.62 122 111.72 n/a n/a 97 689.38 0.00 0.00 0.00
9. MSAE 1 869.30 0.00 6 500.00 585.85 8 955.15 n/a n/a 7 164.12 0.00 0.00 0.00
- HB 54 603.78 0.00 28 900.00 5 845.26 89 349.04 n/a n/a 71 479.23 0.00 0.00 0.00
Σ beneficiary 56 473.08 0.00 35 400.00 6 431.11 98 304.19 n/a n/a 78 643.35 0.00 0.00 0.00
10. MOH-FR 262 940.28 0.00 23 800.00 20 071.82 306 812.10 n/a n/a 245 449.68 0.00 0.00 0.00
- INSERM 9 745.20 0.00 11 375.00 1 478.41 22 598.61 n/a n/a 18 078.89 0.00 0.00 0.00
- SPF 6 404.34 0.00 2 340.00 612.10 9 356.44 n/a n/a 7 485.15 0.00 0.00 0.00
Page 2 of 6
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
ESTIMATED BUDGET FOR THE ACTION Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Estimated eligible1 costs (per budget category) EU contribution Action's estimated receipts
Financial
B. Direct D. Indirect Reimbursement Maximum EU Maximum Income contributions
A. Direct C. Other Action’s
costs of Total costs generated given by third
personnel costs direct costs costs2 rate %3 contribution4 grant amount5 total receipts
subcontracting by the action parties to the
beneficiaries
A.1 Employees C.1 Travel
(or equivalent)
C.2 Equipment
A.2 Natural
persons under C.3 Other goods
direct contract and services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7 7%
d=
a b c e = a+b+c+d f g=e*f h i j k=i+j
0.07 * (a+b+c)
- MOD-FR 29 380.00 0.00 20 900.00 3 519.60 53 799.60 n/a n/a 43 039.68 0.00 0.00 0.00
- IHUMI 91 006.50 0.00 8 900.00 6 993.46 106 899.96 n/a n/a 85 519.97 0.00 0.00 0.00
Σ beneficiary 399 476.32 0.00 67 315.00 32 675.39 499 466.71 n/a n/a 399 573.37 0.00 0.00 0.00
11. HCDCP(KEELPNO) 198 526.50 74 000.00 102 200.00 26 230.85 400 957.35 n/a n/a 320 765.88 0.00 0.00 0.00
- AUTH 29 967.30 0.00 31 300.00 4 288.71 65 556.01 n/a n/a 52 444.81 0.00 0.00 0.00
- NKUA 42 431.98 0.00 50 300.00 6 491.24 99 223.22 n/a n/a 79 378.58 0.00 0.00 0.00
- UoTHESSALY 15 007.20 0.00 0.00 1 050.50 16 057.70 n/a n/a 12 846.16 0.00 0.00 0.00
- EKEPY/NHOC 15 007.20 0.00 0.00 1 050.50 16 057.70 n/a n/a 12 846.16 0.00 0.00 0.00
Σ beneficiary 300 940.18 74 000.00 183 800.00 39 111.80 597 851.98 n/a n/a 478 281.59 0.00 0.00 0.00
12. NNK 51 957.76 0.00 49 900.00 7 130.04 108 987.80 n/a n/a 87 190.24 0.00 0.00 0.00
13. SEMS 77 990.85 0.00 58 625.00 9 563.11 146 178.96 n/a n/a 116 943.17 0.00 0.00 0.00
14. MOHLT 18 577.09 0.00 28 500.00 3 295.40 50 372.49 n/a n/a 40 297.99 0.00 0.00 0.00
- NVSPL 6 813.45 0.00 25 571.00 2 266.91 34 651.36 n/a n/a 27 721.09 0.00 0.00 0.00
Σ beneficiary 25 390.54 0.00 54 071.00 5 562.31 85 023.85 n/a n/a 68 019.08 0.00 0.00 0.00
15. MFH 25 905.03 0.00 82 600.00 7 595.35 116 100.38 n/a n/a 92 880.30 0.00 0.00 0.00
16. RIVM 498 241.05 0.00 44 000.00 37 956.87 580 197.92 n/a n/a 464 158.34 0.00 0.00 0.00
- Erasmus MC 244 164.99 0.00 51 600.00 20 703.55 316 468.54 n/a n/a 253 174.83 0.00 0.00 0.00
Page 3 of 6
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
ESTIMATED BUDGET FOR THE ACTION Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Estimated eligible1 costs (per budget category) EU contribution Action's estimated receipts
Financial
B. Direct D. Indirect Reimbursement Maximum EU Maximum Income contributions
A. Direct C. Other Action’s
costs of Total costs generated given by third
personnel costs direct costs costs2 rate %3 contribution4 grant amount5 total receipts
subcontracting by the action parties to the
beneficiaries
A.1 Employees C.1 Travel
(or equivalent)
C.2 Equipment
A.2 Natural
persons under C.3 Other goods
direct contract and services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7 7%
d=
a b c e = a+b+c+d f g=e*f h i j k=i+j
0.07 * (a+b+c)
Σ beneficiary 742 406.04 0.00 95 600.00 58 660.42 896 666.46 n/a n/a 717 333.17 0.00 0.00 0.00
17. HD 259 848.55 0.00 23 600.00 19 841.40 303 289.95 n/a n/a 242 631.96 0.00 0.00 0.00
- FHI 177 014.36 0.00 36 800.00 14 967.00 228 781.36 n/a n/a 183 025.09 0.00 0.00 0.00
Σ beneficiary 436 862.91 0.00 60 400.00 34 808.40 532 071.31 n/a n/a 425 657.05 0.00 0.00 0.00
18. NIZP-PZH 93 474.54 0.00 73 300.00 11 674.22 178 448.76 n/a n/a 142 759.01 0.00 0.00 0.00
- NVRI 25 900.00 0.00 52 000.00 5 453.00 83 353.00 n/a n/a 66 682.40 0.00 0.00 0.00
Σ beneficiary 119 374.54 0.00 125 300.00 17 127.22 261 801.76 n/a n/a 209 441.41 0.00 0.00 0.00
19. MS 65 324.86 0.00 79 390.00 10 130.04 154 844.90 n/a n/a 123 875.92 0.00 0.00 0.00
- INSA 43 851.87 0.00 78 800.00 8 585.63 131 237.50 n/a n/a 104 990.00 0.00 0.00 0.00
Σ beneficiary 109 176.73 0.00 158 190.00 18 715.67 286 082.40 n/a n/a 228 865.92 0.00 0.00 0.00
20. IPHS 170 840.00 0.00 108 400.00 19 546.80 298 786.80 n/a n/a 239 029.44 0.00 0.00 0.00
21. NIJZ 418 406.80 0.00 91 968.00 35 726.24 546 101.04 n/a n/a 436 880.83 0.00 0.00 0.00
- UL-MF 16 240.00 0.00 25 880.00 2 948.40 45 068.40 n/a n/a 36 054.72 0.00 0.00 0.00
Σ beneficiary 434 646.80 0.00 117 848.00 38 674.64 591 169.44 n/a n/a 472 935.55 0.00 0.00 0.00
22. ISCIII 192 703.50 0.00 76 400.00 18 837.25 287 940.75 n/a n/a 230 352.60 0.00 0.00 0.00
- SERMAS 33 550.00 0.00 7 600.00 2 880.50 44 030.50 n/a n/a 35 224.40 0.00 0.00 0.00
- FIBHULP 11 000.00 0.00 900.00 833.00 12 733.00 n/a n/a 10 186.40 0.00 0.00 0.00
Page 4 of 6
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
ESTIMATED BUDGET FOR THE ACTION Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Estimated eligible1 costs (per budget category) EU contribution Action's estimated receipts
Financial
B. Direct D. Indirect Reimbursement Maximum EU Maximum Income contributions
A. Direct C. Other Action’s
costs of Total costs generated given by third
personnel costs direct costs costs2 rate %3 contribution4 grant amount5 total receipts
subcontracting by the action parties to the
beneficiaries
A.1 Employees C.1 Travel
(or equivalent)
C.2 Equipment
A.2 Natural
persons under C.3 Other goods
direct contract and services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7 7%
d=
a b c e = a+b+c+d f g=e*f h i j k=i+j
0.07 * (a+b+c)
- OSAKIDETZA 4 897.00 0.00 0.00 342.79 5 239.79 n/a n/a 4 191.83 0.00 0.00 0.00
- BC 1 075.00 0.00 13 725.00 1 036.00 15 836.00 n/a n/a 12 668.80 0.00 0.00 0.00
Σ beneficiary 243 225.50 0.00 98 625.00 23 929.54 365 780.04 n/a n/a 292 624.03 0.00 0.00 0.00
23. FOHM 377 891.75 0.00 97 200.00 33 256.42 508 348.17 n/a n/a 406 678.54 0.00 0.00 0.00
24. DH 427 724.71 3 370.00 89 985.00 36 475.58 557 555.29 n/a n/a 446 044.23 0.00 0.00 0.00
- RFL 18 910.00 0.00 6 900.00 1 806.70 27 616.70 n/a n/a 22 093.36 0.00 0.00 0.00
- PHW 166 792.84 0.00 48 332.08 15 058.74 230 183.66 n/a n/a 184 146.93 0.00 0.00 0.00
Σ beneficiary 613 427.55 3 370.00 145 217.08 53 341.02 815 355.65 n/a n/a 652 284.52 0.00 0.00 0.00
25. HSE 5 850.00 0.00 4 500.00 724.50 11 074.50 n/a n/a 8 859.60 0.00 0.00 0.00
26. NAPH 16 000.00 0.00 30 100.00 3 227.00 49 327.00 n/a n/a 39 461.60 0.00 0.00 0.00
Σ consortium 6 585 628.65 287 670.00 2 355 673.32 646 028.03 9 875 000.00 807 7 900 000.00 7 900 000.00 0.00 0.00 0.00
1 See Article 6 for the eligibility conditions.
2 The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme). A beneficiary that receives an operating grant during the action's duration
cannot claim any indirect costs for the year(s)/reporting period(s) covered by the operating grant (see Article 6.2.D).
3 See Article 5.2 for the reimbursement rate.
4 This is the theoretical amount of the EU contribution, if the reimbursement rate is applied to all the budgeted costs. This theoretical amount is capped by the 'maximum grant amount'.
5 The 'maximum grant amount' is the maximum grant amount decided by the Agency. It normally corresponds to the requested grant, but may be lower.
6 See Article 5 for the cost forms.
Page 5 of 6
Grant Agreement number: 848096 — SHARP JA — HP-JA-2018
ESTIMATED BUDGET FOR THE ACTION Associated with document Ref. Ares(2019)4052454 - 26/06/2019
7 Flat rate : 7% of eligible direct costs.
Page 6 of 6
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ROBERT KOCH-INSTITUT (RKI), established in Nordufer 20, Berlin 13353, Germany, VAT
number: DE165893430, (‘the beneficiary’), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary No (‘2’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999515549_75_210--]
1
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-
ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO (INMI), established
in Via Portuense, 292, ROMA 00149, Italy, VAT number: IT05080991002, (‘the beneficiary’),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘3’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999471317_75_210--]
2
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
BUNDESMINISTERIUM FUER ARBEIT, SOZIALES, GESUNDHEIT UND
KONSUMENTENSCHUTZ (BMASGK), established in Radetzkystrasse 2, WIEN 1030, Austria,
(‘the beneficiary’), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘4’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999467243_75_210--]
3
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTRY OF CIVIL AFFAIRS (MCA), established in Trg Bosne i Hercegovine 1, SARAJEVO
71000, Bosnia and Herzegovina, (‘the beneficiary’), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘5’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998728588_75_210--]
4
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), established in ROCKEFELLEROVA 7,
ZAGREB 10000, Croatia, VAT number: HR75297532041, (‘the beneficiary’), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘6’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998128255_75_210--]
5
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
STATNI USTAV JADERNE, CHEMICKE A BIOLOGICKE OCHRANY VVI (SUJCHBO),
established in KAMENNA 71, MILIN 26231, Czech Republic, VAT number: CZ70565813, (‘the
beneficiary’), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘7’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-997581854_75_210--]
6
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
STATENS SERUM INSTITUT (SSI), established in ARTILLERIVEJ 5, KOBENHAVN S 2300,
Denmark, VAT number: DK46837428, (‘the beneficiary’), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘8’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999937402_75_210--]
7
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SOTSIAALMINISTEERIUM (MSAE), established in Suur-Ameerika 1, TALLINN 10122,
Estonia, (‘the beneficiary’), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary No (‘9’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998429731_75_210--]
8
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERE DES AFFAIRES SOCIALES ET DE LA SANTE (MOH-FR), established in
AVENUE DUQUESNE 14, PARIS CEDEX 75350, France, VAT number: N/A, (‘the beneficiary’),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘10’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998887377_75_210--]
9
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
KENTRO ELENCHOU & PROLIPSIS NOSIMATON (HCDCP(KEELPNO)), established
in AGRAFON STREET 3-5, MAROUSI 15123, Greece, VAT number: EL090193594, (‘the
beneficiary’), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘11’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-986568959_75_210--]
10
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NEMZETI NEPEGESZSEGUGYI KOZPONT (NNK), established in ALBERT FLORIAN UT
2-6, BUDAPEST 1097, Hungary, VAT number: HU15598787, (‘the beneficiary’), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘12’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998706957_75_210--]
11
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NEATLIEKAMAS MEDICINISKAS PALIDZIBA (SEMS), established in LAKTAS IELA 8,
RIGA 1013, Latvia, VAT number: LV90009029104, (‘the beneficiary’), represented for the purpose
of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘13’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-904773903_75_210--]
12
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (MOHLT),
established in VILNIAUS G 33, VILNIUS LT 01506, Lithuania, (‘the beneficiary’), represented for
the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘14’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-933839468_75_210--]
13
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
Ministry for Health - Government of Malta (MFH), established in Palazzo Castellania, Merchants
Street 15, Valletta VLT 200, Malta, VAT number: MT12979127, (‘the beneficiary’), represented for
the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘15’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-974144423_75_210--]
14
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), established in
Antonie Van Leeuwenhoeklaan 9, BILTHOVEN 3721 MA, Netherlands, VAT number:
NL821772302B01, (‘the beneficiary’), represented for the purpose of signing this Accession Form
by the undersigned,
hereby agrees
to become beneficiary No (‘16’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999991431_75_210--]
15
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HELSEDIREKTORATET (HD), established in VITAMINVEIEN 4, OSLO 0213, Norway, VAT
number: NO983544622, (‘the beneficiary’), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary No (‘17’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-974772304_75_210--]
16
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NARODOWY INSTYTUT ZDROWIA PUBLICZNEGO-PANSTWOWY ZAKLAD
HIGIENY (NIZP-PZH), established in CHOCIMSKA 24, WARSZAWA 00791, Poland, VAT
number: PL5250008732, (‘the beneficiary’), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary No (‘18’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998403735_75_210--]
17
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (MS), established in Av. João
Crisóstomo, 9, LISBOA 1049-062, Portugal, (‘the beneficiary’), represented for the purpose of
signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘19’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-986364095_75_210--]
18
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS),
established in DR SUBOTICA STREET 5, BEOGRAD 11000, Serbia, VAT number: RS102000930,
(‘the beneficiary’), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘20’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-941063349_75_210--]
19
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ), established in TRUBARJEVA CESTA
2, LJUBLJANA 1000, Slovenia, VAT number: SI44724535, (‘the beneficiary’), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘21’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-948891346_75_210--]
20
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5,
MADRID 28029, Spain, VAT number: ESQ2827015E, (‘the beneficiary’), represented for the purpose
of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘22’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999507886_75_210--]
21
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FOLKHALSOMYNDIGHETEN (FOHM), established in NOBELS VAG 18, SOLNA 171 82,
Sweden, VAT number: SE202100654501, (‘the beneficiary’), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘23’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-949789954_75_210--]
22
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
Department of Health (DH), established in Quarry House, Quarry Hill, Leeds LS2 7UE, United
Kingdom, VAT number: 888815064, (‘the beneficiary’), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘24’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-986454887_75_210--]
23
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HEALTH SERVICE EXECUTIVE HSE (HSE), established in LIMETREE AVENUE 2ND FLO
OAK HOUSE, NAAS, Ireland, VAT number: IE66093541, (‘the beneficiary’), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘25’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-993521919_75_210--]
24
Grant Agreement number: 848096 — SHARP JA
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
AGENTIA NATIONALA PENTRU SANATATE PUBLICA (NAPH), established in 67A
GHEORGHE ASACHI ST, CHISINAU 2028, Moldova (Republic of), (‘the beneficiary’),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘26’)
in Grant Agreement No 848096 (‘the Grant Agreement’)
between TERVEYDEN JA HYVINVOINNIN LAITOS and the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European
Commission ('the Commission'),
for the action entitled Strengthened International HeAlth Regulations and Preparedness in the EU
- Joint Action (SHARP JA).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-907240710_75_210--]
25
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
i print format A4
MODEL ANNEX 4 CHAFEA MGA — MULTI
landscape
FINANCIAL STATEMENT FOR [BENEFICIARY [name]/AFFILIATED ENTITY [name]] FOR REPORTING PERIOD [reporting period]
1 Receipts EU contribution
Eligible costs (per budget category)
Financial
contributions Reimburseme Maximum EU
A. Direct personnel B. Direct costs of C. Other direct 2 Income generated Requested EU
D. Indirect costs Total costs given by third Total receipts 3 4
costs subcontracting costs by the action nt rate % constribution contribution
parties to the
beneficiaries
A.1 Employees (or
C.1 Travel
equivalent)
A.2 Natural persons
C.2 Equipment
under direct contract
and seconded persons
C.3 Other goods and
services
6
5 Actual Actual Actual Flat-rate
Cost form
7%
d= e=
a b c f g h= f + g i j k
0,07 * (a + b + c) a+ b + c + d
[short name beneficiary
/ affiliated entity]
The beneficiary/affiliated entity hereby confirms that:
The information provided is complete, reliable and true.
The costs declared are eligible (see Article 6).
The costs can be substantiated by adequate records and supporting documentation that will be produced upon request or in the context of checks, reviews, audits and investigations (see Articles 12, 13 and 17).
For the last reporting period: that all the receipts have been declared (see Article 5.3.3).
i Please declare all eligible costs, even if they exceed the amounts indicated in the estimated budget (see Annex 2). Only amounts that were declared in your individual financial
statements can be taken into account lateron, in order to replace other costs that are found to be ineligible.
1
See Article 6 for the eligibility conditions.
2
The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme). A beneficiary that receives an operating grant during the duration of the action cannot
claim any indirect costs for the year(s) covered by the operating grant (see Article 6.2.D).
3
See Article 5.2 for the reimbursement rate
4
This is the theoretical amount of EU contribution that the system calculates automatically (by multiplying the reimbursement rate by the total costs declared). The amount you request (in the column 'requested EU contribution') may
have to be less.
5
See Article 5 for the cost forms.
6
Flat rate : 7% of eligible direct costs.
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
ANNEX 5
MODEL FOR THE CERTIFICATE ON THE FINANCIAL STATEMENT (CFS)
This document sets out:
- the objectives and scope of the independent report of factual findings on costs declared
under a EU grant agreement financed under the Health Programme (2014-2020) or
Consumer Programme (2014-2020) and
- a model for the certificate on the financial statement (CFS).
1. Background and subject matter
[OPTION 1 for actions with one RP and NO interim payments: Within 60 days of the end of
the reporting period, the coordinator must submit to the Commission a final report, which
should include (among other documents and unless otherwise specified in Article 15 of the
Grant Agreement) a certified financial statement (CFS; see proposed model below) for each
beneficiary and (if applicable) each affiliated entity, if:
- it requests an EU contribution of EUR 325 000 or more as reimbursement of actual
costs and
- the maximum EU contribution indicated for that beneficiary/affiliated entity in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000 or
more.]
[OPTION 2 for actions with several RPs and interim payments: Within 60 days of the end
of each reporting period, the coordinator must submit to the Commission a periodic report,
which should include (among other documents and unless otherwise specified in Article 15 of
the Grant Agreement) a certified financial statement (CFS; see proposed model below) for
each beneficiary and (if applicable) each affiliated entity, if:
- the cumulative amount of EU contribution the beneficiary/affiliated entity requests as
reimbursement of actual costs is EUR 325 000 or more and
- the maximum EU contribution indicated for that beneficiary/affiliated entity in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000 or
more.
The CFS must be submitted every time the cumulative amount of payments requested (i.e.
including in previous financial statements) reaches the threshold (i.e. a first certificate once
the cumulative amount reaches 325 000, a second certificate once it reaches 650 000, a third
certificate once it reaches 975 000, etc.).
Once the threshold is reached, the CFS must cover all reporting periods for which no
certificate has yet been submitted.]
1
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
The beneficiary must provide the CFS for itself and, if applicable, for its affiliated entity(ies).
The purpose of the audit on which the CFS is based is to give the Agency ‘reasonable
assurance’1 that costs declared as eligible costs under the grant (and, if relevant, receipts
generated in the course of the action) are being claimed by the beneficiary in accordance with
the relevant legal and financial provisions of the Grant Agreement.
The scope of the audit is limited to the verification of eligible costs included in the CFS. The
audit must be conducted in line with point 3 below.
Certifying auditors must carry out the audits in compliance with generally accepted audit
standards and indicate which standards they have applied. They must bear in mind that, to
establish a CFS, they must carry out a compliance audit and not a normal statutory audit. The
eligibility criteria in the Grant Agreement always override normal accounting practices.
The beneficiary and the auditor are expected to address any questions on factual data or
detailed calculations before the financial statement and the accompanying certificate are
submitted. It is also recommended that the beneficiary take into account the auditor’s
preliminary comments and suggestions in order to avoid a qualified opinion or reduce the
scope of the qualifications.
Since the certificate is the main source of assurance for cost claims and payments, it will be
easier to consider amounts as eligible if a non-qualified certificate is provided.
The submission of a certificate does not affect the Agency’s right to carry out its own
assessment or audits. Neither does the reimbursement of costs covered by a certificate
preclude the Agency or the Commission, the European Anti-Fraud Office or the European
Court of Auditors from carrying out checks, reviews, audits and investigations in accordance
with Article 17 of the Grant Agreement.
The Agency expects the certificates to be issued by auditors according to the highest
professional standards.
2. Auditors who may deliver a certificate
The beneficiary is free to choose a qualified external auditor, including its usual external
auditor, provided that:
- the external auditor is independent from the beneficiary and
- the provisions of Directive 2006/43/EC2 are complied with.
Independence is one of the qualities that permit the auditor to apply unbiased judgement and
objective consideration to established facts to arrive at an opinion or a decision. It also means
that the auditor works without direction or interference of any kind from the beneficiary.
1
This means a high degree of confidence.
2
Directive 2006/43/EC of the European Parliament and of the Council of 17 May 2006 on statutory audits of
annual accounts and consolidated accounts or similar national regulations (OJ L 157, 9.6.2006, p. 87).
2
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Auditors are considered as providing services to the beneficiary/affiliated entity under a
purchase contract within the meaning of Article 9 of the Grant Agreement. This means that
the costs of the CFS may normally be declared as costs incurred for the action, if the cost
eligibility rules set out in Articles 6 and 9.1.1 of the Grant Agreement are fulfilled (especially:
best value for money and no conflict of interests; see also below eligibility of costs of other
goods and services). Where the beneficiary/affiliated entity uses its usual external auditor, it is
presumed that they already have an agreement that complies with these provisions and there is
no obligation to find new bids. Where the beneficiary/affiliated entity uses an external auditor
who is not their usual external auditor, it must select an auditor following the rules set out in
Article 9.1.1.
Public bodies can choose an external auditor or a competent public officer. In the latter case,
the auditor’s independence is usually defined as independence from the audited beneficiary
‘in fact and in appearance’. A preliminary condition is that this officer was not involved in
any way in drawing up the financial statements. Relevant national authorities establish the
legal capacity of the officer to carry out audits of that specific public body. The certificate
should refer to this appointment.
3. Audit methodology and expected results
3.1 Verification of eligibility of the costs declared
The auditor must conduct its verification on the basis of inquiry and analysis,
(re)computation, comparison, other accuracy checks, observation, inspection of records and
documents and by interviewing the beneficiary (and the persons working for it).
The auditor must examine the following documentation:
the Grant Agreement and any amendments to it;
the periodical and/or final report(s);
for personnel costs
o salary slips;
o time sheets;
o contracts of employment;
o other documents (e.g. personnel accounts, social security legislation, invoices,
receipts, etc.);
o proofs of payment;
for subcontracting
o the call for tender;
o tenders (if applicable);
o justification for the choice of subcontractor;
o contracts with subcontractors;
o invoices;
o declarations by the beneficiary;
o proofs of payment;
o other documents: e.g. national rules on public tendering if applicable, EU
Directives, etc.;
for travel and subsistence costs
o the beneficiary’s internal rules on travel;
3
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
o transport invoices and tickets (if applicable);
o declarations by the beneficiary;
o other documents (proofs of attendance such as minutes of meetings, reports,
etc.);
o proofs of payment;
for equipment costs
o invoices;
o delivery slips / certificates of first use;
o proofs of payment;
o depreciation method of calculation;
for costs of other goods and services
o invoices;
o proofs of payment; and
o other relevant accounting documents.
General eligibility rules
The auditor must verify that the costs declared comply with the general eligibility rules set out
in Article 6.1 of the Grant Agreement.
In particular, the costs must:
be actually incurred;
be linked to the subject of the Grant Agreement and indicated in the beneficiary's
estimated budget (i.e. the latest version of Annex 2);
be necessary to implement the action which is the subject of the grant;
be reasonable and justified, and comply with the requirements of sound financial
management, in particular as regards economy and efficiency;3
have been incurred during the action, as defined in Article 3 of the Grant Agreement
(with the exception of the invoice for the audit certificate and costs relating to the
submission of the final report);
not be covered by another EU or Euratom grant (see below ineligible costs);
be identifiable, verifiable and, in particular, recorded in the beneficiary's accounting
records and determined according to the applicable accounting standards of the
country where it is established and its usual cost-accounting practices;
comply with the requirements of applicable national laws on taxes, labour and social
security;
be in accordance with the provisions of the Grant Agreement (see, in particular,
Articles 6 and 9-11a) and
have been converted to euro at the rate laid down in Article 15.6 of the Grant
Agreement:
o for beneficiaries with accounts established in a currency other than the euro:
Costs incurred in another currency must be converted into euros at the average
of the daily exchange rates published in the C series of the EU Official Journal
determined over the corresponding reporting period.
3
To be assessed in particular on the basis of the procurement and selection procedures for service providers.
4
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
If no daily euro exchange rate is published in the EU Official Journal for the
currency in question, the rate used must be the average of the monthly
accounting rate established by the Commission and published on its website;
o for beneficiaries with accounts established in euro:
Costs incurred in another currency should be converted into euros applying the
beneficiary’s usual accounting practice.
The auditor must verify whether expenditure includes VAT and, if so, verify that the
beneficiary:
- cannot recover the VAT (this must be supported by a statement from the competent
body) and
- is not a public body acting as a public authority.
The auditor should base his/her audit approach on the confidence level following a review of
the beneficiary's internal control system. When using sampling, the auditor should indicate
and justify the sampling size.
Specific eligibility rules
In addition, the auditor must verify that the costs declared comply with the specific cost
eligibility rules set out in Article 6.2 and Articles 9.1.1, 10.1.1, 11.1.1, 11a.1.1 and 11a.2.1 of
the Grant Agreement.
Personnel costs
The auditor must verify that:
personnel costs have been charged and paid in respect of the actual time devoted by
the beneficiary’s personnel to implementing the action (justified on the basis of time
sheets or other relevant time-recording system);
personnel costs were calculated on the basis of annual gross salary, wages or fees (plus
obligatory social charges, but excluding any other costs) specified in an employment
or other type of contract, not exceeding the average rates corresponding to the
beneficiary’s usual policy on remuneration;
the work was carried out during the period of implementation of the action, as defined
in Article 3 the Grant Agreement and
the personnel costs are not covered by another EU or Euratom grant (see below
ineligible costs);
for additional remunerations: the 2 conditions set out in Article 6.2.A.1 are met (i.e.
that it is part of the beneficiary’s usual remuneration practices and is paid in a
consistent manner whenever the same kind of work or expertise is required and that
the criteria used to calculate the supplementary payments are objective and generally
applied by the beneficiary, regardless of the source of funding used);
for in-house consultants: the 3 conditions set out in Article 6.2.A.2 of the Grant
Agreement are met (i.e. that the in-house consultant works under the beneficiary’s
instructions, that the result of the work carried out belongs to the beneficiary, and that
the costs are not significantly different from those for personnel performing similar
tasks under an employment contract).
5
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
The auditor should have assurance that the management and accounting system ensures
proper allocation of the personnel costs to various activities carried out by the beneficiary and
funded by various donors.
Subcontracting costs
The auditor must verify that:
the subcontracting complies with best value for money (or lowest price) and that there
was no conflict of interests;
the subcontracting was necessary to implement the action for which the grant is
requested;
the subcontracting was provided for in Annex 1 and Annex 2 or agreed to by the
Agency at a later stage;
the subcontracting is supported by accounting documents in accordance with national
accounting law
public bodies have complied with the national rules on public procurement.
Travel and subsistence costs
The auditor must verify that travel and subsistence costs:
have been charged and paid in accordance with the beneficiary's internal rules or usual
practices;
are not covered by another EU or Euratom grant (see below ineligible costs);
were incurred for travels linked to action tasks set out in Annex 1 of the Grant
Agreement.
Equipment costs
The auditor must verify that:
the equipment is purchased, rented or leased at normal market prices;
public bodies have complied with the national rules on public procurement;
the equipment is written off, depreciation has been calculated according to the tax and
accounting rules applicable to the beneficiary and only the portion of the depreciation
corresponding to the duration of the action has been declared and
the costs are not covered by another EU or Euratom grant (see below ineligible costs).
Costs of other goods and services
The auditor must verify that:
the purchase complies with best value for money (or lowest price) and that there was
no conflict of interests;
public bodies have complied with the national rules on public procurement;
the costs are not covered by another EU or Euratom grant (see below ineligible costs).
Ineligible costs
The auditor must verify that the beneficiary has not declared any costs that are ineligible
under Article 6.4 of the Grant Agreement:
6
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
costs relating to return on capital;
debt and debt service charges;
provisions for future losses or debts;
interest owed;
doubtful debts;
currency exchange losses;
bank costs charged by the beneficiary’s bank for transfers from the Agency;
excessive or reckless expenditure;
deductible VAT;
VAT incurred by a public body acting as a public authority;
costs incurred during suspension of the implementation of the action;
in-kind contributions from third parties;
costs declared under other EU or Euratom grants (including those awarded by a
Member State and financed by the EU or Euratom budget or awarded by bodies other
than the Agency for the purpose of implementing the EU or Euratom budget); in
particular, indirect costs if the beneficiary is already receiving an operating grant
financed by the EU or Euratom budget in the same period;
costs incurred for permanent staff of a national administration for activities that are
part of its normal activities (i.e. not undertaken only because of the grant);
costs incurred for staff or representatives of EU institutions, bodies or agencies.
3.2 Verification of receipts
The auditor must verify that the beneficiary has declared receipts within the meaning of
Article 5.3.3 of the Grant Agreement, i.e.:
income generated by the action (e.g. from the sale of products, services and
publications, conference fees) and
financial contributions given by third parties, specifically to be used for costs that are
eligible under the action.
3.3 Verification of the beneficiary’s accounting system
The auditor must verify that:
the accounting system (analytical or other suitable internal system) makes it possible
to identify sources of financing for the action and related expenses incurred during
the contractual period and
expenses/income under the grant have been recorded systematically using a
numbering system that distinguishes them from expenses/income for other projects.
7
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
Certificate on the financial statement (CFS)
To
[Beneficiary/affiliated entity’s full name
address]
We, [full name of the audit firm/organisation], established in [full address/city/country],
represented for signature of this audit certificate by [name and function of an authorised
representative],
hereby certify
that:
1. We have conducted an audit relating to the costs declared in the financial statement of
[name of beneficiary/affiliated entity] (the [‘beneficiary’][‘affiliated entity’]), to which
this audit certificate is attached and which is to be presented to the Consumers, Health,
Agriculture and Food Executive Agency under Grant Agreement No [insert number] —
[insert acronym], covering costs for the following reporting period(s): [insert reporting
period(s)].
2. We confirm that our audit was carried out in accordance with generally accepted
auditing standards in compliance with ethical rules and on the basis of the provisions of
the Grant Agreement and its Annexes (and in particular the audit methodology
described in Annex 5).
3. The financial statement was examined and all necessary tests of [all][[X]%] of the
supporting documentation and accounting records were carried out in order to obtain
reasonable assurance that, in our opinion and on the basis of our audit
total costs of EUR [insert number] ([insert amount in words]) are eligible, i.e.:
actual;
determined in accordance with the [beneficiary’s][affiliated entity’s]
accounting principles;
incurred during the period referred to in Article 3 of the Grant Agreement;
recorded in the [beneficiary’s][affiliated entity’s] accounts (at the date of this
audit certificate);
comply with the specific eligibility rules in Article 6.2 of the Grant Agreement;
do not contain costs that are ineligible under Article 6.4 of the Grant
Agreement, in particular:
costs relating to return on capital;
debt and debt service charges;
provisions for future losses or debts;
interest owed;
doubtful debts;
currency exchange losses;
8
Associated with document Ref. Ares(2019)4052454 - 26/06/2019
bank costs charged by the [beneficiary’s][affiliated entity’s] bank for
transfers from the Agency;
excessive or reckless expenditure;
deductible VAT;
VAT incurred by a public body acting as a public authority;
costs incurred during suspension of the implementation of the action;
in-kind contributions provided by third parties;
costs declared under other EU or Euratom grants (including those
awarded by a Member State and financed by the EU or Euratom budget
or awarded by bodies other than the Agency for the purpose of
implementing the EU or Euratom budget); in particular, indirect costs if
the [beneficiary][affiliated entity] is already receiving an operating
grant financed by the EU or Euratom budget in the same period;
costs incurred for permanent staff of a national administration, for
activities that are part of its normal activities (i.e. not undertaken only
because of the grant);
costs incurred for staff or representatives of EU institutions, bodies or
agencies;
[are claimed according to the euro conversion rate referred to in Article 15.6 of
the Grant Agreement;]
total receipts of EUR [insert number] ([insert amount in words]) have been declared
under Article 5.3.3 of the Grant Agreement and
the [beneficiary’s][affiliated entity’s] accounting procedures are in compliance with
the accounting rules of the state in which it is established and permit direct
reconciliation of the costs incurred for the implementation of the action covered by the
EU grant with the overall statement of accounts relating to its overall activity.
[However, our audit opinion is qualified for:
costs of EUR [insert number]
receipts of EUR [insert number]
which in our opinion do not comply with the applicable rules.]
4. We are qualified/authorised to deliver this audit certificate [(for additional information,
see appendix to this certificate)].
5. The [beneficiary][affiliated entity] paid a price of EUR [insert number]) (including VAT
of EUR [insert number]) for this audit certificate. [OPTION 1: These costs are eligible
(i.e. incurred within 60 days of the end of the action referred to in Article 3 of the Grant
Agreement) and included in the financial statement.][OPTION 2: These costs were not
included in the financial statement.]
Date, signature and stamp
9
Digitally sealed by the European Commission
Date: 2019.06.26 11:51:01 CEST
This document is digitally sealed. The digital sealing mechanism uniquely binds the
document to the modules of the Funding & Tenders Portal of the European
Commission, to the transaction for which it was generated and ensures its integrity and
authenticity.
Any attempt to modify the content will lead to a breach of the electronic seal, which can
be verified at any time by clicking on the digital seal validation symbol.
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111